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Abstract  
Background: The risk of multiple sclerosis (MS) is dependent on multiple variables, including 
geographical location, therefore the risk of MS in children from Sydney Australia will differ from 
children living in the northern hemisphere. There is increasing interest in the early recognition 
and treatment of MS in children.  
The presence of anti-MOG antibodies has signalled the emergence of a clinical subtype of central 
nervous system (CNS) inflammatory demyelination, and this may lead to targeted therapy in 
these children in the future.  
Method: Using univariate and multivariate analysis, we determined the clinical and radiological 
features that were predictive of MS in 88 children from New South Wales, Australia, with a first 
acute demyelinating syndrome (ADS) who were followed for a minimum of one year. We tested 
the McDonald, KIDMUS, Callen and Verhey MRI criteria for paediatric MS.  
The serum of 73 children from our original cohort was tested for anti-Myelin oligodendrocyte 
glycoprotein (MOG) antibodies. A clinical, biochemical and neuroimaging comparison was made 
to determine if the presence of anti-MOG antibodies heralds an emerging demyelinating 
disorder sub-type.  
Results: After a mean follow-up of 5.2 years, 13/88 (15%) of children had MS. Using 
multivariate analysis, preceding infection was protective of MS, and corpus callosal lesions, the 
combined presence of both well and poorly demarcated lesions, and contrast-enhancing lesions 
were predictive of MS. The sensitivity and specificity of the respective radiological criteria were 
McDonald 2005 (69%, 68%), McDonald 2010 (58%, 95%), KIDMUS (8%, 100%), Callen (69%, 
85%) and Verhey (62%, 84%). When McDonald 2010 criteria were applied to baseline and 
serial scans, the sensitivity and specificity was 91% and 93%.  
Anti-MOG antibodies were found more commonly in patients who were younger, had a raised 
erythrocyte sedimentation rate (ESR) and in those who presented with monophasic (86%) and 
chronic recurrent (75%) optic neuritis.  
Conclusion: Despite the long follow-up, the risk of MS appears lower in New South Wales 
children compared to previously reported international cohorts. Radiological features are more 
predictive than clinical features in predicting MS. The McDonald 2010 criteria performed well 
although the dissemination in time criteria on baseline scans is difficult to apply to children 
with encephalopathy.  
Anti-MOG antibodies are more common in young children with ADEM and bilateral optic 
neuritis. The pathogenicity and therapeutic implications of anti-MOG antibodies needs further 
study.  
 
The clinical and radiological components (Chapters 2 and 3) of this thesis have been published 
in Multiple Sclerosis Journal (see Appendix F). 
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PERIVENTRICULAR WHITE MATTER. THE DISTRIBUTION OF THE HYPER-INTENSITIES AROUND 
THE VENTRICLES IS CHARACTERISTIC OF PATIENTS WITH NMO AS THIS IS WHERE THERE IS A 
CONCENTRATION OF AQUAPORIN 4 CHANNEL EXPRESSION(80). ............................................................... 104 
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FIGURE 3-7 MRI BRAIN DEMONSTRATING A PATIENT WHO WOULD BE CLASSIFIED AS NOT MEETING 
THE DISSEMINATION IN TIME CRITERIA ACCORDING TO THE MCDONALD 2010 CRITERIA. LEFT: 
CORONAL FLAIR SEQUENCE DEMONSTRATING A NUMBER OF DEMYELINATING LESIONS IN THE 
JUXTOCORTICAL, DEEP WHITE, PERIVENTRICULAR WHITE MATTER AREAS IN THE RIGHT 
HEMISPHERE. THERE ARE ALSO DOMINANT BASAL GANGLIA LESIONS IN BOTH HEMISPHERES. 
RIGHT: CORONAL T1 SEQUENCE WITH GADOLINIUM DEMONSTRATING THAT ALL OF THE 
HYPERINTENSE LESIONS DESCRIBED ON CORONAL FLAIR (LEFT) ENHANCE WITH GADOLINIUM. 
AS ALL OF THE LESIONS HAVE GADOLINIUM ENHANCEMENT, THIS PATIENT DOES NOT FULFIL 
MCDONALD 2010 DIT BASELINE SCAN CRITERIA. THIS PATIENT’S CLINICAL PRESENTATION 
CONSISTED OF ENCEPHALOPATHY, SWALLOWING ABNORMALITIES, HEMIPLEGIA AND WAS 
CONSISTENT WITH A DIAGNOSIS OF ACUTE DISSEMINATED ENCEPHALOMYELITIS. ....................... 153 
FIGURE 3-8 MRI BRAIN SCAN POSITIVE FOR THE DISSEMINATION IN TIME (DIT) MCDONALD 2010 
CRITERIA OF BASELINE SCAN. LEFT: CORONAL FLAIR SEQUENCE DEMONSTRATING A NUMBER 
OF HYPERINTENSE LESIONS. RIGHT: T1 CORONAL SEQUENCE WITH GADOLINIUM 
DEMONSTRATING THAT ENHANCEMENT OF ALL BUT ONE OF THE LESIONS (MARKED WITH 
ARROW). THIS PATIENT PRESENTED WITH CLINICAL TRANSVERSE MYELITIS CONSISTENT WITH 
THE 2002 DIAGNOSTIC CRITERIA. HER INITIAL MRI SPINE WAS NORMAL, HOWEVER A REPEAT 2 
WEEKS AFTER HER PRESENTATION SHOWED EXTENSIVE CORD DEMYELINATION. SHE WOULD 
THEREFORE FULFIL THE DIT CRITERIA BY HAVING ASYMPTOMATIC GADOLINIUM ENHANCING 
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FIGURE 3-11 KAPLAN-MEIER GRAPH DEPICTING THE RISK OF DEVELOPING MS IF YOU HAVE 0,1,2 OR 3 
OF THE MRI CHARACTERISTICS THAT WERE STATISTICALLY SIGNIFICANT ON THE 
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INVOLVEMENT. RIGHT: T1 SAGITTAL FLAIR SEQUENCE DEMONSTRATING DEEP WHITE MATTER 
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NOW MUCH SMALLER IN SIZE AND INTENSITY CONSISTENT WITH RESIDUAL AREAS OF GLIOSIS. 
THE LESIONS IN THE LEFT CEREBELLUM, CORPUS CALLOSUM, FRONTAL, TEMPORAL, PARIETAL 
AND OCCIPITAL LOBES BILATERALLY ARE WERE NOT SEEN ON THE PREVIOUS MRI. ..................... 224 
FIGURE 4-10 BELOW LEFT: T2 SAGITTAL OF THE SPINE DONE 2 MONTHS AFTER INITIAL EPISODE 
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THE RIGHT), JUXTACORTICAL AND SUBCORTICAL WHITE MATTER. THE LESIONS ARE BILATERAL, 
ASYMMETRICAL AND POORLY DEFINED. .................................................................................................................. 230 
FIGURE 4-14 POST CONTRAST MRI BRAIN SCANS PERFORMED DURING FIRST EPISODE. LEFT: T1 
CORONAL SHOWING PATCHY UPTAKE OF CONTRAST IN THE BASAL GANGLIA AND PARIETAL 
LOBE ON THE RIGHT. RIGHT: T1 CORONAL SHOWS UPTAKE IN THE DEEP WHITE MATTER 
BILATERALLY ALTHOUGH MORE PRONOUNCED ON THE RIGHT. ................................................................. 231 
FIGURE 4-15 MRI BRAIN DURING SECOND CLINICAL RELAPSE. LEFT: T2CORONAL FLAIR SHOWED LEFT 
CEREBELLAR INFLAMMATORY CHANGES. NEW AREAS OF HYPER-INTENSITIES WERE SEEN IN 
THE RIGHT OCCIPITAL LOBE. RIGHT: CORONAL T2 FLAIR SHOWS JUXTACORTICAL 
INFLAMMATORY CHANGES IN THE RIGHT POSTERIOR HEMISPHERE. ...................................................... 233 
FIGURE 4-16 PRE AND POST CONTRAST SCANS DURING 2ND CLINICAL RELAPSE. LEFT SAGITTAL T1 
FLAIR PRE-GADOLINIUM. THE HYPO-DENSE CEREBELLAR LESION IS SEEN.  RIGHT: T1 SAGITTAL 
FLAIR POST GADOLINIUM SHOWS HETEROGENEOUS ENHANCEMENT OF THE VERMIS, SUPERIOR 
AND MIDDLE LOBES OF THE CEREBELLUM. ............................................................................................................ 233 
 
  
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 20 of 279 
Abbreviations used 
Ab  Antibody 
ASOT   Anti-streptolysin O titre 
ADEM  Acute Disseminated Encephalomyelitis 
ADS  Acquired demyelinating syndrome 
BLON  Bilateral optic neuritis 
CDMS  Clinically definite Multiple Sclerosis  
CSF  Cerebrospinal fluid 
CHW  Children’s Hospital at Westmead 
CIS  Clinically isolated Syndrome 
CNS  Central Nervous System 
CRION  Chronic recurrent inflammatory optic neuropathy 
DIS  Dissemination in space 
DIT  Dissemination in time 
ESR  Erythrocyte sedimentation rate 
MOG  Myelin oligodentrocyte glycoprotein 
MRI  Magnetic resonant imaging 
MS  Multiple Sclerosis 
NMO  Neuromyelitis Optica 
NPV   Negative Predictive Value 
NSW  New South Wales 
OCB  Oligoclonal bands 
ON  Optic Neuritis 
PCR  Polymerase chain reaction 
PPV  Positive predictive value 
TM  Transverse Myelitis 
ULON  Unilateral optic neuritis  
  
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 21 of 279 
1. INTRODUCTION TO DEMYELINATION 
1.1 Defining demyelination 
Inflammatory disorders of the central nervous system (CNS) form part of the spectrum of 
autoimmune disorders whereby for reasons as yet unknown, the immune system ‘over-reacts’ 
to external triggers (such as viruses, bacteria, immunisations) causing damage to 
tissue/cells/receptors and this leads to dysfunction. When inflammation occurs in the white 
matter or myelin sheath of the CNS it is referred to as demyelination.  
Demyelination can be temporary (the myelin repairs), recurrent or permanent (resulting in 
scarring and ‘CNS plaques’) (Figure 1-1). Neurological dysfunction mirrors these processes (1).  
Figure 1-1 Demyelination in the CNS: functional recovery versus progressive decline.  
 
Following an episode of demyelination, the axon has two possible destinies. The normal response is for the myelin to 
spontaneous re-myelinate as shown on the left side of the figure. In this process of re-myelination, the myelin has been 
shown to be thinner and shorter that those originally formed however recovery of function is established. When re-
myelination doesn’t occur (like in MS), the axon and neuron are left exposed and vulnerable to damage and this leads to 
the clinical decline in neurological function as seen  in chronic demyelinating disorders like MS.  © Franklin, R. J. M. & 
French-Constant, C. Remyelination in the CNS: from biology to therapy. Nature Reviews Neuroscience 9, 839–855 (2008) 
doi:10.1038/nrn2480.  
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1.2 Demyelination in Children  
In adults, a first presentation of CNS demyelination is often followed by further episodes of 
demyelination separated in space and time, eventually leading to a diagnosis of multiple 
sclerosis (MS). This occurs in 82% of adults presenting with a first CNS demyelinating episode 
in conjunction with an abnormal baseline MRI scan (2). Over time demyelination in the CNS 
becomes irreversible with the formation of ‘plaques’ and axonal loss, leading to permanent 
neurological dysfunction and disability. This is why MS is the single greatest cause of 
neurological disability in young adults (3).  
A number of studies in adults with MS have shown that early introduction of disease-modifying 
therapies, even from the first demyelinating event can delay disability, prevent relapses, halt 
atrophy of the brain and decrease the appearance of new T2-weighted lesions (4, 5). These 
therapies are costly but have potential efficacy in modifying disease progression. Therefore 
discriminating MS from other monophasic causes of CNS demyelination early in the disease 
course, has not only clinical but also economic implications (6). 
In children, CNS demyelination commonly occurs as a monophasic illness in the form of acute 
disseminated encephalomyelitis (ADEM) or a clinically isolated syndrome (CIS) (e.g. example 
optic neuritis) (7-14).  If a child has further CNS demyelinating events, a diagnosis of multiple 
sclerosis is typically made, as in adults.   
It has been estimated that between 5-10 % of adult patients with MS had their first episode of 
demyelination before the age of 16 years (15-18). MS with paediatric onset is associated with 
development of disability and loss of independence at an age approximately 10 years younger 
than in adult-onset MS even though the disease course is often longer (Table 1-1) (17, 19, 20). 
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Table 1-1 Average age from diagnosis to expanded disability status score (EDSS) 3.0 and 6.0 for adults vs 
children with Multiple Sclerosis, extracted from table 3 of Boiko et al (19).  
Level of disability Adult onset MS Group (n=722) Paediatric onset MS group (n=113) 
Time to EDSS 3.0 7.69 +/- 0.42 15.58 +/- 1.16 
Time to EDSS 6.0 14.97 +/- 0.31 19.13 +/- 1.41 
Values are in years with +/- SD. EDSS – expanded disability status scale score.  
An EDSS score of 6.0 or more is equivalent to having no independent mobility. This study showed that the time to mild 
disability (EDSS 3.0) or to loss of independence (EDSS 6.0) is longer in paediatric onset MS compared to adult onset MS. 
 
After a first episode of CNS demyelination, the question of whether a child will have any further 
events and be diagnosed with MS cannot as yet be definitively answered. One of the difficulties 
is trying to decide whether all children who have a further demyelinating event should be 
diagnosed with Multiple Sclerosis and be treated with MS disease-modifying therapy (21-23) or 
if further clinical subtypes exist that may need alternate therapy similar to neuromyelitis optica.  
As stated by the International Paediatric MS Study Group (IPMSSG), now more than ever, ‘the 
distinction between MS and ADEM has become a major clinical issue and is no longer a 
theoretical concern’ and this is because of the recommended early use of MS disease modifying 
therapies (DMT) (24).  
A number of paediatric studies have been conducted in the United Kingdom (UK), Germany, 
France, India, United States of America (USA) and Canada addressing this question. Through 
these studies, a number of clinical and radiological characteristics have emerged that help 
clinicians to differentiate a monophasic episode from MS although they are not definitive. 
However, it is well recognized that the geographical latitude of a country influences the risk of 
relapse and of MS. Disease rates have been shown to vary according to latitude so that with 
increasing distance from the equator in both the northern and southern hemispheres, a higher 
of incidence of MS is observed (Figure 1-2) (25).    
This may be related to sun exposure (through Vitamin D) as was demonstrated in a study 
conducted in monozygotic twins which found that the twin with the least sun exposure was at 
higher risk of developing paediatric onset MS independent of genetic predisposition(26). 
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Therefore the risk of MS here in Australia is expected to be less than in countries like Canada or 
Germany as has been shown in adult studies (Figure 1-2).  
Figure 1-2 Worldwide distribution of Multiple Sclerosis as published by Kurtzke (25).  
 
High prevalence is shown in solid black, medium risk is indicated by dotted shading and low in dashed fill. Blank areas are 
where there was no data (at time of publication).  Australia has areas of medium and high risk. 
 
It is the aim of my thesis to review the different clinical, radiological and immunological 
phenomenology of childhood CNS demyelination occurring in a New South Wales paediatric 
population presenting to a single tertiary children’s hospital. In addition, with review of follow-
up clinic notes and with the aid of a telephone follow-up study, we aim to determine which 
patients have suffered further demyelinating events and have met the diagnostic criteria for MS, 
and which have remained monophasic.   
This will be the first and largest follow-up study after a 1st episode of CNS demyelination in 
Australian children, which will allow comparisons with European and North American cohorts.  
This study will contribute to the development of clearer clinical and radiological criteria for 
diagnosing and differentiating monophasic disorders from the chronic and debilitating disease; 
MS.  
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1.3 Consensus definitions of 2007 
Even though studies on monophasic demyelinating events and MS have been reported 
frequently in the literature over the last decade, early reports (prior to 2007) are difficult to 
compare due to the diverse clinical definitions of ADEM, CIS and paediatric onset MS. In 2007, 
the international paediatric MS study Group (IPMSSG) developed consensus definitions for 
paediatric multiple sclerosis and related disorders (7). This led to the establishment of major 
clinical and neuro-imaging findings typically associated with each demyelinating disorder (7). 
Although these definitions are not absolute, they have established diagnostic criteria based on 
the presenting clinical syndrome and neuro-imaging findings to aid in the diagnosis of MS and 
related disorders.  
 Acute Disseminated Encephalomyelitis (ADEM) 
According to the consensus definition, acute disseminated encephalomyelitis (ADEM) is a 
clinical syndrome that has to fulfil the following criteria: the presentation has to be 
polysymptomatic and there must be encephalopathy defined by either a behavioural change or 
an alteration in consciousness (7). In addition to these clinical findings, there must be MRI 
features of large lesions that typically involve the white matter with or without grey matter 
involvement (7). Relapses that occur within a 3 month period that include encephalopathy are 
still defined as ADEM.    
 Recurrent ADEM (7) 
Recurrent ADEM was defined as a new event with a recurrence of the initial clinical picture, 3 or 
more months after the first event but not whilst on steroid treatment or within a month of 
completing steroid therapy. Imaging must not depict new lesions in recurrent ADEM, although 
pre-existing lesions may have enlarged.  
 Multiphasic ADEM (7) 
If a child experienced a new clinical event, 3 or more months after the first ADEM episode, and 
at least a month after finishing steroid treatment, with different symptoms and signs to the first 
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event, again associated with encephalopathy, then the diagnosis of Multiphasic ADEM is 
assigned. Furthermore an MRI of the brain should demonstrate new areas of involvement but 
previous lesions should have partially or completely resolved unlike in MS when lesions usually 
accrue.   
 Clinically Isolated Syndrome (CIS) 
A clinically isolated syndrome (CIS) is defined by an acute demyelinating illness that may be 
either clinically monofocal (e.g. optic neuritis) or multifocal (e.g. ON and long tract signs), but is 
not usually associated with encephalopathy or fever (7). A brainstem CIS can sometimes be 
associated with encephalopathy owing to the presence of the reticular formation at that location 
(Figure 1-3). An MRI may demonstrate lesions corresponding to the clinical syndrome as well as 
‘clinically silent’ lesions in other anatomical areas. 
Figure 1-3 Picture taken from Pearson’s Education Inc. shows the brainstem (top left )and a transverse section 
of the brainstem at the level of the reticular formation .  
 
‘The reticular formation or brain stem core consists of a complex and ancient system of neuron pools and their axonal 
projections, running from caudal medulla to rostral mesencephalon and in somewhat different guise, through thalamus 
and sub-thalamus. These cell groups sample all information entering and exiting the nervous system. The integrated signal 
is then projected widely throughout the brain stem, upon spinal levels and upon subcortical and cortical cellular arrays, 
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continuously readjusting the excitability (level of gain) of these areas. Moment-to-moment reticular modulation of sensory, 
motor, and higher level brain functions appear central to the ongoing adaptation of the organism to its environment.’(27) 
 Neuromyelitis Optica (NMO) 
Neuromyelitis optica is a recurrent demyelinating disorder of the CNS affecting the optic nerves 
and spinal cord that is only rarely diagnosed in children.  
The classic diagnosis of NMO is made if the following criteria are fulfilled; the patient must have 
optic neuritis and acute myelitis as major criteria. They must also have 2 of 3 supportive 
criteria;  
- Spinal MRI lesions that extend over three or more segments and this is referred to as 
longitudinally extensive transverse myelitis (LETM), and/or 
- An initial MRI brain that is not diagnostic of MS, and/or 
- The presence of antibodies to NMO (NMO-IgG) also known as anti-aquaporin 4 antibodies 
(7). 
More recently NMO has been recognized as a recurrent autoimmune CNS disorder with 
distinctive clinical, neuroimaging and serological findings (28). Therefore the spectrum of NMO 
has widened and children with isolated ON, isolated LETM, patients with recurrent hiccupping, 
vomiting and/or anorexia (without ON or TM) who harbour NMO-IgG have been included in the 
NMO spectrum, as in adults (29-32). These patients are termed either ‘limited NMO’ or as 
having NMO spectrum disorder (NMOSD), and have a high risk of relapse or disability. The 
discovery of the NMO-IgG, has expanded the clinical spectrum of NMO (discussed later). 
 In NMO the demyelination extends across many segments of the spinal cord and there is 
cavitation and necrosis of both the grey and white matter of the spinal cord and optic nerves 
alike (33). Active lesions are infiltrated by eosinophils and neutrophils (unlike macrophages in 
MS) (34). Immunoreactivity against the aquaporin 4 water channel along astroglial foot 
processes is decreased as compared to MS where it is increased (35, 36).  
 Paediatric Multiple Sclerosis (PMS) 
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The definition for multiple sclerosis in children is no different to the adult definition whereby a 
patient must have multiple episodes of CNS demyelination separated in space and time (37). 
According to the criteria, magnetic resonance imaging (MRI) of the brain can be used to meet 
the requirement for dissemination in space (DIT) (6), and more recently, the dissemination in 
time (DIT) criteria, even without a clinical demyelinating event (7, 38).  There must be at least 4 
weeks between events according to the 2007 consensus. A further qualifying factor in children 
is that, if the criteria for ADEM is met in the first clinical event, then a further two episodes of 
demyelination are required (7). 
 
The major findings of my study were performed prior to the publication of the 2012 consensus 
definitions (Krupp et al 2013). A comparison of the 2007 and 2012 consensus criteria with 
reference to my cohort is discussed in the methods chapter (2.2.5.3).  
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1.4 Pathological description 
Pathologically, the hallmark of ADEM is perivenous inflammation with accumulation of 
lymphocytes and foamy macrophages around the perivascular space. The demyelination is 
restricted to the perivascular space and there is a lack of inflammation and demyelination 
around adjacent arterioles and arteries (39, 40). The lesions are found in the white and grey 
matter of the brain, optic nerves and spinal cord and all lesions are usually of the same age (41).   
This is in contrast to the confluent sheets of macrophage infiltration combined with astrocytic 
gliosis and complete demyelination seen well beyond the perivascular space and of variable 
ages in MS (39). The pathology of MS lesions remains contentious even now, and variable 
dominant pathological features are described (42, 43).  
A detailed pathological review of ADEM, MS and NMO is not the subject of this study.  
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2. CLINICAL COMPARISON OF CHILDREN PRESENTING WITH THEIR FIRST CENTRAL 
NERVOUS SYSTEM DEMYELINATION 
2.1 Literature review 
We reviewed the literature by using the search terms ‘acute disseminated encephalomyelitis’, 
‘multiple sclerosis’, ‘optic neuritis’, ‘transverse myelitis’, ‘clinically isolated syndrome’ and 
‘Neuromyelitis optica’ in Medline© and limited our search to papers that had a minimum cohort 
number of 30 patients and were written between 2000 up to the time of writing thesis. We also 
limited our search to ‘children’ or ‘paediatric’ patients. We focused our attention on papers that 
reviewed the clinical and radiological phenomenology of ADEM and those that compared ADEM 
to paediatric onset MS and the diseases that are defined under the group clinically isolated 
syndrome (CIS).  
 Clinical characteristics of demyelinating syndromes: Review of relevant early 
cohorts before the 2007 consensus criteria, divided by nation. 
 United Kingdom (2000) 
In 2000, Dale et al (8) , published a follow-up study of 48 children who presented with 
disseminated demyelination and compared those who remained monophasic with those who 
developed clinically definite MS (CDMS).  The cohort represented children presenting to a 
quaternary hospital in the United Kingdom, with CNS demyelination but excluded patients with 
isolated ON and TM. The diagnosis of ADEM was based on a polysymptomatic presentation. A 
subset of patients who had a recurrent demyelinating event were thought to represent a 
prolonged monophasic immune process and were given the term ‘multiphasic ADEM’ (MDEM). 
If relapses included dissemination in space and time then multiple sclerosis was diagnosed.  
The main positive differentiating findings between ADEM and MS were summarised by Dale et 
al and are shown in Table 2-1.  
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Table 2-1 Clinical differences in ADEM vs. MS which were statistically significant from Dale et al (8) extracted 
from table 6.  
Finding ADEM MS P value 
Preceding infection 74% 38% <0.05 
Polysymptomatic presentation 91% 38% <0.02 
Encephalopathy 69% 15% <0.002 
Pyramidal signs 71% 23% <0.01 
Unilateral optic neuritis 0% 23% <0.01 
Blood leukocytosis 64% 22% <0.05 
ADEM – acute disseminated encephalomyelitis, MS – multiple sclerosis. 
 The most significant findings differentiating ADEM from MS were the presence of 
encephalopathy and a polysymptomatic presentation, which are now firmly established as 
characteristic of ADEM under the 2007 consensus criteria (7).  
The number of patients who were diagnosed with MS after a mean follow-up of 5.6 years was 
13/48 (27%) however as the study excluded children who would be included in the 
monophasic (CIS) group (ON, TM) under the current definitions this rate is likely to be 
inconsistent with the true risk of MS after a first demyelinating event.  
 Australia (2001) 
The only Australian Study investigating children with CNS demyelination was published in 2001 
by Hynson et al (9) and focused mainly on ADEM. This retrospective study examined the clinical 
(and neuroradiological findings - discussed later) features of ADEM in 31 children presenting to 
Melbourne Children’s Hospital which is a tertiary children’s hospital. Patients were included if 
they had a neurologic disturbance of acute onset and had MRI changes in the white matter 
consistent with ADEM.  
The main findings were that ADEM patients; 
- Ranged from 2-16 years of age – mean of 5.9 yrs. 
- Were likely to have a prodromal illness (71%) 
- Had encephalopathy – 42% irritability and 68% impaired conscious state 
- Were likely to present with ataxia (65%) and cranial nerve abnormalities (45%) 
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There were 4/31 (12%) ADEM patients who had clinical relapses off steroids, a month after 
their initial episode. They had new lesions on brain MRI scan and met the criteria for MS. 
There have been no Australian studies to date enrolling all paediatric patients with a 1st episode 
of CNS demyelination (ADEM and CIS) and assessing outcome.  
 South America (2002) 
In Argentina, Tenembaum et al performed a cohort study on 84 patients diagnosed with ADEM 
examining whether clinical and neuroimaging findings could predict future outcome or 
diagnosis (11). Patients were included in the study if they had a presumed inflammatory 
demyelinating event affecting multiple areas of the CNS and if they had a polysymptomatic 
presentation. Patients with a monosymptomatic presentation like optic neuritis or transverse 
myelitis were excluded.  
This study found that 74% of patients had a prodromal infectious event or had a vaccination 
just prior to the demyelinating episode. Out of the 84 patients initially diagnosed with ADEM, 8 
(10%) developed a second clinical episode of demyelination that was polysymptomatic with 
new lesions on MRI and met the diagnostic criteria for MS. These eight patients did not have 
OCB’s in their CSF.  
The study supports a relapsing (multiphasic) form of ADEM as described in the new consensus 
criteria, as opposed to a second episode of CNS demyelination automatically leading to a 
diagnosis of MS.  This finding suggests that negative OCB’s in ADEM could be a possible 
differentiating feature of ADEM from MS, especially in the relapsing form. There was a large 
emphasis on the MRI findings in this paper however this is discussed in the MRI chapter 
(Chapter 3).  
 United States (2004) 
A combined retrospective and prospective study was conducted by Leake et al (44) on 42 
patients diagnosed with ADEM in California, United States. Patients were diagnosed and 
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enrolled in the ADEM cohort if they were less than 20 years old, had an acute or sub-acute 
neurological syndrome, and had imaging indicative of CNS demyelination inconsistent with 
another diagnosis. 
 Recurrent ADEM was defined as having 2 episodes of clinical and radiological demyelination 
with complete resolution of neurological signs over 12 months.  A patient with three or more 
demyelinating episodes was defined as having MS.  
The main findings in the ADEM cohort were: 
- 93% had had an infection in the preceding 21 days 
- Mental status change including agitation and delirium was found in 66% 
- The majority of patients had multiple abnormal symptoms and/or signs (polysymptomatic) 
with over 50% having abnormal extra-ocular movements and 95% having hyper-reflexia.  
- Sensory abnormalities were uncommon (11%). 
The number of patients with an initial diagnosis of ADEM who were later diagnosed with MS 
was 4/42 (9.5%). 
 France (2004 & 2007) 
In a cohort study conducted in France by Mikaeloff et al (18), 296 children from multiple 
centres, with a first episode of acute inflammatory demyelination of the CNS were studied to 
determine what factors were predictive of a second attack.  
In this study ADEM was diagnosed on the basis of a polysymptomatic presentation with mental 
status change, as well as an MRI changes that were consistent with ADEM. There was no use of 
multiphasic or recurrent ADEM, and patients with a second episode of demyelination were all 
classified as MS. 
 The main findings from this study are shown in Table 2-2.   
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Table 2-2 Characteristics of ADEM vs MS in Mikaeloff study 2004 (18).  
ADEM MS 
Age <10yrs Age >10 yrs. 
Infection in month prior to event (51%) Infection in month preceding infection (27%) 
OCB in CSF uncommon (5%) OCB in CSF more common (40%) 
ADEM - acute disseminated encephalomyelitis, MS – multiple sclerosis, OCB – oligoclonal bands, CSF – cerebrospinal fluid. 
The predictive value of intrathecal OCB and subsequent development of MS was supported in 
the study.   
An interesting observation in this study was that patients with a clinically isolated syndrome 
(termed single focal episode by Mikaeloff) were more likely to develop MS (47%) compared 
with the patients with ADEM (29%) after a mean follow-up of 2.9 years (SD 3 years). This 
observation of CIS having an increased risk of progression to MS compared with ADEM has 
since become an established association.  
At the conclusion of the follow-up period (2.9 years), 168/296 (57%) of patients were 
diagnosed with MS. This may however be an overestimation as patients with any clinical relapse 
were diagnosed with MS and furthermore the cohort is representative of patients referred to 
neuro-paediatric centres, not general paediatric hospitals.  
A sub-cohort study was performed by Mikaeloff et al  and published in 2007 (45) based on 132 
patients derived from their original cohort in 2004 (18).  The inclusion criteria included 
children presenting with a first episode of ADEM which they defined as a first episode of CNS 
demyelination with a polysymptomatic presentation, a change in mental state and with a 
compatible MRI. The study examined the clinical characteristics of these patients to determine 
which, if any were more predictive of a chronic relapsing course. 
There were four statistically significant characteristics during the first event that were 
predictive of a relapse; having optic neuritis (in 25% of relapsing patients compared with 9% 
with monophasic ADEM), fulfilling the ‘MRI Barkhof MS criteria’(63 vs 47%), recovering 
completely from the first attack without sequaelae, and finally having a positive family history 
of a CNS inflammatory disorder (45). Apart from the first characteristic (having optic neuritis) 
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the other characteristics have not been frequently studied as risk factors in the development of 
MS. However based on these two studies by Mikaeloff, it would be reasonable to deduce that 
having an episode of isolated optic neuritis (or CIS under the 2007 consensus criteria) is 
associated with a future diagnosis of MS compared with having optic neuritis as part of ADEM.  
 India (2006) 
Documentation of ADEM in developing countries is relatively lacking, however Singhi et al (13) 
published a prospective study in 2006 examining the clinical and radiological features of 52 
children with ADEM.  
The definition of ADEM used for diagnosis was: an acute onset of polysymptomatic neurologic 
signs and MRI evidence of CNS demyelination.  
The main clinical features of the patients in the cohort with ADEM included: 
- A mean age at presentation of 6.14 years  
- 56% had altered sensorium with a further 4% having behavioural changes 
- Fever was present in 64% 
- Approximately 80% of the children had weakness in the pyramidal distribution and 40% 
had cranial nerve abnormalities 
Four patients in the cohort had relapses; 3 with a single relapse (undiagnosed relapsing 
disorder) and 1 with two further episodes who would meet the criteria for MS(7). There were 
no factors reported that predicted relapse. The radiological findings of the study are discussed 
in chapter 3 on MRI in demyelination. 
 Germany (2007) 
In Germany, Pohl et al  (46) conducted a prospective study on 160 patients enrolled from a  
nationwide survey. Patients with suspected or definite MS (n=132) were analysed together, as 
were patients with ADEM or suspected ADEM (n=28). The diagnostic criteria or definitions used 
to diagnose ADEM or MS were not stated in the paper which makes comparison with other 
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studies prior or subsequent to the consensus criteria difficult. Patients presenting with ON 
(‘monosymptomatic visual symptoms) appear to have been included as part of the ‘probable’ 
MS group, however no reference is given to patients presenting with TM.  
The main purpose of the study was to study the incidence of MS and ADEM in Germany 
however, differentiating features between ADEM and MS were also explored. These 
differentiating characteristics are shown in Table 2-3. 
Table 2-3: Comparison of ADEM vs MS from Pohl et al (47) 
Finding ADEM MS 
Mean Age 6.6 years 12.1 years 
Female: male ratio 0.75:1 1.24:1 
Polysymptomatic onset 24 (86%) 88(67%) 
CSF oligoclonal IgG bands 5 (19%) 89 (67%) 
ADEM – acute disseminated encephalomyelitis, MS – multiple sclerosis 
No statistical analysis was carried out on these features, most likely because the studies main 
focus was to determine the incidence of MS and ADEM.  
 Italy (2008) 
In Italy, a single centre prospective study on 68 children with a first episode of demyelination 
was conducted by Atzori et al (48). This study divided patients into two groups – either putative 
ADEM based on clinical, biochemical and neuroimaging criteria, or as MS based on Poser’s 
diagnostic criteria(37) (prior to 2001) and the McDonald criteria (49)(after 2001). Although 
published after the 2007 consensus definitions, this study did not use the new International 
definitions. Initially there were 48 patients in the MS group and 20 in the ADEM group.  
The differentiating features of the two groups based on the initial clinical picture were; the MS 
group were less likely to have a prior infection or febrile illness (12.5% vs 60%) and the ADEM 
group were more likely to have a polysymptomatic onset (70% vs 27%) (No definition of 
‘polysymptomatic’ was given). There was impairment in consciousness in the ADEM group 
(50%) but not in the MS group (0%). Seizures and meningism were only present in the ADEM 
group. These differences were all statistically significant (P value < 0.05). 
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 In the MS group, the average age at diagnosis was 14.4 +/- 2.5 years compared with the much 
younger ADEM patients (8.1+/- 3.8yrs) with a P value of <0.000.  The incidence of MS was 
shown to increase progressively with age.  
 Intrathecal oligoclonal bands were found in 83% of the MS children at presentation compared 
with only 10% of the ADEM patients (P<0.001). There were 2 patients in the ADEM group who 
subsequently developed MS. These two patients initially had no OCB in their CSF but on re-
testing had developed OCB. The only other finding on CSF analysis to differentiate between 
ADEM and MS was that the lymphocyte count was typically higher in the ADEM group compared 
to the MS group; however there was a lot of overlap and this result was not statistically 
significant. These results are summarized in Table 2-4 below.  
Table 2-4: Characteristic trends of ADEM vs MS according to Atzori Study (48) 
ADEM MS 
Polysymptomatic (undefined) (70%) Monosymptomatic (undefined) (73%) 
Encephalopathy+/-Seizures No encephalopathy 
OCB negative in CSF OCB positive in CSF (intrathecal synthesis) 
Lymphocyte counts >30 in CSF Lymphocyte count < 30 CSF 
ADEM – acute disseminated encephalomyelitis, MS – multiple sclerosis, OCB – oligoclonal bands, CSF – cerebrospinal fluid 
A number of MRI characteristics were investigated in this patient cohort however this will be 
discussed in chapter 3 on neuro-imaging.  
 Summary of trends from early cohorts 
Through reviewing the literature prior to the development of the 2007 consensus criteria for 
paediatric MS and related disorders, it is evident that there were many and varied criteria being 
used to define these disorders in children making direct comparison of patient cohorts difficult. 
However common themes evolved and a number of clinical characteristics differentiating ADEM 
from MS emerged in these earlier studies which helped in the formation of the 2007consensus 
criteria. I have summarized characteristics in in Table 2-5.  
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Table 2-5 Summary of findings in early cohorts 
Characteristic ADEM MS 
Age Younger (<10yrs) Older (>10yrs) 
Sex Male>female Female>Male 
Preceding infection &/or fever Both common Uncommon 
Encephalopathy Present Typically Absent 
Neurological presentation Polysymptomatic Often Monosymptomatic 
Cerebrospinal fluid OCB Most commonly negative More commonly Positive 
ADEM – acute disseminated encephalomyelitis, MS – multiple sclerosis, OCB – oligoclonal bands 
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 Clinical features of CNS demyelination in later cohorts (after 2007) 
There have been five major studies that have categorised a first episode of CNS demyelination 
using the 2007 International consensus criteria, and have followed patients to determine the 
clinical phenomenology of patients that later develop MS.  
 United Kingdom, 2007 
The first study was based on a cohort of 40 patients from the UK and published in 2007 by Dale 
and Pillai (50). The 2007 consensus criteria were used and therefore ADEM was defined on the 
basis of a polysymptomatic presentation with encephalopathy and an MRI with multifocal 
lesions involving the white matter. A CIS was diagnosed if the event was monofocal referable to 
a single CNS lesion (e.g. optic neuritis, transverse myelitis, brainstem, cerebellar or hemispheric 
dysfunction), or polyfocal but did not include encephalopathy. Paediatric MS was diagnosed on 
the basis of multiple CNS demyelinating episodes separated in space and time as for adults. 
Relapses had to be at least 4 weeks apart. The mean follow-up time was 2.2 years. The findings 
of the study are summarized in the Table 2-6.  
Table 2-6 Summary of the clinical & biochemical findings from Dale and Pillai (50)  
Characteristic CIS (n = 28) ADEM ( n=12) P-Value 
Fever at presentation 14% 66% <0.01 
Age 
Sex 
More commonly >10 yrs. 
 more likely female 
More commonly <10yrs 
 more likely male 
 
Oligoclonal bands(n=34) 38% (9/24) 0% (0/10) <0.03 
Dx with MS(relapsed) 46% (13/28) 8%(1/12) <0.03 
CIS – clinically isolated syndrome, ADEM – acute disseminated encephalomyelitis, Dx – diagnosed, MS – multiple sclerosis  
The study evaluated and confirmed the usefulness of the consensus criteria. Patients diagnosed 
with CIS where significantly more commonly found to have MS (46%) and only one of the ADEM 
patients was later diagnosed with MS (50).  
The follow-up period for some patients was as little as 6 months which is inadequate when 
trying to definitively show MS progression and this is acknowledged by the authors.  
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The study confirmed that patients with CIS were more likely to have OCB in their CSF, have MRI 
features consistent with the KIDMUS criteria for MS (see chapter 3) and were more likely to 
relapse and progress to MS.  
 United States of America, 2008 
The second study, published in 2008, was conducted in the USA by Alper et al (51). This was a 
retrospective study that compared presenting characteristics of ADEM and MS patients 
however the study only partially adhered to the 2007 consensus definitions. A diagnosis of 
ADEM was made if there was a polysymptomatic presentation associated with one or more 
brain lesions, the presence of encephalopathy, with no relapse 3 months after the initial 
presentation. MS was diagnosed using the McDonald 2001 criteria(49). 
Of the 98 patients initially enrolled, diagnostic assignment was based on 52 patients; 26 MS and 
24 ADEM. A total of 32 patients with CIS based on the 2007 consensus definitions (7), were 
excluded because brain MRI was normal or not done, even though 20 of these patients 
presented with acute transverse myelitis (ATM). This is likely to have biased the results. 
Table 2-7 represents  the characteristics differentiating ADEM from MS patients based on the 
first demyelinating episode according to Alper et al (51). 
Table 2-7 Clinical and biochemical differentiating characteristics between ADEM and MS according to Alper et 
al (51). 
Characteristics ADEM (n=24) MS (n=26) p-value 
Mean age at diagnosis yrs. (SD) 7.0 (4) 14.8 (3.3) <0.001 
Family History of MS  0% 23% (6/26) 0.002 
Encephalopathy 42% (10/24) 0% 0.001 
Fever present 21% (5/24) 0% 0.020 
Seizures 25% (6/24) 0% 0.008 
Most frequent symptom  Weakness 50% Paraesthesia 35% - 
Oligoclonal bands in CSF 0% 44% (8/18) 0.01 
ADEM – acute disseminated encephalomyelitis, MS – multiple sclerosis, CSF – cerebrospinal fluid. 
Perhaps the most significant finding in this study was that of the 26 patients who were 
diagnosed with MS after a mean follow-up of 7 years and 7 months, none had presented with 
encephalopathy as part of their initial demyelinating event (p=0.01, OR+0.03, 95% CI 0.002-
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0.54). It is recognized however, that some MS patients, particularly young ones, can have 
encephalopathy and ADEM as an initial event (52, 53).  
Alper et al then applied the 2007 consensus criteria retrospectively for the first demyelinating 
episode, 40 patients were diagnosed as having CIS and 10 ADEM. The differentiating 
characteristics between these groups are summarized below;  
- 65% (26/40) patients with CIS developed MS whereas 0% (0/10) of the ADEM patients 
developed MS  
- Children without encephalopathy (CIS) had a significantly higher likelihood ratio of being 
diagnosed with MS (p=0.001,OR=0.03, 95% CI 0.002-0.54) 
These later findings are important to the current and future studies of children with a first 
demyelinating episode as they incorporate the consensus criteria.  
 Netherlands, 2008 
The next study was a nationwide, multicentre study in the Netherlands involving 117 children. 
This was conducted by Neuteboom et al and published in 2008 (53). In this study, patients 
presenting with a monofocal CNS demyelinating illness were diagnosed as CIS. Those who had a 
polysymptomatic presentation were defined as Polyfocal CIS (PCIS) and then further 
differentiated on the basis of encephalopathy. MS was diagnosed on the basis of the revised 
McDonald criteria(54).  The study did not therefore strictly apply the 2007 consensus 
definitions. PCIS with encephalopathy would be called ADEM using the consensus criteria. 
In Table 2-8 the results of the study are summarized. The significant findings were that patients 
with a CIS were statistically more likely to have a follow-up diagnosis of MS compared to those 
with a PCIS (with or without encephalopathy). 
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Table 2-8 Summary of findings from Neuteboom et al (53) 
 
Feature 
 
CIS (n=54) 
1PCIS with 
encephalopathy 
(n= 36) 
PCIS without 
encephalopathy 
(n=27) 
P-value       
 (CIS vs all PCIS) 
Mean age onset (y) 10.5 5.6 8.4 <0.001 
Fever 4% 42% 33% <0.001 
Seizures 0% 36% 7% <0.001 
Progression to MS 44% 17% 26% 0.006 
  No significant difference between the two PCIS groups. PCIS – polysymptomatic clinically isolated syndrome. 
Within the PCIS group, the patients without encephalopathy more frequently progressed to MS 
then those with PCIS with encephalopathy (26% vs 17%) although this difference is not 
statistically significant (not shown in Table 2-8). However, had the PCIS without 
encephalopathy patients been included in the CIS group, this result may have become 
significant.   
Oligoclonal band results were based on the final group assignments after follow-up. OCB were 
most frequently found in patients with a final diagnosis of MS (46%) compared to none (0%) in 
the CIS group (monofocal) and only 16% in the PCIS groups. These numbers were not further 
broken down according to the presence or absence of encephalopathy.   
Regarding imaging, the Neuteboom study found that the presence of at least 3 positive Barkhof 
criteria in children of all ages at onset was predictive of progression to MS. It was suggested that 
this could therefore be a valuable prognostic factor for diagnosing MS (discussed in 
neuroimaging - chapter 3).  
Summarising these findings by Neuteboom, CIS patients are more likely to: have oligoclonal 
bands in their CSF at first demyelinating episode, fulfil the MRI KIDMUS criteria for MS, and be 
consequently diagnosed with MS, compared with ADEM patients.  
                                                             
 
1 Polysymptomatic demyelination with encephalopathy would be called ADEM using the 2007 consensus 
criteria.  
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 Canada, 2011 
A prospective national cohort study by Banwell et al (55) examined the clinical, environmental 
and genetic risk determinants of MS. In total 302 patients were recruited who met the inclusion 
criteria which were: age less than 16 years and in conjunction with a CNS acute demyelinating 
syndrome. The clinical, biochemical, radiological and HLA-DRB1*5 status were recorded for all 
patients at initial presentation and then the patients were followed-up over 3 years to 
determine how many patients went on to meet the diagnostic criteria for MS.  
The international criteria were used to define the diagnosis of patients at the end of the follow-
up period, however the investigators designated children with a monophasic illness as having 
an ‘acquired demyelinating syndrome (ADS)’ which can be clinically subdivided into all children 
with a clinically isolated syndrome (CIS-  polyfocal or monofocal deficits without 
encephalopathy), and those with acute disseminated encephalomyelitis (ADEM- polyfocal 
deficits with encephalopathy) (56).  The use of ADS in children has been used by these 
investigators in order to remove the terminology ‘CIS’, which is firmly established in adult MS 
studies as inferring a first episode of MS.  
Figure 2-1 Patient Cohort Subdivided according to final diagnosis.  
 
The 2007 consensus criteria (7) were used to categorize the patient cohort. Therefore patients who had a diagnosis of 
ADEM as their first event, but who subsequently had another clinical event OR an MRI depicting new lesions, were 
classified as having relapsing demyelination and not MS 
Figure 2-1 depicts the cohort according to final diagnosis after follow-up. Of note 2 patients who 
had an initial diagnosis of ADEM, had evidence of further CNS demyelination (one clinically and 
one radiologically) which would be uncategorized in the 2007 criteria.  
Cohort 
(n=302)
MS (n = 63)
* 39 clinical relapses
* 25 MRI dissemination in time 
only
1 withdrew
Relapsing demyelination (n=8) 
* 2 recurrent ON
* 2 recurrent TM
* 2 NMO
*1 ADEM with one non-ADEM event
* 1 ADEM with MRI evidence of dissemination in time
Monophasic ADS
(n= 231)
5 withdrew
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The rate of conversion to MS in this cohort of Canadian children was 21% (63/302). As noted by 
the authors, 25 of these patients were diagnosed as having MS based solely on their MRI 
findings at follow-up as is convention in adult medicine (using the McDonald MRI MS Criteria) 
(49).  The most notable factors that are associated with an increased risk of MS are summarized 
in Table 2-9 below. 
Table 2-9 Findings that were found to be significant in predicting MS in children with ADS extracted from 
Banwell et al (55) tables 1 and 2. 
Significant findings 
Monophasic ADS 
(n=231) 
MS 
(n=63) 
Hazard ratio 
(95% CI) 
Female sex 112 (48%) 41 (65%) 1.87 (1.11-3.14) 
Age at onset yrs. (SD) 8.85 (4.5) 12.0 (3.8) 1.18 (1.10-1.27) 
Initial diagnosis ADEM 70 (30%) 4 (6%) 0.23 (0.08-0.65) 
≥1 T2 lesion on initial MRI 125/223 (56%) 60/61 (98%) 37.65 (5.26-2773.85) 
EBV serology positive 82/185 (44%) 37/49 (76%) 3.39 (1.77-6.50) 
25-[hydro Vit D] mean (nmol/L) 66.4 (20.9) 52.3 (23.1) 0.89 (0.8-0.98) 
HLA-DRB1*15 ≥1 allele 64/212 (30%) 31/60 (51%) 2.21 (1.33-3.67) 
EBV – Epstein bar virus, ADEM – acute disseminated encephalomyelitis, MRI – magnetic resonant imaging, ADS – acute 
demyelinating syndrome, MS – multiple sclerosis, 25-hydroVit D – mean concentration of hydroxyl-vitamin D. 
Patients who were female, older at the time of their initial presentation, and not presenting with 
ADEM were at in increased risk of developing MS. 
The sensitivity of diagnosing MS based on a demyelinating episode in conjunction with an 
abnormal MRI was 98.4%. When analysing the MRI on the basis of T2 lesions, and excluding 
patients with an initial presentation of ADEM, 56 of 116 patients with one or more T2 lesions 
had a final diagnosis of MS at follow-up which corresponds to a 60-fold increased risk of MS. The 
positive predictive value for the presence of one or more T2 lesions on MRI with a follow-up 
diagnosis of MS was 32%. The negative predictive value of a future diagnosis of MS in a patient 
with a normal brain MRI in the context of CIS was 98.6% (a patient with a CIS and a normal 
brain MRI is unlikely to develop MS).  
A diagnosis of MS was found to be independently associated with have remote EBV infection, 
reduced Vitamin D concentrations and having more than one allele for HLA-DRB1*15.  
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The investigators formed a decision tree based on risk for being diagnosed with MS using the 
data above and this is shown in Figure 2-2 taken from the paper. The highest risk conferred is if 
a patient has T2 lesions on MRI, they are older than 11.85 years and the first demyelinating 
event is not ADEM. 
Figure 2-2 Multiple Sclerosis risk stratification algorithm for children presenting with an acute demyelinating 
syndrome. Taken from Banwell et al figure 2 (55). 
 
 British Isles, 2012 
The most recent study was a prospective study on 125 children under the age of 16 years 
(median 10.0 years, range 1.3-15.9 years)  from the British Isles (57).The mean age of first 
demyelinating episode was 9.7 years.  
At their initial demyelinating episode 66% (83/125) presented with CIS and 32% (40/125) 
with ADEM defined according to the 2007 consensus criteria (7, 57).  The CIS group was sub-
grouped as follows: 37% ON, 32% TM and ‘other CIS’ formed the remaining 31%. Clinically, 
ADEM patients were younger (under 10 years, median of 5.3 years) compared to those 
diagnosed with CIS (over 10 years, median for ON, TM and other CIS all over 11.8 years) 
(p=0.00). Only ADEM patients were found to present with seizures (20% vs 0% of any CIS). 
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Pyramidal tract signs were more commonly found in ADEM patients (60%) compared with CIS-
other(38%) and in no patients with ON and TM(57). 
 The investigators examined the CSF of the cohort and found oligoclonal bands to be more 
frequently found in children presenting with CIS compared to ADEM (p=0.01) but ADEM 
patients had more CSF lymphocytes (p=0.005)(57). 
There were a number of significant neuroimaging findings in the study which are discussed in 
the MRI chapter of the thesis.  
 Summary of findings post consensus criteria 
On review of the literature, it can be concluded that up until the 2007 consensus criteria, direct 
comparisons of clinical and radiological characteristics between ADEM, CIS and MS were 
difficult to make as variable and inconsistent definitions were used  (8, 9, 11, 13, 18, 44-46, 48).  
Even after the formation of the 2007 criteria, the definitions have been variably applied (50, 51, 
53). In view of the importance of a timely diagnosis of MS to allow the early use of disease 
modifying therapies, conforming to the current definitions is highly desirable, so that 
comparisons between disease phenotypes, as well as geographical variation, can be made.  
It is the aim of this study to apply the 2007 consensus criteria for the first time to a cohort of 
Australian Children presenting with a 1st episode of CNS demyelination, and to compare the 
clinical phenotype, biochemical, immunological and neuro-imaging characteristics to those 
found in other countries.  
 Optic Neuritis and risk of Multiple Sclerosis (MS) 
A number of observational and case-control studies have explored the risk of developing MS 
after a first episode of ON with reported rates of between 26% and 68% largely dependent on 
whether MRI brain was included as part of the risk assessment (58-60).  
The risk of MS after optic neuritis was examined in a study by Wiljeto et al (60) who performed 
a retrospective study with follow-up on 36 children in Canada who presented with optic 
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neuritis. The study revealed that 36% of the children presenting with ON developed MS within 2 
years of the initial ON diagnosis(60). All of the children diagnosed with MS had white matter 
lesions on their brain MRI outside of the optic nerves at initial presentation which was found to 
have a strong association with MS outcome (p<0.001). Furthermore the children who developed 
MS were more likely to have had bilateral (58%) compared with unilateral (38%)ON 
(p=0.03)(60).  
However in a study by Alper et al (61) in 2009 no association was found between unilateral or 
bilateral ON and risk of MS.  
Most recently a meta-analysis of 31 studies was published by Waldman et al (62) in 2011 to try 
and resolve these issues. A total of 223 children were included in the study. The findings from 
the study were as follows;  72% of children under 10 years of age presented with bilateral ON 
whereas 70% of children 10 years and older presented with unilateral ON, therefore age was 
associated with the presence of unilateral or bilateral ON. Nevertheless there was no association 
between having unilateral or bilateral ON and developing MS after adjusting for age.  
In the Waldman meta-analysis (n=223) the risk of developing MS after an episode of ON was 
reported to be 19% (23). Having an abnormal MRI in conjunction with ON increased the risk of 
MS (OR = 28.0, p=0.001, 95% CI, 6.3-125.1, adjusted for age)(62). 
It has to be noted however that by drawing on 31 studies from around the world and from 
different latitudes, the combined risk may not entirely reflect the differences in rates found in 
countries known to have a high incidence of MS. For example in the study by Wijelto (60) based 
on Canadian children, the risk of subsequently being diagnosed with MS after an episode of ON 
in conjunction with an abnormal MRI was reported to be 68% within a 2 year period.  
 Transverse Myelitis and risk of Multiple Sclerosis (MS) 
Acute transverse myelitis is a neurological condition of heterogeneous aetiology caused by 
inflammatory demyelination of the spinal cord. The physical manifestations of disease are 
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attributable to an intra-parenchymal or perivascular cellular influx of the spinal cord, resulting 
in a breakdown in the blood-brain barrier and subsequently leading to demyelination (63, 64).  
The diagnostic criteria for acute idiopathic transverse myelitis (TM) in adults was established 
by the consortium Working Group in 2002 and includes sensory, motor, bladder/bowel 
dysfunction which is attributable to the spinal cord (65). The criteria are shown in Table 2-10.  
Table 2-10 Consortium Working group definition of idiopathic transverse myelitis (65) 
Inclusion criteria Exclusion criteria 
Development of sensory, motor, or autonomic 
dysfunction attributable to the spinal cord 
Bilateral signs and/or symptoms (though not 
necessarily symmetric) 
Clearly defined sensory level 
Exclusion of extra-axial compressive aetiology by 
neuroimaging (MRI or myelography; CT of spine not 
adequate) 
Inflammation within the spinal cord demonstrated 
by CSF pleocytosis or elevated IgG index or 
gadolinium enhancement. 
If none of the inflammatory criteria is met at 
symptom onset, repeat MRI and lumbar puncture 
evaluation between 2 and 7 d following symptom 
onset meet criteria 
Progression to nadir between 4 h and 21 d following 
the onset of symptoms (if patient awakens with 
symptoms, symptoms must become more 
pronounced from point of awakening) 
History of previous radiation to the spine within the 
last 10 y 
Clear arterial distribution clinical deficit consistent 
with thrombosis of the anterior spinal artery 
Abnormal flow voids on the surface of the spinal 
cord c/w AVM 
Serologic or clinical evidence of connective tissue 
disease (sarcoidosis, Behcet’s disease, Sjogren’s 
syndrome, SLE, mixed connective tissue disorder, 
etc.)* 
CNS manifestations of syphilis, Lyme disease, HIV, 
HTLV-1, Mycoplasma, other viral infection (e.g. HSV- 
1, HSV-2, VZV, EBV, CMV, HHV-6, enteroviruses)* 
Brain MRI abnormalities suggestive of MS* 
History of clinically apparent optic neuritis* 
*Do not exclude disease-associated acute transverse myelitis. 
The inclusion criteria of the initial recommendations of the working group were modified to 
exclude the need to have evidence of spinal cord inflammation (by gadolinium enhancement on 
MRI spine, pleocytosis or increased IgG index in CSF), as a number of patients with partial TM 
did not meet this criteria (66). Even though these diagnostic criteria are yet to be validated in 
children, the most recent studies in paediatric TM have referred to these criteria (67-71).  
The morbidity and mortality of TM in children is difficult to ascertain with certainty because of 
the rarity of the condition in children, the lack of consistent definitions used, as well as the 
selection bias inherent in cohorts from tertiary referral centres that manage more severely 
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affected patients. However, most case series in children report functional outcomes that are 
concerning with only between 25-50% making a complete recovery (67, 68, 70, 72, 73). Whilst 
most of the studies on transverse myelitis in children were done prior to the establishment of 
the 2002 adult diagnostic criteria for idiopathic transverse myelitis, the outcome is still 
concerning.  
The risk of a future diagnosis of MS from an initial episode of transverse myelitis has been 
investigated in paediatric cohorts and has been shown to vary from between 3% and 43% (70) 
depending on the case series and definition of TM used. The risk of MS after myelitis when 
compared to demyelination in other CNS locations appears to be lower (18, 70). 
At the time of first demyelinating episode, the presence of OCB in the CSF and ‘silent’ 
demyelinating lesions on brain MRI, have been described as evidence of disease chronicity and 
have been found more frequently in TM patients who were later diagnosed with MS (70).  
There have not been many TM paediatric studies that have examined the brain MRI with respect 
to MS MRI criteria. However in a study of 38 children with idiopathic TM by Thomas et al (70), 
five children were found to have MS after a mean follow-up of 4.5 years. Of these five patients, 
four were reported to have MRI brain lesions present during their TM episode however only 
two of these patients met the McDonald 2001 criteria. In the monophasic group (n=33) 14 
patients had MRI brain lesions with five of these patients also fulfilling the McDonald 2001 
criteria. In total 2/ 7 (29%) patients in that met the McDonald criteria for MS had a follow-up 
diagnosis of clinically definite MS (70). 
 Monophasic patients  
When compared to multiple sclerosis, children who experience a monophasic CNS 
demyelinating disorder in the form of Acute disseminated encephalomyelitis (ADEM) were 
generally thought to make a full physical recovery with no ongoing disability (9, 11). However 
studies have reported that in patients with ADEM, complete physical recovery only occurs  in 
approximately 75%, even after sufficient follow up (8, 10, 44, 74, 75). Neurocognitive and 
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behavioural outcome has been investigated in patients with ADEM and it has been found that 
between 10-100% of patients were reported as having deficits in one or more domains on 
neurocognitive testing (8, 76, 77). In view of these and other studies, it was the suggestion of 
one study that all patients diagnosed with ADEM undergo neurocognitive testing and review 
(76).  
Other studies have examined MRI brain lesion load and risk of functional outcome, however 
whilst one study showed a relationship between these two parameters (78), others have not 
(11).  
In children who present with clinically isolated syndrome in the form of monophasic optic 
neuritis as the first CNS demyelinating event, the outcome has been reported to be more 
favourable with visual acuity being normal or near normal in 83-96% of children (60, 79).  
Therefore, it is important to follow-up and assesses all monophasic patients in order to engage 
with necessary therapeutic support.  
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 Neuromyelitis Optica (NMO) – background and literature review 
In the spectrum of CNS demyelinating disorders, there is a rare but distinct disease 
characterized by severe recurrent attacks of myelitis and optic neuritis and it is referred to as 
Neuromyelitis optica (NMO) or Devic’s Disease (80).  
It was thought that NMO was a subset of MS, however it is now recognized as a distinct entity 
with its own set of diagnostic clinical and neuroimaging criteria as well as immunological 
laboratory findings(81).  
The introduction of the NMO IgG as a part of the diagnostic criteria has led to the term NMO 
spectrum disorder being increasingly employed as a diagnosis.  The presence of NMO IgG is 
strongly suggestive of a relapsing course and therefore should motivate the need to treat sooner 
and more intensely with immune suppression (31, 82, 83).  
The majority of adults with NMO suffer a recurrent course (80-90%) whilst only a small 
percentage (10-20%) have a monophasic course (28). Patients are more likely to have a 
recurrent course if there is a long duration between the first two episodes of demyelination, 
they are older, female and the first episode of TM is not associated with a flaccid paralysis (28).  
NMO has the following clinical features;  
Optic neuritis presents with ocular pain with loss of vision, which is often severe and can be 
successive (for example right followed quickly by left ON)(84, 85). Up to 60% of patients with 
recurrent NMO develop blindness in one or both eyes, whereas only 22% of those with a 
monophasic course will develop blindness. 
Myelitis which is usually severe and symmetrical para-paresis or tetra-paresis with a 
symmetrical sensory level and often including sphincter disturbance (28). This is different to 
TM in MS which typically presents with asymmetrical weakness which can be partial or 
complete (28, 86). Lesions which extend up into the medulla can present with intractable 
vomiting, nausea or anorexia (29, 87). 
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The biochemical features of NMO are as follows; 
Cerebrospinal fluid (CSF): from adult studies, 14-79% of patients (85, 88) with NMO have CSF 
pleocytosis. A high protein is also found in 46-75% of patients (28). OCB is relatively uncommon 
in NMO, found in less than 40% of patients (compared to 85% of patients with MS)(28). 
Serum autoantibodies: long before the discovery of the NMO IgG, NMO as a disease was 
considered a distinct ‘autoimmune’ condition. A number of autoantibodies were more 
frequently found in the serum of patients with NMO including anti-nuclear antibodies (ANA) 
found in 50% of patients. Non-organ specific antibodies (e.g. anti-Ro) were found in up to 77% 
of patients with relapsing TM or clinical NMO(80) . NMO patients were also frequently found to 
have other autoimmune conditions including thyroiditis, systemic lupus erythematosus or 
Sjogren’s Syndrome (10-40%) (80). The discovery of the NMO IgG signalled a turning point in 
the diagnosis of NMO, separating it from MS. 
NMO IgG binds to water channel aquaporin 4 (AQP4) which is the most abundant water channel 
in the CNS (89, 90). AQP4 is concentrated at the astrocytic foot processes which are aligned near 
the basement membrane (91).  NMO IgG is found in 78% of children with a relapsing course of 
NMO, but only 12.5% of patients with a monophasic course (31). The relapsing NMO IgG 
positive children are more likely to have progressive disabilities (31). 
The binding of NMO IgG to AQP4 has a characteristic pattern on immunohistochemistry; IgG 
binds selectively to the luminal face of micro vessels, pia, sub-pia and Virchow-Robin sheaths of 
the brain (Figure 2-3), and also the distal collecting tubules of the kidney, where AQP4 is highly 
expressed (80).  
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Figure 2-3 NMO IgG immunohistochemical staining showing the characteristic pattern of staining along the 
astrocytic foot processes aligning the basement membrane (arrow) in the cerebrum (left) and around the 
distal collecting tubules of the kidneys (right). Courtesy of K. Riney Mater Hospital, Queensland Australia 
                  
MRI features in NMO; 
The brain MRI is often normal early in the course of the disease apart from optic nerve 
enhancement in 55-84% of patients (28, 85).  As time passes and relapses occur, new 
asymptomatic brain lesions are increasingly found in up to 84.8% of patients with NMO (28, 
92).  
In the spinal cord, T2 weighted longitudinally extensive (>3 vertebral segments) lesions have 
been found to be frequently associated with transverse myelitis in adult NMO (93). These spinal 
lesions often have cavitation (Figure 2-4) and necrosis, which is unusual for the spinal lesions 
seen in MS.  
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Figure 2-4 MRI spine of a 15 year old male who presented with clinical 
transverse myelitis. The MRI depicts longitudinally extensive transverse myelitis 
(LETM) plus cavitation. His anti-NMO IgG was found to be positive. 
A relapsing course of NMO is seen in 80-90% of patients, which is 
associated with considerable morbidity and mortality (80). The five 
year survival rate in adults has been shown to be less than 70%, with 
50% of the remaining being paraplegic (49) prior to the use of 
effective immunosuppressive treatment.  Prompt and intensive 
immunosuppressive treatment has been shown to decrease the 
chance of relapse and hence permanent disability that ensues (94, 
95), therefore it is essential that the diagnosis be made and 
treatment instituted promptly.   
 Paediatric NMO cohorts 
Published cohorts of paediatric NMO are relatively lacking, and there are few published studies 
investigating the usefulness of testing for NMO IgG in paediatric patients presenting with a first 
episode of CNS demyelination. 
In 2008, Banwell et al (31) published a prospective study with follow-up  involving 87 children 
presenting to two major hospitals (one in Canada, one in Argentina) with acquired 
inflammatory demyelination of the CNS. All patients in the study were enrolled on the basis that 
serum was available for testing for the NMO IgG in a blinded fashion. Five groups were formed; 
NMO according to the pre-NMO IgG criteria of 1999 (85),   ON, TM, ADEM-LETM and Relapsing 
remitting MS (RRMS) according to a number of hallmark papers (7, 59, 65) as shown in Figure 
2-5 below. 
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Figure 2-5 Patient groups in Banwell study of 2008 (31).  
 
First column (left) depicts the five patient groups. The middle column depicts the course of the patients, i.e. 
whether they were monophasic or had a recurrent course. The final column on the right shows the percentage 
of patients in the group that were positive for NMO IgG.NMO – neuromyelitis optica, ON – optic neuritis, TM – 
transverse myelitis, ADEM – acute disseminated encephalomyelitis, LETM – longitudinally extensive 
transverse, RRMS – relapsing remitting multiple sclerosis. 
 
In total 11% (n=10/87) of patients presenting with an acute inflammatory demyelinating 
disorder were positive for NMO IgG. The most significant predictor of being seropositive was 
having a relapsing as opposed to a monophasic course of NMO  (78% vs 12.5%, p=0.007) which 
is similar to results in adult relapsing NMO cohorts in which 86% are seropositive (31, 89).  
Having NMO and being positive for the NMO IgG did not confer a more severe disease course in 
this cohort, although the follow-up time was significantly shorter in the monophasic as opposed 
to the recurrent NMO group (median 1.1 years vs 4.95 years, p=0.016).  
 Another important finding from the study (31) was that none of the patients with monophasic 
ON, TM or ADEM-LETM were positive for NMO IgG.  
NMO 
(n=17)
Monophasic
(n=8) 
1/8 (12.5%) 
Recurrent
(n=9)
7/9 (78%) 
ON (n=13)
Monophasic
(n=8)
0/8 (0%)
Recurrent
(n=5)
1/5 (20%) 
TM (n=13)
Monophasic
(n=12)
0/12 (0%)
Recurrent 
(n=1, LETM)
1/1 (100%)
ADEM with 
LETM(n=3)
Monophasic 
(n=3) 
0/3 (0%)
RRMS 
(n=41)
All patients 
(n=41)
0/41 (0%)
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The study by Banwell also reviewed MRI in NMO (31). The most significant findings in the study 
were that; In the NMO group, brain MRI was abnormal in 53% (both seropositive and negative), 
with brainstem lesions being most commonly found.  
Having longitudinally extensive TM (LETM) (in the context of ADEM or not) on spinal MRI alone 
(found in 15% of RRMS group) is not predictive of a relapsing demyelinating disorder. The one 
patient with LETM who was also seropositive for NMO IgG relapsed. Therefore having NMO IgG 
antibodies and LETM is indicative of a relapsing course however a larger study cohort is needed 
for statistical power. In an adult study 56% of adult patients with LETM and NMO IgG positive 
relapsed (93). 
The prevalence and clinical course of NMO in a German paediatric cohort was investigated by 
Huppke et al in 2010 (82). The cohort of 118 patients was divided into 6 groups; paediatric MS 
(n=94), CIS(n=2), ON (n=11)(no brain lesions), TM/LETM(n=1), ADEM(n=3) and NMO (n=6) 
according to the consensus criteria of 2007 (7). From the cohort of 118 patients, 1.7% (n=2) 
were found to be positive for NMO IgG. Of the 6 patients with clinical NMO, one was positive for 
NMO IgG, this patient had a more severe form of the disease with multiple relapses. The other 
five NMO patients had a monophasic course and were NMO IgG negative. Therefore as the 
author points out, the NMO IgG may be used to prognosticate which of the patients with NMO 
were prone to a relapsing course, and required more intensive immunosuppressive 
therapy(82).  The other patient who was NMO IgG positive had recurrent ON and was the only 
patient with recurrent ON (N=4) who had an abnormal baseline MRI brain. Table 2-11 
summarizes the study findings. 
As was found in the study by Banwell et al (31), LETM which was found in 12% of the RRMS 
patients, was not associated with NMO IgG in paediatrics, as it is in adults. 
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Table 2-11 Summary of findings in CNS demyelinating subtypes from study by Huppke et al (82).  
Characteristic MS(n=94) ON(n=11) NMO(n=6) CIS(n=2) ADEM(n=3) Myelitis(n=1) 
Recurrent 
episodes 
94 (100%) 8(73%) 2(32%)  2(67%) 0% 
Monophasic 
episodes 
0 3(27%) 3(50%)  1(33%) 1(100%) 
MRI Brain 
Lesions 
typical of 
MS 
94(100%) 
10 (91%) no 
lesions 
3(50%) 
nonspecific 
lesions, 
3 (50%) no 
lesions 
100% lesions 
typical for 
MS 
100% lesions No lesions 
MRI Spine 
71(76%) had 
lesions, 
11(12%) 
LETM 
0% 
abnormal 
LETM in 
5(83%) 
- 
Not 
specified 
LETM in 
100% 
CSF OCB +ve 94(100%)  0%    
NMO IgG +ve 0 1 1 0 0 0 
In the MS group, 12% had a spinal MRI which showed LETM but all were found to be NMO IgG negative. In the ON group, 
one patient was found to have an abnormal brain MRI and was also found to be NMO IgG positive. 
A direct comparison of paediatric and adult onset NMO was one of the main features of a study 
by Collongues et al (83).  A cohort of 125 NMO patients were identified as meeting the 2006 
criteria for NMO (96); 12 paediatric and 113 adult patients. When comparing paediatric to adult 
onset NMO in the Collongues et al (83) study the main findings were that; 
- paediatric NMO patients took longer to reach higher disability scores (2EDSS >4) compared 
with adults (15 vs 4.4 yrs.; p=0.04) 
- pediatric NMO patients had a shorter time to severe residual visual loss compared with 
adults (1.3 vs 11.3 yrs; p=0.06). This was thought to be due to a higher lesion load found on 
the MRI brain of children compared to adults with NMO. The association between shorter 
time to severe visual loss and lesion load on MRI was found to be statistically significant 
(p<0.01) in an adult NMO study (98) 
                                                             
 
2 The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple 
sclerosis 97. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability 
status scale (EDSS). Neurology. 1983;33(11):1444-52. Epub 1983/11/01. 
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2.2 Methods: Clinical comparison of patients presenting with their first episode of CNS 
demyelination 
 Patient recruitment 
Patients for the study represent all children presenting to a tertiary children’s hospital, The 
Children’s Hospital at Westmead (CHW), NSW, Australia, with their first episode of CNS 
demyelination between January 1997 and June 2010. Ethics approval was given by the Ethics 
committee of CHW (SSA No: 07/CHW/40). 
The patient cohort was formed by identifying all patients presenting with CNS demyelination 
using the two hospital coding systems that have been used during the 12 year time period 
specified and by searching the databases of the paediatric neurology consultants at CHW.  
The following search terms were used;  Encephalitis, myelitis, encephalomyelitis, 
meningoencephalitis, multiple sclerosis, neuromyelitis optica, acute disseminated 
encephalomyelitis  (including neuromyelitis optica), other demyelinating diseases of the central 
nervous system (includes diffuse sclerosis, central demyelination of the corpus callosum, acute 
transverse myelitis, demyelinating disorders of the CNS unspecified) and optic neuritis. These 
search terms yielded the following hospital codes; GO4 (G04.0, G04.8, G04.9), GO5 (G05.1, 
G05.8), G35, G36 (G36.0, G36.1, G36.8, G36.9), G37 (G37.0, G37.1, G37.3, G37.4, G37.8, G37.9) 
and H46.  
Patient medical records were then individually reviewed and patients were included in the 
cohort if they; presented with a first clinical episode of CNS demyelination with an 
inflammatory or demyelinating cause, associated with MRI neuroimaging changes consistent 
with the diagnosis as defined by the 2007 consensus criteria (7).  
Patients were excluded if their first episode of CNS demyelination was prior to 1997. The 
following conditions were captured by the search terms but were excluded; post-varicella 
cerebellitis, cerebral vasculitis, viral or bacterial encephalitis, Rasmussen encephalitis, systemic 
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or cerebral systemic lupus erythematous, a genetic or autoimmune channelopathy, pre-existing 
oncological disease, histiocytosis, a metabolic encephalopathy,  conversion disorder, 
demyelination secondary to oncological treatment (e.g. TM post spinal irradiation), acute 
myelopathy secondary to compression, dysmyelination from infancy, or if they developed 
demyelination as part of an autoimmune movement disorder.  
The age cut-off for patients recruited for the study was 16 years of age. Children who present to 
CHW who are 16 years and above, and have not been previously treated for a known medical 
condition at the hospital, are referred to the nearest adult hospital for evaluation and treatment.  
Out of a potential cohort of 221 records, 93 patients were identified as meeting the inclusion 
criteria initially. 
 Patient database – retrospective clinical, biochemical, serological data 
Once the 93 patients were identified as meeting the inclusion criteria a database was then 
created representing the clinical and biochemical profile for each patient (Appendix A).   
Basic data including the name, date of birth, date of admission, age at onset for each patient was 
collected as well as detail concerning the clinical presentation including symptoms and signs, 
season of presentation, CSF findings etc. Of note is that the seasonal division for the study is 
based on the southern hemisphere seasonal division of months which are as follows; spring – 
September to November, summer – December to February, autumn – March to May and winter 
– June to August. 
Detailed information was obtained for every patient and the clinical characteristics that were 
collected were defined as follows (Appendix A). 
Preceding infection:  a preceding infection was documented if the infection occurred within 
30 days of the presenting neurological illness. Any illness occurring before this time period was 
documented as a negative response. The cut-off of 30 days was based on timing of the 
inflammatory immune response whereby immunoglobulin class switching occurs after 
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approximately 10-14 days, peaks at 21 days and disappears by 35 days (99). Given the 
assumption that an immune response is responsible for the inflammatory disorders in question, 
we considered this to be a valid cut-off time.  
Encephalopathy:  encephalopathy was defined as either a change in mental status and/or a 
behavioural change (for example marked irritability) as defined in the consensus criteria of 
2007(7). Evidence of encephalopathy was found by searching diligently through the 
documented history. We acknowledge that irritability can be part of any serious illness in a 
child (rather in encephalopathy alone) as has been identified by previous investigators (100), 
however we made every effort to ensure that the observation was made on at least 2 occasions 
separated by more than 24 hours, by more than one of the care-providers of the patient and/or 
by the medical and allied health staff. 
Pyramidal signs: findings of weakness associated with upper motor neuron signs (hyper-
reflexia, increased tone) without sensory disturbance, were assigned positive for pyramidal 
signs. This finding implied injury to the brain or upper motor neurons of the spinal cord. 
Cerebellar signs: the patient was documented as positive for cerebellar signs if they had two 
or more of the following clinical signs; ataxia, nystagmus, truncal instability, intention tremor, 
dysdiadokokinesis/poor coordination or slurred speech. Ataxia had to be due to a disturbance 
in balance as opposed to it being secondary to weakness or a sensory abnormality.  
Brainstem involvement:  the brainstem includes the midbrain, pons and medulla. A 
disturbance of this area of the brain was documented as positive if there were a combination of 
predominately cranial nerve (III-XII) abnormalities. 
Bulbar dysfunction: was separated from purely brainstem dysfunction and was defined as 
paralysis secondary to a disturbance in cranial nerves IX (glossopharyngeal), X (Vagus), XII 
(hypoglossal) or their nuclei, that are found at the level of the medulla (or bulb).  A positive 
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result was recorded if there were difficulties with swallowing and speech that was not due to 
encephalopathy. 
Clinical optic neuritis: in order to be positive for optic neuritis the patient had to have a 
documented progressive visual loss with or without a change in colour vision,  pain with ocular 
movements or headache as is found in the majority of patients with optic neuritis (60, 101). 
Optic disc changes are only present in a third of patients diagnosed with clinical optic neuritis 
and was therefore not required for the diagnosis (101) . Patients with normal discs were 
grouped with the optic neuritis patients and were not subdivided into a retro bulbar optic 
neuritis group.  
Transverse myelitis(TM):  Clinical characteristics that established the patient as having TM 
included; sensory loss or paraesthesia with a sensory level, weakness in one or more limbs that 
was bilateral but not necessarily symmetrical, urinary dysfunction and pain. The diagnosis of 
idiopathic transverse myelitis was supported if there was spinal cord inflammation on spinal 
MRI along with the absence of an alternative inflammatory or infective myelopathy as has been 
established by the Transverse Myelitis Consortium Working Group in 2002 (65).  CSF 
pleocytosis, an elevated CSF IgG index or the presence of T2 imaging changes with gadolinium 
enhancement on spinal MRI were used as indicators of spinal cord inflammation, but not 
essential for diagnosis. 
Bowel and Bladder disturbance: this characteristic was pertaining to both disturbances in 
urinary and bowel function. A positive response was documented if there was urinary retention, 
hesitancy or incontinence. For bowel disturbances, a positive finding was recorded if there was 
medically significant constipation (requiring therapy) or if the patient became incontinent of 
faeces (rare).   
Extrapyramidal signs: The extrapyramidal system pertains to the circuitry of the basal 
ganglia, patients described as having dystonia or involuntary movements of the limbs were 
recorded as positive for this characteristic. 
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Peripheral neuropathy: if a patient described a change of sensation with loss of movement of 
a limb and this was shown to be secondary to a nerve conduction problem on nerve conduction 
studies, then the patient was positive for this characteristic. 
Classification: Based on the first admission, patients were assigned a presenting diagnosis 
according to the 2007 international consensus criteria (7), of either ADEM or CIS as described 
below.  
 Classification of patients 
The classification of patients at the time of their first presentation was based on the following 
definitions. 
 Acute Disseminated Encephalomyelitis (ADEM) (7) 
Patients were diagnosed as having had an episode of acute disseminated encephalomyelitis if 
their presentation was polysymptomatic, they had encephalopathy and the neuroimaging was 
consistent with an inflammatory demyelinating process (7). They must not have had a previous 
episode of demyelination.  The presence of encephalopathy was essential to the diagnosis and 
was represented as either a behavioural change in the form of confusion or excessive irritability, 
or by an alteration in consciousness (e.g. lethargy, coma) as recorded in the patient notes by 
medical and nursing staff on more than one occasion and lasting at least 24 hours. Any new 
clinical features occurring within 3 months of presentation where included as part of the 
primary (1st) presentation of ADEM. 
 Clinically Isolated Syndrome (CIS) (7) 
Patients were diagnosed as having a clinically isolated syndrome if it was their first episode of 
CNS symptoms with a presumed inflammatory demyelinating cause with no previous history of 
a demyelinating event. The presenting symptoms in the group were either monofocal (e.g. Optic 
Neuritis, Transverse Myelitis) or multifocal (multiple sites of CNS affected e.g. ON with 
hemispheric dysfunction) but did not include encephalopathy except in the cases of brainstem 
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CIS. Any new clinical features occurring within 30 days were included as part of the primary 
presentation of CIS. 
When a patient had brainstem signs along with encephalopathy, the neuroimaging was used to 
help determine the sub-classification as either ADEM or CIS. That is, if there were solely lesions 
in the brainstem that would more than likely include the reticular formation, and there were no 
other lesions in the brain, a patient was categorised as having CIS. If there were multiple lesions 
on MRI in multiple sites, then ADEM was the sub-class given.  We acknowledge that this may 
mean a number of patients who essentially have ADEM, may be given the diagnosis of CIS or 
vice versa.  However as the diagnosis of CIS carries with it a greater degree of risk of relapse, we 
thought it a suitable conservative decision. 
All patients included in the study were discussed with Dr Russell Dale who has done a number 
of similar studies in the UK (8, 50). Where the record was not clear or the case was difficult to 
categorize, a second exploratory discussion of the clinical, biochemical and neuroimaging 
findings occurred with Dr Dale to help establish whether the patient should firstly be included 
in the cohort and secondly whether the patient had ADEM or CIS.   
As definitions of ADEM, MS, CIS were inconsistent prior to 2007; each patients file was reviewed 
with a propensity to ignore the documented diagnosis in the notes. The need to include 
encephalopathy as a major criterion for diagnosing ADEM meant that a number of patients had 
to be re-assigned for the study.  
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 Follow-Up Study: Telephone Questionnaire 
Although some patients had ongoing follow-up, in many of them the natural follow-up from 
clinic summaries was short (under 2 years). The purpose of the follow-up study was to 
determine which patients with ADEM/CIS who had presented to CHW between 1997 and 2010 
with a first episode of CNS demyelination fulfilled the criteria for multiple sclerosis.   
In order to determine this rate, it was the aim of the study to make contact with the 93 patients 
who had presented to CHW with a first episode of CNS demyelination to determine if they had 
had any further episodes of demyelination and if they had remained well. 
Using the demographic information from hospital records, a letter including an information 
sheet and a consent form, was sent out to the patient cohort outlining the follow-up study 
(Appendix A and B).  
Every patient that consented was then contacted and a telephone questionnaire was performed 
(Appendix C) to determine if they had remained well since they were last reviewed at CHW or if 
they had had any further demyelinating episodes and subsequently been diagnosed with MS. 
The MS diagnoses were subsequently confirmed with the treating physician. 
Once the follow-up component of the study had been concluded, patients whose follow-up 
duration was under 12 months were also excluded from the study. It was deemed inappropriate 
to confer a Non-MS Diagnosis if follow-up was insufficient to allow for relapse/recurrence of 
demyelinating episodes which is most likely to occur within 12-24 months following the initial 
episode.  
Therefore there was a total of 88 patients included in the analysis with 5 being excluded for 
inadequate follow-up (<12 months).  
 Classification of patients at follow-up 
Based on the follow-up questionnaire in conjunction with information from natural follow-up in 
clinics, patients were then classified as having either; 
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 Multiple Sclerosis (MS):  
MS was diagnosed if a patient had multiple episodes of CNS demyelination with evidence of 
dissemination in space (DIS) and time (DIT) otherwise referred to clinically definite MS 
(CDMS)(38) (37). According to the criteria, magnetic resonance imaging (MRI) of the brain can 
also be used to meet the requirement for dissemination in space and time even without a 
clinical event (7).   
A qualifying factor in children is that, the criteria for ADEM must not be met, namely there 
cannot be encephalopathy during the first event. If a patient’s first CNS demyelinating episode is 
ADEM, then two subsequent non-ADEM events are required for an MS diagnosis using the 2007 
definitions (7).  
 The 2013 consensus criteria (102) were released just prior to our study completion and the 
impact that these criteria had on our study are discussed in chapter 2.2.5.3 that follows. 
 Non-Multiple Sclerosis (non-MS) 
 This group is subdivided into the following subtypes. 
Monophasic: this was used for patients who had no further neurological events and no new 
diagnoses to account for their original presentation. 
Recurrent optic neuritis (ON): Recurrent optic neuritis was given if a patient had a recurrence 
of ON with no new area of clinical demyelination and no new lesions on MRI (initial and 
subsequent scans normal).  
Neuromyelitis Optica (NMO): A patient was diagnosed with Neuromyelitis optica if they had 
optic neuritis and/or acute myelitis as major findings. They also had to have 2 of 3 supportive 
findings; either spinal MRI lesions that extends over three or more segments (called 
longitudinally extensive transverse myelitis – LETM), a brain MRI performed at the onset of 
symptoms not diagnostic of MS or have antibodies to NMO (NMO-IgG) also known as anti-
aquaporin 4 antibodies.   
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It is no longer essential to observe an episode of ON and TM to make the diagnosis of NMO, and 
therefore if a patient has longitudinally extensive TM and a positive NMO IgG, they met the 
criteria for NMO spectrum disorder (NMOSD). 
Other: includes new non-neurological diagnoses.  
For the patients that did not give consent or who were not contactable (insufficient or incorrect 
demographic information), natural follow-up from clinic attendance alone was used.    
As part of the questionnaire, patients were asked if they consented to have their stored serum 
used for the study (see MOG chapter) and if they would be willing to participate in a gene study 
by providing us with a saliva sample from which DNA could be extracted (see HLA 
descriptions).  
 Consensus criteria of 2012 
My study was commenced and the data analysed using the clinical definitions of the 2007 
consensus criteria by Krupp et al (7) however just after the publication of our major findings, 
the international paediatric MS society study group (IPMSSSG) published its updated definitions 
by Krupp et al in 2013 (102). The 2012 definitions can be summarized as follows: 
 Acute disseminated encephalomyelitis (ADEM) 
Similarities: the definition of ADEM as an episode of CNS demyelination that is 
polysymptomatic and associated with encephalopathy has remained. There cannot have been a 
previous episode of CNS demyelination. Any relapse within 3 months of the event is considered 
to be the same event.  
Differences: Multiphasic ADEM has been revised. A patient can have two episodes of CNS 
demyelination greater than 3 months apart consistent with ADEM. However if a patient has 
more than 2 episodes of ADEM is thought to represent a chronic relapsing disorder and 
therefore the diagnosis would be more consistent with either MS or NMO. There can be no new 
lesions found on subsequent MRI brain imaging.  
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 Clinically isolated syndrome (CIS) 
Similarities: an episode is defined as a clinically isolated syndrome if the presentation is mono- 
or multi-focal and there is no associated encephalopathy.  
Differences: A baseline MRI brain scan can be used to diagnose MS from the first demyelinating 
episode. Therefore for a diagnosis of CIS in a patient over 12 years of age, baseline MRI brain 
imaging cannot fulfil McDonald 2010 MRI MS criteria (otherwise the diagnosis is MS, not CIS). 
 Paediatric Multiple Sclerosis (MS)  
MS can be diagnosed if there has been  
1. Two episodes of demyelination without encephalopathy separated by 30 days with evidence 
of dissemination of time and space  
2. One episode of non-ADEM demyelination with MRI brain imaging that fulfils McDonald 
2010 DIS criteria and there has been new lesions on follow-up MRI (DIT) 
3. One episode of ADEM followed by a non-encephalopathic event three or more months after 
the first associated with new MRI lesions fulfilling McDonald 2010 DIS criteria 
4. One episode of non-ADEM demyelination with a brain MRI that fulfils McDonald 2010 MS 
criteria for both DIS and DIT (children over 12 years only).  
Similarities: Points 1 and 2 above are the same as the 2007 definitions.  Having two clinical 
episodes of CNS demyelination involving different areas of the brain (no encephalopathy) fulfils 
both DIS and DIT criteria.  The appearance of a new lesion on progress MRI following one 
episode of CNS demyelination not consistent with ADEM fulfils DIS and DIT criteria for MS.  
Differences: Points 3 and 4 are new to the definitions. MS can now be diagnosed if a patient has 
had ADEM and one further no-ADEM event, then they also fulfil a diagnosis of MS (no longer 
need two non-ADEM episodes).  Secondly MS can be diagnosed after just one CNS demyelinating 
episode based on their clinical presentation (no encephalopathy) and MRI findings (fulfilling 
McDonald 2010 DIS and DIT criteria) if they are older than 12 years of age.  
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 Implications of the 2012 criteria for our study 
There were no patients in our cohort who had ADEM followed by a subsequent episode of 
ADEM therefore the new definitions do not alter our study. Secondly there were no patients 
with one episode of ADEM and then one non-encephalopathic demyelinating episode. The 
diagnosis of clinically definite MS in all our patients was made on the basis of clinical relapse 
(n=13). 
If we were to strictly apply the 2012 criteria, there would be three further patients who would 
fulfil the diagnosis of MS and these patients are discussed in chapter three (radiological 
chapter).  
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 Functional Status at follow-up 
Based on the telephone questionnaire and the-patient clinic notes recorded in outpatient clinics, 
the functional status of the patients at the time of follow-up was determined. As can be seen 
from Appendix D, patients were asked a number of questions referring to their (or their child’s) 
current functional status with regards to motor, visual, learning etc. Where applicable, patients 
were asked follow-on questions in addition to those listed. For example if there was residual 
weakness, they were asked as to their ability to walk unaided. If learning problems were 
present we enquired whether they were present prior to the onset of CNS demyelination. The 
aim of this further questioning was to determine whether reported abnormalities were as a 
consequence of the demyelinating episode or pre-existing and to determine if they were 
significant.  The symptoms reported had to be ongoing for more than 12 months after the 
episode of demyelination to allow for natural recovery after brain injury.  The main categories 
that the functional outcomes were divided into are as follows: 
- Residual problems: if a patient had ongoing dysfunction in any system in general (e.g. 
motor, visual etc.) 
- Motor abnormality: included fine motor, gross motor. We did not differentiate between 
flaccid paralysis and other milder forms of weakness.  
- Visual abnormality: if visual loss was an ongoing concern following the demyelinating 
event. This did not include a refractive error in patients who were already wearing glasses 
prior to the event.  
- Sphincter disturbance: included patients who had ongoing issues with bowel and bladder 
dysfunction. The vast majority of patients who had ongoing issues in this category had to 
self-catheterize.  
- Learning disorder: this category included ongoing concerns with memory and 
concentration following their episode of CNS demyelination. We did not require a formal 
neuropsychological assessment for a positive response in this category.  
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- Psychological abnormality: functional abnormalities in this category included differences 
in the patient’s personality, mood and affect following the event. Although a number of 
patients were being managed by psychologists this was not a requirement for a positive 
response in this category.  
When comparing the functional outcome in our study the most obvious choice would have been 
to use Kurtke’s functional system (FS) and the expanded disability status score (EDSS) which is 
the most widely used scale to score neurological impairments in adults with MS (97). However 
we did not use it for the following reasons. Firstly although the EDSS has been used in paediatric 
studies previously, it is not validated for use in children. Secondly the scale requires a score in 
very distinct examination domains, which are not easily attainable in the examination of 
children where development is the main indicator of neurological maturity, and this is neglected 
in the scale.  Thirdly and most importantly, our study was retrospective in nature apart from the 
addition of a telephone follow-up questionnaire. Therefore although we had reasonable clinical 
information from outpatient clinic documentation for a substantial number of our patients, in 
some cases (patients who were now adults) the review had been many years prior to our study. 
Therefore for a large proportion of our cohort we had to rely on the telephone questionnaire for 
the latest, most up to date physical and psychological findings. This leads to reporting bias and 
likely an underreporting of subtle neurological abnormalities. Furthermore in order to validate 
the EDSS in our cohort, the examination of all patients would have needed to be performed by at 
least two clinicians blinded to the clinical background.  This was beyond the scope of this study 
as it was retrospective in nature  
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 Treatment review 
Intravenous methyl prednisone (IVMP) at a dose of 30mg/kg/day to a maximum of 1g/day 
given for 3 doses is the standard initial treatment at our institution for an episode of CNS 
demyelination. However, patients with mild episodes may be admitted and observed for a 
period of time without treatment and if recovery is detected then no treatment may be given. 
More recently in view of the ongoing morbidity associated with particular subgroups of CNS 
demyelination like acute TM, intravenous immunoglobulin (IVIG) is also commonly given at our 
institute at a dose of 1-2g/kg over 2-5 days.  
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 Statistical analysis 
Statistical analyses were completed using SPSS (version 17.0). Comparisons between ADEM and 
CIS, and then MS and Non-MS were performed using Pearson’s Chi-Square test for nominal 
categorical variables (e.g. sex, fever etc.), and the Mann-Whitney U Test was used for continuous 
variables (e.g. age in months/years). P-values were reported for categorical data and the null 
hypothesis rejection criterion α was set at 0.05. 
We used a survival modal analysis in SPSS (version 17.0) for calculating the Hazard ratio with 
95% confidence interval, the outcome of interest being development of MS. This was done by 
first constructing Cox proportional hazards models for a univariate analysis, where zero time 
was the initial episode of CNS demyelination and the event of interest was multiple sclerosis 
diagnosis as per the consensus criteria of 2007. For the Non-MS Patients, the time between first 
demyelinating episode and time of last follow-up was used.  
The proportional hazards condition which states that covariates are multiplicatively related to 
the hazard was applied. If a covariate was found to be significant or near significant in the 
univariate analysis, then it was applied in the multivariate analysis using a Cox regression.   
The hazards ratio assumes that all patients who have a first episode of CNS demyelination will 
eventually develop MS, and even though this isn’t the case in paediatric demyelination it is the 
method commonly applied to paediatric data to try and predict outcome (55, 103). 
Advice on statistical analysis was taken from biostatistician Elizabeth Barnes, University of 
Sydney, Australia.  
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2.3 Results of clinical study comparison of patients presenting with a first 
demyelinating episode and according to their follow-up diagnosis 
The results of this study have been published in a peer reviewed journal published in 2013. The 
title of the paper is “Risk of multiple sclerosis after a first demyelinating syndrome in an 
Australian Paediatric cohort: clinical, radiological features and application of the McDonald 
2010 MRI criteria” and it is found in ‘Multiple Sclerosis’ ejournal published in April 2013. A copy 
of the paper is found in Appendix E. 
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 First Acute Demyelinating Episode: Clinical and Biochemical findings 
 Formation of Cohort 
Between January 1997 and June 2010, 221 patients were identified through the hospital coding 
system with a possible diagnosis of a CNS inflammatory demyelinating disorder and of these, 88 
were selected for the study as meeting the inclusion criteria. This included elimination of 
patients who had follow-up of less than 12 months.  The mean age of the cohort (n=88) as a 
whole was 8.3 years (median 7.8 years, range 1.3 – 15.4 years). 
Of the 88 patients in the cohort, 36 (41%) were classified as having ADEM and 52 (59%) as 
having CIS according to the 2007 international consensus criteria (7) based on a detailed review 
of their clinical and radiological findings during their first episode of CNS demyelination (Figure 
2-6). 
Figure 2-6 Formation of Patient cohort. Children who met the criteria for ADEM or CIS based on their first 
inflammatory CNS demyelinating episode were included in the study cohort. Patients were then categorized as 
having one of two diagnoses based on their initial presentation; ADEM or CIS. 
 
ADEM – acute disseminated encephalomyelitis, CIS – clinically isolated syndrome 
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assessed 
for eligibility
133 patients 
excluded 93 patients met 
inclusion 
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The year of patient presentation is presented in Figure 2-7 and divided according to first 
episode diagnosis. There are fluctuations in the year of presentation that does not follow a 
particular pattern although the number of presentations looks to be generally increasing which 
may reflect the expanding population in Western Sydney. 
Figure 2-7 Distribution of cohort as a function of year of presentation. Patients with acute disseminated 
encephalomyelitis (ADEM) are represented by the ‘black’ columns and those with Clinically Isolated syndrome 
(CIS) by the ‘grey’ columns. NOTE: the study closed mid-2010 therefore the number of patients for 2010 is 
incomplete. 
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 Clinical characteristics of Acute Disseminated Encephalomyelitis (ADEM) vs 
Clinically Isolated Syndrome (CIS) during first episode of CNS demyelination 
The clinical characteristics of patients presenting with CIS and ADEM at the time of the first 
inflammatory demyelinating event are shown in Table 2-12.  
Table 2-12 Demographics and clinical characteristics of patients according to first demyelinating episode 
diagnosis; Acute disseminated encephalomyelitis (ADEM) or Clinically Isolated Syndrome (CIS).  
CHARACTERISTIC   ADEM (n=36) CIS (n=52) 
p-value (Chi-
square test) 
Sex  Female 14 (38.5%) 29 (55.8%) 0.15 
Age  Mean 6.2 yrs. 9.8 yrs. <0.00 
Range 1.7-14.6yrs 1.3 -15.4yrs - 
Median 5.6 yrs. 11.4 yrs. - 
Season presenting Spring 5 (13.9%) 13 (25.0%) 0.20 
Summer 7 (19.4%) 10 (19.2%) 0.90 
Autumn 8 (22.2%) 11 (21.2%) 0.90 
Winter 16 (44.4%) 18 (34.6%) 0.32 
Preceding infection   33 (91.7%) 22 (42.3%) <0.00 
Fever Present   21 (58.3%) 8 (15.4%) <0.00 
Meningism   9 (25.0%) 4 (7.7%) 0.02 
Encephalopathy   36 (100%) 1 (1.9%) <0.00 
Behavioural change   18 (50.0%) 1 (1.0%) <0.00 
Pyramidal Signs    25 (69.4%) 7 (13.5%) <0.00 
Distribution of weakness Hemiplegia 7 (19.4%) 3 (5.8%) 0.05 
Monoplegia 2 (5.6%) 2 (3.8%) 0.71 
Paraplegia 6 (16.7%) 8 (15.4%) 0.87 
Quadriplegia  11 (30.6%) 5 (9.6%) 0.01 
Transverse Myelitis   3 (8.3%) 17 (32.7%) 0.01 
Sensory disturbance   1 (2.8%) 14 (26.9%) <0.00 
Cerebellar Signs   21 (58.3%) 10 (19.2%) <0.00 
Brainstem Signs   11 (30.6%) 6 (11.5%) 0.03 
Bulbar weakness   7 (19.4%) 2 (3.8%) 0.02 
Optic neuritis   2 (5.6%) 24 (46.2%) <0.00 
Urinary +/or bowel disturbance 9 (25.0%) 12 (23.1%) 0.84 
Seizures   12 (33.3%) 3 (5.8%) <0.00 
Extrapyramidal Signs  6 (16.7%) 0 (0%) <0.00 
Values are number of patients, n and percentage (%) unless otherwise specified.  
There was no significant difference in the sex of patients presenting with either ADEM or CIS, 
even though over 61% of patients presenting with ADEM were male. 
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The distribution of the entire cohort as a function of age in years is depicted in Figure 2-8. There 
is a bimodal peak of age presentation at 3-5 years and then at 12-13 years. These two peaks 
represent the trend for ADEM patients to present at a younger age than CIS patients as is shown 
in Figure 2-9.  
Figure 2-8 Distribution of cohort at time of first CNS demyelinating episode as a function of age in years. There 
is a bimodal peak in age of presentation; the first at age 3-7 years and the second at 13-15 years of age. 
 
The difference in age of presentation between ADEM and CIS is statistically significant; ADEM vs 
CIS (6.2 yrs. vs 9.8 yrs., p= <0.00) as is shown in Table 2-12.  
Forty four percent of patients diagnosed as having ADEM presented in winter (June to August) 
as shown in Figure 2-10, however there is no statistical significant difference for season of 
presentation between the two groups (Table 2-12).  
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Figure 2-9 Box plot showing the age distribution of patients in the ADEM vs CIS groups. ADEM patients were 
younger than the CIS patients (p<0.00).  
 
Figure 2-10 ADEM and CIS patients groups divided according to season of presentation. Even though there was 
no statistical significance between season of presentation and the clinical presentation (i.e. either ADEM or 
CIS), 45% of patients with an ADEM presentation presented in winter. 
 
ADEM – acute disseminated encephalomyelitis, CIS – clinically isolated syndrome 
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The patients with ADEM more commonly presented with a history of a preceding infection as 
well as fever (p-value < 0.00). The preceding infection in the ADEM patients (33/36) was 
described as; fever and vomiting (n=8), fever and sore throat (n=4), Chicken pox (n=4), fever, 
headache, lethargy and a sore neck (n=5), an upper respiratory infection (n=3), glandular fever 
(n=2), hand-foot-mouth disease (n=1), diarrhoea and fever (n=1), pneumonia (n=1), otitis 
media(n=1), a non-specific viral infection (n= 1), a urinary tract infection (n=1) and  fever of 
unknown origin (n=1).  
All of the ADEM patients had encephalopathy and/or a behavioural change compared with only 
one of the CIS patients who had presented with a brainstem CIS , as would be expected given the 
consensus criteria (7).  
The next two most common clinical findings in the patients presenting with ADEM were 
pyramidal tract signs (25/36, 69.4%) as well as cerebellar signs (21/36, 58.3%) and this is 
statistically different from the CIS patients who most commonly presented with optic neuritis 
(24/52, 46.2%) followed by transverse myelitis (17/52, 32.7%), as would be expected.  
There were significant differences in the distribution of weakness between the two groups; 
ADEM patients were more likely to have either hemiplegia (p=0.05) or quadriplegia (p=0.01) 
compared with those with CIS. There was no difference in the number of patients presenting 
with either a monoplegia or paraplegia. There were 13 CIS patients who had sensory deficits 
and this was high compared to only two patients who had sensory deficits in the ADEM group 
(p-value <0.00), although this could be due to under-reporting of sensory dysfunction in ADEM. 
There was a higher number of patients with bulbar and brainstem signs in the ADEM cohort in 
comparison to those with CIS however the number of patients with positive findings for both 
these signs was under 10 in both the CIS and ADEM group making the statistical significance 
less reliable.  
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The presence of seizures during the first demyelinating episode was significantly increased in 
the ADEM compared to the CIS group (12/36 vs 3/52, p<0.00). 
ADEM patients significantly more often presented with extrapyramidal signs most often 
manifested as dystonic movements, but this symptom/sign was not seen in the CIS group (6/36 
vs 0/52, p<0.00). 
Peripheral neuropathy was uncommon in both groups with only one ADEM patient having mild 
multifocal axonal sensorimotor polyneuropathy on nerve conduction study (NCS) testing during 
his presentation. However nerve conduction studies were only performed in three patients so 
this may be an underestimate of peripheral nerve involvement in the cohort.  
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 CSF comparison: ADEM vs CIS 
Cerebrospinal fluid analysis (CSF) was performed on 63 patients (32 with ADEM and 31 with 
CIS). Patients with optic neuritis had CSF analysis performed less often and most of these 
patients are in the CIS group.  
The most significant findings were that the patients presenting with ADEM had CSF containing 
higher numbers of inflammatory cells (polymorphs and monocytes) compared with CIS patients 
as shown in Table 2-13.  
Table 2-13 Cerebrospinal fluid findings divided according to first episode diagnosis: Acute disseminated 
encephalomyelitis (ADEM) and clinically isolated syndrome (CIS).  
CSF characteristic mean  
1st Episode Diagnosis 
p-value 
ADEM  CIS 
CSF cell count and biochemistry mean (SD) (n=32) (n=31)  
Polymorphs 9 (17) 1 (3) 0.02 
Mononucleocytes 22 (30) 9 (14) 0.03 
*Protein (corrected) 0.38 (0.28) 0.33 (0.15) 0.14 
Glucose 3.3 (0.9) 3.9 (1.5) 0.06 
Oligoclonal band analysis (OCB) (n=15) (n=25)  
Intrathecal OCB 0 2 - 
Mirrored OCB 4 6 - 
Negative OCB 11 17 - 
*Protein level is corrected for the number of red blood cells found in the CSF due to a traumatic tap.  
For the cell count and biochemistry, the mean count for each value is shown along with the standard deviation 
(SD). For the OCB analysis the number of patients (n) is shown only. The total number of patients that had CSF 
oligoclonal band (OCB) analysis was 40.   
 
Analysis of the cerebrospinal fluid for the presence of OCB was performed on 40/88 (45%) 
patients in the cohort. The presence of ‘intrathecal’ OCB is a significant indicator of CNS 
autoimmunity and inflammation. The presence of ‘mirrored’ OCB was designated when OCB 
were present in both blood and CSF and this is less predictive of multiple sclerosis.  
There were 15 (42%) patients who presented with ADEM tested for OCB. No ADEM patient had 
confirmed intrathecal OCB (Table 2-13). There were 25/52 (48%) CIS patients tested for OCB. 
There were two patients who had intrathecal OCB and one of these patients was diagnosed with 
MS at follow-up (Table 2-13).  
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 Results of Follow-up Study: MS vs Non-MS 
 Patient cohort based on follow-up diagnosis 
Of the 88 patients that were mailed information for the follow-up component of the study, the 
total number of patients that consented and took part in the follow-up telephone questionnaire 
was 74/88 (84%). For the remaining 14/88 (16%) patients, we relied on documentation from 
natural follow-up in the hospital specialist clinics.   
The breakdown of the patient cohort at follow-up is depicted in Figure 2-11. After a mean 
follow-up time for the entire cohort of 5 years 2 month (median 4.7 years, range 1.0 - 13.9 
years) there were 13 patients diagnosed with clinically definite MS (CDMS) and 75 with non-MS 
(Figure 2-11). 
There were no patients who had an initial episode of ADEM followed by a non-ADEM relapse 
who would fulfil MS criteria using the new 2013 paediatric MS criteria(102).  
Figure 2-11 Breakdown of patient cohort based on diagnosis at follow-up.  
 
* All 13 patients have been diagnosed with Multiple Sclerosis (MS) on the basis of clinical relapse with 
supportive MRI findings and are therefore clinically definite MS (CDMS). NMOSD – Neuromyelitis spectrum 
disorder. ON – optic neuritis.  
Patient cohort (n=88)
*CDMS (n=13) Non-MS (n=75)
Monophasic (n=70)
Recurrent ON 
(n=4)
NMOSD (n=1)
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If we were to base a diagnosis of MS on dissemination in time (DIT) demonstrable on MRI 
according to the McDonald 2010 as is standard in adult neurology, then there would be an 
additional three patients who would meet criteria in our cohort. One of these patients has 
neuromyelitis optica and the other two patients are discussed in the MRI chapters 3.3.5.2 and 
3.3.5.3.  Although these two patients had DIT using follow-up MRI, their current clinicians did 
not feel these patients have MS as they are atypical. These patients are discussed in more detail 
in the MRI results (Chapter 3).  
 Clinical characteristics of 1st episode of demyelination based on follow-up 
diagnosis: MS compared to Non-MS  
The clinical characteristics of the patients based on their findings at their first episode of CNS 
demyelination, but divided according to their follow-up diagnosis are shown in Table 2-14.  
Even though the mean age of first demyelinating episode was lower in the Non-MS patients 
compared to the MS patients, this difference was not statistically significant in our cohort. 
As can be seen from Table 2-14, the seasonal variation at presentation was not significantly 
different between the two groups.  
The age of first demyelinating event was not significantly different in the MS group compared to 
the non-MS group although as shown in Figure 2-12 the patients with MS were trending 
towards being older. 
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Table 2-14 Clinical characteristics of cohort divided according to diagnosis at follow-up; Non-Multiple Sclerosis 
and Multiple Sclerosis (MS).  
Values are number of patients, n and percentage (%) unless otherwise specified.  
The significant differences between those with a follow-up diagnosis of MS and Non-MS were as 
follows; MS patients were significantly less likely to have had a preceding infection (31% vs 
69%, p=0.01) and a behavioural change (0% vs 26.3%, p=0.04) but they were significantly more 
likely to present with cerebellar signs (62% vs 29%, p=0.02) compared to those with a 
monophasic (non-MS) course. However the number of patients with these findings is less than 
10 and therefore the statistical significance is less reliable. As would be expected the features 
typical of ADEM namely behavioural change, preceding infection, were more commonly found in 
the Non-MS patients, although this was not always statistically significant.  
CHARACTERISTIC  
Non-MS 
(n=75) 
MS 
(n=13) 
P-value 
Sex  Female 37 (49.3%) 6 (46.2%) 0.86 
Age onset (years) 
  
Mean 8.1 yrs. 10.4 yrs. 0.41 
Range 1.3-15.4 2.5-14.9 - 
Median  7.3 12.1 - 
Season presenting Spring 15 (18.8%) 4 (30.8%) 0.32 
Summer 15 (20.0%) 2 (15.4%) 0.7 
Autumn 16 (21.3%) 3 (23.1%) 0.89 
Winter 30 (40.0%) 4 (30.8%) 0.53 
Preceding infection  51 (68.0%) 4 (30.8%) 0.01 
Fever Present  26 (34.7%) 3 (23.1%) 0.41 
Meningism  13 (17.3%) 0 (0%) 0.1 
Behavioural change  19 (25.3%) 0 (0%) 0.04 
Pyramidal Signs present 29 (38.7%) 3 (23.1%) 0.28 
Distribution of weakness Hemiplegia 9 (12.0%) 1 (7.7%) 0.62 
Monoplegia 3 (4.0%) 1 (7.7%) 0.52 
Paraplegia 13 (17.3%) 1 (7.7%) 0.33 
Quadriplegia  15 (20.0%) 1 (7.7%) 0.32 
Transverse Myelitis  17 (22.7%) 3 (15.0%) 0.97 
Sensory disturbance  12 (80.0%) 3 (20.0%) 0.53 
Cerebellar Signs  23 (30.7%) 8 (61.5%) 0.03 
Brainstem Signs  14 (18.7%) 3 (23.1%) 0.7 
Bulbar weakness  8 (10.7%) 1 (7.7%) 0.74 
Optic neuritis  22 (29.3%) 4 (30.8%) 0.92 
Urinary +/or bowel disturbance 20 (26.7%) 1 (7.7%) 0.14 
Seizures  14 (18.7%) 1 (7.7%) 0.33 
Extrapyramidal Signs  6 (8.0%) 0 (0%) 0.29 
Peripheral Neuropathy 1 (1.3%) 0 (0%) 0.68 
First episode diagnosis CIS 42 (56%) 10 (77%) 0.16 
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Figure 2-12 Age comparison of patients divided according to follow-up diagnosis; Multiple sclerosis (MS) group 
compared to Non-MS group.  
 
There is a bimodal peak in the age distribution in the Non-MS group (grey) although there is a slightly higher 
proportion of children under 10 years of age compared to over 10 years. In the MS group (black) there is also a 
bimodal peak however the majority of children (9/13) are in the over 10 year’s peak. 
There were no other significant clinical findings between the two groups (MS vs Non-MS), which 
is most likely due to the small numbers, especially in the MS group.  
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 Univariate analysis of clinical characteristics 
The results of the univariate analysis using Cox regression are shown in Table 2-15 below. 
When time course is taken into consideration, two characteristics were found to be significant.  
Having a preceding infection was found to be protective of developing MS with a HR 0.22 (0.07-
0.73), p-value 0.02. A number of further features appeared to be protective of MS but were not 
statistically significant including presenting with encephalopathy, behavioural changes, urinary 
and/or bladder disturbance and extrapyramidal signs (Table 2-15). 
Having cerebellar dysfunction was predictive of MS with a hazard ratio of 4.52(CI 1.42-14.45), 
p-value 0.01. A number of other features were predictive of MS but were not statistically 
significant included presenting with sensory changes and optic neuritis.  
Table 2-15 Univariate analyses of clinical characteristics at presentation that were associated with a diagnosis 
of MS vs Non-MS.  
CHARACTERISTIC  Univariate analyses p-value 
Sex Female 1.01 (0.324-3.15) 0.98 
Season Presenting Spring 0.19 (0.12-1.52) 0.19 
 Summer 2.58 (0.54-12.3) 0.24 
 Autumn 0.89 (0.19-4.09) 0.88 
 Winter 0.88 (0.26-2.95) 0.83 
Preceding infection  0.22 (0.07-0.73) 0.02* 
Fever Present  0.47 (0.12-1.87) 0.29 
Meningism  0.41 (0.0-36.23) 0.35 
Encephalopathy  0.33 (0.09-1.26) 0.11 
Pyramidal Signs present  0.44 (0.12-1.63) 0.22 
Transverse Myelitis  0.94 (0.44-2.03) 0.88 
Sensory disturbance  1.63 (0.45-5.91) 0.46 
Cerebellar Signs  4.52 (1.42-14.45) 0.01* 
Brainstem Signs  0.98 (0.26-3.64) 0.97 
Bulbar Weakness  1.52 (0.19-12.36) 0.71 
Optic Neuritis  1.42 (0.42-4.81) 0.58 
Urinary +/or faecal disturbance 0.30 (0.04-2.35) 0.25 
Seizures  0.65 (0.14-3.00) 0.58 
Extrapyramidal Signs  0.04 (0.0-115.03) 0.43 
Peripheral Neuropathy  n/a - 
1st episode diagnosis CIS 2.87 (0.75-11.04) 0.13 
*Statistically significant findings that were applied to the multivariate analysis with significant radiological characteristics. 
Values are number, n and percentage (%). CIS – clinically isolated. A value higher than 1 suggests increased risk and less 
than 1 suggests reduced risk. 
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The two significant clinical findings (marked with * in the table) were used in the multivariate 
analysis as described in the MRI chapter.  
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 CSF comparison: MS vs Non MS 
Cerebrospinal fluid analysis was tested on 8/13 (62%) patients with MS and 55/75 (73%) with 
Non-MS and is shown in Table 2-16. There were no significant differences in the mean cell 
counts or biochemical composition of the CSF between the two groups.  
Table 2-16 Cerebrospinal fluid (CSF) findings divided according to follow-up diagnosis: Non-Multiple Sclerosis 
(Non-MS) and Multiple Sclerosis (MS). 
CSF characteristic  
Follow-up Diagnosis  
Non-MS  MS p-value 
CSF count and biochemistry, mean (SD) (n=55) (n=8)  
Polymorphs 6 (14) 9 (22) 0.59 
Mononucleocytes 24 (46) 4 (3) 0.24 
*Protein (corrected) 0.4 (0.4) 0.36 (0.1) 0.77 
Glucose 3.7 (1.3) 3.6 (0.8) 0.75 
Oligoclonal band analysis (OCB) (n=36) (n=4)  
Intrathecal OCB 1 1 - 
Mirrored OCB 11 0 - 
Negative OCB 27 3 - 
*Protein level is corrected for the number of red blood cells found in the CSF due to a traumatic tap. OCB values are 
number of patients, n.  
In total 40/88 (45%) patients in the cohort had CSF analysis for the presence or absence of 
Oligoclonal bands (Table 2-16).There was one patient with MS who was positive for intrathecal 
OCB, the remaining three that were tested were negative. 
In the non-MS group, one (2%) patient was found to have intrathecal OCB. This patient 
presented with bilateral ON at 13 years of age as her first CNS demyelinating episode. Her initial 
MRI did have 3 lesions outside the visual pathway however she did not fulfil any of the 
established or proposed MRI MS criteria (49, 54, 103-105). She was followed up for 15 months 
in the hospital clinic and had had no further demyelinating episodes. She was however lost to 
follow-up after this time. There were 11 (31%) patients who had mirrored OCB and 27(75%) 
patients were OCB negative.   
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 Treatment  
The number of patients initially treated with IVMP was 68/88 (77.2%). This did not differ 
between patients with a follow-up diagnosis of MS (76.9%) and those with non-MS (77.3%) 
(p=0.56).  
Intravenous immunoglobulin (IVIG) was given at 1-2g/kg over 2-5 days in 14/88 (15.9%) 
patients. Ten of the patients treated with IVIG had severe TM with flaccid paralysis often 
requiring intensive care unit (ICU) admission. Three of the remaining patients given IVIG had an 
initial presentation of ADEM requiring ICU admission for decreased level of consciousness with 
significant weakness. The IVIG was given concurrently with the IVMP. The last patient was a 
patient who presented with unilateral ON initially and was treated with IVMP. The patient then 
re-presented in 5 weeks with worsening vision and was subsequently treated with IVIG.  
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  Multiple Sclerosis Group 
The number of patients that were diagnosed with clinically definite MS (CDMS) after a mean 
follow-up of 5 years 2 months (median 4.7 years, range 1.0 – 12.4 years) was 13/88 (14.8%). 
These patients are represented in Table 2-17 which summarises the clinical presentation of 
each patient diagnosed with MS at follow-up.  
Six patients were female (46.2%) thus there was no difference in the sex of the patients with a 
follow-up diagnosis of MS. There was also no difference in the sex distribution of patients with 
post-pubertal disease onset with four patients over the age of 11 years at first demyelinating 
episode being female and four male. The mean age of first presentation was 10.4 years of age 
(2.5 – 14.9 years).  
All patients with MS had an abnormal MRI at baseline that fulfilled one or more of the currently-
established-adult or proposed-paediatric MS MRI criteria including all four patients who 
initially presented with Optic Neuritis (discussed later).  
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Table 2-17 Characteristics of the patients that had a follow-up diagnosis of Multiple Sclerosis from youngest to 
oldest.   
Initials MD KB CR SW JF BL MG MH MB AS KM MP MZ 
Age, Sex 
3 yrs., 
female 
4 yrs., 
male 
5 yrs., 
female 
6 yrs., 
male 
11 yrs., 
female 
11 yrs., 
male 
12 yrs., 
female 
12 y,  
male 
13 yrs., 
male 
14 yrs., 
female 
14 yrs., 
female 
15 yrs., 
male 
15 yrs., 
male 
Ist Episode              
Encephalo
pathy 
- - yes yes - yes - - - - - - - 
Pyramidal 
signs 
yes - - yes yes yes - - - - - - - 
Cerebellar 
Signs 
yes yes yes yes - yes - - yes - yes - yes 
Brainstem 
Signs 
yes - - - - yes - - - - yes - - 
Visual 
Symptoms 
- - - - ULON - ULON ULON - - - ULON - 
Transverse 
Myelitis 
- - - - - - - - yes yes - - yes 
Seizures - - - yes - - - - - - - - - 
Sensory 
Changes 
- - yes - - - yes - yes yes - - yes 
Initial MRI 
Fulfils MS 
diagnosis 
as per 
McDonald 
(2001, 
2010), 
KIDMUS, 
Callen &/or 
Verhey 
criteria 
McD 
2001/ 
2010, 
Callen, 
Verhey 
McD 
2010 
McD 
2010, 
Verhey 
McD 
2001/ 
2010, 
Callen, 
Verhey 
McD 
2001/ 
2010, 
Callen, 
Verhey 
McD 
2001/ 
2010, 
Callen, 
Verhey 
McDon
ald 
2010 
McD 
2001/ 
2010, 
KIDMU
S 
Callen, 
Verhey 
McD 
2001/2
010 
McD 
2001/ 
2010, 
Callen, 
Verhey 
McD 
2001/ 
2010, 
Callen 
Callen, 
Verhey 
McD 
2001/ 
2010, 
Callen, 
Verhey 
1st Episode 
Classificati
on 
BStem 
-  CIS 
Cereb - 
CIS 
ADEM ADEM 
ON - 
CIS 
ADEM 
ON - 
CIS 
ON - 
CIS 
TM - 
CIS 
TM - 
CIS 
Cereb - 
CIS 
ON - 
CIS 
TM - 
CIS 
Subsequen
t Episodes 
2nd 
INO, 
3rd LL 
weak 
2nd 
cereb 
ataxia, 
3rd 
ULON, 
4th 
ULON 
2nd 
ON, 
3rd 
BStem 
CIS, 
4th ON 
2nd 
ON, 
3rd ON 
2nd 
ULON, 
3rd 
paraes 
2nd LL 
weak, 
3rd 
ophtha 
2nd 
ON, 
3rd 
paraes 
2nd 
BStem 
CIS, 
3rd ON 
2nd 
ON 
2nd 
cereb 
ataxia, 
3rd ON 
2nd 
ON, 
3rd 
INO 
2nd 
left 
sided 
weak 
2nd 
paraes, 
3rd ON 
Progress 
MRI 
New 
Lesions 
New 
Lesions 
N/A 
New 
Lesions 
N/A 
New 
Lesions 
New 
Lesions 
New 
Lesions 
New 
Lesions 
New 
Lesions 
New 
Lesions 
N/A N/A 
Time from 
1st episode 
to MS 
diagnosis 
1.3 
years 
5.5 
years 
4.5 
years 
1.6 
years 
3.3 
years 
1.0 
year 
1.0 
year 
0.6 
years 
1.0 
year 
0.3 
years 
0.3 
years 
8.0 
years 
0.4 
years 
Disease 
Modifying 
Therapy 
β-Int 
alt. 
therap
y 
N/S β-Int none β-Int β-Int β-Int N/S MMF Fingo. Glat. N/S 
Length of 
follow-up 
4.8 
years 
6.8 
years 
4.7 
years 
12.4 
years 
8.6 
years 
3.1 
years 
2.6 
years 
5.1 
years 
5.0 
years 
1.5 
years 
2.2 
years 
10.6 
years 
0.4 
years 
Functional 
status at 
last follow-
up 
No 
impair, 
dx with 
T1DM 
No 
impair 
Not 
known 
No 
impair 
No 
impair 
No 
impair 
Mig, 
Pain in 
LL 
Colour 
vision 
impair, 
poor 
memor
y & 
learnin
g 
No 
impair 
No 
impair 
No 
impair 
Limp, 
LL 
weak., 
dx with 
T1DM 
No 
impair 
McD – McDonald, ULON – unilateral Optic Neuritis, ON – optic neuritis, BStem – brainstem, cereb – cerebellar, CIS – 
clinically isolated syndrome, ADEM – acute disseminated encephalomyelitis, N/A – not available, DMT disease modifying 
therapy, weak – weakness, opthal – ophthalmoplegia, paraes – paraesthesia, MS – multiple Sclerosis, LL – lower limbs, N/S 
– not specified, alt. therapy – alternative therapy, β-Int – beta interferon, MMF – mycophenolate, Glat -Glatiramer acetate, 
Fingo. – Fingolimod, impair – impairments, dx – diagnosed, Mig – migraine, T1DM – Type 1 diabetes mellitus. 
There were 12/13 that fulfilled the McDonald 2010 DIS criteria, nine (9/13) patients who 
fulfilled the McDonald 2005 DIS and Callen criteria, eight (8/13) that fulfilled the Verhey MRI 
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criteria, seven (7/13) (54%) that fulfilled the McDonald 2010 DIT and DIS criteria, and one 
(1/13) patient whose MRI fulfilled the KIDMUS criteria for MS (discussed further later). 
At follow-up there were two patients who had physical disabilities secondary to MS progression 
(MH and MP). Both of these patients were male and young adults at follow-up.  
Five (5/13) patients were on standard therapy with β-interferon. One patient was on 
Fingolomid and one on Natalizumab. There was one patient (KB) on ‘alternative therapies’ out 
of patient choice. There was one patient (JF) who had had two clinical relapses but had not thus 
far seen a neurologist as an adult and continues without therapy. One patient (AS) has been on 
Mycophenolate and remains relapse free on this treatment after suffering three relapses within 
a 4 month period. This patient is discussed in the MOG chapter.   
The mean time from initial demyelinating episode until MS diagnosis was 2.2 years (median 1.0 
years, range 0.3 to 8.0 years). The cumulative percentage of patients fulfilling MS criteria as a 
function of time is shown in Figure 2-13. Over 70% of MS patients had their second MS defining 
event within 2 years of their initial CNS demyelinating event.  
Figure 2-13 Graph representing the cumulative percentage of patients diagnosed with Multiple Sclerosis as a 
function of time. 
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In all there were 3/13 patients with MS who had ADEM as their first demyelinating event, the 
remaining 10/13 had CIS, but this was not statistically significant. As shown in Figure 2-14, 8% 
of patients initially diagnosed with ADEM had a follow-up diagnosis of MS and 19% of those 
with CIS had a follow-up diagnosis of MS.  
The number of relapses reported in the 13 patients with a follow-up diagnosis of MS was 37 
with the mean number of relapses in each patient being 2.9 (median 2.0, range 1-10). The mean 
annualised relapse rate was 1.04.  
Figure 2-14 Percentage of patients with a follow-up diagnosis of MS; comparison of entire cohort with patients 
initially diagnosed with ADEM and CIS. Three patients (8%) whose initial diagnosis was ADEM were later 
diagnosed with MS. Ten patients (19%) whose initial diagnosis was CIS were later diagnosed with MS. 
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 Multiple Sclerosis (MS) after a first episode of Acute disseminated 
encephalomyelitis (ADEM)  
There were 3/36 (8%) patients in the ADEM group who had a follow-up diagnosis of MS after a 
mean follow-up (n=36) of 4.7 years (median 4.3 years, range 1.0– 13.9 years). 
The characteristics of these three patients are as follows; two were male, one female, their mean 
age was 7.0 years (range 4.8-10.8 years). Clinically these patients all had a preceding infection 
and encephalopathy. In addition, all three presented with cerebellar signs, two had pyramidal 
signs, one had seizures and one had brainstem involvement.  
 Multiple Sclerosis (MS) after a first episode of clinically isolated syndrome (CIS)  
There were 10/52 (19%) patients in the CIS group (n=52) who had a follow-up diagnosis of MS 
after a mean follow-up of 5.8 years (median 5.1 years, Range 1.0– 13.7 years). The 
characteristics of these 10 patients are as follows; the mean age was 11.4 years (range 2.5 to 
14.9 years), five were male and five were female. Five presented with cerebellar signs, 4/10 
with optic neuritis, 3/10 with transverse myelitis, 3/10 with paraesthesia, and one (1/10) with 
a brainstem CIS (including bilateral internuclear ophthalmoplegia).   
The percentage of CIS patients with a follow-up diagnosis of MS separated according to CIS 
clinical phenotype is presented in Figure 2-15. 
Even though a high percentage of patients with Brainstem CIS and Cerebellar CIS met the 
criteria for MS at follow-up, the number of patients with these presentations is small compared 
to the number that presented with ON and TM (Figure 2-15). 
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Figure 2-15 Division of CIS group according to clinical phenotype and comparison to entire cohort. The five 
columns to the right are the CIS subgroups. The black shaded area in each column represents the percentage 
of patients in the subgroup that had a follow-up diagnosis of MS. CIS – clinically isolated syndrome, ON – optic 
neuritis CIS, TM – transverse myelitis. 
 
2.3.2.6.2.1 Clinically isolated Syndrome (CIS) presenting as Optic Neuritis (ON) and the 
risk of Multiple Sclerosis (MS) 
In our CIS cohort, 24/52 (46%) patients had ON as their presenting phenotype in their first CNS 
demyelinating episode. Of these 24 patients, four (17%) had a diagnosis of MS after a mean 
follow-up time of 6.9 years (range 1.3 to 11.9 years).  
The characteristics of these four patients with MS are as follows: two were male and two female. 
The mean age at first event was 12.6 years (range 11.4-14.6 years). All four had unilateral as 
opposed to bilateral ON and this was significant (p=0.01) although the cohort size is under 10.  
When the entire ON cohort was divided according to age into <10 years and ≥10years, there was 
no statistical difference in whether a patient had unilateral or bilateral optic neuritis and MS 
(p=0.06) although it did near significance.  
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2.3.2.6.2.2 Clinically isolated syndrome (CIS) presenting as Transverse Myelitis (TM) and 
the risk of Multiple Sclerosis (MS) 
In our CIS cohort there were 17/52 (33%) who presented with transverse myelitis. At follow-up 
3/17 (18%) TM patients had a diagnosis of MS after a mean follow-up of 4.7 years (1.0 to 12.2 
years). Their mean age at first event was 14.0 years (range 12.9- 14.9 years).  The 
characteristics of these three patients are as follows; two were male and one female. The two 
male patients had partial TM with paraesthesia as their major presenting symptom in addition 
to asymmetrical weakness in the upper limbs. The one female patient , AS presented with flaccid 
bilateral lower limb pain and paralysis and is described in detail later (MOG chapter) as she was 
atypical; her inflammatory markers were elevated and she was anti-MOG antibody positive.  
 Functional Outcome of MS group 
In the 13 patients diagnosed with MS, residual problems were present in 31% after a mean 
follow-up of 5.1 years (0.3-12.4 years). The breakdown by functional subclass is shown in 
Figure 2-16.  
Figure 2-16 Functional outcome of MS patients at follow-up (mean 5.1 years). The ‘black column’ shows the 
total percentage of MS patients that had any residual abnormalities at follow-up. The ‘grey’ columns show the 
breakdown of residual problems into functional subgroups   
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 Non-Multiple Sclerosis (MS) Group 
 Monophasic Patients 
In the Non-MS group (n=75), 70/75 (93.3%) of patients had a monophasic course. The mean 
age of the non-MS group was 8.1 years (median 7.3 years, range 1.3 to 15.4 years). There were 
33/36 ADEM patients and 37/52 CIS patients who had a monophasic course. The mean follow-
up time for this group was 5.2 years (median 4.7 years, range 1.0 to 13.9 years). There were 37 
(49%) females and 38 (51%) males. The clinical profile of each of these patients is shown in 
Table 2-18.  
The initial MRI brain was normal (no lesions) in 16/72 (21%) of patients who had a scan 
available for review. There were 43/75 (57%) of the monophasic patients who fulfilled one or 
more of the MRI MS criteria however this will be discussed further in the MRI chapter.  
Table 2-18 Clinical summary of monophasic patients (n=75). The patients are sorted according to their initial 
demyelinating episode presentation (ADEM, CIS) and then presented with ascending age. *There was one 
patient with ADEM who was in status on arrival to the hospital and as such was intubated and went to ICU.  
Initial 
Sex, Age 
at Onset 
(years) 
season 
inf'n 
&/or 
feve
r 
First Episode Clinical 
intern 
class 
MRI MS criteria 
Follow-
up time 
(years) 
CW f, 1.7 winter yes Enceph, Hemipl, Seizures, Extrapyr ADEM - 13.9 
IM f, 1.8 winter yes Enceph, Monopl, Brainstem, Bulbar ADEM McDonald 2005, 2010, 6.9 
KN f, 1.8 winter yes 
Enceph, Hemipl, Cerebellar, Brainstem, 
Sphincter 
ADEM McDonald 2005, 2010 5.0 
DM m, 2 winter yes 
Enceph, Quadpl, Cerebellar, Brainstem, 
Extrpyr 
ADEM 
McDonald 2010, Callen, 
Verhey 
6.7 
MS m, 2.3 summer yes 
Mening, Enceph, Quadpl, Cerebellar, 
Bulbar, Seizures, Extrapyr 
ADEM McDonald 2005, 2010 7.5 
EL m, 2.8 autumn yes Enceph, Parapl, Cerebellar, Sphincter ADEM McDonald 2005, 2010, 2.3 
KM m, 2.9 autumn yes Mening, Enceph, Quadpl, Cerebellar ADEM McDonald 2005, 2010, 9.4 
RD m, 3.1 summer yes Enceph, Parapl, Cerebellar ADEM McDonald 2010 2.3 
NM m, 3.3 winter yes Enceph, Quadpl, Cerebellar, Extrapyr ADEM - 6.1 
AP f, 3.8 autumn yes Mening, Enceph, Brainstem, ADEM McDonald 2010 9.9 
AH m, 4.2 summer yes Enceph, Quadpl, Cerebellar, Seizures ADEM - 4.3 
BB m, 4.3 winter yes Enceph, Quadpl, Cerebellar, Seizures ADEM McDonald 2005, 2010 5.1 
AT m, 4.3 spring yes Encph, Quadpl ADEM - 3.3 
HB m, 4.8 winter yes Enceph, Quadpl ADEM - 2.9 
JA m,, 5.3 winter yes Enceph, Cerbellar, Seizures ADEM McDonald 2005, 2010 1.0 
BE m, 5.4 winter yes Enceph, Parapl, Brainstem, Bulbar ADEM McDonald 2010 2.0 
TiP f, 5.6 winter yes Enceph, Quadpl, Cerebellar ADEM McDonald 2005, 2010 4.9 
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SG f, 5.7 summer yes Enceph, BLON ADEM 
McDonald 2005, 2010, 
Callen, Verhey 
3.3 
AW m, 6.3 winter yes Enceph, Cerebellar, Seizures, Extrapyr ADEM 
McDonald 2005, 2010, 
Callen, Verhey 
2.0 
AlA f, 6.7 autumn yes Enceph, Hemipl, Seizures ADEM Callen 5.2 
NV m, 6.8 autumn yes 
Meningism, Enceph, Hemipl, Cerebellar, 
Brainstem, TM, Sphincter 
ADEM 
McDonald 2005, 2010, 
Callen, Verhey 
5.3 
AC m, 7.1 autumn no *Enceph, Seizures ADEM - 2.3 
ZZ f, 7.2 winter no Enceph, Hemipl, Bulbar ADEM McDonald 2010, Callen 3.0 
HB m, 7.3 spring yes Enceph, Parapl, TM, Sphincter, Sensory ADEM McDonald 2005, 2010 4.6 
LC m, 7.7 spring yes Enceph, Cerebellar ADEM McDonald 2005, 2010 1.8 
HP m, 8.4 autumn no 
Mening, Enceph, Parapl, Cerebellar, 
Brainstem, Bulbar 
ADEM McDonald 2010 3.0 
DI f, 8.7 spring yes Enceph, Hemi, Cerbellar, BLON ADEM 
McDonald 2005, 2010, 
Callen, Verhey 
4.3 
BrB m, 9.5 winter yes 
Mening, Enceph, Cerebellar, Sphincter, 
Seizures 
ADEM McDonald 2005, 2010 1.0 
MP f, 9.9 summer yes Encph, Brainstem, Seizures ADEM McDonald 2005, 2010 3.4 
SD f, 10.6 winter yes 
Enceph, Cerbellar, Brainstem, Bulbar, 
Sphincter 
ADEM McDonald 2005, 2010 1.9 
TP m, 11.1 autumn yes 
Mening, Enceph, Quadpl, Brainstem, 
Sphincter, Seizures, Extrapyr 
ADEM McDonald 2010 8.2 
SS f, 14.1 spring yes 
Mening, Enceph, Parapl, TM, Sphincter, 
Seizures 
ADEM - 4.7 
LP f, 14.6 summer yes Mening, Enceph, Hemipl ADEM McDonald 2005, 2010 12.6 
BH m, 1.3 summer no Quadpl, TM, Sensory CIS - 10.4 
AM f, 2.6 summer no Cerebellar, Seizures CIS McDonald 2010 1.0 
AK m, 3.2 spring yes Enceph, Cerebellar, Brainstem CIS McDonald 2010 4.7 
AY f, 3.4 spring no BLON CIS - 2.9 
WJ m, 3.8 winter yes Parapl, TM, Sphincter CIS - 3.9 
RS f, 3.8 spring yes Cerebellar, Seizures CIS McDonald 2005, 2010 6.8 
SQ f, 4.3 winter no ULON CIS - 3.8 
ST f, 4.8 autumn yes Monopl, Seizures CIS - 5.3 
TD m, 5 autumn yes Mening, Parapl, TM, Sphincter CIS McDonald 2005, 2010 6.0 
DF m, 5.3 winter yes Cerbellar, Brainstem, Bulbar CIS McDonald 2010 2.9 
IP f, 6.8 autumn no Brainstem CIS McDonald 2010, Verhey 2.1 
MC f, 7.3 winter yes Mening, BLON CIS - 7.8 
AdA m, 8.1 winter yes Quadpl, TM, Sphincter CIS - 3.8 
AeA f, 8.7 autumn yes Mening, Monopl, TM CIS - 3.0 
JM f, 8.7 winter yes ULON CIS McDonald 2010, Callen 11.9 
RL m, 8.8 spring no BLON CIS - 10.7 
PC m, 9.3 summer yes ULON CIS - 4.6 
ME f, 9.4 winter yes ULON CIS - 9.0 
NW f, 10 winter yes Parapl, TM, Sphincter, Sensory CIS - 12.2 
AB m,10.7 spring no Hemipl, BLON CIS 
McDonald 2010, Callen, 
Verhey 
5.7 
PG f, 11.4 autumn yes BLON CIS - 8.0 
LTY m, 11.5 autumn yes BLON CIS - 4.1 
CB f, 11.8 winter no ULON CIS - 6.3 
NB f, 12.3 summer no Parapl, TM, Sphincter, Sensory CIS McDonald 2010 2.5 
JeN f, 12.6 summer no BLON CIS - 1.3 
TP m, 12.7 winter no ULON CIS - 7.1 
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AF f, 12.8 autumn yes Quadpl, TM, Sphincter, Sensory CIS - 1.0 
FJ f, 12.9 summer no Parapl, TM, Sphincter, Sensory CIS - 10.6 
JN m, 12.9 summer yes BLON CIS 
McDonald 2005, 2010, 
Callen, Verhey 
4.3 
MK m, 13.4 spring no Brainstem CIS McDonald 2010, Verhey 13.7 
AaK m, 14 spring yes Hemipl, Sensory CIS 
McDonald 2005, 2010, 
Callen, Verhey 
5.8 
KH f, 14.4 winter yes Quadpl, TM, Sphincter, Sensory CIS McDonald 2010 5.1 
AVDS m, 14.4 summer no BLON CIS - 6.3 
BM m, 14.8 autumn yes Mening, Monopl, TM CIS - 4.2 
TR f, 15 spring no Quadpl, TM, Sphincter, Sensory CIS McDonald 2010 4.8 
SC f, 15.3 summer no Parapl, TM, Sphincter, Sensory CIS - 5.5 
MN m,15.4 winter yes BLON CIS McDonald 2010 9.9 
BLON – bilateral optic neuritis, ULON – unilateral optic neuritis, Parapl – paraplegia, Monopl – monoplegia, Hemipl – hemiplegia, 
Enceph – encephalopathy, TM – transverse myelitis, ON – optic neuritis, Mening – meningitis 
 
 
The breakdown of residual problems according to the system involvement is shown in the 
Figures 2-17 and according to initial demyelinating episode (ADEM and CIS) in Figure 2-18. 
There were residual medical problems reported in 46% (32/70) of the monophasic group. The 
mean follow-up time for the patients with residual problems was 5.3 years (SD 3.1 years) and 
5.4 years (SD 3.4 years) for those with no residual problems. Therefore the residual problems 
recorded are unlikely to be due to an insufficient follow-up.  
The most common abnormality at follow-up was in the motor system with 21% (15/70) of the 
monophasic group having a motor abnormality which included upper limb and/or lower limb, 
fine and/or gross motor dysfunction. Learning difficulties was the next most common at 13% 
(9/70) which were most commonly difficulties with concentration and memory.  
There was no statistical difference in the functional outcome of the patients when comparing 
their age of presentation.  
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Figure 2-17 Monophasic patients functional status at follow-up based on clinic notes review and telephone 
questionnaire. The first ‘black’ column depicts the percentage of patients that had any abnormality at follow-
up and the ‘grey’ columns show abnormalities broken down into functional systems 
 
Motor AbN – motor abnormality included upper and/or lower limb weakness or flaccid paralysis. Visual AbN – visual 
impairment as a consequence to the initial demyelinating event. Sphincter AbN – bladder or bowel incontinence requiring 
ongoing management. Psych prob – psychological problems encountered by the child requiring psychological input after 
discharge (included depression, anxiety). Learn Diff – learning difficulties that arose following discharge and were ongoing 
(lasted over 6 months). 
When the monophasic group was divided according to their initial demyelinating event, patients 
with ADEM had more residual problems following their demyelinating episode compared with 
CIS (46% vs 40% respectively). There was no significant difference in the residual problems or 
functional subgroups between patients with an initial diagnosis of ADEM vs CIS although having 
a visual abnormality was higher in the CIS group and neared significance with a p-value of 0.07, 
as would be expected.  
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Figure 2-18 Follow-up functional abnormalities in Monophasic patients (Non-MS group) divided according to 
first demyelinating event.   
 
Motor AbN – motor abnormality included upper and/or lower limb weakness or flaccid paralysis. Visual AbN – visual 
impairment as a consequence to the initial demyelinating event. Sphincter AbN – bladder or bowel incontinence requiring 
ongoing management. Psych prob – psychological problems encountered by the child requiring psychological input after 
discharge (included depression, anxiety). Learn Diff – learning difficulties that arose following discharge and were ongoing 
(lasted over 6 months). 
There were a further five patients who had recurrent neurological symptoms and this includes 
four patients (4.3%) who had recurrent ON and one patient who fulfilled the criteria for (1.1%) 
Neuromyelitis Optica spectrum disorder (NMOSD). They are discussed in detail below.  
 Patients with relapsing demyelinating diseases other than MS.  
In the non-MS group there were five patients who had a relapsing demyelinating disorder other 
than MS and they are as follows.  
2.3.2.7.2.1 Four patients with Chronic Relapsing Inflammatory Optic Neuropathy (CRION) 
There were four (5%) of total patient cohort who had relapsing optic neuropathy without new 
clinical presentations other than ON. 
48%
27%
3%
6%
12%
18%
43%
16% 16%
14%
5%
8%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
Residual
Problems
Motor AbN Visual AbN Sphincter
AbN
Psych prob. Learn. Diff
P
e
rc
e
n
ta
ge
 o
f 
p
at
ie
n
ts
ADEM (n=33)
CIS (n=37)
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 102 of 279 
The clinical, neuroimaging and neuro-immunological findings of these patients is summarised in 
Table 2-19 below.  
Table 2-19 Summary of clinical and radiological findings in four patients with chronic recurrent inflammatory 
optic neuropathy (CRION).  
Characteristic Patient 1 - AR Patient 2 - EW Patient 3 - CM Patient 4 - SV 
Age 5 years 7 years 12 years 13 years 
Sex Female Female Female Female 
Preceding illness No No No Yes 
Past Medical 
History 
Nil Sig 
T1DM & 
Hashimoto’s 
thyroiditis 
Nil Sig Nil Sig 
Unilateral or 
Bilateral ON in 1st 
Episode 
Bilateral Bilateral Unilateral Bilateral 
MRI brain  
Normal brain, 
Optic nerve 
enhancement 
Normal brain 
Normal brain, 
Optic nerve 
enhancement 
Normal brain, 
Optic nerve 
enhancement 
Relapse, time 
after first episode 
ULON, 2 years BLON, 2 years   
ULON, 2 years and 
 ULON, 4 years 
ULON, 10 years  
Progress MRI 
Normal, no 
enhancement 
Normal, No 
enhancement 
Brain normal, 
Optic nerves 
enhancement 
Brain normal, 
Optic nerve 
enhancement 
Follow-up time 2.8 years 11.9 years 8.7 years 10 years 
Findings at follow-
up 
Normal Vision Normal Vision 
Persistently 
decreased VA on 
right.  
Normal Vision 
Anti-MOG 
antibody 
Positive Positive Negative Positive 
NMO IgG 
performed 
Negative Negative *Not tested Negative 
ULON – unilateral optic neuritis, BLON – bilateral optic neuritis, MOG – myelin oligodendrocyte glycoprotein , T1DM – type 
1 diabetes mellitus, NMO – neuromyelitis optica. *Insufficient serum stored for testing 
 
The mean time of follow up was 8.4 years (range 2.8 to 11.9 years). All four patients were 
female. All four patients had a normal MRI brain (with or without optic nerve enhancement) at 
the time of their initial demyelinating episode and on subsequent presentations. It is interesting 
that three (3/4) of the CRION patients were anti-MOG antibody positive and these patients were 
also NMO IgG negative. These results are further explored in chapter 4 as part of the MOG study. 
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2.3.2.7.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) (32)  
TH was a previously healthy 15 year old Australian boy of Caucasian origin who presented with 
a progressive subacute spinal cord syndrome. His illness began ten weeks prior to his admission 
when he began to complain of pins and needles that initially affected his feet but that later 
affected the whole of his legs. In the four weeks before presentation, his walking became 
increasingly altered with unsteadiness and reduced exercise capacity. His upper limbs also 
became involved in the fortnight preceding admission.  He developed urinary frequency but 
there was no history of retention. He had no alteration in thinking, he was not confused and 
there was no change in his behaviour. His vision remained normal.  
On examination, he had a normal cranial nerve (and in particular visual) examination. He had 
loss of light touch and proprioception, impaired coordination with abnormal repetitive finger 
movements, but normal power and reflexes in his upper limbs. His lower limb examination 
revealed mild pyramidal weakness, pathologically brisk reflexes, up-going plantar response, and 
loss of light touch and proprioception. He had a sensory level at T2, absent abdominal reflexes, 
altered anal sphincter tone and evidence of urinary retention on abdominal examination. He 
had a spastic gait and was only able to walk 50 metres.  
On MRI of his spine T2 sequences were performed and showed severe oedema and 
enhancement in a patchy distribution from C1 to T7. In addition MRI T1 sequences revealed 
cavitation, and patchy Gadolinium enhancement (Figure 2-19 left). His MRI brain demonstrated 
asymptomatic white matter lesions (Figure 2-19 right). 
CSF revealed 3 mononuclear cells, 0 polymorphs, no red cells, normal protein (0.3 g/dl), normal 
glucose, neopterin, cytospin, and negative oligoclonal bands. CSF polymerase chain reaction was 
negative for enterovirus and herpes simplex virus. Serology for Epstein Barr virus was positive 
compatible with previous infection. Serology for anti-nuclear antibody and anti-cardiolipin 
antibody was negative, and Vitamin D titre was normal.  
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Figure 2-19 Left:  MRI spine Sagittal T2 with Gadolinium shows cavitating, patchy and enhancing lesion from C1 
to T6. Right: MRI brain coronal flair sequence depicting non-specific white matter changes that are diffuse and 
asymmetrically distributed. The lesion in the right parietal lobe extends down to the periventricular white 
matter. The distribution of the hyper-intensities around the ventricles is characteristic of patients with NMO as 
this is where there is a concentration of aquaporin 4 channel expression(80). 
       
 
Clinically he met the criteria for idiopathic transverse myelitis (TM) and was initially treated 
with intravenous Steroids (IV methylprednisolone 1g/day for 5 days) followed by intravenous 
immunoglobulin (IVIG) (2g/kg over 3 days) as is the trend at our institute for moderate to 
severe TM.  
However in view of the MRI spine changes (longitudinally extensive TM with cavitation), he was 
suspected of having Neuromyelitis optica (NMO) as has been previously described in adults 
(93). Serology for Neuromyelitis optica IgG was sent for testing and according to the National 
Reference Laboratory was positive with a titre of 1:640. Testing for autoantibodies against AQP 
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4 was positive (score 3+)(106). A diagnosis of a ‘limited form’ of NMO or NMO spectrum 
disorder was made.  
TH improved clinically within a week of starting therapy (IV methylprednisolone and IVIG), and 
was discharged after a two week admission with residual sensory ataxia and pyramidal tract 
signs. He was given a prolonged tapering course of prednisolone starting at 60mg/day.  
In addition, during the first month of treatment once the NMO IgG returned a positive result, he 
was started on Mycophenolate mofetil 1000mg twice a day given the risk of relapse and 
associated morbidity was high according to a number of studies (80). 
At six months, his functional motor performance was normal. He was running and surfing at his 
previous ability. However, his examination was still abnormal with brisk reflexes and up-going 
plantar response in his lower limbs, and absent abdominal reflexes. 
His progress MRI spine revealed residual damage with cavitation and his MRI brain showed 
partial improvement in the asymptomatic white matter lesions (Figure 2-20). His NMO-IgG 
remained positive, titre 1:160. 
At 3 years follow-up he remains well and has had no further relapses or episodes of 
demyelination. He remains on Mycophenolate (mofetil) and is under the care of an adult 
neurologist.  
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Figure 2-20 MRI of spine during first demyelinating episode (left), at 2 months (middle) and at 12 months 
(right). 
                 
Left: T2 sagittal spine on day 2 of admission with transverse myelitis. The cord changes are similar to the initial 
scan taken on admission (day 1 of presentation) however gadolinium enhancement was no longer present. 
Middle: T2 sagittal spine 2 months after presentation shows an interval decrease in size and signal intensity of 
the spinal lesions. There is resolution of previous cord expansion. No enhancement post gadolinium was seen 
(not shown).  Right: T2 sagittal spine 12 months after initial presentation shows a great improvement of the 
cord. There is residual damage and cavitation of the spine however the cord expansion has resolved. No 
gadolinium enhancement was found (not shown).      
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2.4 Discussion of clinical findings  
Differentiating between a monophasic CNS demyelinating disorder and a chronic relapsing CNS 
demyelinating disorder has been the subject of many clinical studies in the past decade (8, 9, 11, 
18, 44-46, 50, 53, 78, 104, 107). The significance of such a distinction derives from the 
importance of early recognition of MS (and likewise NMO) and initiation of disease modifying 
therapy as this has been shown to prolong independence and the time to disability (4, 5).  
This is the first follow-up study of children from Australia with a first episode of CNS 
demyelination which is important as the risk of adult MS is dependent upon geographical 
location and studies are yet to confirm if this applies to children as well.  
 First Episode: Acute disseminated encephalomyelitis and Clinically Isolated 
Syndrome 
In our retrospective review of 88 children presenting to a tertiary children’s hospital with a first 
episode of CNS demyelination, the majority of children in our cohort presented with CIS (n=52, 
59%) as opposed to ADEM (n=36, 41%).  
The proportion of children in our cohort whose initial presentation was ADEM is high (41%) 
compared with Canada 22% (56), the UK 30% (50), the Netherlands 24% (71) and with France 
29% (18). The reason for this higher rate is unclear although the mean age of our whole cohort 
is 8.3 years (median 7.9 years, range 1.3 –15.4 years) which is low compared to a Canadian 
study that reported a mean age of 10.5 years (range 0.66 – 18.0 years)(56) and an American 
study that reported a mean age of 12.6 years (0.7 – 18.0 years)(108). This may contribute to our 
higher rate of ADEM compared with other cohorts internationally. Secondly it could be 
postulated that a difference in the definition of ADEM could account for some of the 
discrepancies especially for studies published prior to the 2007 consensus criteria or post 2007 
that did not comply with these consensus definitions (18).  
The characteristics of patients presenting with ADEM were as follows. Children with ADEM 
were younger (mean 6.2 years, range 1.7-14.6) compared with those presenting with CIS (mean 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 108 of 279 
9.8 years, range 1.3-15.4) and had a history of a preceding or inter-current infection, often 
associated with fever. These characteristics are in accordance with previously published studies 
in the literature both before (8, 9, 11, 18, 44-46) and after the establishment of the 2007 
consensus criteria (50, 109).  There was no specific seasonal effect in presentation between 
those with ADEM and CIS even though more children from both groups presented in winter (not 
significant) and this is consistent with other studies including a recent Canadian study (8, 56). 
The clinical presentation of the ADEM patients included encephalopathy (in all patients by 
definition), seizures, meningism, pyramidal tract, cerebellar, brainstem and bulbar 
abnormalities. Of these characteristics (not including encephalopathy), pyramidal tract 
dysfunction was the most frequently clinical abnormality found (25/36, 69%). This is 
compatible with previous studies although these studies use different terminologies such as 
‘long tract signs’ or ‘long tract dysfunction’ (8, 11, 18, 44). 
In contrast, children who presented with CIS were older (9.8 years, range 1.3-15.4) and were 
more likely to present with optic neuritis (p<0.00) and transverse myelitis (p=0.01) compared 
to those with ADEM. This is to be expected as by definition TM and ON are subtypes of CIS and 
they do not usually present with encephalopathy.   
In general the patients with CIS more often had a specific or isolated area of neurological 
dysfunction (often termed a monofocal presentation such as ON, TM, sensory changes) as 
compared to ADEM patients who were more severely affected with multiple symptoms and 
signs such as hemiplegia, quadriplegia, cerebellar, brainstem abnormalities. These findings not 
only reflect the diagnostic criteria used (7) but also confirm observations made in previously 
published studies (6, 48).  
The findings in ADEM both clinically and radiologically are distinct from those in CIS but the 
pathophysiological basis of this distinction is unclear.  
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 Follow-up diagnosis: Factors contributing to MS risk 
Prior to the 2007 criteria, definitions of ADEM, MS and other demyelinating disorders were 
almost entirely ‘centre’ based, which makes direct comparison difficult.  There are a number of 
studies however that used the 2007 criteria and were similar to our study and they are 
summarised in Table 2-20 below.  
Table 2-20 Risk of MS after a first episode of CNS demyelination according to country or residence. Studies are 
presented in descending order of latitude. 
Country 
(median latitude) 
2007 
Consensus 
Definition
s Used 
Cohort 
size (n) 
Upper 
Age 
Limit 
(years) 
Population 
base 
FU  
% 
Ris
k  
of 
MS 
Source 
Netherlands 52’22N Yes 86 18.0 Multicentre 
4.0  
yrs. 
23
% 
Ketelslegers et al,  
J Neurol 2012 
UK 51’32N Yes 40 16.0 Quaternary 
2.2 
yrs. 
35
% 
Dale et al,  
DMCN 2007 
France 48’48N No 296 16.0 Multicentre  
2.9 
yrs. 
57
% 
Mikaeloff et al,  
J Paediatr, 2004 
Canada 43’40N Yes 302 18.0 Multicentre 
3.1 
yrs. 
21
% 
Banwell et al, 
 Lancet Neurol 2011 
USA 37’47 Yes 81 18.5 Multicentre 
3.3 
yrs. 
35
% 
Langer-Gould,  
Neurology 2011 
Australia 34’0S Yes 88 16.0 
Single 
Tertiary 
5.1 
yrs. 
15
% 
This study 
FU – follow-up time 
The risk of MS after a first demyelinating episode ranges from 21% in Canada up to 57% in 
France. These studies have been discussed previously however there are a number of factors 
that makes direct comparisons between our study and these studies difficult.  
Some cohorts were taken from multiple centres therefore the clinical information may not 
always have been consistent (18, 108) . The definitions used in some of these cohorts, even after 
the 2007 consensus were not standardised (51, 53). Some countries defined MS whenever a 
patient had a second demyelinating episode even if the first episode was ADEM (18), although 
this is now incorporated into the 2013 criteria (102).  
Other studies excluded mono-symptomatic presentations (e.g. ON/TM) and therefore are not 
representative of all CNS demyelinating patients (46, 51).  
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An increased risk of MS in some studies could also be reflected in the diagnosis of MS in children 
being based on an MRI brain scan found to show evidence of dissemination in time (DIT) at 
follow-up without a second clinical event. Even though we acknowledge that this is standard in 
adult neurology and has now been introduced into paediatric neurology with the publication of 
the 2012 consensus criteria (102), we have only presented the patients with clinically definite 
MS and found our rate to be 15% despite our long mean follow-up.  We have however discussed 
the three patients who would under the 2012 consensus definitions be diagnosed with MS 
based on their initial MRI or follow-up scan according to the McDonald 2010 criteria in chapter 
3. 
Furthermore as not all studies (nor our study) routinely performed follow-up MRI brain scans 
in all patients, directly comparing studies that have diagnosed MS based on follow-up imaging 
(with or without a clinical relapse) (55, 71) with those that relied on clinical relapse alone is 
difficult (50). 
Nevertheless, the risk of MS in NSW children after a mean follow-up 5.2 years is 15% which is 
low in comparison with the reported risk in previous studies. There are other potential factors 
contributing to this ‘lower rate of MS’ including latitude and age of cohort which are discussed 
further.  
 Study length  
This study is the longest follow-up period for a study examining risk of MS after a first episode 
of CNS demyelination in a paediatric cohort using the 2007 consensus definitions. Study length 
and follow-up are two very important characteristics in analysing risk of MS after a first episode 
of demyelination. We know from past experience that most children who will suffer a second 
episode of demyelination and be diagnosed with MS will do so within 2 years of their first 
episode (110, 111).  However, there are a number of children who will relapse after this time. 
For example, in our cohort of 13 children who had MS, the mean time after the first CNS 
demyelinating episode until the MS defining relapse was 2.2 years (median 1.0 years, range 0.3 
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to 8.0 years) however as can be seen from the range, patients were diagnosed with MS up to 8 
years after their first episode (see figure 2-13, page 93). Therefore the length of our study 
(mean 5.2 years) is of reasonable length to infer MS risk, although prolonged follow-up would 
be even more favourable.  
 Geographical latitude of a country and risk of MS   
Geographical latitude has been shown to influence the risk of MS in adults, with disease rates 
rising with increasing distance from the equator in both the northern and southern 
hemispheres (25).  
As is shown in Table 2-20 the latitude of Australia is closer to the equator and therefore is much 
lower compared to other countries listed. A difference in latitude contributes to the amount of 
sunshine a person receives and therefore to how much active vitamin D is present in the body. A 
number of adult and paediatric studies have shown the association of low vitamin D levels with 
a higher risk of MS relapse (55, 112). Although we did not test vitamin D levels (insufficient 
serum) in our cohort, it is plausible that by being closer to the equator and having longer 
periods of sun exposure (and therefore more vitamin D) the risk of MS for children from NSW, 
Australia would be lower compared to other international cohorts.  
This is the first study to test the MS risk in children from an area of medium risk rather than 
high MS risk. It would be interesting to compare MS risk in children from different Australian 
capital cities (Brisbane, Melbourne, Perth, Tasmania) as done by Hammond et al whose seminal 
work was important in confirming the latitude hypothesis in adults with MS (113). 
 Upper Age limit in cohort   
As can be seen in Table 2-20, the upper age limit in some of the ‘paediatric’ cohorts from around 
the world has included patients up to 18.5 years of age. The rate of MS increases with increasing 
age (46). By having an upper age limit that moves into the ‘adult’ age range, the number of 
apparent ‘paediatric’ patients experiencing their first episode of demyelination will be 
increased. For example, the study by Langer-Gould et al reports a mean age of 12.6 years (range 
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0.7-18.5 years) for patients experiencing their first acute demyelinating syndrome with the MS 
risk found to be 35% whereas the mean age in our cohort (n=88) was 8.3 years (range 1.3 – 
15.4 years) and our MS risk was lower at 15%. This age difference between cohorts is likely 
influencing the MS risk in the different published studies.  
 Gender and MS 
Previous studies have found that children diagnosed with MS were more often female and older 
(>10 years) (18, 46, 48, 55, 108) compared to those with a monophasic course. However this 
was not found in the current study, possibly due to the small numbers of MS patients, and the 
age cut-off of 16 years used in this study. The influence of gender is considered to only become 
relevant after puberty and therefore the age of cut-off at 16 as opposed to 18 years may 
influence this finding.  
 Oligoclonal bands (OCB) and MS  
Unfortunately oligoclonal band (OCB) analysis was not performed in all patients of our cohort 
and therefore no real statistical conclusions could be drawn. Comparatively speaking there was 
one OCB positive patient in each group at follow-up (MS and Non-MS), both of whom were 
classified as having CIS during their first episode.  
The patient who was OCB positive in the Non-MS group had an initial presentation of bilateral 
ON and was followed up for 15 months in the hospital outpatient clinic but was not able to be 
contacted for the telephone interview. This follow-up time is too short and this child is 
theoretically still at a high risk of MS.  
The utility of OCB in diagnosing MS in adults is well established and the presence of OCB are of 
prognostic value in helping to predict the likelihood of a second demyelinating attack (114, 
115). OCB are an established part of the adult MS diagnostic criteria (54, 116) although CSF 
examination is used progressively less often partly due to the increasing dependence on MRI.  
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In children, studies examining OCB and their association with MS are less clear and in fact 
controversial. The presence of OCB in the CSF of paediatric patients with MS ranges from 8-92% 
(48, 114, 117, 118). There are various explanations to account for the diversity of these results 
including the timing of lumbar puncture, the age at first demyelinating episode and technical 
issues related to the way analysis has been done (114). 
The low yield in our cohort of MS patients (1/4 of those tested was positive for intrathecal OCB) 
and in other paediatric cohorts raises the question of the usefulness of this test in paediatric 
demyelination. With the increasing emphasis on MRI findings we suggest OCB may be used less 
often, except in patients were the diagnosis is unclear and supportive evidence is needed.   
 Multiple Sclerosis group  
After a mean follow-up of 5.2 years, the risk of CDMS in NSW children is 15%. Four of the 
patients were diagnosed with CDMS within the 12 month period following their first 
demyelinating episode (4/13, 31%). This is similar to adult studies were 30% of patients have 
their second event within 12 months (119). However this is higher than the 23% of patients 
with at least one relapse in the first 12 month period reported in a Canadian study (19).  
The annualised relapse rate for our cohort was 1.04 per year.  This is high compared to a study 
from Canada were the annualised rate in a paediatric population was found to be 0.54 (+/-0.05 
per year)(19). However our study findings are similar to a study from the USA, where children 
with MS were found to have an annualised relapse rate of 1.13 (120). The reason for these 
differences is unclear however it may be related to early institution of disease modifying 
therapy in countries with a higher risk of MS such as in Canada. Gorman et al directly compared 
the annualized relapsed rate between paediatric onset MS and adult onset MS (120). This study 
found that the annualized relapse rate was much higher (1.13 per year) in the paediatric cohort 
compared with the adult cohort (0.4 per year), p=0.001 (120), and one of the obvious 
confounders in this study was that 28% of the adult patients were treated with disease 
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modifying therapy following the first CIS, compared to 0% of the children, although the authors 
did try to account for this.  
 Multiple Sclerosis (MS) after Acute disseminated encephalomyelitis (ADEM)  
The number of children from the ADEM group that had a follow-up diagnosis of MS was 3/36 
(8%). This is lower than previously reported rates of between 10-29% (8, 18, 44, 45) in studies 
prior to 2007 but more comparable with the rates of 0-17% found in studies using the 
consensus criteria of 2007 (50, 53, 55, 108, 109). Our study therefore adds to the literature in 
confirming that children in NSW, Australia are also at lower risk of MS if their first CNS 
demyelinating episode was ADEM.  
The presentations of the three patients initially diagnosed with ADEM are not particularly 
distinctive in predicting that these patients were at risk of MS. In particular these three patients 
did not have ON or TM as part of their presenting episode.  
 Multiple Sclerosis (MS) after a first episode of Clinically Isolated Syndrome (CIS)  
In our CIS cohort a total of 10/52 (19%) of patients had a follow-up diagnosis of MS. This is low 
when compared to previously published studies examining risk of MS after CIS from around the 
world;  UK 46% (50),  Netherlands  44% (53) and 33% in the USA (108). The reason why 
children with CIS in NSW, Australia were less likely to have a subsequent diagnosis of MS is 
unclear however as previously discussed the younger age of our overall cohort compared to 
other studies internationally may contribute to this lower rate.  
As CIS is composed of patients with transverse myelitis and optic neuritis, many studies have 
investigated the risk of MS from these distinct clinical syndromes independently and therefore 
we have discussed them independently below.  
 Risk of Multiple Sclerosis (MS) after Optic Neuritis (ON) 
In our CIS cohort (n=52), 24 patients presented with ON and only four of these ON patients 
(17%) had a follow-up diagnosis of MS after a mean follow-up of 6.9 years (1.3 to 11.9 years). 
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This rate is identical to a study from the US that reported 17% of ON children subsequently 
being diagnosed with MS after a mean follow-up of 4.3 years (0.1-13.4 years) (79) however the 
number of patients that were followed up in this US study was only 18/29 (62%).  This MS rate 
is also similar to the 19% reported in a meta-analysis by Waldman et al (23) where multiple 
international studies were analysed. Our MS risk after ON however is much lower than the 36% 
of patients diagnosed with MS at follow-up in a Canadian study (60) after a mean follow-up  2.4 
years (0.3 to 8.3 years). 
In summary the risk MS after an episode of ON in children from NSW, Australia is low (17%) 
compared with cohorts internationally. The presence of an abnormal MRI brain scan in 
conjunction with ON increases the risk of MS and will be discussed in MRI chapter. The risk of 
MS after ON is similar as the risk of MS for the total cohort (n=88) (17% vs 15%).  
 Risk of Multiple Sclerosis (MS) after Transverse Myelitis (TM) 
In our CIS cohort there were a total of 17/52 (33%) patients who had clinical transverse 
myelopathy at presentation.  
Of these seventeen patients, three (18%) had a follow-up diagnosis of MS after a mean follow-up 
of 4.7 years (1.0 to 12.2 years), which is similar to a recent study on Canadian children who had 
a follow-up MS rate of 13% (70). However this is high compared with the 3% that was reported 
in Dutch children in 2011 (71). This apparent discrepancy may to some extent be explained by 
the way in which TM was restricted to patients with a pure spinal cord syndrome in the Dutch 
study. Therefore if a patient presented with clinical TM but had MRI brain lesions, they were 
classified as a polyfocal acute demyelinating syndrome and not TM even if these MRI brain 
lesions were ‘clinically silent’. This is different to our cohort where we diagnosed TM on the 
basis of clinical presentation and spinal imaging even if there were ‘clinically silent’ brain MRI 
lesions.  
Our study therefore confirmed that presenting with clinical TM as a first demyelinating disorder 
has a low risk of subsequent MS.   
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 Functional outcome of MS group 
Of the 13 patients diagnosed with clinically definite MS, 31% had a functional deficit according 
to parent or personal reporting at follow-up. Interestingly this is lower than was reported in the 
monophasic group (43%) despite the length of follow-up being marginally longer in the MS 
groups (5.1 years vs 4.9 years). 
It is well established in the literature that MS is a risk factor for cognitive problems with 40-
65% of adult MS patients experiencing difficulties (121, 122). It has been demonstrated that this 
also occurs in paediatric onset MS with 35%-70% of children showing impaired cognitive 
performance on more than one cognitive task during formal testing in studies (123, 124). 
Similarly a European cohort has demonstrated that up to 41% of children and adolescents with 
MS demonstrate cognitive impairment when tested against matched controls (125). Although 
we did not perform formal neuropsychological testing, our study showed that 15% of MS 
patients reported learning difficulties and although this is less than number quoted in studies 
previously performed, we assume that subtle changes that would be revealed in formal testing 
which were likely to have been missed by our questionnaire. Furthermore, as most of our MS 
patients are now adults, self-reporting in this domain may have been biased.  
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 Non-Multiple Sclerosis Group at follow-up 
 Functional outcome of monophasic group. 
The Non-MS group (n=75) was largely composed of children who suffered a monophasic course 
(n=70).  
The follow-up functional status of our monophasic patients as a group was concerning with 
almost 50% of patients complaining of ongoing morbidity based on the telephone interview. 
This morbidity is higher than has been previously reported (17-43%), ( 8,9,75,79) and the 
reason for this is not completely evident. One might speculate that factors such as referral bias 
could exist, as our institute has a large research interest in neuroinflammatory conditions, and 
could see sicker patients.  
The monophasic ADEM patients appeared more likely to have functional impairments than the 
monophasic CIS patients. The age of patients with ongoing sequelae was not influential on the 
outcome as has been found in some studies (74).  
The current understanding is that ADEM patients are less likely to have ongoing sequelae and 
are less likely to have a future diagnosis of MS (6). Often patients with a diagnosis of ADEM are 
followed up for a short time and are assumed to return to normal even though a number of 
studies have shown residual deficits in between 17 and 43% of ADEM patients (8, 9, 74, 76, 78).  
Our study has also shown that residual deficits are common according to parent and self-
reporting. The number of patients reported to have motor (21%), learning (13%) and/or a 
psychological problem (8%) at follow-up was concerning. We acknowledge that the 
questionnaire used for our follow-up review is not standardized, however even with this taken 
into consideration, the results of this study indicate a need to perform further prospective 
analysis of patients with a first demyelinating disorder from a neurocognitive, neurological and 
neuropsychiatric perspective to further develop the evidence for ongoing review, support and 
early intervention as suggested by Deery et al (76).   
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 The outcome of children with CIS is variable. When ON is the clinical phenotype, children are 
thought to make a better recovery compared to adults with ON (60). When TM is the clinical 
phenotype however, ongoing sequelae is present in a significant proportion of children (68, 
126).  This is similar in our study where the majority of patients with ongoing motor and 
sphincter disturbance in the CIS group had TM as their initial presentation.   
 Chronic recurrent inflammatory optic neuropathy: CRION 
Four patients had a recurrence of optic neuritis alone. These four patients would meet the 
description of chronic relapsing inflammatory optic neuropathy (CRION) described in an adult 
cohort and published by Kidd et al (127). Three out of the four patients had bilateral ON and all 
but one had rapid recovery with steroids. All four patients had normal MRI’s with or without 
enhancement of the optic nerves. One patient had initially presented with left optic neuritis but 
a fortnight after completing her high dose intravenous steroid therapy without oral taper, she 
re-presented with right ON which is described in many of the patients by Kidd et al(127). 
One distinction in our cohort was that the mean time from first episode of optic neuritis, until 
relapse was 4 years (2 to 10 years) and this is longer compared to other previous published 
studies (127) .  
 Neuromyelitis optica spectrum disorder (NMOSD) 
In our cohort there was one patient who was diagnosed with a limited form of NMO. As the 
spectrum of NMO has widened (28, 80) it has become increasingly important to consider the 
diagnosis of NMO especially in the context of severe episodes of demyelination with imaging 
that is not characteristic of MS or ADEM. Our patient had an abnormal baseline MRI brain scan 
that fulfilled McDonald 2010 criteria as was discussed in the MRI chapter (3.3.5.2). Having a 
baseline abnormal MRI scan has been found to occur in 53% of patients with NMO in children 
(31). Although NMO is uncommon in children, NMO requires specific therapy and therefore a 
high index of suspicion based on clinical, serological and radiological grounds has to be 
executed by clinicians so that this very important and serious diagnosis is not missed. 
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In our case of NMOSD, spinal neuroimaging was the clue to his diagnosis. He had lesions that 
extended over three vertebral segments in the cervical and thoracic cord that were cavity-like 
and the lesions occupied most of the cross-sectional area of the cord. This type of lesion has 
been described and established in the literature as being associated with NMO(28, 96) as 
distinct from typical spinal lesions in patients with MS that are usually less than three vertebral 
segments, asymmetric and often only occupy the posterior segment of the cord (28, 128), and 
do not cavitate. Our case was NMO IgG positive but has not had any episodes of optic neuritis or 
a recurrence of his transverse myelitis- he therefore meets the criteria for a ‘limited form’ of 
NMO or ‘NMOSD’.  The case was treated empirically with intravenous methylprednisolone with 
steroid taper when the diagnosis of transverse myelitis was made at his initial presentation. 
However in view of the positive NMO IgG an immunosuppressant was started in view of the 
morbidity and mortality associated with NMO(31). He has remained symptom and relapse free 
on Mycophenolate for over 3 years but remains NMO IgG positive. 
The first line therapy as recommended by the European federation of neurological societies 
(EFNS) is to use Azathioprine (with Prednisolone until Azathioprine is at a therapeutic level) or 
Rituximab and to consider Cyclophosphamide, Mitoxantrone, Mycophenolate and Methotrexate 
as second line therapies however, the panel acknowledges that the evidence for these 
medications is based on expert preferences as there are no randomized controlled trials in 
either adults or children to date (28). In considering therapy for our patient the side effect 
profile and relapse prevention potential were the main considerations. In our focused literature 
review at the time, the study by Jacob et al (129) indicated that Mycophenolate was of benefit in 
NMO and may in fact be superior to Azathioprine in terms of side effects.  
More recently a review of treatments for NMO was published recommending that either  
Azathioprine, Mycophenolate, Rituximab or Prednisone be trailed as first line therapy (130). 
The choice of which of the four medications should be chosen would be influenced more by 
physician prescribing experience, cost, side-effect profile, patient choice and route of 
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administration as there was insufficient data to differentiate between the therapies based on 
efficacy.  
 Comparison of patients diagnosed with MS and Non-MS at follow-up 
The number of patients who were diagnosed with MS after a mean follow-up period of 5.2 years 
(median 4.7 years, range 1.0 -13.9 years) was 13/88 (15%). Of the remaining 75/88 (85%) 
patients, 70/88(80%) had a monophasic course, and 5 (6%) were diagnosed with recurrent 
inflammatory neurological diseases other than MS.  
When we compared the clinical and biochemical characteristics of the MS and Non-MS groups 
there were three discriminating characteristics that differentiated between them: having a 
preceding infection (protective), behavioural changes (protective) and cerebellar signs 
(predictive). Age of onset, sex and season were not influential of MS diagnosis in our cohort as 
has been found in previous studies (18, 46, 48, 55, 108).  
When we performed a univariate analysis only two factors statistically differentiated between 
patients with and without MS: a preceding infection was protective and having cerebellar signs 
was predictive of MS. It is not surprising that a preceding infection is protective of MS since 
ADEM would have formed a large part of the Non-MS group and is typically considered a post-
infectious inflammatory disease. Previous studies comparing ADEM and MS have clearly shown 
this ‘infectious’ association in ADEM (6, 18, 107).  
The predictive value of cerebellar dysfunction leading to a diagnosis of MS is less obvious as 
previous studies both support (6, 131) and refute (46, 48) this finding. Interestingly ADEM 
patients more frequently presented with pyramidal and cerebellar signs however cerebellar 
signs were more prominent in MS compared to Non-MS patients. This may reflect the difficulty 
with determining the origin of ataxia in a patient who is encephalopathic and weak as being a 
reflection of cerebellar dysfunction and not purely from damage to the pyramidal tracts. This is 
less difficult in patients with isolated demyelinating presentations (eg optic neuritis, hemi-
cerebellar syndrome). 
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When we performed a multivariate analysis using both clinical and radiological characteristics 
(next chapter), having a preceding infection was found to remain significant in being protective 
of MS however having cerebellar signs no longer remained significant (see MRI chapter). 
Nevertheless MRI Brain characteristics were more highly predictive than any clinical feature in 
predicting MS outcome (see chapter 3).    
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2.5 Limitations of our study 
There are a number of limitations to the retrospective clinical component of the study. We 
acknowledge that although we were diligent in searching for patients in the cohort that fulfilled 
the inclusion criteria, there may have been a number of patients with less severe disease who 
presented to peripheral hospitals or to peripheral ophthalmologists with optic neuritis who 
were not referred to our centre and are therefore not part of the study. We believe this number 
would be low for a number of reasons. MRI for patients under 7-8 years of age is done under 
general anaesthetic across the state and therefore over half of children are referred to our 
hospital for ongoing investigation and management even if their disease is mild. There is also 
centralization of childhood neurological disease management in Australia and most 
demyelinating patients will be seen at the tertiary hospitals, of which there are only two in the 
state of NSW. The catchment for our institution is large encompassing most of the greater west 
of Sydney and NSW (population ~ 4.5 million) and our institution is also large on a nursing: bed 
ratio compared with the other tertiary children’s institute.  
By searching the hospital database using the coding system, we were able to identify patients 
diagnosed with CNS demyelinating disorders admitted across all specialties (e.g. 
ophthalmology).  Ophthalmologists were not directly contacted in our study as we relied on the 
hospital coding system to identify children who may have presented and were admitted under 
the ophthalmologists with optic neuritis however it is conceivable that a small percentage of 
children may have presented to outpatient clinics and were treated without admission. 
However this is likely to be a small number as most children who present with CNS 
demyelination are reviewed by the child neurology team.  
Secondly the retrospective nature of our study has its own disadvantages especially in terms of 
clinical documentation and accuracy of the clinical record. Although every effort was made to 
obtain all clinical, laboratory, and MRI data at all times the data was not 100% complete 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 123 of 279 
reflecting the challenges inherent in working in the paediatric context. This issue was 
particularly notable in spinal fluid analysis which was inconsistently performed in our cohort.  
The final weakness of the study was the number of patients with MS was small (n=13), and 
therefore some of the statistical comparisons would be less significant or potentially under-
powered.  
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3. MRI AND DEMYELINATION 
3.1 Literature review  
 Neuroimaging in childhood CNS demyelinating disorders  
Demyelinating disorders mostly affect white matter, via immune mediated mechanisms. This 
white matter damage creates lesions that are visible on brain and spinal MRI. The use of 
contrast (e.g. gadolinium) is used to demonstrate acute lesions which are associated with 
disruption of the blood brain barrier. 
As previously discussed, in 2007 the international paediatric MS study group proposed clinical 
criteria for demyelinating disorders in children (7). Even though the 2007 definitions included 
neuroimaging descriptions for each of the demyelinating conditions, definitive diagnostic MRI 
criteria were not firmly established in children. This is important because being able to identify 
and promptly diagnose the chronically debilitating disorder MS could alter management and 
treatment.  
 McDonald MRI criteria 
In 1997, Barkof et al  (132) conducted a study examining the MRI of 74 adult patients 
presenting with clinically isolated neurological syndromes. Barkof found that the following 
features had an accuracy of 80% in predicting conversion to clinically definite MS (all had to be 
present); 
- a gadolinium enhancing lesion or nine T2 hyper intense lesions if no gadolinium enhancing 
lesions were present, 
- at least one infratentorial lesion  
- at least one juxtacortical lesion  
- at least three periventricular lesions.  
These criteria were agreed upon by international consensus, and incorporated into the 
diagnosis of MS as the Barkhoff criteria.  
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An international panel with the National MS society of America (NMSS) reviewed and then 
revised these criteria both in 2001(49) and again in 2005 (54). The McDonald criteria 
incorporated MRI into the diagnostic algorithm for MS in adults and became an established 
standard for fulfilling the dissemination in space (DIS) and later (2005) the dissemination in 
time (DIT) criteria.  
The 2005 McDonald MRI criteria (54) are summarised as follows: 
An MRI must show 3 of the following to be consistent with MS: 
- Nine or more white matter lesions  (T2 hyper-intensity) or one  Gadolinium enhancing 
lesion (Note: spinal cord lesions can be counted towards the total T2 lesions and are also 
equivalent to brain Gadolinium enhancing lesions) 
- One infratentorial or spinal cord lesion 
- One juxtacortical lesion 
- Three or more periventricular lesions 
In order to fulfil dissemination in time (DIT) for the 2005 McDonald criteria there needed to be 
a second clinical event or evidence of dissemination in time (DIT) using imaging as follows: 
1. Detection of gadolinium enhancement at least 3 months after the initial clinical event, if not at 
the site corresponding to the initial event 
2. Detection of a new T2 lesion at any time compared with a reference scan done at least 30 days 
after the onset of the initial clinical event.  
In 2010 the ‘International panel for diagnosis in MS’ met to discuss and revise these criteria 
(38). The panel reviewed the requirements for having dissemination in time (DIT) and space 
(DIS) and the applicability of the criteria to paediatric, Asian and Latin American populations 
(38). After extensively reviewing the literature and studies done since the 2005 McDonald 
criteria, a number of modifications were made.  
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These modifications are demonstrated in Table 3-1 extracted from the original paper by Polman 
et al (38). 
Table 3-1 The 2010 revised McDonald Criteria for the diagnosis of MS taken from table 4 of Polman et al (38). 
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The main changes to the criteria were as follows:  
- The dissemination in space (DIS) criteria were simplified (Table 3-1, row 2). 
- The dissemination in time (DIT) criteria were updated to allow follow-up scans to be 
performed at any time (abolished 30 day requirement). The presence of a combination of 
asymptomatic gadolinium-enhancing and non-enhancing lesions could substitute a follow 
up MRI scan for DIT (Table 3-1, row 3).  
- On reviewing the application of the criteria to the paediatric population, the panel felt that 
the criteria for demonstrating dissemination in space (DIS) showed high sensitivity and/or 
specificity for children presenting with acute demyelination in the form of CIS.  However the 
panel confirmed that the application of the McDonald criteria is inappropriate for children 
presenting with an ADEM-like illness and therefore suggested adherence to the consensus 
definitions of 2007(7) in these cases. Therefore a child with ADEM would need two further 
non-ADEM like events or one non-ADEM like event with accrual of further lesions on MRI at 
follow-up to meet the diagnostic criteria for MS (38). 
 McDonald Criteria and Paediatric MS; similarities and differences 
The McDonald MRI MS criteria are based on lesion appearance in adult MS patients alone. When 
the revised McDonald criteria were applied to a paediatric population with a first episode of 
demyelination, the sensitivity and specificity were lower than in adults, especially in the 
McDonald MRI MS criteria versions prior to 2005 (104, 133).  
The McDonald MRI MS criteria were tested in a cohort of 20 Canadian children ultimately 
diagnosed with MS and only 53% of children with MS met the McDonald 2001 criteria for lesion 
dissemination in space (DIS) at the time of their initial demyelinating event (133). Furthermore 
in a French study of 116 children presenting with a first acute CNS demyelinating event, the 
McDonald 2001 MRI MS criteria had a sensitivity of only 52% and a specificity of 63%(104).  
Revisions to the McDonald MRI MS criteria (2005 and 2010) have improved the applicability of 
the adult MRI MS criteria to children.  
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The McDonald 2010 MRI MS criteria were tested retrospectively in a paediatric cohort of 
clinically definite MS patients by Sadani et al (134). The McDonald 2010 dissemination in space 
(DIS) criterion was met by 84% of the patients on their baseline scan. The dissemination in time 
criterion (DIT) applied to the baseline scan showed gadolinium enhancement in 11/18 (61%) of 
patients given contrast. The authors conclude therefore that 61% of patients with MS fulfilled 
that DIT criterion in their baseline MRI scan (134). However the investigators do not state 
whether there was a combination of enhancing and non-enhancing lesions and whether the 
lesions that were enhancing were asymptomatic as is required in the McDonald 2010 criteria.  
Most recently the McDonald 2005 and 2010 MRI MS criteria were tested prospectively against a 
paediatric demyelinating cohort and were found to have a high sensitivity (100%) and 
specificity (86%) for children older than 11 years of age diagnosed with a relapsing remitting 
course of MS and who did not have a first episode presentation that met the diagnostic criteria 
for ADEM (135). However even when the entire cohort of children presenting with acute 
demyelinating syndrome (ADS) is used to test the McDonald 2010 criteria (including those with 
ADEM and younger than 11 years), the sensitivity and specificity was the same. This is 
important because between 5- 30% of children initially diagnosed with ADEM, relapse and are 
subsequently diagnosed with MS (8, 9, 11, 18, 55) which the authors acknowledge is an ongoing 
issue previously addressed when the McDonald 2010 MRI MS criteria were first proposed(38, 
135).  
There is however, a subgroup of paediatric patients in whom the initial imaging is well 
correlated to a future diagnosis of MS like in adult studies. This is in children whose first ADS is 
acute optic neuritis(58). 
 In a series  by Riikonen et al (58), the MRI of 14 children with ON was reviewed and of the 8 
that demonstrated white matter lesions in the brain, 7 were eventually diagnosed with MS (58).  
Furthermore in a prospective study by Wilejto et al in 2006 (60) that examined the MRI of 35 
children with isolated ON, 12 children met the McDonald MRI MS criteria for lesion 
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dissemination in space, 10 (83%) of whom were subsequently diagnosed with MS. This is 
comparable to an adult study of 139 patients presenting with acute demyelination of whom 
80% met the criteria for dissemination in space and a diagnosis of MS after a mean follow-up of 
49 months (136).  
Most recently a meta-analysis of published optic neuritis studies in children was published by 
Waldman et al (23). This meta-analysis study found that age and the presence of MRI lesions 
found outside the visual system (not just fulfilling McDonald MRI MS Criteria) at first 
demyelinating episode increased the risk of MS. ON with an abnormal MRI brain significantly 
increased the risk of MS with an OR 27.0 (6.27-125.14, p<0.001) even after adjusting for age.  
A number of theories as to why the MRI appearance of children with MS differs from adults with 
MS have been proposed and were summarized by Banwell et al in 2007 (137). 
She proposed the following possible theories: 
1) “The subclinical phase of MS is brief in young MS patients and therefore fewer pre-existing 
lesions are present during the first episode of demyelination” 
2) “Full myelin maturation proceeds in a caudal-rostral pattern until early adulthood which 
may influence the lesion appearance in young people” 
3) “The immunological immaturity of children may alter the passage of immune cells through 
the blood-brain-barrier and secretion of cytokines”  
4) “The capacity for myelin repair may be substantially different in children compared with 
adults” 
 Trends in Paediatric MRI: differentiating Acute disseminated encephalomyelitis 
from Multiple Sclerosis 
Even though diagnostic MRI criteria for MS and ADEM had not been clearly established in 
children up till 2012, a number of studies had characterized trends helping to differentiate 
between these disorders.  
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Dale et al (8) in a study of 48 children presenting with disseminated demyelination 
demonstrated that: 
- Periventricular lesions where more common in patients diagnosed with MS (92%) 
compared with ADEM (44%) (p<0.01)  
- On follow-up MRI, 90% of ADEM patients had complete or partial resolution lesions as 
opposed to 100% of the MS patients who had new lesions on their MRI(8). 
Hynson et al in 2001 (9) found that in a cohort of 31 children presenting with ADEM at a 
tertiary children’s hospital in Victoria Australia, the MRI lesions; 
- Were asymmetrical but bilateral 
- Distributed in the frontal/parietal subcortical white mater (80%) 
- Distributed in the deep grey matter in 61% of the cohort (39% basal ganglia, 32% 
thalamus).  
- Had resolved in 75% of patients (although only 8 (25% ) patients had had a follow-up MRI) 
In Argentina, Tenembaum et al  performed a cohort study on 84 patients diagnosed with ADEM 
examining whether clinical and neuroimaging findings can predict future outcome or diagnosis 
(11). The investigators reviewed the MRI of patients that were performed at diagnosis and 
annually during the 6.5 year follow-up period. They proposed the hallmark of magnetic 
resonance imaging (MRI) features in ADEM were multifocal or diffuse white matter changes, 
and then divided the 84 ADEM patients further into four groups;   
1) Small lesions only (<5mm) [52 patients],  
2) Large confluent white matter lesions [20 patients],  
3) Additional symmetric bi-thalamic involvement [10 patients] and  
4) Acute haemorrhagic encephalomyelitis (AHEM)[2 patients].  
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 131 of 279 
Based on these findings, the study found that no particular clinical presentation predicted 
radiologic subgroup allocation. Importantly however, all of the ADEM patients had complete or 
partial lesion resolution with no new lesions on follow-up MRI.  
A study by Singhi et al (13) from an ADEM cohort in India found similarly that: 
- The frontal (30%) and parietal (50%) white matter were involved most commonly 
- Lesions were often in the grey matter (17% basal ganglia, 30% thalamus)  
- Repeat MRI at 6 months after the initial ADEM event showed either complete or significant 
lesion resolution in 75%. 
Atzori et al (48) studied 68 Italian children with a first episode of demyelination. In the study 
the researchers compared the MRI of patients with ADEM and those diagnosed with MS.  
The most significant findings were: 
- that the lesion distribution involved the periventricular white matter in 80% of the MS 
patients as opposed to 10% of the ADEM patients. 
- 50% of the ADEM patients had inflammatory lesions in the basal ganglia/thalamus 
compared to only 10% of the MS patients. 
- At follow-up, >50% of lesions in the ADEM group had disappeared, and the remaining 
lesions showed a marked reduction in their attenuation. In MS patients, new lesions 
accumulated in 80%, and the remaining 20% showed either attenuation of pre-existing 
lesions or no change. These differences were statistically significant. 
The association of MS with a particular kind of Periventricular lesion (referred to as 
perpendicular ovoid lesions  - PVPOLs or ‘Dawson’s fingers’) was confirmed in a study by Alper 
et al (51). They found PVPOLs to be completely absent in the MRI of patients presenting with 
ADEM but present in 58% of patients later diagnosed with MS (p<0.001, OR = 127, 95%CI 6.5-
2463) (51). 
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In summary these studies established the following MRI features were more common in ADEM; 
- Large, bilateral white matter lesions 
- Deep grey lesions 
- Partial or complete resolution of lesions on progress MRI brain scan.  
Whereas the findings on MRI more consistent with MS were; 
- Periventricular perpendicular ovoid lesions (PVPOL’s) 
- Periventricular lesions 
- Having new lesions on progress MRI brain scans.  
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 Proposed MRI criteria in Children: KIDMUS, Callen, Verhey 
There have been 3 major studies that have proposed MRI MS criteria for the diagnosis of MS and 
for prognostication of further demyelinating events in children.  
 KIDMUS Criteria 
The first study is by Mikaeloff et al (104) which is a French study examining the MRI of 116 
children with a first episode of acute CNS inflammatory demyelination over a 12 year period.  
The study found and devised the KIDMUS criteria which required the following two features in 
order to fulfil MS criteria; 
- the sole presence of well-defined lesions, and  
- the presence of corpus callosum long axis perpendicular lesions (Dawson’s fingers or PVPOL 
as discussed by Alper). 
The KIDMUS criteria were found to be 100% specific for a subsequent relapse and therefore a 
diagnosis of MS. However despite this high specificity, of the 52 patients diagnosed with MS, 41 
of them had MRI scans that did not meet the two KIDMUS criteria yielding a sensitivity of only 
21%.  The study found that overall, when comparing the KIDMUS criteria to the Barkhof criteria 
(132) the KIDMUS criteria was more specific in predicting relapse but that the Barkhof criteria 
(see above) were more sensitive.  
Dale and Pillai tested the KIDMUS criteria on a cohort of 40 patients from the UK after applying  
the 2007 consensus criteria (50) to the patients in the cohort to determine their clinical 
phenotype. The study found that patients presenting with CIS were more likely to fulfil the 
KIDMUS criteria for MS (54%) compared to patients presenting with ADEM (0%). Of the 54% of 
patients who were KIDMUS positive, 62% of these patients were then found to have been 
diagnosed with MS at follow-up (Table 3-2).  
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Table 3-2 Radiological findings in Dale and Pillai (50). This study showed that CIS patients were more likely to 
have MRI consistent with MS according to the KIDMUS criteria. 
Characteristic CIS (n = 28) ADEM ( n=12) P-Value 
Fulfilled KIDMUS MRI criteria for MS 54% (13/28) 0% <0.01 
KIDMUS positive and diagnosed with MS 62% (8/13) -  
CIS – clinically isolated syndrome, ADEM – acute disseminated encephalomyelitis.  
 Callen Criteria 
There have been two different MS MRI criteria published by Callen et al; the first is paediatric 
MRI MS diagnostic criteria (138) and the other diagnostic criteria are for differentiating MS 
from ADEM based on MRI findings (105). 
In a retrospective review of 21 paediatric patients (<18 years) with clinically definite MS 
(CDMS) who had both a baseline and progress MRI scan available for review,  MRI brain lesion 
characteristics were analysed and the KIDMUS and 2001 McDonald MRI MS criteria were tested 
(138).   
Based on their analysis the investigators proposed a modified version of the McDonald 2001 
MRI MS criteria for the diagnosis of paediatric MS based on the baseline MRI brain scan. 
According to Callen et al (138), there was evidence that a child had dissemination in space (DIS) 
on a baseline scan if they had at least two of; 
- ≥5 T2 lesions and/or 
- ≥2 periventricular lesions and/or 
- ≥1 brainstem lesion.  
They found these criteria to be more sensitive than the McDonald 2001 MRI MS criteria (85% vs 
76%) and KIDMUS criteria (47%). The specificity of the Callen MRI MS criteria was also 
impressive (98%) but slightly less than the McDonald 2001 (100%) and the KIDMUS MRI MS 
criteria (100%). 
In order to use MRI to help differentiate ADEM from MS, Callen et al (105) published a 
retrospective study analysing the initial MRI scans of 28 children with clinically definite MS and 
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20 with ADEM. In the study each MRI was examined by clinicians blinded to the clinical 
diagnosis and the McDonald (49) and KIDMUS (104) MRI MS criteria were also tested. The 
images were also assessed for lesion character and number, presence or absence of ‘black holes’ 
seen on T1 sequences, gadolinium enhancement and for the presence and character of spinal 
lesions.  
Demographically the clinical features of MS and ADEM patient groups were similar to previous 
studies, in that ADEM patients were younger and more often male.  
Callen et al (105) found that the MRI features at the initial demyelinating event that were more 
compatible with MS rather than ADEM had two of the following three features;   
- ≥2 periventricular lesions, and/or 
- The presence of black holes, and/or 
- Lesion distribution pattern that is not diffuse bilateral. Diffuse bilateral lesions refer to 
lesions with hazy, ill-defined borders (cannot be traced) and this appearance has to account 
for the majority (>90%) of the image. 
The specificity of these criteria was 95% in prognosticating a diagnosis of MS, with a sensitivity 
of 81%.  
Total lesion number was not reliably predictive of an MS diagnosis based on imaging during a 
first demyelinating event. However, the mean number of periventricular lesions was 
significantly greater in the MS (7.5 +/- 9.9) compared with the ADEM group (1.4 +/- 2.3) with a 
p-value of 0.004.  
A summary of the accuracy of the Callen criteria in comparison to the previously proposed 
McDonald and KIDMUS criteria in differentiating ADEM from MS is shown in Table 3-3 below. 
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Table 3-3 Comparison of KIDMUS and McDonald MRI criteria tested by Callen in patients with MS (n=28) and 
ADEM (n=20), extracted from table 4, Callen et al (105) 
Accuracy Statistic KIDMUS McDonald 
Callen criteria 
for MS 
Callen criteria 
for MS vs 
ADEM 
Sensitivity 29% 68% 75% 81% 
Specificity 100% 30% 25% 95% 
 
The Callen criteria have been tested against the Barkhof and the KIDMUS criteria in a paediatric 
cohort of patients with CNS demyelination by Ketelslegers et al (139). Patients were recruited 
into the study if they had presented to a major paediatric neurology centre in the Netherlands 
over a 13 year period, and fulfilled the 2007consensus criteria for monophasic ADEM (not 
exclusively with encephalopathy but positive for being polyfocal and monophasic) or had been 
diagnosed with clinically definite MS with more than 2 episodes of demyelination.  
In all, 49 patients were recruited; 28 with MS and 21 with ADEM.  The mean follow-up time was 
approximately 3.5 years for both groups however the standard deviation values were large 
indicating that the follow-up time for some of the patients would have been under a year.  
Figure 3-1 shows how the patients were divided and the results for each of the groups analysed 
according to the Callen, KIDMUS and Barkhof MRI diagnostic criteria. 
Figure 3-1 Taken from Ketelslegers et al (139) “STARD flow diagram”. 
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The study showed that of the three criteria currently being investigated in paediatric 
demyelinating disorders, the imaging criteria with the highest sensitivity was the Callen criteria 
(75%), with a specificity of 95% (Table 3-4).  
The table below summarises the test findings when the Barkhof, KIDMUS and Callen criteria 
were tested in the Dutch paediatric cohort of MS and ADEM patients.  
Table 3-4 Testing the proposed paediatric MRI Multiple Sclerosis criteria on a Dutch cohort published by 
Ketelslegers et al study of paediatric ADEM and MS. 
Test Property Barkhof 
KIDMUS 
(both criteria) 
Callen MS 
vs ADEM 
Sensitivity (%) 61 11 75 
Specificity (%) 91 100 95 
Positive predictive value (%) 90 100 96 
Negative predictive value (%) 63 46 74 
 
This study was a positive step in affirming the Callen criteria as a diagnostic radiological tool in 
differentiating paediatric ADEM from MS however the cohort was relatively small and further 
follow-up time would be needed to ensure the ADEM group remained monophasic. Also the 
study did not strictly conform to the 2007 international consensus criteria making future 
comparisons difficult.  
 Verhey criteria 
Most recently the Canadian paediatric demyelinating disorders network published their MRI 
findings from a cohort of 284 patients in a paper by Verhey et al (103).  The study was a 
national prospective inception cohort study of children who presented with an acquired 
demyelinating syndrome (ADS) of the CNS throughout Canada over a 6 year period. Patients 
were categorized according to the international paediatric CNS demyelinating disorders criteria 
of 2007 (7) and then followed up regularly, including having progress MRI scans.  
The investigators defined 14 MRI parameters which were binary (present or absent) but 
excluded seven on the basis of them not being related to the primary outcome (MS diagnosis) or 
because they were highly correlated with the seven retained parameters  
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The MRI scoring tool for CNS demyelination used by Verhey et al extracted from panel 1 of the 
publication (103) is shown in the 14 numbered dot points below. The parameters highlighted in 
grey are the 7 parameters that were used during analysis (103).  
1. Bilateral lesion distribution: T2 lesions on either side of, or spanning across, the midline in the 
supratentorial or infratentorial regions 
2. Gyral projection: T2 lesion continuously projecting from subcortical white matter at the depth of a 
sulcus into a gyrus, extending to abut the cortical ribbon at the gyral apex 
3.  (A) T1 hypointensity: T1 lesion present at incident demyelinating event with all or a portion of the 
lesion being hypointense relative to cortical grey matter; should be hyperintense on T2-weighted images (B) 
Persistent T1 hypointensity: T1 hypointensity present at incident demyelinating event and persisting for at 
least 3 months, as assessed on serial scans 
4. Lesion contrast enhancement: nodular or ring-link hyperintense signal on T1-weighted post contrast 
enhancement corresponding to a T2 lesion; not hyperintense on T1-weighted pre-contrast scan 
5. Leptomeningeal contrast enhancement: linear or nodular hyperintense signal (minimum 3 mm in 
length or diameter) of the pia and arachnoid mater on T1-weighted post contrast imaging; scan acquisition 
under sedation or general anaesthesia could show pseudoleptomeningeal enhancement 
6. Periventricular lesion: white matter T2 lesion abutting any portion of the lateral ventricles; lesions 
involving the corpus callosal white matter are included, but deep grey matter lesions (see parameters 10 and 
11) are excluded 
7. Cerebral white matter lesion: supratentorial non-juxtacortical (see parameter 8) and non-
periventricular (see parameter 6) white matter T2 lesion; intracallosal lesions (see parameter 9) are excluded 
8. Juxtacortical lesion: supratentorial white matter T2 lesion contiguous with the cortical ribbon (i.e., 
affecting subcortical U-fibres11,12) 
9. Intracallosal lesion: T2 lesion contained entirely within the margins of the corpus callosum 
(anatomical boundaries defined in webappendix p 4–5; adapted from Callen and colleagues5); 1 mm of 
normal-appearing white matter surrounding the lesion should be confirmed as intracallosal and not 
periventricular (see parameter 6) 
10. Thalamic lesion: T2 lesion either entirely or partially contained within the thalamus; bithalamic lesions 
counted as discrete lesions 
11. Basal ganglia lesion: T2 lesion either entirely or partially contained within the caudate nucleus 
(includes head and tail), putamen, or globus pallidus (includes internal and external segments) 
12. Internal capsule lesion: T2 lesion centred in the anterior or posterior limb of the internal capsule 
(anatomical boundaries defined in webappendix 6; adapted from Callen and colleagues5) 
13. Brainstem lesion: T2 lesion within the brainstem, which extends from the most inferior aspect of the 
medulla oblongata (at the level of the pyramidal decussation) to the most superior portion of the midbrain (at 
the level of the red nuclei); posterior anatomical limits defined in webappendix 6–7 
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14. Cerebellar lesion: T2 lesion involving white or grey matter of the cerebellar white matter and cortices, 
dentate nuclei, vermis, or flocculus; anterior anatomical limits of the cerebellum defined in webappendix 6 
 
The seven retained parameters were those that were independently associated with MS in the 
univariate analyses according to the authors (103).  
Of the 284 children included in the study, the initial MRI of 98(35%) patients were found to be 
normal (including 2 later diagnosed with MS), with the remaining 186 (65%) having one or 
more T2-weighted lesions and this was strongly predictive of a subsequent diagnosis of MS 
(sensitivity 96%, specificity 42%).  
The strongest predictor (Table 3-5) for patients who would develop MS was the presence of one 
or more T1-hypointense lesions on presenting MRI with a sensitivity of 95% and specificity of 
88% and a positive predictive value of 68% (54 of the 57 patients that developed MS had an 
initial MRI depicting T1-hypointense lesions) and a negative predictive value of 99% (199 of the 
202 with no T1-hypointensities did not develop MS). This association was even stronger if the 
T1-hypointense lesions were still present after 3 months as was the case in 54 of the cases that 
developed MS compared with only 11 of the 26 cases with monophasic ADS who had T1-
hypointense lesions that persisted.  
The second strongest predictor (Table 3-5) of developing MS was having one or more 
periventricular lesions present on the initial MRI. Having these lesions present increased the 
likelihood of developing MS 12 fold with a sensitivity of 86% and a specificity of 72%. The 
positive predictive value (PPV) in having periventricular lesions was 44% (49 of the 112 
children with periventricular lesions developed MS) with a negative predictive value of 95% 
(164 of the 172 patients without periventricular lesions did not develop MS).  
Interestingly thalamic lesions were more predictive of a monophasic as opposed to a relapsing 
illness (p=0.02) with a reduced MS risk of 61%. This is similar to a number of the earlier studies 
by Atzori (107), Tenembaum (11) and Hynson(9).  
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Table 3-5 Extracted from Verhey et al table 2(103), depicts the MRI features that predicted most significantly 
the conversion to MS. 
 
The investigators further analysed the likelihood of developing MS if a patient had one or more 
periventricular lesions and one or more T1-hypointense lesions and found 48 of the 57 children 
diagnosed with MS met both parameters (sensitivity 84%, specificity 93%).  
Furthermore Verhey et al compared their two new parameters (≥ 1 periventricular lesions and 
≥ 1 T1hpointense lesions) to the previously proposed criteria for diagnosing MS on the basis of 
MRI findings and the results of this analysis are shown in Table 3-6 below.  
These two proposed Verhey criteria (Table 3-6, column 1) perform well when compared to the 
previously proposed criteria in terms of sensitivity and specificity. More importantly, as Verhey 
points out, these two parameters are relatively easy to implement as opposed to some of the 
previously proposed criteria which are subject to interpretation.  
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Table 3-6 Comparison of the previously proposed MRI criteria for diagnosing MS in children extracted from 
Verhey et al table 4 (103). Note: column’s labelled Paediatric MS and Paediatric MS-ADEM have been 
previously referred to as the Callen criteria. Description of the criteria is given below the table.  
 
The aim of our study will be to test all of the previous criteria proposed for paediatric 
demyelinating disorders by two assessors blinded to the clinical outcome. Furthermore I will be 
grouping MRI brain features that can help to prognosticate which children have a higher risk of 
developing a MS in Australian children.   
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3.2 Methods for Neuro-imaging 
  Paediatric cohort 
The patient cohort was formed using the method described in chapter 2. Brain MRI was 
available on 86/88 patients included in the study. Of the remaining two patients with no brain 
imaging available, one patient presented with clinical bilateral ON and did not have an MRI of 
the brain or spinal cord performed.  The other patient presented with clinical TM and only had a 
spinal MRI. Both patients were therefore excluded from the MRI study as the proposed criteria 
for diagnosing MS in children could not be tested.  
In total, the number of scans that were retrospectively reviewed and assessed was 86. All 86 
patients had their baseline brain MRI scan during the admission for their first demyelinating 
event (Figure 3-2).  
There were no controls used for this study as we were testing the established adult McDonald 
MRI MS criteria (38, 54) and the three proposed paediatric MRI criteria for CNS demyelination 
by KIDMUS(104), Callen(105, 138) and Verhey (103) .  
Figure 3-2 Breakdown of patient cohort for MRI retrospective review.  
 
# this patient had clinical transverse myelitis. * This patient had clinical bilateral Optic neuritis. 
 
Clinically 
elligible 
patients (n=88)
Brain MRI available 
for review
(n= 83)
Total number 
of Brain MRI's 
reviewed 
(n=90)
Brain MRI from another 
hospital and normal
(n=3)
in study
86
No brain MRI
(n=2)
#Spinal MRI 
performed
(n=1)
*No Spinal MRI
(n=1)
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 Quantitative analysis of Brain and Spinal MR Images 
 The images were acquired on a 1.5 Tesla magnet with slices between 3mm and 5mm thick and 
an inter-slice gap of up to 2.5mm. Sagittal, coronal and axial T1 sequences as well as sagittal, 
coronal and axial T2 sequences and/or fluid attenuated inversion recovery (FLAIR) sequences 
were performed. Gadolinium was not given to all patients however where gadolinium was used 
to look for enhancement, T1 sequences were acquired at least 5 minutes after its injection. 
All images that were reviewed were scored by two experts in the field who were blinded to the 
clinical diagnosis.  The two experts were Associate Professor Russell Dale (RCD) who has 
proven experience in demyelinating disorders and neuroimmunology. The other was Dr 
Kristina Prelog (KP) who is a staff specialist in radiology with a special interest in 
neuroradiology.  The first review was done independently by the primary researcher (ET) with 
RCD, and then RCD, KP and ET met to review and discuss cases where there was a discrepancy 
in what was recorded on the data sheet until a consensus was reached 
For each of the patients in the cohort fluid-attenuated inversion recovery (FLAIR), T1 and T2 
sequences were reviewed. To optimise the search for lesions in the supra-tentorial region of the 
brain, FLAIR images were used where available.  
The table in Appendix F was used to document each patient’s images in terms of lesion 
presence, number and characteristics.  
 Lesion Location 
Lesion location was categorized in a similar manner as described by Mikaeloff et al (104) and 
was as follows;  
Periventricular: lesions adjacent to the lateral or third ventricular surfaces or callosum. 
Cortical: lesions found in the grey matter of the cortex 
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Juxtacortical: within the subcortical white matter found directly adjacent to the grey matter, 
these are often called ‘U’ fibres 
Deep white matter: lesions located in the white matter (myelinated axons) found below both 
the cortex and juxtocortical areas of the brain, including the internal capsule (anterior and 
posterior limb including genu), and surrounding the deep nuclei (thalamus, globus 
pallidus, putamen). 
Corpus callosum: lesions involving the white matter connecting the hemispheres in a 
transverse fashion (Figure 3-3 Left) 
Perpendicular periventricular ovoid lesions (Dawson’s Fingers): well defined ovoid lesions 
that are perpendicular to the corpus callosum (Figure 3-3 Right). 
Figure 3-3 Left: demonstrates three lesions in the corpus callosum the caudal most lesion is indicated with an 
arrow. Right: demonstrates the presence of perpendicular periventricular ovoid lesions or “Dawson’s” fingers 
(arrows).  
       
Internal capsule: lesions involving the white matter axonal fibres that run between the 
cerebral cortex and the pyramids of the medulla 
Thalamus and basal ganglia: lesions involving the deep grey matter nuclei 
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Brainstem: lesions located in any part of the brainstem from the midbrain down to the medulla 
and including both axonal white matter and grey matter nuclei.  
Cerebellar: lesions infratentorially located within the cerebellar hemispheres.   
All the supratentorial lesions are depicted in Figure 3-4.  
Where there was more than one lesion, a tally was made for each location and then summated 
to give the total number of T2 lesions and total number of Periventricular lesions as specified in 
the proposed criteria (see Appendix F). 
Figure 3-4 Taken from Callen et al (138). An axial T2-weighted image taken at the level of the genu of the 
corpus callosum and it shows examples of most of the location categories assessed in the study. The 
infrantentorial lesions are not shown.   
 
 Lesion characteristics  
Firstly it was noted whether lesions were symmetrically or asymmetrically distributed both for 
white matter and for grey matter (see Appendix F). This was determined by looking at an axial 
T2 image at the level of the greatest lesion concentration and determining whether the lesions 
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were symmetrically or asymmetrically distributed in both hemispheres and in both white and 
grey matter.  
The next characteristic was to determine if lesions were either well or poorly defined. The 
definition of a ‘poorly defined’ or ‘diffuse’ lesion  (Figure 3-5 Left) refers to lesions with hazy, ill-
defined borders as previously described as being more typical of ADEM compared to CIS/MS (8, 
104, 107, 140). The opposite of this is a ‘well defined’ lesion (figure 3-5 Right) that has a 
discrete border or outline. This feature has been incorporated into two of the proposed MRI 
criteria for diagnosing paediatric MS; namely the KIDMUS and Callen (104, 105, 138). Where 
lesions were distributed in both hemispheres and the greater majority of lesions (>90%) were 
poorly defined, then the summative lesion description was recorded as ‘diffuse bilateral’.  
Figure 3-5 Left: Axial T2-weighted image. This image is from a patient with ADEM. Seen are lesions which 
somewhat spare the periventricular area. The multiple lesions in the scan are typically described as poorly 
defined or diffuse. Right: T1 sagittal FLAIR sequence. This image is from a patient with MS, and shows 
predominantly periventricular lesions. The lesions in this image are typically described as well-defined or 
discrete. The arrow depicts a classic example of a well-defined lesion. These figures come from Dale et al (8). 
                
 
These definitions have been extracted from a substantial number of previous studies and 
papers, we do acknowledge that these definitions are subjective. Although we have not been 
able to improve the interpretation of ‘well-defined’ and ‘poorly-defined’ in our study, 
understanding the pathophysiology as to why lesions are more discrete or diffuse may help to 
Poorly defined 
lesion 
Well 
defined 
lesion 
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develop new technologies that may assist in the interpretation of these lesions in the future. For 
example a particular substrate may be identified on MR spectroscopy (MRS) that is indicative of 
MS and therefore the need to differentiate lesions based on their appearance may become less 
important in time. 
The ‘sole presence’ of either ‘well defined’ or ‘poorly defined’ lesions implies that every lesion 
was either well or poorly defined. If there was a mixed picture of well and poorly defined lesions 
then it was documented accordingly.   
As previously stated and well established in the literature, T2 and FLAIR are the most 
appropriate imaging techniques to visualize CNS demyelinating lesions. However where there 
were hypo-dense lesions on the T1-weighted images, the description of ‘T1 black hole’ was 
applied in our study (Figure 3-6 left and right). There is controversy surrounding the definition 
of a ‘black hole’ on T1 images. Some investigators use the term to describe any hypo-dense 
lesions found on T1-weighted images (105, 138). Traditionally however, the term has been 
applied to chronic non-enhancing lesions (sequential MRI scan)  that were found to be 
consistent with irreversible axonal damage histologically (141).  In our study we have applied 
the use of ‘black hole’ by the former definition (any hypo dense lesion observed using T1 
imaging) as was described by Callen at el (105) to allow for consistency in testing of the 
proposed Callen MRI diagnostic criteria in our cohort. We acknowledge that by applying this 
definition of a ‘black hole’ we may be overcalling this finding as some patients may have T1 
hypo-intensity’s that are transient hyper-acute black holes. 
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Figure 3-6 Left: T1 weighted image from a child with ADEM taken during the acute phase.  Depicted are 
examples large hypo-dense lesions in the white matter of the brain which are classified as ‘black holes’. These 
‘black hole’ are large and atypical of MS Right: T1 weighted sagittal image from a child with MS taken during 
the acute phase. Another example of a ‘black hole’, which is more typical of MS. 
                 
In a paper by Verhey et al (103) the definition used for a T1-hypodense lesion was  a lesion 
present at the initial demyelinating episode with a portion of the lesion being hypointense 
relative to cortical grey matter. The lesion should also be hyperintense on T2-weighted images 
(103). This study was unfortunately published after our analyses had already been conducted; 
however we feel that, even though we defined black holes as hypointense relative to its 
surrounding tissues (both white and grey) rather than hypo-dense relative to cortical grey, we 
are in fact referring to the same type of lesions. We ensured that these ‘black holes’ were 
hyperintense on T2 weighted images as per Verhey et al (142).  
Gadolinium (GAD) enhancement was documented where contrast had been given and images 
were available for review.  In total 78/88 patients had been given GAD. Scans were also 
assessed to determine if there was a combination of asymptomatic enhancing and non-
enhancing lesions as would fulfil DIT in the McDonald 2010 criteria (38).  
Lesion size was not determined in terms of a measured diameter, however we did record the 
presence or absence of ‘hyper-intense, large, confluent lesions’ that were greater than 2 gyri on 
T2-FLAIR as described by Chabas et al (143). These lesions were found to be a distinct 
‘T 1 Black 
hole’ ‘T 1 Black 
hole’ 
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phenotype in pre-pubertal patients who develop MS compared with post-pubertal >11 yrs. old 
patients with MS.  
 Spinal cord imaging 
Where available, spinal cord MRI was also reviewed by the two blinded reviewers RCD and KP. 
In total 42 out of 88 (47%) patients had a spinal MRI performed. Two of the 42 patients had 
spinal MRI alone (no brain MRI). Both T1 and T2 sequences were reviewed.  
Imaging characteristics that were recorded are shown in Appendix F. Lesion presence or 
absence was noted. This was followed by a general description of the location of the lesion 
including cervical, thoracic or lumbar region.  Each lesion was compared to the neighbouring 
vertebrae and then size was documented as follows; less than 3 vertebral segments, greater 
than 3 vertebral segments, or involving the whole spinal cord.  
The characteristics of each lesion was recorded in a similar way to those recorded in the brain; 
‘discrete lesions’ had well defined borders, whereas ‘ill-defined’ or ‘diffuse’ lesions had poorly 
defined boarders.  
Statistical analysis was used to compare the MRI spine of patients with lesions as is described in 
chapter 3.2.4.  
 Follow-Up MRI scan review 
Follow-up MRI brain and spine scans were reviewed. The main characteristics that were 
recorded for the follow-up scans was how long after the initial event the scan was performed, 
secondly whether the lesions on the scan had either partially or completely resolved or thirdly 
whether there were new lesions present.  
In order to be included in the progress scan analysis patients had to have at least an MRI of the 
brain (n=54). There were 14 patients who had a progress MRI of the spine in addition to a 
progress brain MRI.  There were an additional four patients that only had a progress spinal MRI 
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and these patients were excluded from the progress MRI analysis. Therefore the total number of 
patients reviewed for the progress MRI scan comparison was 54.  
 Testing of proposed MRI criteria for Paediatric MS: McDonald, KIDMUS, Callen and 
Verhey 
Once the images were reviewed, data was then extracted in order to test the four proposed MRI 
MS criteria as described below. The four MRI criteria as summarised in Table 3-7 were applied 
to the baseline scan for comparison of their efficacy in predicting which patients will have MS at 
follow-up.  
The definition of MS used was in keeping with the 2007 consensus criteria(7); a patient had to 
show evidence of two or more asymptomatic lesions to demonstrate dissemination in time and 
space (DIT and DIS) in combination with two or more clinical demyelinating events.  
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Table 3-7 Summary of established adult (McDonald) and proposed paediatric MRI MS criteria.  
McDonald 
2005(54) 
DIS* 
An MRI must show 3 of the following: 
1. ≥9 white matter lesions in the brain 
or spinal cord OR one gadolinium 
enhancing lesions in the brain or 
spinal cord 
2. ≥1 infratentorial (or spinal) lesion 
3. ≥1 juxtocortical lesion 
4. ≥3 periventricular lesions 
DIT# 
Can be fulfilled in two ways; 
1. Gadolinium enhancing lesion >3 
months after initial event OR 
2. New T2 lesion at least 30 days after 
baseline scan 
McDonald 
2010(38) 
DIS 
An MRI must show one T2 lesion in at 
least 2 of 4 areas; 
1. Periventricular 
2. Juxtacortical 
3. Infratentorial  
4. Spinal Cord (must not be a 
symptomatic lesion) 
DIT 
Can be fulfilled in two ways: 
1. Simultaneous presence of 
asymptomatic gadolinium enhancing 
and non-enhancing lesions at any time 
(including baseline scan) OR 
2. New T2 and/or gadolinium enhancing 
lesion on serial MRI 
KIDMUS (104) An MRI must have both: 
1. Sole presence of well-defined lesions AND 
2. the presence of lesions perpendicular to the long axis of corpus callosum 
Callen (138) 
(For diagnosing 
paediatric MS) 
To diagnose paediatric MS an MRI must show two or more of the following; 
1. ≥5 T2 lesions 
2. ≥2 periventricular lesion 
3. ≥1brainstem lesion 
Callen (105) 
(For 
differentiating 
ADEM from MS) 
To diagnose MS as opposed to ADEM an MRI must have 2 or more of the following: 
1. ≥2 periventricular lesions 
2. Black holes on T1 images 
3. Lesion distribution that is not diffuse bilateral. 
Verhey (103) A future diagnosis of MS strongly correlated with an MRI that showed both : 
1. ≥1 periventricular lesions and 
2. ≥1 T1-hypotense lesions 
* DIS – dissemination in space, the presence of lesions in multiple areas of the brain. 
# DIT – dissemination in time, evidence of lesion accumulation with time. 
 McDonald 2005 
According to the 2005 McDonald Criteria (54) in order to meet the dissemination in space 
criteria (DIS), an MRI must show 3 of the following; 
- Nine or more white matter lesions in brain and/or spinal cord (T2 hyper-intensity) or one 
Gadolinium enhancing lesion in the brain or spinal cord. 
- One infratentorial (or spinal) lesion 
- One juxtacortical lesion 
- Three or more periventricular lesions 
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To fulfil dissemination in time (DIT) criteria a patient had to either have a second clinical event 
or there were two ways to demonstrate (DIT) using neuro-imaging: 
1. Detection of gadolinium enhancement at least 3 months after the onset of the initial clinical 
event, but not at the site corresponding to the initial event AND/OR 
2. Detection of a new T2 lesion if it appears at any time compared with a reference scan done at 
least 30 days after the onset of the initial clinical event.  
Therefore in order to test the McDonald 2005 we applied the DIS criteria to the baseline scan. 
DIT was not used for the 2005 McDonald criteria analysis because of the time requirement.  
 McDonald 2010 
The McDonald 2010 Dissemination in space (DS) (38) criteria can be demonstrated on brain 
MRI by one T2 Lesion in at least 2 out of 4 of the following areas of the CNS: 
- Periventricular 
- Juxtacortical 
- Infratentorial 
- Spinal cord (NB: a qualifying factor for lesion count is that if a patient has a brainstem or 
spinal cord syndrome then symptomatic lesions do not contribute and are excluded from 
the total lesions count) 
Gadolinium enhancement is not required for the DIS criteria.  
In addition there are two variations of the McDonald 2010 DIT criteria that can be applied with 
no restriction on time (time factor was abolished in the McDonald 2010 revised criteria (38)). 
DIT can be demonstrated by either: 
1. Simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions 
at any time including the baseline MRI brain scan, and/or 
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2. A new T2 and/or gadolinium-enhancing lesion on follow-up MRI, with reference to the scan 
from their first episode of CNS demyelination.  
Therefore both DIT and DIS criteria are able to be met during the first clinical presentation of 
CNS demyelination based on MRI findings (Figure 3-7 and Figure 3-8)).  
Figure 3-7 MRI brain demonstrating a patient who would be classified as not meeting the dissemination in 
time criteria according to the McDonald 2010 criteria. Left: Coronal FLAIR sequence demonstrating a number 
of demyelinating lesions in the juxtocortical, deep white, periventricular white matter areas in the right 
hemisphere. There are also dominant basal ganglia lesions in both hemispheres. Right: Coronal T1 sequence 
with gadolinium demonstrating that all of the hyperintense lesions described on coronal flair (left) enhance 
with gadolinium. As all of the lesions have gadolinium enhancement, this patient does not fulfil McDonald 
2010 DIT baseline scan criteria. This patient’s clinical presentation consisted of encephalopathy, swallowing 
abnormalities, hemiplegia and was consistent with a diagnosis of acute disseminated encephalomyelitis. 
 
Figure 3-8 MRI brain scan positive for the dissemination in time (DIT) McDonald 2010 criteria of baseline scan. 
Left: Coronal FLAIR sequence demonstrating a number of hyperintense lesions. Right: T1 coronal sequence 
with gadolinium demonstrating that enhancement of all but one of the lesions (marked with arrow). This 
patient presented with clinical transverse myelitis consistent with the 2002 diagnostic criteria. Her initial MRI 
spine was normal, however a repeat 2 weeks after her presentation showed extensive cord demyelination. She 
would therefore fulfil the DIT criteria by having asymptomatic gadolinium enhancing and non-enhancing 
lesions. 
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 KIDMUS  
The proposed MRI MS criteria devised by Mikaeloff et al (104) to help predict an MS diagnosis 
were that an MRI had to demonstrate; 
- the sole presence of well-defined lesions and  
- lesions perpendicular to the long axis of the corpus callosum 
We tested the presence of both of these characteristics because this yielded the highest 
specificity as reported by the investigators.  
 Callen 
Callen proposed two different MRI criteria, and we tested both of them.  
The proposed criteria for diagnosing paediatric MS (a modified version of the McDonald 
criteria) (138) were as follows;  
The MRI must show two of the following lesion patterns: 
- Five or more T2 lesions and/or 
- Two or more periventricular lesions and/or 
- One or more lesions in the Brainstem  
The MRI criteria used to differentiate MS from ADEM (105) predicted that a scan was consistent 
with a diagnosis of MS as opposed to ADEM if the MRI had two or more of the following; 
- 2 periventricular lesions and/or 
- ‘black holes’ and/or 
- Lesion distribution pattern that is not diffuse bilateral.  
 Verhey  
Verhey et al (103) found that having the following two parameters most strongly correlated 
with a future diagnosis of MS; 
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- One or more periventricular lesions AND 
- One or more T1-hypotense lesions. 
The definitions used for the above criteria as defined by Verhey and used in our study are as 
follows: 
Periventricular lesion  - white matter T2 lesion abutting any portion of the lateral ventricles; 
lesions involving the corpus callosal white matter are included, but deep grey matter lesions are 
excluded 
T1 hypointensity- T1 lesion present at incident demyelinating event with all or a portion of 
the lesion being hypointense relative to cortical grey matter. The lesion should be hyperintense 
on T2-weighted images. 
Comment: as stated previously our study and review of the brain and spinal MRI’s for our 
patient cohort had been conducted prior to the publication of the study by Verhey et al (103) 
and even though we did not regard the hypointensity to be relative to the cortical grey, we 
believe the lesions we were referring to as ‘black holes’ are similar with the T1-Hypointense 
lesions described by the author Verhey.  
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 Statistical method 
All Analyses were performed by the primary investigator and author using SPSS © (version 
17.0).  
Categorical data were summarized for each MRI brain characteristic and then Pearson’s Chi-
Square test was used to test for association between categorical variables. P-values were 
reported for categorical data and the null hypothesis rejection criterion α was set at 0.05. We 
did not make any adjustments for multiple comparisons.  
Univariate analysis was performed for each significant characteristic (p-value <0.05) using the 
Cox proportional hazard model.  
For the Cox model, time zero was the time of the first CNS demyelinating event. The outcome of 
interest was a diagnosis of MS and therefore time to diagnosis (both clinically and 
radiologically) was the second time measurement in these patients. For the patients with a Non-
MS Diagnosis, the second time measurement was time at telephone or clinic follow-up 
(whichever was most recent). The patient cohort was censored at the conclusion of the follow-
up component of the study (September 2011). 
A multivariate analysis using the Cox model with backward selection was then performed using 
the characteristics which were found to be significant in the univariate analysis.  
We report unadjusted hazard ratios with a 95% CI in the univariate and multivariate analyses. 
Kaplan-Meier curves were used for descriptive purposes.  
Although all statistical tests were performed by the primary researcher ET, all statistical 
methods were discussed with and reviewed by Ms Elizabeth Barnes, Biostatistician, NHMRC 
clinical trials Centre, University of Sydney to confirm the validity of what was being performed 
by the primary investigator. 
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3.3 Results of Neuro-imaging study 
 First episode of demyelination- imaging comparisons. 
 Brain MRI characteristic comparison:  ADEM vs CIS  
In total the MRI brain was available for review on 86/88 (97%) patients in the cohort with a 
mean follow-up of 5.2 years (range 1.0 to 13.9 years)(Figure 3-9). The average time from 
clinical presentation to hospital and MRI was 1.3 days (range 0-10 days). This does not include 
the prodromal time or pre-presentation symptom time period. In patients with enhancement of 
the optic nerves but no lesions in the brain outside the optic nerves, the MRI brain was defined 
as ‘normal’.  
Figure 3-9 MRI brain scans divided according to diagnosis at presentation. 
 
TM – transverse myelitis, ON – optic neuritis, ADEM- acute disseminated encephalomyelitis, CIS – clinically 
isolated syndrome.  
The MRI brain was normal in 18 patients with CIS and in 1 patient with ADEM (Figure 3-9). In 
the CIS group 11 of the patients with normal MRI brain were diagnosed with clinical ON, and 7 
of the patients had TM (and an abnormal spinal MRI). The one ADEM patient with a normal MRI 
Enrolled in 
Cohort (n=88)
MRI Brain 
Available
(n=86)
ADEM (n=36)
Normal MRI brain 
(n=1)
Patient had TM and an 
abnormal spine MRI
Abnormal 
MRI brain 
(n=35)
CIS (n=50)
Normal MRI brain 
(n=18)
11 patients had ON 
7 patients had TM
Abnormal 
MRI brain 
(n=32)
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brain had presented with encephalopathy and TM and the spinal imaging was abnormal in this 
patient. Repeat MRI brain was also normal.  
Lesion site varied significantly between patients presenting with CIS compared to those with 
ADEM as depicted in Table 3-8. ADEM patients had lesions that were bilaterally distributed 
(33/36, 92%) and more often had lesions found in the deep white, juxtacortical, internal 
capsule, cortical grey matter, basal ganglia, thalamus, brainstem and in the cerebellum 
compared to patients with CIS and this was statistically different (Table 3-8).  
The lesion load (number) and size (>2 gyri) was greater in ADEM patients compared to those 
with CIS and again this was a statistically significant difference (Table 3-8). There was no site in 
the brain where CIS patients more frequently had lesions compared to ADEM patients.  
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Table 3-8 MRI Brain characteristic differences between ADEM and CIS patients 
Characteristic of MRI (Brain MR n=86) ADEM (n=36) CIS (n=50) p-value 
LESION SITE    
Periventricular 17 (47.2%) 17 (34.0%) 0.22 
Deep White Matter 25 (69.4%) 16 (32.0%) <0.00 
Juxtacortical 29 (80.6%) 25 (50.0%) <0.00 
Corpus Callosum 7 (19.4%) 4 (8.0%) 0.12 
Dawson’s Fingers (PPOL) 0 (0%) 5 (10.0%) 0.05 
Internal Capsule 14 (38.9%) 8 (16.0%) 0.02 
Cortical Grey 22 (61.1%) 11 (22.0%) <0.00 
Basal Ganglia 16 (44.4%) 2 (4.0%) <0.00 
Thalamus 20 (55.6%) 7 (14.0%) <0.00 
Brainstem 24 (66.7%) 11 (22.0%) <0.00 
Cerebellar  14 (38.9%) 8 (16.0%) 0.02 
LESION DISTRIBUTION    
Symmetrical grey matter lesions 17 (47.2%) 3 (6.0%) <0.00 
Asymmetrical grey matter lesions 8 (22.2%) 9 (18.0%) 0.63 
Symmetrical white matter lesions 5 (13.9%) 2 (4.0%) 0.1 
Asymmetrical white matter lesions 27 (75.0%) 28 (56.0%) 0.07 
Bilaterally distributed 33 (91.7%) 26 (52.0%) <0.00 
LESION NUMBER    
T2lesions <five 4 (11.1%) 13 (26.0%) 0.09 
T2 five to nine lesions 5 (13.9%) 6 (12.0%) 0.8 
T2 > nine lesions 26 (72.2%) 13 (26.0%) <0.00 
Periventricular > two  9 (25.0%) 10 (20.0%) 0.58 
Periventricular > three 8 (22.2%) 8 (16.0%) 0.46 
LESION CHARACTERISTICS    
Solely well-defined lesions 2 (5.6%) 3 (6.0%) 0.93 
Solely poorly-defined lesions 32 (65.4%) 20 (40.0%) <0.00 
Both well- and poorly defined lesions 1 (2.8%) 9 (18.0%) 0.03 
T1 black holes present 12 (33.3%) 16 (32.0%) 0.9 
Large lesions >2gyri 26 (72.2%) 10 (20.0%) <0.00 
Contrast enhancing (n=78 given contrast) 7/34 (20.6%) 14/44 (31.8%) 0.27 
Asymp. enhancing and non-enhancing lesions (n=78) *n/a 10 (20.0%) - 
Note: where the p value was less than 0.00, the result was recorded as <0.00 (i.e. to 2 decimal places). *N/A –non-
applicable because in patients with ADEM it cannot be conclusively stated whether a lesion is asymptomatic in view of the 
presence of encephalopathy.  
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 Spinal MRI comparison: ADEM vs CIS  
Spinal MRI was generally performed in patients with clinical findings attributable to the spinal 
cord. MRI spine was done in 42/88 (47%) patients of whom 35 had a spinal abnormality 
compatible with myelitis; 14 in the context of ADEM and 21 with CIS.  
The comparison and analysis of patients presenting with ADEM and CIS who had MRI spinal 
lesions present is shown in Table 3-9.  
There was only one characteristic that neared significance in the MRI spine in the two groups: 
lumbar cord lesions were more common in patients with ADEM compared with CIS (p=0.05).   
Only one patient from the CIS group with extensive involvement of the cord including cavitation 
was diagnosed with longitudinally extensive transverse myelitis (LETM) and was found to have 
NMO IgG. This patient met the diagnostic criteria for NMO spectrum disorder.  
We have only recently begun testing for the NMO IgG auto-antibody. We retrospectively tested 
64/88 patients in the cohort for AQP4 antibody and found one patient who was positive. This is 
discussed further in the myelin oligodendrocyte glycoprotein (MOG) study chapter 4.  
Table 3-9 MRI spine characteristic differences in patients with ADEM vs CIS. Only patients with an abnormal 
spinal scan are compared (n=35). 
Characteristics of Spinal Cord Lesions ADEM (n=14) CIS (n=21) p-value 
LESION LOCATION    
Cervical Cord 11 (78.6%) 16 (76.2%) 0.87 
Thoracic Cord 9 (64.3%) 15 (71.4%) 0.66 
Lumbar Cord 10 (71.4%) 8 (38.1%) 0.05 
LESION EXTENT    
Less than 3 Vertebrae 3 (21.4%) 9 (42.9%) 0.19 
Greater than 3 Vertebrae 7 (50.0%) 7 (33.3%) 0.32 
Whole Cord 4 (28.6%) 5 (23.8%) 0.75 
LESION APPEARANCE    
Poorly Defined Margins 14 (100%) 21 (100%) - 
Well Defined Margins 0 (0%) 0 (0%) 1 
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 Progress MRI scan comparison 
The number of patients in the cohort (n=88) that had a progress MRI of the brain with or 
without an MRI of the spine was 54/88 (61%); 26 who initially had ADEM and 28 CIS. When 
comparing the progress scans (Table 3-10), the only finding that was significant between these 
two groups was  that the CIS patients more commonly had new lesions on follow-up MRI of the 
brain and/or spine compared with ADEM patients (32.1% vs 7.7%, p=0.03), and were therefore 
likely to be diagnosed with MS.  
Table 3-10 Comparison of progress MRI brain and/or spine of patients initially diagnosed with ADEM or CIS 
Characteristics of progress MRI Brain +/- Spine (n=54) ADEM (n=26) CIS (n=28) p-value 
No Change from Previous 1 (3.8%) 6 (21.4%) 0.06 
Complete Resolution 7 (26.9%) 3 (10.7%) 0.13 
Partial Resolution 16 (61.5%) 10 (35.7%) 0.06 
New Lesions 2 (7.7%) 9 (32.1%) 0.03 
ADEM – acute disseminated encephalomyelitis, CIS – clinically isolated syndrome. 
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 Brain MRI comparison based on follow-up diagnosis: Multiple Sclerosis vs Non-
Multiple Sclerosis.  
Neuro-imaging characteristics of the MRI brain from the initial demyelinating episode (baseline 
scan) were compared in the cohort according to diagnosis at follow-up: MS or Non-MS. In total 
13/88 (15%) patients were diagnosed with MS and 75/88 (85%) with Non-MS.  
The Non-MS Patient group (n=75) included patients with a monophasic course (n=70), and 
those with recurrent ON alone (n=4) and NMO (n=1). 
There were a number of statistically significant differences in the brain imaging of patients who 
had a follow-up diagnosis of MS compared to those with Non-MS as shown in Table 3-11.  
Patients with a follow-up diagnosis of MS had lesions more frequently found in the 
periventricular and deep white matter, corpus callosum and ovoid lesions perpendicular to the 
corpus (Dawson’s fingers) compared to those with Non-MS (Table 3-11). Lesion load (number) 
was greater in patients with a follow-up diagnosis of MS with 10/13 (77%) of patients having 
over nine T2 lesions compared with only 29/73 (40%) of those with Non-MS (p=0.01).  
Contrast was given to 78/86 (91%) patients undergoing an MRI brain. Gadolinium 
enhancement occurred significantly more in the lesions of patients with a follow-up diagnosis of 
MS compared to Non-MS (p<0.00). Gadolinium enhancing lesions were associated with a greater 
than 6-fold increase in MS risk (Table 3-11). 
Having a combination of gadolinium enhancing and non-enhancing asymptomatic lesions also 
occurred significantly more in patients with MS compared to those with Non-MS (58% vs 5%, 
p<0.00).  
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Table 3-11 Comparison of MRI brain characteristics at first demyelinating episode of patients with a follow-up 
diagnosis of MS vs Non-MS. 
Characteristic of MRI (n=86) MS (n=13) Non-MS (n=73) 
p-
value 
LESION SITE    
Periventricular 13 (100%) 21 (28.8%) <0.00 
Deep White Matter 12 (92.3%) 29 (39.7%) <0.00 
Juxtacortical 12 (92.3%) 42 (57.5%) 0.02 
Corpus Callosum 5 (38.5%) 6 (8.2%) <0.00 
Dawson’s Fingers (PPOL) 5 (38.5%) 0 (0%) <0.00 
Internal Capsule 6 (46.2%) 16 (21.9%) 0.07 
Cortical Grey 6 (46.2%) 27 (37.0%) 0.53 
Basal Ganglia 0 (0%) 18 (24.7%) 0.04 
Thalamus 4 (30.8%) 23 (31.5%) 1.00 
Brainstem 7 (53.8%) 28 (38.4%) 0.30 
Cerebellar  6 (46.2%) 16 (21.9%) 0.07 
LESION DISTRIBUTION    
Asymmetrical white matter lesions 12 (92.3%) 43 (58.9%) 0.02 
Symmetrical white matter lesions 1 (7.7%) 6 (8.2%) 1.00 
Asymmetrical grey matter lesions 5 (38.5%) 12 (16.4%) 0.07 
Symmetrical grey matter lesions 0 (0%) 20 (27.4%) 0.03 
Bilateral  lesions 13 (100%) 46 (63.0%) 0.01 
LESION NUMBER    
T2 lesions < five 1 (7.7%) 16 (21.9%) 0.24 
T2 five to nine lesions 2 (15.4%) 9 (12.3%) 0.76 
T2≥ nine lesions 10 (76.9%) 29 (39.7%) 0.01 
Periventricular >two  8 (61.5%) 11 (15.1%) <0.00 
Periventricular >three 7 (53.8%) 9 (12.3%) <0.00 
LESION CHARACTERISTICS    
Solely poorly-defined lesions 3 (23.1%) 49 (67.1%) <0.00 
Solely well-defined lesions 2 (15.4%) 3 (4.1%) 0.11 
Both well- and poorly defined lesions 8 (61.5%) 2 (2.7%) <0.00 
T1 black holes present 8 (61.5%) 20 (27.4%) 0.02 
Large lesions >2gyri 4 (30.8%) 32 (43.8%) 0.38 
Contrast-enhancing lesions (n=78) 10/12 (83.3%) 11/66 (16.7%) <0.00 
Asymp. enhancing and non-enhancing lesions (n=78) 7/12 (58.3%) 3/66 (4.5%) <0.00 
MRI: magnetic resonance imaging; MS: Multiple Sclerosis. Note: where the p value was less than 0.00, the result was 
recorded as <0.00 (i.e. to 2 decimal places). 
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 Univariate and Multivariate analysis of MRI brain characteristics 
The results of the univariate analyses with confidence intervals and p-values are shown in Table 
3-12 below. Characteristics which were significant (p-value <0.05) and had significant 
confidence intervals were analysed in the multivariate analysis and are marked with an asterisk 
(*).   
There were in total 11 characteristics in the univariate analyses which were significant 
predictors of MS; 10 increased and one reduced the risk of MS. The 10 characteristics that 
increased the risk of MS included having lesions in the deep white matter, corpus callosum and 
ovoid lesions perpendicular to the corpus callosum (Dawson’s fingers). Also having over nine T2 
lesions, over two or three periventricular lesions, a combination of well and poorly defined 
lesions, contrast enhancing lesions (Table 3-12), asymptomatic enhancing and non-enhancing 
lesions and T1 ‘black holes’ were predictive of MS. The characteristic which was protective of 
developing MS was the presence of solely poorly defined lesions. Although having symmetrical 
grey matter lesion distribution was also significant (p=0.03) the confidence interval crossed 1.0 
and was both predictive and protective of MS so therefore it was excluded.  
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Table 3-12 MRI predictive model for MS in children with acute demyelinating syndrome (univariate analyses) 
CHARACTERISTIC (n=86) Hazard Ratio 95.0% CI p value 
LESIONS SITE    
Periventricular 144.9 1.09-19218.69 0.05 
Deep white matter  15.83 2.05-121.98 <0.00* 
Juxtacortical  7.92 1.03-60.97 0.05 
Corpus callosum  5.78 1.87-17.90 <0.00* 
Dawson’s fingers  19.68 6.16-62.89 <0.00* 
Internal capsule  2.83 0.96-8.42 0.06 
Cortical grey  1.46 0.49-4.36 0.5 
Basal ganglia  0.04 0-11.52 0.26 
Thalamus 1.07 0.33-3.48 0.91 
Brainstem  1.99 0.67-5.97 0.22 
Cerebellar 2.79 0.94-8.32 0.07 
LESION DISTRIBUTION    
Asymmetrical white lesions 6.9 0.89-53.08 0.06 
Symmetrical white lesions 1.34 0.17-10.49 0.78 
Asymmetrical grey matter lesions 2.82 0.92-8.65 0.07 
Symmetrical grey matter lesion 0.23 0.00-8.70 0.03 
Bilateral lesions 42.5 0.38-4714.89 0.12 
LESION LOAD (NUMBER)    
T2 lesions < 5 1.75 0.63-4.86 0.28 
T2 5 to 9 lesions 0.96 0.45-2.04 0.9 
T2 >9 lesions 5.18 1.41-19.03 0.01* 
Periventricular lesions >2 7.76 2.521-23.87 <0.00* 
Periventricular lesions >3 7.75 2.55-23.56 <0.00* 
LESION CHARACTERISTIC    
Solely poorly defined lesions 0.19 0.05-0.71 0.01* 
Solely well-defined lesions 3.09 0.68-13.98 0.14 
Both well and poorly defined lesions 17.85 5.79-54.95 <0.00* 
T1 black holes present 3.43 1.12-10.51 0.03* 
 Large lesions >2 gyri 0.65 0.2-2.13 0.48 
Contrast enhancing lesions  (n=78) 17.31 3.77-79.41 <0.00* 
Asymp. enhancing & non-enhancing lesions (n=78) 15.65 4.93-49.72 <0.00* 
*Characteristics analysed in the multivariate analysis. Hazard ratios refer to prognostic value of each MRI parameter on 
rate of MS versus non-MS. A hazard value greater than 1 implies a hazard towards the outcome of interest (MS diagnosis) 
and less than one but greater than zero implies protection from the outcome of interest.CI – confidence interval. Were 
there were less MRI scans available to test a characteristic, the number available are shown in brackets.  
A multivariate analysis was performed with the significant MRI characteristics (*), as well as the 
two significant clinical characteristics from the analyses in chapter 2(preceding infection and 
cerebellar signs).  
Using multivariate analyses, there were three MRI characteristics that were found to be 
significant predictors of MS in our cohort; having lesions in the corpus callosum, having a 
combination of well and poorly defined lesions and having lesions that were contrast enhancing 
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(Figure  3-10). Having a preceding infection remained a significant protective clinical 
characteristic (Table 3-13). 
Table 3-13 Clinical and MRI predictors of MS at first episode of CNS demyelination (multivariate analysis). 
Characteristic 
Hazard Ratio 
(HR) 
95.0% Confidence Interval (CI) 
p-value 
Lower Upper 
Preceding infection 0.16 0.03 0.89 0.04 
Presence of poorly and well defined lesions 13.93 3.29 59.07 <0.00 
Contrast enhancing lesions 8.05 1.62 39.94 0.01 
Corpus Callosum lesions 7.80 1.71 35.54 0.01 
Hazard ratios refer to prognostic value of each MRI parameter on rate of MS versus non-MS from the multivariate 
analyses. A hazard value greater than 1 implies a hazard towards the outcome of interest (MS diagnosis) and less than one 
but greater than zero implies protection from the outcome of interest. 
These four characteristics (Table 3-13) were independently associated with MS. The strongest 
predictor of MS was having a combination of both well and poorly defined lesions with HR 13.93 
(CI 3.29-59.07, p<0.00). 
The images from Figure 3-10 demonstrate the significant characteristics on MRI brain found on 
the multivariate analysis for our cohort.  
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Figure 3-10 Demonstration of lesions found to 
be significant on multivariate analysis in 
predicting MS diagnosis versus Non-MS. Right: 
T2 sagittal flair demonstrating lesions in the 
corpus callosum in a male with MS. Middle left 
and right: MRI brain sagittal T1 sequences with 
and without contrast in a female patient with 
MS. The image on the left was taken prior to 
contrast and the image of the right after 
contrast was given. The images clearly show that 
the lesions found in this patient are contrast 
enhancing. Bottom left and right: T2 Axial (left) 
and Sagittal MRI brain scans of patient KM with 
a combination of both well-defined (circled) and 
poorly-defined (square) lesions.  
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Having all three radiological characteristics that were significant in the multivariate analysis on 
a MRI was strongly predictive of MS (HR 9.64, CI 4.00 – 23.20). The probability of an event free 
survival is dramatically reduced if all three are present as shown in the Kaplan-Meier graph in 
Figure 3-11.  
Figure 3-11 Kaplan-Meier Graph depicting the risk of developing MS if you have 0,1,2 or 3 of the MRI 
characteristics that were statistically significant on the multivariate analysis for our cohort, as described in 
table 3-10. 
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 MRI in Clinically Isolated Syndrome (CIS) - subgroup Optic Neuritis (ON) 
Of the CIS patients (n=52) in our cohort that presented with ON (n=24), 23/24 (96%) had an 
MRI performed. There were 12/23 (52%) patients with an MRI that had lesions found in the 
brain outside the optic pathway and were therefore abnormal.  
There were four patients in the CIS –ON subgroup that had a follow-up diagnosis of CDMS after 
a mean follow-up time of 6.9 years (range 1.3 to 11.9 years). The MRI brain scan of all four 
patients with a follow-up diagnosis of CDMS was abnormal at baseline with lesions present 
outside the optic pathway. Three of these patients fulfilled the McDonald 2010, Callen and 
Verhey MRI MS criteria, two fulfilled the McDonald 2005 and one the KIDMUS MRI MS Criteria. 
One patient fulfilled all criteria for MS. 
There was an additional 8/23 (35%) ON patients who had abnormal MRI brain scans but who 
were not diagnosed with MS at follow-up.  
The risk of MS after ON was significantly more likely if the first episode MRI brain was abnormal 
with lesions outside the optic pathway (p=0.04). 
Out of the eight patients that had abnormal baseline MRI brain scans but did not have MS at 
follow-up, three fulfilled the 2010 McDonald DIS criteria including one who also fulfilled DIT 
criteria (on baseline scan), two fulfilled the Callen paediatric MS MRI criteria, one the Verhey 
paediatric MRI MS criteria and one the McDonald 2001 criteria for MS. No patient fulfilled the 
KIDMUS criteria. Two patients fulfilled more than one MRI MS criterion. 
The remaining 11 ON patients who had a brain MRI had normal scans (apart from enhancing 
optic nerves) during their first CNS demyelinating episode. Four of the patients with normal 
MRI baseline brain scans had a follow-up diagnosis of chronic relapsing inflammatory optic 
neuropathy (CRION).  
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In summary, four of 12 (33%) patients with ON with an abnormal baseline brain MRI had CDMS 
after a mean follow-up of 6.9 years (1.3-11.9 years) compared to none of 11 (0%) ON patients 
who had a normal baseline brain MRI after a mean follow-up of 6.7 years (2.85-11.9 years).  
 MRI in Clinically Isolated Syndrome (CIS) - subgroup transverse myelitis (TM) 
In our CIS cohort (n=52), 17 patients were diagnosed with TM however one patient only had an 
MRI of the spine. Seven patients (7/16) had a normal MRI brain scan.   The MRI brain and spine 
findings of the 17 TM patients are summarised in Table 3-14. 
There were three (3/17, 18%) patients with TM who had a follow-up diagnosis of CDMS after a 
mean follow-up of 3.7 years (range one to 10.2 years). All three patients with TM who 
developed CDMS had brain MRI findings that met one or more criteria for MS at their first 
demyelinating episode (Table 3-14). Therefore three of nine (33%) patients with TM who had 
an abnormal MRI brain scan at baseline had a follow-up diagnosis of MS.  
There were an additional six patients that had abnormal MRI brain scans and of these five TM 
patients had an initial MRI brain that fulfilled one or more MS MRI criteria who did not have MS 
(mean follow-up of 4.6 years) (Table 3-14). Interestingly, this included the one patient 
diagnosed with NMO who fulfilled all four MS-MRI criteria. There was only one patient under 
the age of 11 years who fulfilled McDonald 2005 and 2010 DIS criteria.  
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Table 3-14 Summary of imaging findings of patients who presented with transverse myelitis (n=17) ordered 
according to age at presentation. There was one patient who only had an MRI spine and did not have an MRI 
brain scan.  
Initials 
Age 
(years) 
MRI Spine 
lesion location 
MRI brain MRI MS criteria fulfilled 
CDMS at 
follow-up. 
Follow-up 
time (years) 
BH 1.3 C,T Normal -  10.4 
WJ 3.8 L Normal -  3.9 
TD 5.0 C,T,L Abnormal McDonald 2005, 2010 DIS  6.0 
AdA 8.1 C Normal -  3.8 
AlA 8.7 C,T,L Normal -  3.0 
NW 10.0 C,L Normal -  12.2 
NB 12.3 T Abnormal McDonald 2010 DIS  2.5 
AF 12.8 C Abnormal -  1.0 
MB 12.9 T Abnormal McDonald 2005, 2010 DIS Yes 5.0 
FJ 12.9 T Not done -  10.6 
AS 14.2 C,T Abnormal McDonald 2005, 2010 DIS & DIT, Callen, Verhey Yes 1.3 
KH 14.4 C,T,L Abnormal McDonald 2010 DIS  5.1 
BM 14.8 C,T,L Normal -  4.2 
MZ 14.9 C Abnormal McDonald 2005, 2010 DIS & DIT, Callen, Verhey Yes 1.0 
TR 15.0 C,T,L Abnormal McDonald 2010 DIS & DIT  4.8 
SC 15.3 C,T,L Normal -  5.5 
TH 15.4 T,C (cavitating) Abnormal McDonald 2005, 2010 DIS & DIT, Callen, Verhey NMO 1.0 
CDMS – clinically definite Multiple Sclerosis, DIS – dissemination in time, C – cervical, T- thoracic, L – lumbar, 
NMO – neuromyelitis optica. References for MRI MS criteria: McDonald 2005 (54), 2010 (38), Callen (138), 
Verhey (103) 
In summary there were three of nine (33%) patients with TM who had an abnormal MRI brain 
scan who were diagnosed with CDMS after a mean follow-up of 3.7 years (one to 10.6 years) 
compared to none of seven (0%) of patients with a normal baseline MRI brain scan after a mean 
follow-up of 6.1 years (three to 12.2 years).  
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 Spinal MRI comparison: MS vs Non-MS 
A baseline MRI of the spine was performed on 42/88 patients in the cohort; six of the 13 
patients with MS and 36 of 75 patients with Non-MS.  
In total 35 patients were found to have spinal cord lesions; 5 who were diagnosed with MS and 
30 of the Non-MS Patients.  The MRI comparison of the patients with spinal lesions is shown in 
Table 3-15. 
Table 3-15 MRI Spine characteristics at initial demyelinating episode divided according to diagnosis at follow-
up.  
Spinal MRI Characteristic MS (n=5) Non-MS (n=30) P-Value 
Lesion Location    
Cervical Cord 3 (60.0%) 24 (80.0%) 0.32 
Thoracic Cord 4 (80.0%) 30 (100%) 0.55 
Lumbar Cord 0 (0%) 18 (60.0%) 0.01 
Lesion Extent    
Less than 3 Vertebrae 5(100%) 7 (23.3%) <0.00 
Greater than 3 Vertebrae 0 (0%) 14 (46.7%) 0.05 
Whole Cord 0 (0%) 9 (30.0%) 0.16 
Lesion Appearance    
Poorly Defined Margins 5 (100%) 30 (100%) 1 
Well Defined Margins 0 0 0 
MS- multiple sclerosis 
The statistically significant differences were that patients diagnosed with MS at follow-up had 
less extensive lesions (< 3 vertebrae) compared with the Non-MS patients (p<0.00), who were 
more likely to have lesions extending greater than three vertebrae (p=0.05). MS patients were 
less likely to have lesions in the lumbar cord as opposed to those with Non-MS (p=0.01) (Table 
3-15). 
  
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 173 of 279 
 Progress MRI brain and spine comparison 
In total 54/88 patients had a progress MRI of the brain and 13 of these patients also had an MRI 
of the spine. There were 12/14 MS patients and 42/74 Non-MS patients who had a progress 
MRI brain with or without an MRI of the spine. There were an additional four patients who had 
an MRI of the spine but not an MRI of the brain. These patients were excluded from the progress 
MRI study comparison.  
The mean time from first episode of inflammatory demyelination to progress scan was 1.8 years 
(median 1.4 years, range 0.3 to 4.4 years) for the MS group and 1.1 years (median 0.6 years, 
range 0.2 to 6.1 years) for the Non-MS group.  
The results of the study comparison are shown in Table 3-16.  
Table 3-16 Progress MRI brain +/- Spine comparison of patients with a follow-up diagnosis of Multiple Sclerosis 
(MS) and Non-Multiple Sclerosis (Non-MS).  
Characteristics of progress MRI Brain +/- Spine (n=54) MS (n=12) Non-MS (42) p-value 
No Change from Previous 0 (0%) 7 (16.7%) 0.13 
Complete Resolution 0 (0%) 10 (23.8%) 0.06 
Partial Resolution 3 (25.0%) 23 (54.8) 0.07 
New Lesions 9 (75.0%) 2 (4.8%) <0.00 
MS – multiple sclerosis 
The most significant finding was that patients with MS had new lesions on a progress scan more 
frequently than the Non-MS patients as would be expected (75% vs 5%, p<0.00).  
There were nine (9/12) patients in the MS group who had new lesions however the other three 
patients had an initial progress scan at CHW that did not show new lesions however further 
scans done at the adult hospitals where they are now being managed were consistent with MS 
as per correspondences from treating specialists.  
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 Testing of Neuroimaging criteria 
 A comparison of the adult and three proposed paediatric MRI criteria for 
predicting and/or diagnosing MS.  
The results from testing the established adult MS neuroimaging criteria and the 3 proposed 
paediatric MS neuroimaging criteria are shown in Table 3-17. For the proposed paediatric 
criteria, the Callen: ADEM versus MS(105) criteria faired the best overall with a sensitivity of 
69% and a specificity of 85%.  
Table 3-17 Comparative analysis of established adult (McDonald) and proposed paediatric (KIDMUS, Callen, 
Verhey) neuroimaging criteria for diagnosing MS based on baseline MRI brain scan from first episode of CNS 
demyelination. PPV – positive predictive value, NPV – negative predictive value 
Accuracy 
McDonald 
2005 DIS(54) 
* 
McDonald 
2010 (38) # 
KIDMUS(
104) 
Callen  
ADEM vs 
MS (105) 
Callen 
Paed 
MS(138) 
Verhey(103) 
This 
Study** 
Sensitivity % 
(data) 
95% CI 
69% 
(9/13) 
39-89% 
58% 
(7/12) 
29-84% 
8% 
(1/13) 
0-38% 
69% 
(9/13) 
39-90% 
69% 
(9/13) 
39-90% 
62% 
(8/13) 
32-85% 
 
100% 
(13/13) 
72-100% 
 
Specificity % 
(data) 
95% CI 
68% 
(50/73) 
56-79% 
95% 
(63/66) 
86-99% 
100% 
(73/73) 
94-100% 
85% 
(62/73) 
74-92% 
66% 
(48/73) 
54-76% 
84% 
(61/73) 
73-91% 
77% 
(56/73) 
65-85% 
PPV % 
(data) 
95% CI 
28% 
(9/32) 
14-47% 
70% 
(7/10) 
35-92% 
100% 
(1/1) 
5-100% 
45% 
(9/20) 
24-68% 
26% 
(9/34) 
14-45% 
40% 
(8/20) 
20-64% 
43% 
(13/30) 
26-62% 
NPV % 
(data) 
95% CI 
93% 
(50/54) 
81-98% 
93% 
(63/68) 
83-97% 
86% 
(73/85) 
76-92% 
94% 
(62/66) 
84-98% 
92% 
(48/52) 
81-98% 
92% 
(61/66) 
82-97% 
100% 
(56/56) 
92-100% 
*The 2005 McDonald DIT criteria is based on a progress scan done >3months after first demyelinating event and thus was 
not used in this comparison which examined the five sets of criteria and their ability to predict MS based on the baseline 
scan of the first demyelinating event. # the dissemination in time criterion (DIT) was applied to the baseline scan (presence 
of asymptomatic gadolinium enhancing and non-enhancing lesions) therefore the total patients who got contrast and could 
be tested for this analysis was 78. **1 of 3 characteristics found on multivariate analysis to be predictive of MS in this 
study; lesions in the Corpus callosum, contrast enhancing lesions or the presence of both well and poorly defined lesions.  
In our multivariate analysis there were three radiological characteristics which were 
statistically significant predictors of MS, and these are shown in the last column of Table 3-17. 
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Having just one of these three characteristics on MRI has a sensitivity of 100%, a specificity of 
77% in diagnosing MS based on the MRI brain at first demyelinating episode.  
 Dissemination in time (DIT) from McDonald 2010 MS MRI criteria 
 Dissemination in time (DIT) based on contrast enhancement in baseline scan 
There were 78/86 (91%) patients in the cohort who were given contrast during their first MRI 
brain scan; 12 patients with MS and 66 patients with Non-MS (Figure 3-12). There was a total of 
10/78 (13%) patients who met the DIT criterion on their baseline MRI scan.  
Out of the 12 patients with a follow-up diagnosis of MS there were seven (7/12, 58%) patients 
who had asymptomatic gadolinium enhancing and non-enhancing brain lesions on their 
baseline MRI and therefore met the McDonald 2010 DIT criterion.  
There were three (5%) Non-MS Patients who fulfilled the DIT criterion on their baseline MRI 
scans. The first patient (TH) has NMO. Of the other two patients, one (MK) also had a new lesion 
found on a serial scan (DIT serial) and is discussed in the next section.  The last patient (TR) is a 
female who presented with TM at 15.0 years and after a follow-up of 4.8 years has had no 
further demyelinating episodes.  All three patients fulfilled McDonald 2010 DIS criteria based on 
their initial MRI scans and could therefore be considered as meeting the McDonald 2010 (DIT 
and DIS) diagnostic criteria for MS on their baseline MRI brain scan.  
There were an additional five patients with ADEM who had a combination of enhancing and 
non-enhancing lesions but as they were in the context of encephalopathy (as per ADEM 
definition) we could not determine if these lesions were asymptomatic and therefore they were 
categorised as DIT baseline negative. Notably however, two (2/5) of these patients had a follow-
up diagnosis of MS.  
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Figure 3-12 Breakdown of the cohort as a function of McDonald 2010 DIT criterion applied to baseline scan 
(asymptomatic contrast enhancing and non-enhancing lesions). 
  
*There were five patients who had a combination of contrast enhancing and non-enhancing lesions but as they 
were in the context of ADEM, we could not determine if the lesions were asymptomatic and they are therefore 
DIT negative in our cohort. Of note is that two of these patients had a follow-up diagnosis of MS. 
 Dissemination in time (DIT) based on new lesion acquisition on follow-up MRI  
The McDonald 2010 criteria dissemination in time (DIT) criterion for a serial scan is based on 
having one or more new T2 and/or gadolinium-enhancing lesion(s) with reference to a baseline 
scan, irrespective of the timing of the baseline MRI(38).  
Of the 88 patients in our cohort, 54 (61%) patients had a follow-up scan at CHW and were 
available for review; 12/13 in patients with MS and 42/75 with Non-MS. On average the follow-
up brain MRI scans were done 1.3 years (median 0.7 years, range 0.2 to 6.1 years) after the 
initial baseline scan (during first demyelinating episode). 
The results from reviewing the follow-up scans are shown in Table 3-18. The most significant 
result was that patients with MS were more likely to have new lesions on their follow-up scans 
compared to those with Non-MS (9/12 vs 2/42, p <0.00). Patients with MS are therefore also 
more likely to fulfil the DIT criterion based on a serial scan compared with Non-MS Patients, as 
would be expected.  
MRI cohort 
(n=86)
No contrast 
given (n=8)
Contrast 
given (n=78)
DIT baseline Positive
(n=10) 
MS (n=7) Non-MS (n=3)
DIT baseline Negative
(n=68) 
*MS (n=5) Non-MS (n=63)
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Table 3-18 Results of progress MRI Brain scans done at follow-up.  
Characteristic of progress Brain MRI (n=54) MS (n=12) Non-MS (n=42) p-value 
No Change from Previous 0 (0%) 3 (7.1%) 0.87 
Complete Resolution 0 (0) 12 (28.6%) 0.04 
Partial Resolution 3 (25.0%) 25 (59.5%) 0.04 
New Lesions 9 (75.0%) 2 (4.8%) <0.00 
MS – multiple sclerosis 
In the MS group, there were three patients whose serial MRI brain scans were done as 
convalescent scans and no new T2 lesions were found. These patients were diagnosed with MS 
as adults (n=2) and overseas (n=1) and have had further supportive imaging. However the 
further scans which demonstrated new lesions were not performed at our institute and were 
therefore not available for review.  
There were two patients (JN and MK, described below) classified in the Non-MS group who had 
new lesions on convalescent MRI brain scan who after a significant follow-up of 4.3 and 13.7 
years respectively, did not have clinical relapses and were therefore considered non-MS in our 
study. The first patient JN was male and had initially presented with bilateral optic neuritis at 
age 13 years. He had one lesion found on a follow-up MRI performed 8 months after his initial 
demyelinating episode but has since been regularly seen by an adult neurologist who is an 
international authority in MS who felt that this patient did not have MS after a follow-up period 
of 4.3 years and further negative progress MRI scans.  This patient has therefore been classified 
as Non-MS. We understand that this is not in keeping with the McDonald 2010 (DIT) criteria for 
MS diagnosis, but as there are no validated MRI criteria for children (apart from the 2007 
consensus clinical criteria), we did considered this to be reasonable. The second patient (MK) 
who had a new lesion on progress MRI was subsequently diagnosed with seizures and 
intracranial hypertension. He has had no further lesions found on subsequent MRI brain scans, 
and after a follow-up period of 13.7 years he has had no further demyelinating events. We 
therefore have categorised him in the Non-MS group for the same reasons we described above.  
The Non-MS group were more likely to have complete or partial resolution of lesions compared 
with the MS group (Table 3-18).  
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 McDonald 2010 – application of the Dissemination in time (DIT) criterion on 
baseline and serial MRI scan.  
We tested the different components of the McDonald criteria to see which of the characteristics 
(DIS vs DIT) would have the best sensitivity and specificity and these are shown in Table 3-19. 
The number of scans available for analysis in each of the categories varied and therefore 
influenced outcome (Table 3-19). For example the number of patients who had contrast given 
during their baseline scan and who also had a follow-up MRI scan was 51 therefore testing how 
many patients fulfilled both DIS and DIT (baseline or serial) could only be performed on these 
51 patients.  
All MS patients in our cohort that met the DIT criterion applied to the either the baseline scan or 
to the serial MRI scan also met the DIS criterion at baseline. 
Overall however it can be seen that the DIS criterion based on the initial scan yielded a high 
sensitivity but a low specificity (92% and 44% respectively). The addition of the DIT criterion 
applied to the baseline scan (asymptomatic gadolinium enhancing and non-enhancing lesions) 
decreased sensitivity of the McDonald 2010 criteria but improved the specificity (58% and 95% 
respectively). The best overall sensitivity and specificity (91% and 93% respectively) for the 
cohort as a whole was seen when the criteria were applied on patients who had both a baseline 
MRI scan with contrast and a follow-up scan of which there were 51 patients. 
However the overall best sensitivity and specificity of the McDonald 2010 criteria was 100% 
and 83% which was found when we applied the criteria to patients presenting with CIS alone 
(excluding ADEM patients).  
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Table 3-19 Analysis and comparison of the McDonald 2010 criteria subdivided into dissemination in space (DIS) 
and the two components of the dissemination in time criterion (DIT).  
FACTORS 
CONSIDERED 
Total MRI Cohort CIS MRI Cohort only 
DIS 
(n=86) 
DIT 
baseline 
(n=78) 
DIS plus 
DIT 
baseline 
(n=78) 
DIS 
plus 
DIT any 
(n=51) 
DIS 
baseline 
(n=50) 
DIT  
baseline 
(n=44) 
DIS plus 
DIT 
baseline 
(n=44) 
DIS 
plus 
DIT any  
(n=27) 
 
Sensitivity 
(95% CI) 
 
 
92% 
(62-
100) 
 
58% 
(29-84) 
 
58% 
(29-84) 
 
91% 
(57-
100) 
 
90% 
(54-99) 
 
70% 
(35-92) 
 
70% 
(35-92) 
 
100% 
(63-
100) 
 
Specificity 
(95% CI) 
 
 
44% 
(32-56) 
 
95% 
(86-99) 
 
95% 
(86-99) 
 
93% 
(79-98) 
 
60% 
(43-75) 
 
91% 
(75-98) 
 
91% 
(75-98) 
 
83% 
(58-96) 
 
Positive Predictive 
Value (95%CI) 
 
23% 
(13-37) 
 
70% 
(35-92) 
 
70% 
(35-92) 
 
77% 
(46-94) 
 
36% 
(19-57) 
 
70% 
(35-92) 
 
70% 
(35-92) 
 
75% 
(43-93) 
 
Negative Predictive 
Value (95% CI) 
 
97% 
(82-
100) 
 
93% 
(83-97) 
 
93% 
(83-97) 
 
97% 
(85-
100) 
 
96% 
(78-100) 
 
91% 
(75-98) 
 
91% 
(75-98) 
 
100% 
(75-
100) 
We tested the cohort as a whole and then only the CIS patients. The criteria were tested only on patients who had the 
appropriate scans done for all criteria analysed therefore the numbers of MRI scans available varied and is shown in 
brackets (n) under the title. ‘Baseline’ refers to MRI brain done during the first demyelinating event. ‘Any’ refers to the 
presence of DIT on either the baseline or serial MRI brain scan. CI – confidence interval. 
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3.4 Discussion of MRI findings 
 MRI brain characteristics in first episode of demyelination: ADEM versus CIS 
In our retrospective cohort study of children presenting to a tertiary children’s hospital with a 
first episode of CNS demyelination, children who presented with ADEM had MRI brain scans at 
presentation with features that differed significantly to children presenting with CIS. 
Our study confirms a number of MRI brain characteristics consistent with a diagnosis of ADEM 
that have been previously described.  
Juxtacortical (subcortical) white matter lesions and deep white matter lesions were found in 
81% and 69% of patients with ADEM respectively and this is consistent with a previous 
Australian study on ADEM (9) as well as an international study (13). Lesions in the deep grey 
matter (thalamus and basal ganglia) has also been previously reported to be a common feature 
of ADEM (9, 13, 14) and this is also confirmed in our study with 56% and 44% of patients with 
ADEM having lesions in the thalamus and basal ganglia respectively. Periventricular lesions did 
not differentiate between ADEM and CIS patients in our study however periventricular lesions 
were differentiating when comparing MS to Non-MS Patients (discussed later). Similarly, 
Dawson’s fingers (PPVOL) were not useful in differentiating between children with ADEM and 
CIS however this characteristic was useful when comparing MS to non-MS patients which is 
consistent with previous studies (109).  
The MRI of ADEM patients was more likely to have bilaterally distributed but asymmetrical 
lesions compared with the MRI from CIS patients as has  been previously described by Hynson 
et al (9). 
Two other significant characteristics of the ADEM patients were that the lesion load (T2>9) and 
size of lesions (>2 gyri) were greater in children with ADEM compared with CIS. These findings 
are interesting because the 2010 McDonald MRI MS Criteria used in adults includes having ‘nine 
or more white matter lesions (T2 hyper-intensity)’ as one of its criterion (38). Having already 
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shown that only a small proportion of children with ADEM had a follow-up diagnosis of MS 
supports the argument that this criterion is not applicable to children as has been suggested in 
more recent paediatric studies (103, 138) particularly if the clinical presentation is that of 
ADEM. However it is even more interesting that of the 10 children who had a final diagnosis of 
MS and over 9 T2 lesions, seven were in children who had an initial diagnosis of CIS. Therefore if 
the clinical picture does not meet a diagnosis of ADEM, then lesion load is helpful in predicting 
which children may develop MS.  
 MRI spine comparison in ADEM versus CIS 
Spinal cord MRI findings were not that significantly different in patients presenting with ADEM 
and CIS. As spinal imaging was not performed on all patients (only n=42) during their first 
demyelinating episode, it is difficult to draw any real conclusions from the comparison.  
 MRI brain characteristic based on follow-up diagnosis: Multiple Sclerosis vs Non-
Multiple Sclerosis 
 Multivariate analysis: MRI characteristics of MS versus Non MS 
We performed univariate and multivariate analyses to compare the MRI characteristics of 
children who presented with CNS demyelination and had a follow-up diagnosis of MS and 
compared them to the non-MS group. The characteristics that were found to be highly 
correlated with a diagnosis of MS during the first episode of CNS demyelination were having 
contrast enhancing lesions, having a combination of well and poorly defined lesions and having 
lesions in the corpus callosum. 
The strongest predictor that we found in our cohort of children to be predictive of MS was 
having a combination of well and poorly defined MRI brain lesions. This is biologically logical as 
MS is a chronic disorder often with asymptomatic periods before the first demyelinating clinical 
episode and typically there are active and inactive lesions in the CNS.  Active lesions are more 
likely to be poorly defined due to surrounding oedema compared to inactive lesions which are 
more likely to be well defined.  
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Previously the KIDMUS group proposed that the ‘sole presence of well-defined lesions’ was 
typical of MS (as opposed to ADEM) (71) and Callen et al similarly suggested that ‘lesions 
distribution pattern that is not diffuse bilateral’ was also typical of MS (138). Therefore based 
on these two studies, as well as a number of others that categorise the MRI lesion characteristics 
of ADEM as opposed to MS patients (8, 107, 140) it is commonly accepted that MS patients are 
more likely to have well-defined lesions as opposed to the lesions commonly seen in patients 
presenting with ADEM which are ‘diffuse’ or poorly defined.  
Lesion characteristics on MRI have not been included in the diagnostic MRI criteria for MS in 
adults apart from whether the lesions are contrast enhancing or not (38, 49, 54). The main 
problem with the characteristic of ‘poorly’ or ‘well-defined’ lesions is that this characteristic is 
subject to interpretation.  
The presence of contrast enhancing lesions has been one of the diagnostic criterion for 
diagnosing MS in adults for the last decade and indeed forms part of the McDonald 2010 Criteria 
(38). It is not however a characteristic that has been proposed in any child MRI diagnostic 
criteria to date. Our study has found contrast enhancement to be a significant feature in the MRI 
of children with MS however our small cohort of children with MS (n=13) makes it difficult to 
definitively confirm this finding. We do note however, that a larger cohort published by Verhey 
et al (103) also reported that contrast enhancing lesions were a significant factor in helping to 
predict an MS outcome based on a first demyelinating episode MRI scan with a HR 11.88 (CI 
6.47-21.82) and even though this characteristic did not make it into their proposed diagnostic 
criteria, it is an important characteristic to consider especially as it has been replicated in our 
study.  Although it has been argued that contrast enhancing lesions can be found in any patient 
with an acute CNS demyelinating event because of a break down in the blood-brain barrier 
secondary to inflammation (103), our study confirms that contrast enhancement is more 
common in MS compared to non-MS.  
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 183 of 279 
It is important to point out that all scans used for comparison were baseline MRI scans 
performed prior to initiation of treatment with Interferon-beta or other immunomodulation 
which have been shown to decrease the number of contrast enhancing lesions (ref). Therefore 
the finding of contrast enhancement in patients with a follow-up diagnosis of MS may indeed be 
a reflection of a process contributing to MS progression. The break-down in the blood brain 
barrier in MS may act as a passage way to ‘prime’ the immune system contributing to future 
demyelinating events. 
The third MRI predictor of a future diagnosis of MS from our study was the presence of lesions 
in the corpus callosum. This MRI characteristic has been found to be a significant predictor of 
MS in two paediatric MRI MS studies; in the  KIDMUS study where it is one of the criterion for 
MS (104) and in the Verhey study (103). The difficulty with comparing the results in a number 
of studies when it comes to this (and other) lesion locations is that in some studies they 
combine perpendicular periventricular ovoid lesions with corpus callosum lesions (103, 104) 
whereas other studies describe these characteristics independently (138) as we have in this 
study. However, both corpus callosum and periventricular lesions have been shown to be highly 
correlated with a diagnosis of MS in many previous studies (103, 105, 144).  
 MRI in CIS subgroup Optic neuritis (ON) 
There were four (4/24, 17%) patients in our CIS-ON who had a follow-up diagnosis of MS. The 
finding of an abnormal MRI brain scan in ON has been found to be more predictive of a future 
MS diagnosis compared to having ON with a normal MRI in children (60, 62, 79). Similarly all 
four ON patients in our cohort with a follow-up diagnosis of MS had an abnormal baseline MRI 
scan and this was statistically more common than in those with ON and a normal MRI brain 
(p=0.04).    
 MRI in CIS subgroup Transverse myelitis (TM) 
There were three (3/17, 17%) patients with idiopathic TM who were diagnosed with CDMS at 
follow-up. In all three patients the baseline brain MRI met one or more of the MRI diagnostic 
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criteria for MS. However there were an additional five TM patients whose initial MRI brain also 
met one or more of the MRI criteria for MS who at follow-up did not have MS after a mean 
follow-up of 4.6 years.  
There are limited studies on TM in children due to the rarity of the condition. However, from the 
studies that have been published no clear association has been made between TM, an abnormal 
brain MRI and MS (70). This is similar to our study where although the three patients with a 
follow-up diagnosis of MS had initial MRI brain scans that met one or more of the diagnostic 
MRI criteria for MS, there were an additional five patients who were not diagnosed with MS at 
follow-up who also fulfilled one or more of these criteria. Therefore the utility of using MRI 
brain MS criteria in children whose first demyelinating episode is TM is not clearly established 
in paediatrics. Further prospective paediatric studies need to be done to further analyse the 
relationship between TM and risk of MS.  
 Testing the McDonald and three proposed paediatric MRI MS criteria 
In our retrospective cohort study of children presenting to a tertiary children’s hospital in NSW, 
Australia we compared the sensitivity and specificity of the established adult (two editions) and 
three proposed MRI criteria for the diagnosis of MS in children applied to their initial or 
baseline MRI brain scan.  
We found the proposed Callen criteria to have the best combined sensitivity (69%) and 
specificity (85%) in diagnosing MS based on a baseline scan. The Callen criteria were more 
specific than the 2005 McDonald Criteria but less specific and more sensitive than the 2010 
McDonald criteria. The Callen criteria were less specific but far more sensitive than the KIDMUS 
criteria. The Callen and Verhey criteria had similar sensitivity and specificity although the Callen 
criteria were a little more sensitive and specific compared to the Verhey criteria. The similar 
sensitivities between the Callen and Verhey criteria is comprehensible as these criteria have 
significant similarities; the presence of periventricular lesions and T1-hypointense lesions are 
characteristics shared by both these criteria.  
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Age has been a factor in previous paediatric cohorts found to render the McDonald Criteria less 
sensitive in children compared with adults, especially in those under 10 years (53). The mean 
age of patients in our cohort was 8.3 years (median 7.7 years, STD 4.3 years) and the sensitivity 
of the McDonald 2010 applied to the baseline MRI scan in our cohort was low (58%). 
However when we applied the McDonald DIT criteria on the baseline MRI brain scan or the 
follow-up scan, the sensitivity and specificity improved and the criteria performed the best out 
of all the MRI MS criteria in our cohort (91% and 93% respectively). This is consistent with a 
recent Canadian study that applied the McDonald criteria to a paediatric cohort presenting with 
an acute demyelinating syndrome (ADS) and found the sensitivity to be 100% with a specificity 
of 86%(135). Therefore application of the DIS criteria to a baseline scan is useful and predictive 
of MS. However ultimately in our cohort, it was the progress MRI scans in combination with the 
baseline scan that is best in diagnosing MS definitively. In order to further test the usefulness of 
the McDonald 2010 DIS and DIT criteria in diagnosing MS in children, further prospective 
paediatric cohorts are required.  
The ‘International Panel on Diagnosis of MS’ who formed the McDonald 2010 Criteria endorsed 
the criteria for use in most paediatric cases. They did however suggest that applying the criteria 
to patients under the age of 11 years or to those with ADEM would be inappropriate (38). Our 
study along with the study by Sadaka et al when all patients with an acute demyelinating 
syndrome (ADS) (including younger patients and those with ADEM) are included. As noted 
previously determining whether a lesion is asymptomatic in an encephalopathic ADEM patient, 
remains difficult.” 
In testing and reviewing the radiological characteristics that have been found to be predictive of 
a future diagnosis of MS it can be seen that there are overlaps between those established for 
adults (McDonald 2010) and those that have been proposed for children (KIDMUS, Callen, 
Verhey). We do not wish to propose another set of criteria however we would like to see the 
paediatric MS group bring together these studies and perhaps form a scoring system of ‘MS risk’ 
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for diagnosing children with MS based on their initial MRI scan but also supported by their 
clinical findings. There are a number of definite associations that have been made in the past 
such as having ON and an abnormal MRI greatly increased the risk of MS, which can also be 
incorporated into this scoring system not unlike the table published by Polman et al (38) that 
describes different pathways for diagnosis MS according to both clinical and radiological 
presentations.  
 MRI spine comparison in MS vs Non-MS Patients 
The characteristic of the MRI spine in patients diagnosed with MS was that the lesions were 
short (under 3 vertebrae) compared to those with Non-MS. This finding is similar to what has 
been previously described in adult studies where spinal lesions in adults with MS are found 
peripherally and involve only short segments of spinal cord (145). Although a large proportion 
of the patients with a Non-MS diagnosis had lesions that extended beyond 3 vertebral segments, 
only one patient was found to be NMO IgG positive and was diagnosed with NMOSD. While 
LETM in adults has been included as a feature of NMO spectrum disorder and should make 
clinicians consider testing for NMO IgG (28), LETM in children is more likely to be ‘idiopathic’ 
rather than NMO.  
LETM is more common in children than in adults especially in the context of ADEM and other 
monophasic demyelinating disorders (e.g. Idiopathic TM). In a review of childhood transverse 
myelitis by Pidcock et al (68) the average length of spinal cord involvement was six vertebral 
segments. Likewise other studies have reported a high frequency of LETM (71-92%) in children 
with idiopathic TM (145-147).   
In a retrospective study of 87 children with demyelinating CNS disorders, NMO IgG antibody 
analysis was performed. Of the 10 children with isolated LETM, only one patient with myelitis 
was positive for NMO IgG and this patient had a recurrent course (31). Therefore our cohort 
supports the concept that most children with LETM do not have NMO spectrum disorder.  
 Follow-up MRI brain scan comparison 
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Of the 13 patients who were diagnosed with MS, new lesions were found on the follow-up MRI 
scans in nine (9/12) patients that had an MRI performed at our institution. This is in keeping 
with the well-established fact that MS patients accumulate lesions over time.  
We do accept that given the low number of follow-up scans, we may be underestimating the 
number of children who are likely to have progressed to MS, however in view of our long follow-
up (61months) we estimate that this number would be potentially small. Having a further 
follow-up in 5 years would be useful to determine whether further patients now have MS. 
 
4. ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG) ANTIBODY – CLINICAL 
AND HLA ASSOCIATIONS 
4.1  Literature review of anti-Myelin Oligodendrocyte Glycoprotein (MOG) antibody 
and demyelination 
Children presenting with a first episode of demyelination can be diagnosed as having ADEM, CIS 
or even MS according to the 2012 consensus criteria (102). When recurrent episodes of 
demyelination occur either clinically or radiologically a diagnosis of MS is typically made. It is 
important to differentiate between patients that will have a monophasic course from those who 
will develop a chronic relapsing demyelinating disorder such as MS, as this has therapeutic 
implications.  
As it stands currently when a child has a second demyelinating event (with supportive 
neuroimaging) there are two main diagnoses that can be applied; paediatric onset MS, and 
neuromyelitis optica (NMO) according to the 2007 and 2012 definitions (7, 102). The literature 
also describes a third disorder referred to as chronic recurrent inflammatory optic neuropathy 
(CRION) and all three of these diagnoses have previously been described in chapters 1-3. 
However there are likely to be more subsets of demyelinating disorders within the relapsing 
demyelinating group currently falling under the definition of MS with differing 
immunopathology and who may require different therapy.  
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The response to disease modifying therapies in paediatric onset MS has not be well investigated, 
however Yeh et al published a retrospective study of 258 paediatric MS patients and found that 
44 % of patients switched to another first- or second-line therapy during a 3-year period 
because of an inadequate treatment response or lack of adherence as determined by treating 
professionals (148). Studies have indicated that the paediatric annualised relapse rate is higher 
in children compared to adults (120). It has also been proposed that inflammatory 
demyelination is not one disease but a number of different autoimmune processes as has been 
established with the discovery of the anti-NMO IgG antibody in Neuromyelitis optica, that has 
differentiated NMO from MS (89, 149).  
The disease mechanism resulting in recurrent demyelination in paediatric MS is unknown. In 
the adult literature, a number of studies and drug trials over the last 10 years have come closer 
to helping us understand the pathogenesis of recurrent demyelination. Even though the 
relationship between paediatric onset and adult-onset MS is not completely clear, the adult 
studies may help improve our understanding of the immunological processes involved in 
paediatric demyelination. 
Previously it was thought that the pathological process of MS was primarily T-lymphocyte 
mediated, however more recently it has been and  shown that B cells also play an important role 
in demyelination (150, 151).   
Over a decade ago it was established that intrathecal oligoclonal bands (OCB) were present in 
92% of children with clinically definite paediatric onset MS similar to adult onset-MS (118). 
However the specific role that these oligoclonal IgG antibodies have in the pathogenesis of CNS 
demyelination is as yet unresolved.   
In a study of 104 adult MS patients, Hauser et al (152) performed a randomized, double blind, 
placebo-controlled study using a genetically engineered monoclonal antibody  called Rituximab 
that depletes CD20+ B cells. In the study, it was shown that reducing the number of B cells with 
Rituximab resulted in a significant reduction in the number of gadolinium-enhancing lesions on 
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MRI and the number of clinical relapses in the these patients suggesting that B cells play a major 
role in the disease process (152).  
As B cells differentiate, they become plasma cells and produce antibody. Auto-antibodies that 
bind to myelin antigens have been of great interest for many years. There are a number of 
myelin antigens (Figure 4-1), including myelin oligodendrocyte glycoprotein (MOG), myelin 
basic protein (MBP) and proteo-lipid protein (PLP) that autoantibodies could target. Indeed it 
has been previously shown that antibodies to myelin basic protein are present in early MS 
(153). Myelin Oligodendrocyte Glycoprotein (MOG) has been an antigen of great interest as it is 
expressed on the surface of oligodendrocytes and therefore accessible to antibodies without the 
cells needing to be damaged (154, 155). 
Figure 4-1 Possible target antigens on the myelin sheath. The proteins that form the myelin sheath include; 
MAG, myelin-associated glycoprotein;  MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; 
PLP, proteolipid protein. Of these, MOG (arrow) is present on the surface of the sheath and therefore 
accessible to antibodies. Extracted from Hemmer et al. Nat Rev Neuro 2002 (156) 
 
A number of studies on animal models have shown that autoantibodies directed against MOG 
can lead to demyelination (157, 158) . A monoclonal antibody against myelin oligodentrocyte 
glycoprotein (MOG) caused severe demyelination in animals with experimental autoimmune 
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encephalomyelitis (EAE) but not in animals with an intact blood brain barrier (BBB), suggesting 
that disruption of the BBB was necessary for antibody to gain access to the CNS (157, 159). Anti-
MOG antibodies have been found in active lesions of patients with MS, and shown to be of high 
affinity (160). 
Anti-MOG antibodies (Abs) have been studied in adult-onset MS (119, 153, 161-163) however 
results have been conflicting with the antibody being found in MS or CIS, but also other 
neurological disorders as well as in healthy controls. The main reason for this discrepancy is 
thought to be differences in technical approaches for antibody detection and configuration as 
previous assays used denatured MOG utilizing Western Blotting to test for anti-MOG antibodies 
(164, 165).  
Over the last decade it has become increasingly apparent that antibody assays must use 
antigens expressed in their conformational state using transfected cell lines in order to mimic 
most accurately what is taking place in vivo. The AQP4 and NMDA-R antibodies are two 
clinically important examples of antibody detection that use cell based assays expressing 
antigens in their conformational state.  
There have been a number of significant studies on Anti-MOG antibodies in children with acute 
demyelination using native MOG expressed using transfected cells (164, 166-169). All of these 
studies confirm that anti-MOG antibodies are found in paediatric demyelination, and may be a 
useful biomarker. 
The first study, published in 2007 by O’Connor et al (166) used a tetramer radioimmunoassay 
(RIA) for anti-MOG Ab detection. This study expressed MOG as a tetramer using a mouse 
hybridoma cell line. In the study, whose main emphasis was scientific methodology rather than 
clinical discernment, it was found that auto-antibodies were more common in patients with 
ADEM than in adult-onset MS patients (166).  
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The Table 4-1 below summarizes the findings of the O’Connor paper. A fifth of the ADEM 
patients were found to have anti-MOG antibodies however the age range of this group indicates 
that a substantial number of the patients were adults. The other problem, from a paediatric 
standpoint, is that the CIS group does not have any patients in the paediatric age range. 
Furthermore, the 2007 consensus criteria were not applied to defining the patients clinically 
and a follow-up of the patients was not performed. Putting this aside however, the study was 
important in showing that MOG-specific auto-antibodies are more commonly found in patients 
with ‘ADEM’ compared to those with MS and more commonly found in children compared with 
adults.  
 
Table 4-1 Serum samples showing Anti-MOG antibody findings in demyelinating disorders, taken from 
O’Connor et al (166).  
Serum Samples (number) 
Median Age in  
years (range) 
Anti-MOG IgG Anti-MOG IgM 
ADEM (n=69) 8.5 (0.8-41) 19% 3% 
Paediatric MS (n=19) 13 (5-17) 5% 0% 
Adult CIS (n=32) 43 (22-54) 0% 0% 
Control (n=75) 40 (22-64) 1% 0% 
Of note in this sample of results is that the cohort is not purely paediatric. In particular the ADEM group of patients is a 
combination of adults and children and the CIS patient group does not seem to contain any paediatric aged patients. 
The second study conducted by McLaughlin et al (167) was a corroborative study from a similar 
group to the first study but analysed larger paediatric and adult-onset MS groups.  A total of 131 
patients with paediatric onset MS, 254 with adult-onset MS, 30 with CIS (adults) and 13 with 
NMO (adults) were analysed. There were a number of significant findings.  
Firstly 21.3% of the paediatric-onset MS serum samples were positive for anti-MOG antibodies 
compared to only 4.3% of adult-onset MS patients (p=4.48 x 10-7). Secondly, there was a high 
correlation between a younger age of disease onset and positivity for the anti-MOG antibodies. 
Of Patients under 10yrs of age, 38.7% were anti-MOG Ab positive, compared to 14.7% of 
patients 10-18yrs (p=0.009) (167). Thirdly, of the MS patients with positive anti-MOG Ab 
(n=28), 31% had ADEM as an initial event. By comparison, of the MS patients with negative anti-
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MOG Ab (n=105) only 8% had ADEM as an initial event. Furthermore, of the 16 MS patients 
whose initial event was ADEM, 8 (50%) had positive anti-MOG Ab. See Figure 4-2.  
Therefore in summary, this study showed that anti-MOG antibodies were more frequently found 
in patients who had; 
- an initial ADEM-like episode 
- a younger age of onset (<10yrs) 
- Paediatric onset MS compared with adult-onset MS 
 
 
Figure 4-2 Flow diagram showing the breakdown of the paediatric MS cohort from McLaughlin et al (167).  
 
*Of the patients whose initial event was ADEM-like (n=16), 8/16 (50%) were found to be anti-MOG antibody 
positive. MS – multiple sclerosis, MOG – myelin oligodendrocyte glycoprotein, Ab – antibody, ADEM – acute 
disseminated encephalomyelitis. 
A third study by Brilot et al (164) tested for the presence of antibody to native MOG in 47 
children (19 ADEM; 28 CIS) recruited from the UK with a first episode of CNS demyelination. 
The study applied the 2007 consensus criteria (7) and was strictly a paediatric cohort with 
paediatric controls. 
The findings of the study were that (164); 
Pediatric MS 
(n=131)
21% anti-MOG 
Ab Positive
(n=28)
31% initially 
had *ADEM 
(n=8)
69% other 
initial diagnosis 
(n=22)
79% anti-MOG 
Ab Negative
(n=103)
8% intially had 
*ADEM 
(n=8) 
92% other 
initial diagnosis 
(n=95)
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- 47% of children with a first episode of demyelination had elevated anti-MOG antibodies and 
of these 40% had high titres to the MOG.  
- There was no association between being anti-MOG antibody positive and the initial 
demyelinating event diagnosis (i.e. CIS or ADEM), although detailed clinical comparisons 
were not performed.  
- Anti-MOG Ab positivity did not predict conversion to MS (2 year follow-up) in patients with 
an initial episode of either ADEM or CIS. 
- Higher titres of anti-MOG IgG were found in younger (<10 years) ADEM/CIS patients 
(p=0.023)  
- CSF anti-MOG IgG were more elevated in the CIS group suggesting intrathecal synthesis. 
- Anti-MOG Ab was found to cause natural killer cell-mediated cytotoxicity which may be 
pathologically important in explaining the process of demyelination.  
The fourth study conducted in Austria by Di Pauli et al (168) recruited a total of 78 paediatric 
patients (27 ADEM, 18 CIS, 18 Relapsing remitting MS, 15 Other neurological disorder3) and 188 
adult patients (7 ADEM, 20 CIS, 71 MS, 43 Other neurological disorder4, 47 controls). The 
paediatric group was allocated to the different subsets of demyelinating disorders according to 
the consensus criteria (7). The findings in the study were that anti-MOG Ab were found in the 
serum of;  
- 44.1% of ADEM patients  
- 7.9% of CIS patients  
                                                             
 
3 Other neurological disorders included; Parkinson’s’ disease, epilepsy, brain tumours, traumatic brain injuries, CNS 
vasculitis, meningitis, neuroborreliosis, viral encephalitis, limbic encephalitis, chronic tension headache, 
radiculopathy, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, vestibular neuritis, 
peripheral nerve paralysis, hereditary neuropathy, sleeping disorders 
4 Other neurological disorders included; Parkinson’s’ disease, epilepsy, brain tumours, traumatic brain injuries, CNS 
vasculitis, meningitis, neuroborreliosis, viral encephalitis, limbic encephalitis, chronic tension headache, 
radiculopathy, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, vestibular neuritis, 
peripheral nerve paralysis, hereditary neuropathy, sleeping disorders 
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- 2.2%  of patients with MS  
- 1.7%  of healthy controls 
When analysed there was a 44.1% sensitivity and 97.4% specificity for the presence of anti-
MOG antibodies in patients with ADEM compared to all other diagnoses tested. There was also 
an association found between antibody titre and clinical recovery in the ADEM patients; a full 
recovery was associated with either a decrease of anti-MOG Ab titre or conversion to sero-
negativity (168). This was in contrast to ADEM patients with incomplete recovery whose anti-
MOG Ab titres remained high (168). 
As has been found in two previous studies (164, 167), there was a statistically significant 
association between the age of patients who were positive for anti-MOG Ab with 24% of 
paediatric patients being positive compared to 5% of adult patients (p<0.001). 
The investigators also tested for intrathecal anti-MOG antibodies in the CSF of 33 paediatric 
patients. CSF Anti-MOG Ab were found only in the patients who had high titre antibodies in their 
serum. All patients who were low titre positive or negative for Anti-MOG Ab in serum were 
negative for the CSF antibody (168). 
A study by Probstel et al (170) was an international corroborative longitudinal study examining 
anti-MOG antibodies in paediatric patients with demyelinating disorders. The new consensus 
criteria were applied to the patient cohort (7). There were two components to the study; the 
first was a cross-sectional study in which the serum from 251 participants (161 children, 90 
adults) was analysed for anti-MOG Ab. The paediatric cohort (n=161) consisted of patients with 
ADEM (n=54), CIS (n=7),  MS (n=65), other neurological conditions (n=21) and the remaining 
14 were children with non-neurological conditions. The second component of the study was a 
longitudinal study of 77 paediatric children presenting with a first episode of demyelination and 
followed with serial clinical and serological reviews.  
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Consistent with the previous cohorts, the study found that anti-MOG Ab were found in a subset 
of children with ADEM (35%), and more frequently in younger children with 65% of anti-MOG 
antibody positive patients being under 8 years of age,( p<0.001).   
There was no clinical or management correlation found between anti-MOG Ab and disease 
course in any of the patient groups (ADEM, MS or CIS). This confirms published adult studies 
that have shown no significant correlation between the presence of anti-MOG antibody and a 
diagnosis of clinically definite MS after a first demyelinating event (171).  
As in previous studies, elevated anti-MOG antibody was found in a higher proportion of 
paediatric patients compared with adult-MS patients (25% vs 6%). 
The results of the longitudinal study were in line with the study by Di Pauli (168) whereby 
serial analysis for the anti-MOG Ab showed antibody reduction in the majority of the 
monophasic ADEM group with 63% becoming sero-negative over a 12 month period.  This 
differed to the MS participants whose anti-MOG Ab titre tended to stay elevated (in 75%).  
More recently Rostasy et al 2012 (172) investigated anti-MOG Ab in children presenting with 
acute optic neuritis. In the study of 37 children, 22 who had monophasic ON and 15 had 
recurring ON. The demographic, clinical and MRI findings were reviewed and then the patients 
were divided into three main groups;  
1. Those with a single episode of ON with a normal MRI (n=10) 
2. Those with recurrent ON but no OCB and no MRI lesions indicative of MS (n=15) 
3. Those with a single episode of ON with MRI scans indicative of MS (n=12).  
The study found that 80% of the children with recurrent ON were positive for the anti-MOG Ab 
compared to only 20% of those with monophasic ON and in 25% in those with ON and MRI 
lesions indicative of MS. Therefore the study identified a subset of children with CNS 
demyelination who were likely to have recurrent episodes of ON who were anti-MOG Ab 
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positive but did not have MS. Furthermore the study showed a low correlation between being 
anti-MOG Ab positive and developing chronic debilitating disease like MS.  
A further study by Rostasy et al published in 2013 described eight children who fulfilled the 
diagnostic criteria for definite NMO who were tested for both NMO IgG and anti-MOG 
antibodies. Of the eight patients recruited 2/8 patients were seropositive for the NMO IgG 
antibody but negative for anti-MOG antibody. Three (3/8) had neither anti-MOG nor anti-NMO 
IgG antibodies whilst 3/8 had high titres of anti-MOG antibodies alone.   These three patients 
with high titres of anti-MOG antibodies where found to have persistently raised antibodies on 
repeat testing and continued to be NMO IgG antibody negative.  Even though these three 
patients initially had recurrent attacks of demyelination, none of the patients had clinical 
episodes or new MRI findings following institution of a disease modifying therapy (2 patients 
with IVIG, 1 with both Prednisolone and Azathioprine). This was in contrast to the NMO patients 
with anti-NMO IgG antibodies (negative anti-MOG antibodies) who despite therapy had further 
inflammatory demyelinating events.  Therefore the ‘NMO-like’ patients who were anti-MOG 
antibody positive were found to have a more treatment responsive disease course (173).  
In Germany, Huppke et al (174) studied eight patients extracted from an initial cohort of 132 
patients presenting with acute CNS demyelination. These eight patients initially presented with 
ADEM (either monophasic or multiphasic) and had further CNS demyelinating attacks of optic 
neuritis (one or more episodes) and had a median follow-up of 6 years. These patients were felt 
to represent a separate clinical entity as they didn’t fulfil the 2007 definition of MS5 having had 
ADEM followed by ON but with no evidence of DIT or DIS either clinically or on MRI.  
                                                             
 
5 These patients would fulfil a diagnosis according to the 2012 paediatric MS criteria       102. Krupp LB, Tardieu M, 
Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for 
pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 
2007 definitions. Mult Scler. 2013. Epub 2013/04/11. 
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All eight patients in the study shared the following features (174);  
- First demyelinating event was ADEM 
- Second demyelinating event was ON (range 2-9 episodes) 
- MRI that showed partial or complete resolution after episode of ADEM and no new lesions 
or any contrast enhancing lesions during relapse with ON or on serial 6 monthly MRI scans. 
- CSF was repeatedly negative for OCB. 
- NMO IgG analysed during attacks of ON (not ADEM) was negative in all patients. 
- The patients had high titres of anti-MOG antibodies. 
These patients appear to represent a distinctive demyelinating subtype that is emerging. 
These results support the findings of an adult study by Mader et al (175) in which patients with 
NMO (n=45) (fulfilling diagnostic criteria) and those at ‘high risk’ of NMO (n=53) (compatible 
with NMO spectrum disorder but not fulfilling criteria) were tested for anti-MOG antibodies.  
NMO IgG antibodies were found in 42/45 (93%) of NMO patients and in 32/53(60%) of NMOSD 
patients. Of the NMO IgG antibody negative patients, it was found that anti-MOG antibodies 
were found in two of the three (66%) NMO patients and in 7/21 (33%) of the NMOSD patients 
(175).Therefore in the NMO/NMOSD group in total there were 9/24 (38%) of patients who 
were NMO IgG sero-negative who were found to be anti-MOG antibody positive.  Anti-MOG 
antibodies were also detected in 42% of adult patients with ADEM in the study. 
Similar findings have been replicated in a study by Kitley et al in the UK where 4/27 (15%) of 
NMOSD patients (defined as sequential TM then ON or vice versa) who were sero-negative for 
the NMO IgG antibody were positive for anti-MOG antibodies (176). In this study it was also 
found that the NMOSD patients who were anti-MOG Ab positive also had a more favourable 
outcome compared to those with either NMO IgG positive antibodies or in those in whom no 
antibodies were identified. However as the cohort size was small (<10) it is difficult to be 
definitive about this latter finding (176).  
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Summary of anti-Myelin oligodendrocyte glycoprotein antibody studies 
The major findings from these collective studies are as follows: 
- Paediatric patients are more often Anti-MOG Ab positive compared with adult patients with 
demyelinating disorders 
- Younger patients (<10yrs) have higher titres of anti-MOG Ab compared to older paediatric 
patients (10-18yrs) 
- Anti-MOG Ab are commonly found in paediatric patients presenting with ADEM 
- Anti-MOG Ab titres are more likely to decline and sometimes convert to sero-negativity in 
patients with monophasic ADEM 
- Serial testing for the presence of anti-MOG antibodies is more helpful than a single 
measurement at disease onset in distinguishing between a monophasic and chronic course. 
Anti-MOG Ab in patients with MS are more likely to persist and/or rise. 
- Anti-MOG Ab may participate in the pathogenesis of demyelination. 
- Anti-MOG Ab may be found in patients with NMO-like patients who are negative for NMO 
IgG, including relapsing optic neuritis. 
- Anti-MOG Ab positive patients with NMOSD have a milder disease course compared to those 
who are NMO IgG positive.  
The clinical picture of patients with anti-MOG antibodies is evolving and emerging.  This is 
obviously an area needing further investigation as there may be a specific clinical and/or 
radiological phenotype of patients with anti-MOG antibodies. More importantly, if anti-MOG ab 
participate in disease, it is possible that anti-MOG Ab positive patients may require a 
therapeutic approach similar to NMO, with immune suppression rather than typical MS 
treatment.  
It is the aim of this part of the study to test anti-MOG Ab in Australian children and further 
develop our understanding of the clinical and radiological association of anti-MOG antibodies in 
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paediatric demyelinating disorders. We will use our detailed clinical and radiological 
parameters to determine if there are demographic, clinical or radiological differences between 
the patients with positive and negative anti-MOG Ab.  It is the intention of the study to help 
determine whether anti-MOG Ab would be of benefit as a biological marker in helping to define 
a demyelinating subgroup or to help prognosticate which children will have a relapsing 
demyelinating course after an initial demyelinating event. In addition, if anti-MOG Ab have a 
proven pathogenic function, treatments which reduce the effector function of auto-reactive 
lymphocytes or deplete autoantibody production could be considered, such as with 
Mycophenolate mofetil (MMF) or Rituximab. In addition, we will examine whether the 
production of anti-MOG Ab has any correlation with the most common genetic marker in 
demyelination- HLA DRB1501. 
  
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 200 of 279 
4.2 Literature review of HLA association with CNS demyelination 
As we will correlate HLA DRB1501 with anti-MOG antibodies, I will review the HLA literature in 
brief.  
MS has been shown to develop in genetically susceptible populations (177). Even though gene 
susceptibility increases one’s risk for developing MS, a number of environmental exposures, 
including low Vitamin D levels, Epstein bar virus infection, smoking and  geographical latitude 
of residence (178), (55), (179, 180), (181) are known to play a role in determining the risk of 
MS and hence the disease manifesting. The precise interaction between inheritable (genes and 
sex) with extrinsic factors (vitamin D, EBV) has not as yet been determined. 
Through a number of adult studies in MS, the genes shown to exert the strongest effect in MS 
are the Human Leukocyte Antigen (HLA) types (182). Although over 50 genes have now been 
associated with MS using large genome association studies, HLA DRB15 still remains by far the 
strongest genetic risk factor (183, 184).  
As previously discussed, the clinical course for children presenting with their first episode of 
CNS demyelination is often monophasic, compared with adults who are likely to progress to MS. 
The question as to whether children who will progress to MS have the same biological 
susceptibilities as adults is an area of research that is only recently expanding in the paediatric 
literature.  
 Previous genetic studies in children examining MS risk. 
There are three large studies that have explored the question of gene susceptibility for 
developing MS in children. The findings of these studies can be summarised as follows: 
 Boiko AN et al 2002 (185): 
This study compared the frequency of the HLA DR2 allele in 56 Russian children (<16 years) 
with clinically definite MS to 234 adult MS patients and 328 healthy controls.  A positive 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 201 of 279 
association was found between paediatric onset MS and the presence of DR2(15) alleles and 
DR2(15)-bearing genotypes compared to healthy controls.  
No correlation was found between the age at MS diagnosis with the presence of the DR2 allele 
(DRB15) as the frequency of the allele was the same between paediatric onset and adult onset 
MS.  
One interesting finding was that the investigators showed that carriers of the DR2 allele were 
prone to develop MS at a younger age compared with non-carriers if they were of Swedish and 
Norwegian (Northern European) descent compared to native Russians. Therefore an interplay 
between genetic susceptibility and environment was predicted.  
  Disanto MD et al 2011 (179):  
This study was part of the Canadian National Paediatric Demyelinating Disorders Study (co-
investigators). There were 266 children enrolled in the study and at follow-up 64 (24%) met the 
diagnostic criteria for MS. The presence of one or both DRB1*15 alleles increased the risk of MS 
during the follow-up period of 3.2 ± 1.5 years. Of the children who had the DRB1*15 allele, 
34/93 (37%) were diagnosed with MS compared to 30/173 (17%) who did not have the allele 
(p<0.00, odds ratio 2.7).  There was an increased susceptibility to MS in children with European 
ancestry (where both parents reported European ancestry), which is similar to findings in 
adult-onset MS.  
 Banwell B et al, 2011 (55):  
This nationwide prospective study conducted on Canadian children examined the contribution 
of HLADRB1*15 as well as remote EBV infection, vitamin D status to development of MS. In the 
study 302 children presenting with their first acute demyelinating episode were enrolled who 
met the Consensus definitions for acute demyelination. Of the 302 patients, HLA typing was 
performed on 279 patients (60 with MS, 7 with ‘other’ relapsing demyelination and 212 with 
monophasic ADS).  The presence of one or more HLADRB1*15 alleles was found in 97/279 
(35%) children. Patients who had HLADRB1*15 allele had a statistically significant increased 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 202 of 279 
risk of MS (HR 2.32, 95% CI 1.25-4.3). One or more alleles were found in 31/60(51%) of 
patients who were diagnosed with MS and in 64/212 (30%) patients who had a monophasic 
ADS.  Decreased Vitamin D levels and previous EBV infection were also associated with a 
significant increased risk of MS, however there was no correlation between the three risk 
factors when combined together.  
Although the subject of this thesis is predominantly the clinical, radiological and immunological 
phenomenology of childhood acute demyelination, the association of HLADRB1*15 with anti-
MOG antibody was also examined.  
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4.3 Methods: Anti-Myelin oligodendrocyte glycoprotein (MOG) antibody and clinical 
correlations. 
 Patient cohort 
The initial patient cohort was formed using the method described in chapter 2. Patients who 
had less than 12 months follow-up were not excluded in this component of the study. Patients 
were included in the MOG study if they had serum available for testing and if the patient or their 
family were available for written consent. The one patient with NMO (TH) was excluded from 
this analysis because NMO has already been shown to be a distinct disease entity.   
A total of 60 patients met these criteria.  An additional 13 patients were recruited in the MOG 
study between June 2010 and June 2013. Eleven of these additional patients presented with 
their first episode of CNS inflammatory demyelination at our hospital. Two additional patients 
presented in South Australia (Adelaide) and the clinical, radiological data was sent to us along 
with a serum sample. All 13 extra patients included in the study had both clinical and 
radiological data available for review and the same clinical and radiological approach was 
applied to these additional patients as described in chapters 2 and 3.  In total 73 patients were 
included in the MOG study.  
We are thankful to Dr Fabienne Brilot, Vera Merheb and Raani-Yogeeta Anusuiya Kumaran for 
testing our MOG cohort for anti-MOG antibodies, AQP4 antibodies and for performing HLA 
testing. Analysis of the clinical and radiological phenotype was done by the author of the thesis 
(ET).   
 Flow cytometry cell-based assay for the detection of anti-human MOG antibody in 
patient serum 
Human MOG cDNA was subcloned into the pLVX-IRES-ZsGreen1 vector (Clontech) which 
contains an encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES), positioned 
between the multiple cloning site (MCS) and ZsGreen1. This allowed the translation of two 
separate proteins driven by the transcription of a single bicistronic mRNA (work of Ms Raani-
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Yogeeta Anusuiya Kumaran for the degree of Bachelor of Medical Sciences (Honours), 
Department of Pathology, University of Sydney). 
To produce the MOG-expressing lentivirus, HEK293T cells were used, they stably express the 
SV40 large T antigen which makes them optimal cells for lentivirus production. Hek293T cells 
were seeded seeded in a 6-well plate (BD Biosciences™, USA) at a density of 6 x 105 cells/well or 
8 x 105 cells/well and incubated overnight at 37°C. Viral vectors including the viral backbone, 
pLXV-IRES-ZsGreen1-MOG or the pLXV-IRES-ZsGreen1 vector alone; VSVG, a viral envelope 
vector and PSPAX2, a viral packaging vector were transfected using polyethylenimine (PEI, 
Sigma Aldrich, USA) into HEK293T cells and cultured at 37°C 5% CO2. The DNA, PEI, and 0.9% 
sodium chloride (NaCl, Sigma Aldrich, USA) solution was vortexed for 10 seconds. After being 
incubated for 10 minutes at room temperature, the solution was applied to cells and incubated 
for 18 hours at 37C and 5% CO2. Media was changed after 18 hours; virus-containing 
supernatant was collected 48 hours and 72 hours later. The virus-containing supernatant was 
centrifuged for 20 min at 300 rpm, isolated and aliquoted into 1 mL tubes, and stored at -80°C. 
The viral particles were then used to transduce HEK293 cells to confirm the production of 
viable lentiviruses. Control lentiviruses (no MOG expression) were produced by transfecting 
cells with vectors without the coding region for human MOG.  
In order to express native MOG in HEK293 cells, cells were seeded in a 48-well plate (BD 
Biosciences™, USA) and incubated overnight at 37°C; viral particles were added at 1:1, 1:2 and 
1:3 dilutions on cells and cultured for 24 hours. Viral particles were removed after 24 hours and 
fresh media was added. Cells were cultured for another 48 hours; once ZsGreen1 expression 
was verified the cells were upscaled.  
Antibodies against conformational native MOG were detected by cell-based assay according to 
published protocols (164, 186-188). Native MOG-expressing MOG cells (HEK293MOG+ cells) and 
control HEK 293 cells (HEK293MOG- cells ) were harvested using versene, washed with DPBS (-
Ca2+/Mg2+) containing 2% FBS (DPBS + 2% FBS), re-suspended and counted. Cells were 
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seeded in a V-bottom 96-well plate (Cellstar, Grenier bio-one, Germany) at a density of 50,000 
cells per well. Cells were incubated at room temperature for one hour with serially diluted 
monoclonal anti-MOG antibody (mAb 8-18C5, generous gift of Dr Emily Mathey, Brain and Mind 
Research Institute, Royal Prince Alfred Hospital, NSW), for surface expression curves and with 
patient sera at a 1/50 dilution. Cells were washed three times with DPBS + 2 % FBS and 
incubated at room temperature for one hour with Alexa Fluor 647-conjugated secondary 
donkey anti-mouse IgGs antibody (AF647, Invitrogen, USA) for surface expression curves and 
goat anti-human AF647 (Invitrogen, USA) for patient sera at a 1/100 dilution. Cells were 
washed three times with PBS + 2% FBS and re-suspended for analysis. 7-AAD (BD Biosciences™, 
USA) was added to all samples in order to analyze live cells. A total of 10,000 events per well 
was acquired on a BDLSRII flow cytometer (BD Biosciences™, USA) running on Diva software 
and a high-throughput sampler. Flowjo (Treestar, USA) was used to analyse FACS results, and 
data were plotted using Prism software. Binding was expressed as mean fluorescence intensity 
as previously described (164, 186, 188).  
Levels of antibody binding in ZsGreen1-positive-transduced cells were expressed as ΔMFI. 
ΔMFI was determined by the subtraction of mean fluorescence intensity obtained with 
HEK293MOG+ cells from the mean fluorescence intensity obtained with HEK293MOG- cells. A ΔMFI 
value greater than mean + 3 SDs of values of the control sera was considered positive. Each 
experiment was performed at least three times. Cell-based assays were performed by blinded 
investigator and data were unblinded in order to calculate the threshold of positivity.  
All cell-based assays were optimized on prior assessment of antigen surface expression. Cell-
based assays were performed in the Neuroimmunology laboratory (Institute for Neuroscience 
and Muscle Research at Kids Research Hospital, the Children’s Hospital at Westmead, Sydney 
Children’s Hospitals Network, University of Sydney) by Mrs Vera Merheb. Data was initially 
analysed by Dr Fabienne Brilot-Turville.  
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Serum from n=73 patients in the demyelination cohort were used to assess anti-MOG Ab 
positivity.  
Serum was also tested for anti-AQP4 Ab ELISA using the AQP4 autoantibody ELISA kit (RSR 
Limited, UK). The assay was performed by Dr Louise Wienholt at Royal Prince Alfred Hospital 
according to the manufacturers’s instructions. There was adequate serum in 64/73 patients for 
testing and all tested were negative for AQP4 Ab (serum).  
 Clinical and biochemical comparison of patients who were anti-MOG antibody 
positive and anti-MOG antibody negative. 
73 patients met the inclusion criteria, 31 were anti-MOG antibody positive and 42 anti-MOG 
antibody were negative. Based on this grouping, the clinical and biochemical characteristics of 
the patients during the first demyelinating event were compared.  
There were two biochemical comparisons made; firstly comparison of the CSF cell counts, 
protein and glucose level and secondly we compared the erythrocyte sedimentation rate (ESR) 
of both groups. The ESR was determined to be either normal (<20mm/hr.) or elevated if it was 
above 20 mm/hr.  
Patients were followed up via review of outpatient clinic notes in conjunction with a telephone 
questionnaire as described in chapter 2.3.4. Follow-up was available on all 73 patients.  
At follow-up patients were defined to be relapsing if they met the diagnostic criteria for MS at 
follow-up and/or they presented with clinical CNS inflammatory demyelinating relapses of any 
kind with or without a radiological correlate.  
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4.4 Method for MOG cohort Neuroimaging  
MRI brain imaging was available on 70/73 of patients in the MOG cohort (29/31 in the anti-
MOG Ab positive group and 41/42 in the anti-MOG Ab negative group). 
Of the remaining three patients with no brain imaging available, one patient presented with 
clinical bilateral ON and did not have an MRI of the brain or spinal cord performed during their 
admission. The other two patients presented with clinical transverse myelitis and both had a 
spinal MRI performed. All three patients were therefore excluded from the MOG brain MRI 
study. 
In addition to the MRI brain scans, there were 36 patients who had an MRI spine which were 
reviewed. A comparison was made on 30 spinal MRI scans that had lesions (11/31 in the anti-
MOG antibody positive group and 19/42 of the anti-MOG antibody negative group).  
The quantitative analysis of the MRI brain (and spine) was the same as was described in chapter 
3.2.2 and shown in Appendix F. 
Once the images were reviewed the data was used to test the four proposed MRI MS criteria as 
described in chapter 3.2.3. The object of this study was to determine if imaging in anti-MOG 
antibody positive patients was distinctive from anti-MOG antibody negative patients with 
regards to fulfilling MRI MS criteria.  
Progress MRI brain scans were done on 41/73 (55%) patients (20/31 anti-MOG antibody 
positive group and 21/42 where anti-MOG antibody negative group) and of these 11 also had a 
progress MRI of the spine.  A comparison of the progress scans based on antibody status was 
made.  
The purpose of this component of the study was to determine if there was a radiological 
phenotype that differentiates patients with a relapsing course of CNS inflammatory 
demyelination according to whether they are anti-MOG antibody positive or negative.  
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4.5 Method for HLA-DRB1*1501 Genotyping 
DNA was extracted from patient saliva using a saliva-specific DNA extraction kit according to 
the manufacturer’s instructions (Orangene, DNA genotek). This work was performed by Mrs 
Vera Merheb (Neuroimmunology group, CHW).  
Saliva samples were collected from 40 patients. The concentration of the extracted DNA was 
quantified by Nanodrop 2000, it was aliquoted and stored long term at -20C and at -4C.  
In order to genotype the patients for HLA-DRB1*1501, Polymerase Chain Reaction (PCR) was 
used. A set of primers were designed to flank a single nucleotide polymorphism (SNP) called 
rs9271366 which lies on chromosome 6 at position 32,694,832. rs9271366 lies upstream of the 
allelic variation (A → G), and can be used to tag it (ANZgene, Nature Genetics, 2009).  
Patients with the allelic A are negative for HLA-DRB1*1501, whereas patients positive for the 
SNP are HLA-DRB1*1501-positive.  
DNA was amplified using Polymerase Chain Reaction (PCR). 10-20 ng of each DNA sample was 
added to a reaction mixture containing Buffer D (Roche), HLA DRB1 Forward 1 primer, HLA 
DRB1 Reverse 1 primer (Table 4.2) and Taq DNA polymerase (Invitrogen, USA), and DEPC H2O 
(Bioline, Aus). A negative control without DNA and a positive control known to contain DNA 
were also run in each reaction. PCR reactions were run at these conditions: 95C for 2 minutes; 
5 cycles of 30 seconds at 95C, 64C and 72C; 35 cycles 72C of 30 seconds at 95C, 60C and 
72C; and 10 minutes at 72C, samples were then held at 4C. 
PCR samples were then visualised by 1.5% agarose gel electrophoresis. DNA products should be 
approximately 237 base pairs. Samples were then purified with an exosap reaction to purify the 
amplified DNA. Shrimp Alkaline Phosphatase (SAP, 1 u/µL) and Exonuclease 1 (New England 
Biolabs, USA) were added to each PCR tube containing each sample. The samples underwent 
PCR at 37C for 30 minutes and 80C for 20 minutes.  
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Samples were then ready to be sequenced by the Australian Genomic Research Facility (AGRF, 
Westmead) using a Forward Sequencing HLA-DRB1 1501 primer, DEPC H2O, and DMSO (Sigma 
Aldrich, USA). Samples were also prepared using a reverse HLA-DRB1 1501 primer in separate 
tubes. Sequences were analysed for presence or absence of the SNP using the software 
Sequencer (work of Ms Raani-Yogeeta Anusuiya Kumaran for the degree of Bachelor of Medical 
Sciences (Honours), Department of Pathology, University of Sydney). 
Table 4-2 Primers used for HLA-DRB1*1501 genotyping 
Primer Annealing sequence Method 
HLA DRB1 Forward 1 TGTGGCCAAGACTAGCAT PCR amplification of DNA 
HLA DRB1 Reverse1 AAATGTTGAGATTCAGAGAGACCA 
PCR amplification of DNA & 
Reverse HLA DRB1 sequencing 
HLA DRB1 S Forward 1 CAAGACTAGCATTGTCTTCAG HLA DRB1 sequencing 
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4.6 Results of clinical comparison between patients who were anti-MOG antibody 
positive and negative.  
In total 73 patients were identified through the hospital coding system (n=71) and from one 
external hospital (n=2) as having a first episode of CNS inflammatory demyelination and had 
serum available for testing of the anti-MOG antibody. The 73 patients were divided according to 
whether they were anti-MOG antibody (Ab) positive (n=31) or anti-MOG antibody negative 
(n=42). Anti-MOG Ab positivity was defined as increased antibody binding to MOG with a 
threshold mean Ctl +(3X std dev Ctl)= 1047.876373. Using this threshold 0/24 of the control 
patients were positive compared to 31/73 (42%) of the demyelinating cohort, p<0.00) (Figure 
4-3).  
Figure 4-3 Anti-MOG antibody comparison of control (Ctl) patients against those with demyelination (DEM) 
courtesy of Dr Fabienne Brilot (Neuro-immunology group, CHW).   
 
The dotted line represents the threshold of positivity. The control group is composed of general medical 
controls (n=24) including enteropathy(n=1), acute pyogenic granuloma (n=1), asthma (n=1), other non-
inflammatory neurological diseases including epilepsy and adrenoleukodystrophies (n=5) and healthy controls 
(n=16).The figure demonstrates the results of 71 demyelinating patients performed in one assay (in total 73 
serum samples were tested). MFI - Mean fluorescence Intensity 
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The clinical characteristics of the two patient groups (anti-MOG antibody positive and negative) 
during their first demyelinating event were compared and is presented in Table 4-3. 
Table 4-3 Demographics and clinical characteristics of patients according to anti-MOG antibody status.  
CHARACTERISTIC  
Anti-MOG Ab 
Positive (n=31) 
Anti-MOG Ab 
Negative (n=42) 
p-value (Chi- 
square test) 
Sex Female 18 (58.1%) 19 (45.2%) 0.28 
Age  Mean 7.5 yrs.  9.5 yrs. 0.05 
 Range  2.0-15.3 yrs. 1.3-15.3 yrs. - 
 Median age 6.7 yrs. 10.4 yrs. - 
Season presenting Spring 7 (22.6%) 12 (28.6%) 0.56 
 Summer 6 (19.4%) 13 (31.0%) 0.26 
 Autumn 8 (25.4%) 6 (14.3%) 0.22 
 Winter 10 (32.3%) 11 (26.2%) 0.57 
Preceding infection  20 (64.5%) 25 (59.5%) 0.67 
Fever Present  15 (48.4%) 11 (26.2%) 0.05 
Meningism  5 (16.1%) 5 (11.9%) 0.60 
Encephalopathy  14 (45.2%) 15 (35.7%) 0.42 
Pyramidal Signs   13 (41.9%) 14 (33.3%) 0.45 
Transverse myelitis  5 (16.1%) 10 (23.8%) 0.72 
Sensory disturbance  3 (9.7%) 11 (26.2%) 0.08 
Cerebellar Signs  11 (35.5%) 16 (38.1%) 0.82 
Brainstem Signs  2 (6.5%) 16 (38.1%) <0.00 
Bulbar weakness  0 (0%) 6 (14.3%) 0.03 
Optic Neuritis  10 (32.2%) 5 (11.9%) 0.20 
Urinary +/or faecal disturbance 10 (32.3%) 10 (23.8%) 0.42 
Seizures  4 (12.9%) 6 (14.3%) 0.87 
Extrapyramidal Signs  1 (3.2%) 5 (11.9%) 0.18 
Peripheral Neuropathy  0 0 - 
1st Episode diagnosis ADEM 14 (45.2%) 14 (33.3%) 0.30 
 CIS 17 (54.5%) 28 (66.7%) 0.30 
Follow-up diagnosis MS  7 (22.6%) 8 (19.0%) 0.71 
Recurrent demyelinating disorder (any) 10 (32.2%) 9 (21.4 %) 0.46 
All values are number of patients, n and percentage (%) unless otherwise indicated. MOG – myelin oligodendrocyte 
glycoprotein, Ab – antibody. ADEM – acute disseminated encephalomyelitis, CIS – clinically isolated syndrome, MS – 
multiple sclerosis 
 
There were no significant differences in the sex of patients who were anti-MOG Ab positive or 
negative. The mean age of patients neared significance (p=0.05) with anti-MOG Ab positive 
patients being younger than those who were negative (Figure 4-4).  
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 212 of 279 
Figure 4-4 Comparison of age at presentation in patients who were anti-MOG antibody positive and negative. 
Patients who were anti-MOG antibody positive are younger than those who are anti-MOG antibody negative. 
 
When we divided patients into two groups based on age; under 10 years (n=42) and 10 years 
and over (n=31), there was a significant difference with the patients under 10years of age being 
more likely to be anti-MOG Ab positive compared to those over 10 years  (23/42 vs 8/31, 
p=0.01).  
Patients who were anti-MOG Ab positive were more likely to present with fever compared to 
those who were negative (48% vs 26%) and this neared significance (p=0.05). There were two 
clinical characteristic that were differentiating between the two groups; anti-MOG Ab positive 
patients less commonly presented with bulbar dysfunction compared to those who were 
negative (0% vs 14%, p=0.03) and anti-MOG Ab positive patients less commonly had brainstem 
dysfunction compared to those who were negative (7% vs 38%, p<0.00). 
We compared the patient groups to further explore the correlation between age and anti-MOG 
antibody status. We divided the patients according to clinical phenotype and this is shown in 
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Figure 4-5. Although there was no statistical correlation between age and antibody status with 
clinical phenotype, the anti-MOG antibody positive patients were generally younger in each 
clinical subtype except the subgroup with TM (Figure 4-5). 
Figure 4-5 Comparison of clinical phenotype divided according to anti-MOG antibody status and compared by 
age of onset.  
 
Although no statistical significance was found between the age of patients who were anti-MOG antibody positive and 
negative, there is a general trend in all clinical phenotypes with the exception of those presenting with transverse myelitis 
for the anti-MOG antibody positive patients to be younger than those who were negative with the same clinical 
presentation. 
 
There was no statistical difference in the anti-MOG antibody positivity according to the first 
episode diagnosis (ADEM vs CIS). 
The anti-MOG antibody positive patients were followed up for a mean of 5.1 yrs. (median 
4.1years, range 0.3-12.6 years) and the anti-MOG antibody negative patients were followed for 
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mean of 4.1 (median 3.9 years, range 0.1-13.7 years) and there was no statistical difference in 
the follow-up time.  
At follow-up 19/73 patients had a relapsing demyelinating disorder (15 with MS, 4 with 
CRION). There was no correlation between whether patients had subsequent demyelinating 
events and the presence or absence of anti-MOG antibodies in their initial serum.   
We compared the clinical phenotype of patients at follow-up divided according to whether they 
were antibody positive or negative and this is shown in Table 4-4. 
Table 4-4 MOG cohort divided according to clinical phenotype at follow-up.  
Clinical Phenotype 
Number of 
patients 
Females 
Mean Age (Std 
Dev.) years 
anti-MOG Ab 
positive 
Mean FU time 
years (range) 
ON (monophasic) 7 4 (57%) 8.5 (3.7) 6 (86%) 6.0 (2.9-10.7) 
TM 13 9 (69%) 10.3 (4.5) 4 (31%) 4.9 (0.3-12.2) 
‘Other CIS’ 10 2 (25%) 8.8 (4.1) 0 3.5 (0.2-13.7) 
ADEM 24 9 (38%) 6.6 (3.6) 11 (46%) 3.8 (0.1-12.6) 
Recurrent ON (CRION) 4 4 (100%) 9.3 (3.7) 3 (75%) 8.4 (2.8-11.9) 
MS 15 9 (60%) 9.8 (4.9) 7 (47%) 4.3 (0.5-12.4) 
The clinical phenotypes that involved recurrent episodes of demyelination are shaded. The number of patients with a 
relapsing course was 19.  Std Dev. – standard deviation, ‘Other CIS ‘– brainstem, hemispheric, cerebellar and polyfocal CIS. 
Ab – antibody, ON – optic neuritis, TM – transverse myelitis, CIS clinical isolated syndrome, ADEM – acute disseminated 
encephalomyelitis, MS – multiple sclerosis. 
The following significant differences were found. There was a significantly increased number of 
patients who were anti-MOG antibody positive in the monophasic ON group when compared to 
the rest of the cohort follow-up (6/7 vs 25/66, p=0.02). All the patients in the monophasic ON 
group had bilateral ON (BLON).  
We further sub-analysed patients with optic neuritis (ON) on the basis of clinical phenotype, 
anti-MOG antibody status and follow-up diagnosis as shown in Figure 4-6. Of the 15 patients 
with ON in our MOG cohort, 10 had BLON and 5 had ULON. Patients with BLON were more likely 
to be anti-MOG antibody positive compared to the ULON patients (9/10 vs 1/5, p=0.01).   
MRI brain was performed on 14/15 patients with ON (one patient with BLON did not have an 
MRI). Patients with ON (BLON or ULON) who were positive for anti-MOG antibodies were more 
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likely to have a normal MRI brain compared to those without anti-MOG antibodies (5/9 vs 1/5) 
(statistics not done due to small cohort size). 
Of the 10 patients with bilateral ON, nine were anti-MOG antibody positive and of these nine 
patients who were anti-MOG antibody positive 3/9 (33%) had recurrent ON at follow-up 
(CRION) (Figure 4-6). The remaining 7 BLON patients had a monophasic course. However there 
was no statistically significant correlation between being anti-MOG antibody positive in CRION 
compared to all other demyelinating subtypes (3/4 vs 28/69, p=0.18), although this may be 
underpowered. 
Figure 4-6 Breakdown of patients with Optic neuritis according to disease course and anti-MOG antibody 
status.  
 
The number of patients who were anti-MOG antibody positive is shown in the shaded boxes. One patient with 
ON did not have an MRI.ON – optic neuritis, MRI – magnetic resonance imaging, AbN – abnormal, MS – 
multiple sclerosis,  
 
There was a statistical significant reduction in the number of anti-MOG positive patients with no 
‘Other CIS’ compared with the rest of the MOG cohort (0/10 vs 31/63, p=0.03). 
There was no statistical significant difference in anti-MOG Ab positivity in patients with 
monophasic TM compared with the rest of the MOG cohort (4/13 vs 27/60, p=0.35). Similarly, 
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anti-MOG 
positive (n=9)
- 5 Normal MRI
Recurrent 
demyelination (n=4)
- 3 Normal MRI (CRION)
Monophasic 
(n=5)
- 2 Normal MRI
ULON 
(n=5)
anti-MOG 
negative (n=4)
-1 Normal MRI
Recurrent 
demyelination (n=4)
-1 Normal MRI (CRION)
anti-MOG 
positive (n=1)
-0 Normal MRI
Recurent 
demyelination (n=1)
-0 Normal MRI
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there was no statistical significant difference in anti-MOG Ab positivity in patients with ADEM 
compared with the rest of the MOG cohort (11/24 vs 20/49, p=0.68).  
There was no significant difference in anti-MOG antibody positivity in patients with MS and the 
rest of the MOG cohort (7/15 vs 24/58, p=0.71). 
Figure 4-7 Comparison of patients divided according to follow-up clinical phenotype and separated by whether 
they were anti-MOG antibody positive or anti-MOG antibody negative. 
 
All 7 patients in the ‘monophasic ON’ group had bilateral ON at presentation.  The relapsing patients (n=19) are 
represented in the recurrent ON and MS columns to the right of the dotted line.  ON – optic neuritis. , TM – transverse 
myelitis, ‘Other CIS’ – including brainstem, cerebellar, hemispheric, polyfocal clinically isolated syndrome, ADEM- acute 
disseminated encephalomyelitis, MS – multiple sclerosis. 
 
There was also no statistical difference in anti-MOG antibody positivity in patients with 
relapsing demyelinating disease (MS or recurrent ON) compared with a monophasic course 
(TM, Monophasic ON or other CIS) (10/19 vs 21/54, p=0.30). 
We compared the clinical features of patients with a relapsing course (n=19) who were 
antibody positive and negative (Figure 4-7). The one feature that was discriminating between 
the two groups was the absence of brainstem dysfunction in the anti-MOG Ab positive group 
compared to the anti-MOG Ab negative group (0% vs 44%, p=0.02). There were no other 
statistically significant differences, although the relapsing cohort was small (n=19). 
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In Table 4-5 the relapsing patient’s positive for Anti-MOG antibodies are shown and in Table 4-6 
the relapsing patients negative for Anti-MOG antibodies are shown.  
Table 4-5 Characteristics of patients who were anti-MOG antibody positive and had a relapsing course.  
Initials AH KB DK AR SW FS ElW JF SV AS 
Age at 
onset 
(yrs.) 
2.6, f 4.2, m 5.1, m 5.3, f 5.5, m 5.8, f 7.1, f 11.4, f 12.8, f 14.2,f 
Clinical 
presentati
on of first 
event 
Enceph. 
Cereb. 
ataxia 
Cereb. 
Enceph. 
Cereb 
BLON 
Enceph. 
Quad. 
Cereb. 
Seizures 
Hemi. BLON ULON BLON ITM 
internatio
nal class 
ADEM CIS ADEM CIS ADEM CIS CIS CIS CIS CIS 
Clinical 
relapse(s) 
 
[number] 
1st Para. 
2nd 
Ataxia. 
3rd Limp 
[3] 
1st Cereb 
2nd 
ULON 3rd 
ULON 
 
[3] 
Hemi. 
Cereb. 
 
 
[1] 
1st BLON 
2nd BLON 
 
 
[2] 
1st 
ULON. 
2nd 
ULON  
 
 
[2] 
1st ULON 
2nd 
ULON 
 
 
[2] 
BLON 
 
 
 
[1] 
1st ULON 
2nd 
Paraes. 
 
[2] 
ULON 
 
 
 
[1] 
1st 
ULON, 
2nd 
Bulbar & 
Cereb. 
ataxia 
[2] 
FU 
duration 
years 
2.0 6.8 2.5 2.8 12.4 2.0 11.9 8.6 10.0 1.3 
FU 
Diagnosis 
MS MS MS CRION MS MS CRION MS CRION MS 
ADEM – acute disseminated encephalomyelitis, CIS – clinically isolated syndrome, BLON – bilateral optic neuritis, ULON – 
unilateral optic neuritis, MS – multiple sclerosis, CRION – chronic immune optic neuropathy, Enceph.- encephalopathy, 
Cereb. – Cerebellar, Quad. – Quadraparesis, Hemi.- hemiparesis, Paraes. – Paraesthesia, Para. - Paraplegia 
Table 4-6 Characteristics of patients who were anti-MOG antibody negative and had a relapsing course.  
Initials MD BL MG CM MB KM MP TA EmW 
Age in 
yrs., sex 
2.5, f 10.8, m 12.1, f 12.1, f 12.9, m 14.4, f 14.6, m 14.9, f 15.3, f 
Clinical 
Presentati
on first 
episode 
Hemi. 
Cereb. 
Brainstem 
Enceph. 
Mono. 
Cereb. 
UNON ULON 
Cereb. 
TM 
Cereb. 
Brainstem
. Sensory 
ULON 
Mon0. 
Ophthal. 
ULON 
internatio
nal class 
CIS ADEM CIS CIS CIS CIS CIS CIS CIS 
Clinical 
relapse(s) 
 
[number] 
1st INO 
 2nd Para 
 
 
[2] 
1st Para 
2nd 
Opthal. 
 
 
[2] 
1st to 5th 
ULON, 
2nd-8th 
Paraes. 
9th-10th 
ULON 
[10] 
1st ULON 
2nd ULON 
 
 
[2] 
1st ULON 
 
 
 
[1] 
1st ULON. 
2nd INO. 
3rd-5th 
Para 
[5] 
1st Hemi. 
 
 
 
[1] 
1st Opthal 
2nd 
Paraes. 
[2] 
New 
lesions 
progress 
scan 
Follow-up 
duration 
years 
4.8 3.1 2.6 8.7 5.0 2.2 10.6 0.5 1.5 
Follow-up 
Diagnosis 
MS MS MS CRION MS MS MS MS MS 
ADEM – acute disseminated encephalomyelitis, CIS – clinically isolated syndrome, BLON – bilateral optic neuritis, ULON – 
unilateral optic neuritis, MS – multiple sclerosis, CRION – chronic immune optic neuropathy, Enceph. – Encephalopathy, 
Mono. – Monoparesis, Cereb. – Cerebellar, Ophthal. – Ophthalmoplegia, LL – lower limb, Paraes. – Paraesthesia, Hemi. – 
Hemiparesis, Brainstem. – Brainstem dysfunction 
We compared the erythrocyte sedimentation rate (ESR) of the two groups (data available on 
n=40). The anti-MOG Ab positive patients were significantly more likely to have a raised ESR 
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compared with those who were anti-MOG Ab negative (9/19 vs 3/21, p=0.02). We analysed the 
groups to determine if ESR was affected by follow up diagnosis or age and we found the 
following; there was no significant difference in the ESR for MS vs Non-MS groups (3/9 vs 9/31, 
p=0.80), and no difference when we compared ESR findings according to age under 10 years 
and 10 and over (6/20 vs 6/20, p=1). 
Table 4-7 shows the results of our analysis comparing the cerebrospinal fluid (CSF) findings of 
patients during their first CNS inflammatory demyelinating event divided according to whether 
they were anti-MOG Ab positive or negative. There was a significant difference in the mean 
number of polymorphs found in patients who were anti-MOG antibody positive compared to 
those who were anti-MOG antibody negative.  
In our MOG cohort 16/31 patients who were anti-MOG antibody positive and 27/43 of those 
who were anti-MOG antibody negative had oligoclonal band testing (n=43 total). Intrathecal 
OCB were found in 0/16 patients who were anti-MOG Ab positive compared with 5/27 (19%) 
who were anti-MOG Ab negative (p=0.07). 
Table 4-7 Cerebrospinal fluid (CSF) findings when comparing patients who were anti-MOG antibody positive 
and negative. 
CSF characteristic  
Anti-MOG Ab 
Positive(n=32) 
Anti-MOG Ab 
Negative(n=31) 
p-value 
Cell type and biochemistry: mean (SD)    
Polymorphs 11 (20.1) 3 (12.3) <0.00 
Monocytes 20 (28.4) 17 (39.6) 0.80 
*Protein (corrected) 0.36 (0.23) 0.39 (0.44) 0.44 
Glucose 3.9 (1.7) 3.8 (1.0) 0.06 
*Protein level is corrected for the number of red blood cells found in the CSF due to a traumatic tap.  
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4.7 Results of neuroimaging comparison according to anti-MOG antibody status. 
The comparison of MRI brain imaging characteristics in the cohort divided according to anti-
MOG antibody status is shown in Table 4-8. 
Table 4-8  MRI brain characteristics of patients who were anti-MOG antibody positive compared with those 
who were anti-MOG antibody negative 
Characteristic of MRI  
(n=70) 
Anti-MOG 
positive 
(n=29) 
Anti-MOG 
negative (n=41) 
p-value 
(chi-
square) 
LESION SITE       
Periventricular 13 (44.8%) 19 (46.3%) 0.90 
Deep White Matter 15 (51/7%) 22 (53.7%) 0.87 
Juxtacortical 17 (58.6%) 28 (68.3%) 0.41 
Corpus Callosum 6 (20.7%) 4 (9.8%) 0.20 
Dawson’s Fingers (PPOL) 2 (6.9%) 5 (12.2%) 0.47 
Internal Capsule 10 (34.5%) 13 (31.7%) 0.81 
Cortical Grey 12 (41.4%) 12 (29.3%) 0.25 
Basal Ganglia 7 (24.1%) 8 (19.5%) 0.64 
Thalamus 10 (34.5%) 7 (17.1%) 0.09 
Brainstem 10 (34.5%) 18 (43.5%) 0.43 
Cerebellar  7 (24.1%) 13 (31.7%) 0.49 
LESION DISTRIBUTION       
Asymmetrical white matter lesions 16 (55.2%) 29 (70.7%) 0.48 
Symmetrical white matter lesions 3 (10.3%) 3 (7.3%) 0.49 
Asymmetrical grey matter lesions 7 (24.1%) 8 (19.5%) 0.74 
Symmetrical grey matter lesions 7 (24.1%) 6 (14.6%) 0.71 
Bilaterally lesions 19 (65.5%) 28 (68.3%) 0.81 
LESION NUMBER       
T2 lesions <5 3 (10.3%) 10 (24.4%) 0.14 
T2 five to nine lesions 4 (13.8%) 3 (7.3%) 0.37 
T2≥ nine lesions 15 (51.7%) 20 (48.8%) 0.81 
Periventricular >two 5 (17.2%) 12 (29.3%) 0.25 
Periventricular >three 5 (17.2%) 9 (22.0%) 0.63 
LESION CHARACTERISTICS       
Solely poorly-defined lesions 18 (62.1%) 19 (46.3%) 0.19 
Solely well-defined lesions 0 5 (12.2%) 0.05 
Both well- and poorly-defined lesions 4 (13.8%) 10 (24.4%) 0.28 
T1 Black holes present 8 (27.6%) 14 (34.1%) 0.56 
Large lesions >2gyri 14 (48.3%) 16 (39.0%) 0.43 
Contrast enhancing (n=63) 9/25 (36.0%) 13/38 (34.2%) 0.88 
Note: where the p value was less than 0.00, the result was recorded as <0.00 (i.e. to 2 decimal places). PPOL – 
perpendicular periventricular ovoid lesions 
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There were no MRI brain imaging characteristics that were differentiating between the two 
groups although the sole presence of well-defined lesions neared statistical significance 
(p=0.05), being more commonly found in anti-MOG antibody negative patients. 
There were 30 patients who had an abnormal MRI of the spinal cord. The comparison of the 
spinal lesion characteristics is shown in Table 4-9. There were no differentiating characteristics 
in patients according to anti-MOG antibody status although anti-MOG antibody positive patients 
had lesions more commonly in the thoracic and lumbar cord (not sig). In particular 
longitudinally extensive transverse myelitis (LETM) was not more commonly found in anti-MOG 
antibody positive patients (p=0.8). 
Table 4-9 Comparison of MRI spine lesion characteristics in patients divided according to anti-MOG antibody 
status.  
Spinal MRI Characteristic (n=30) 
Anti-MOG 
Antibody 
positive (n=11) 
Anti-MOG 
Antibody 
negative (n=19) 
p-value 
(chi-
squared) 
LESION LOCATION    
Cervical Cord 8 (72.7%) 17 (89.5%) 0.24 
Thoracic Cord 10 (90.9%) 11 (57.9%) 0.06 
Lumbar Cord 8 (72.7%) 9 (47.4%) 0.18 
LESION EXTENT    
Less than 3 Vertebrae 3 (27.3%) 6 (31.6%) 0.80 
Greater than 3 Vertebrae 7 (63.6%) 7 (36.8%) 0.16 
Whole Cord 1 (9.1%) 6 (31.6%) 0.16 
*Longitudinally extensive transverse myelitis (LETM) 8 (72.7%) 13 (68.4%) 0.80 
LESION APPEARANCE    
Poorly Defined Margins 11 (100%) 18 (94.8%) 0.54 
Well Defined Margins 0 1 (5.3%) 0.54 
All values are number of patients, n and percentage (%).*LETM included all patients with lesions that extended to more 
than 3 vertebra and those with involvement of the whole cord.  
 
We tested the previously proposed paediatric and established adult MRI MS criteria in patients 
who were anti-MOG antibody positive and negative and the results are shown in table 4-10.  
Even though there no significant difference in the number of patients who fulfilled MRI MS 
criteria between patients who were anti-MOG antibody positive and negative, there was a 
general trend towards the anti-MOG antibody positive patients fulfilling criteria less frequently 
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than the anti-MOG antibody negative patients (Table 4-10). This could have been related to the 
younger age of the anti-MOG antibody positive patients. 
Table 4-10 Testing of paediatric and adult MRI MS criteria in patients according to anti-MOG antibody status.  
MRI Criteria 
Anti-MOG Antibody 
 positive (n=29) 
Anti-MOG Antibody  
negative (n=41) 
p-value 
McDonald 2010(38) 7 (36.8%) 12 (63.2%) 0.63 
KIDMUS(104) 0 (0%) 1 (2.4%) 0.4 
Callen MS(138) 9 (31.0%) 16 (39.0%) 0.31 
Callen ADEM vs MS(105) 6 (20.7%) 13 (31.7%) 0.49 
Verhey(103) 5 (17.2%) 11 (26.8%) 0.35 
MOG – myelin oligodendrocyte glycoprotein, MS – multiple sclerosis, ADEM – acute disseminated encephalomyelitis 
The results from comparing the progress MRI brain and spine scans (where available) are 
shown in Table 4-11.  There were no significant differences in the neuroimaging of patients who 
were anti-MOG antibody positive compared with those who were negative, although anti-MOG 
Ab positive patients were more likely to have complete resolution of lesions.  
Table 4-11 Progress MRI brain +/-spine comparison divided according to anti-MOG antibody status.  
Characteristic of FU Brain +/- spine MRI (n=41) 
Anti-MOG Ab 
positive (n=20) 
Anti-MOG Ab 
negative (n=21) 
p-value 
No Change from Previous 2 (10%) 2 (9.5%) 0.96 
Complete Resolution 6 (30.0%) 3 (14.3%) 0.22 
Partial Resolution 6 (30.0%) 8 (38.1%) 0.59 
New Lesions 6 (30.0%) 8 (38.1%) 0.59 
Values are number of patients, n and percentage (%). MOG – myelin oligodendrocyte glycoprotein, Ab – antibody.  
Nineteen patients had a relapsing course, 10/19 were anti-MOG antibody positive and 9/19 
were anti-MOG antibody negative. The cohort size in each group was small and therefore we 
have not reported all the MRI brain characteristic comparisons as the numbers were low and 
often under five.  However there was one significant finding  in the relapsing cohort; patients 
who were anti-MOG antibody positive were more likely to have large lesions measuring over 
two gyri compared to those who were negative for anti-MOG antibody (60% vs 11.1%, p=0.01). 
Again, this could have been related to the younger age of the anti-MOG antibody positive 
patients.  
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4.8 Anti-MOG antibody positive patients with a relapsing course - case examples  
 Case 1 –Multiple Sclerosis and atypical inflammatory markers 
First Episode of demyelination 
Patient AS was a previously healthy 14 year old girl of Samoan descent who presented with a 
rapidly progressive spinal cord syndrome. Her illness began a week prior to admission when 
she began to experience mid back pain. Two days prior to presentation she began to develop 
weakness in her lower limbs and on the day of admission she was unable to move her legs and 
therefore unable to walk. She also reported numbness and paraesthesia in her lower limbs. Her 
upper limbs were unaffected. There was no history of a preceding infection, trauma or recent 
immunisation. 
On examination AS was alert, orientated and there was no change in her personality. Her cranial 
nerve and upper limb examinations were normal. She could not walk. Her lower limbs 
demonstrated flaccid paralysis with power 0/5 throughout all muscle groups. Her plantar 
responses were however up-going bilaterally. Her deep tendon reflexes were present and 
normal at the knees and ankles. Abdominal reflex was absent. Sensation was demonstrated to 
be intact. There was no sensory level documented.   She was found to have urinary retention 
and an in-dwelling catheter was inserted.  
Her MRI spine was normal. The MRI of her brain (Figure 4-8) showed large T2 enhancing 
lesions in the sub-cortical white matter, the centrum semi-ovalae and corona radiata of both 
hemispheres. The lesions were diffusion restricted (evidence of cytotoxic oedema). Lesions 
were also mildly contrast enhancing post gadolinium. Her MRI brain fulfilled MRI MS McDonald 
2010 criteria.  
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Figure 4-8 MRI brain performed on admission. Left: T2 sequence MRI brain of AS at initial presentation. There 
is evidence of diffuse sub-cortical white matter involvement. Right: T1 sagittal FLAIR sequence demonstrating 
deep white matter and peri-callosal involvement.  
   
   
AS had a lumbar puncture and an MRI performed. Her CSF glucose (3.4 g/dL)) and protein 
(0.3g/dL) were normal however there was 2 x10 6 mononuclear cells and 2 x 10 6 erythrocytes 
found. There was no growth on the CSF culture and PCR for herpes and enterovirus was 
negative. NMO IgG was negative.  
Of particular note is that the ESR of AS was raised at 93 mm/hr.( normal 0-20mm/hr.) as was 
her ASOT titre at 1200IU (0-200IU) and her globulin levels 46g/L (17-38 g/L). Her ANA titre 
and dsDNA were normal as were complement levels. 
Based on the clinical picture the patient was diagnosed with clinical transverse myelitis with 
disseminated CNS lesions and was treated with intravenous methylprednisolone (IVMP) at 
1g/day for 3 days and intravenous immunoglobulin (IVIG) 2g/kg over 3 days. 
Her recovery was swift and by her fifth day of admission, there was only mild detectable 
weakness in the lower limbs and she was able to mobilise. Her urinary symptoms also improved 
and the catheter was removed. AS underwent a short period of rehabilitation, and then was 
discharged home on a weaning schedule (over a 6 week period) of oral prednisone. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 224 of 279 
Second Episode of demyelination 
Two weeks after completing her oral steroid taper and 2 months after her initial presentation, 
AS represented to hospital with a headache and visual disturbance in the left eye. This 
progressed to difficulty with swallowing and with gait disturbance again. On examination she 
was found to have nystagmus on left lateral gaze in combination with a lower motor neuron 
right sided facial nerve palsy. She was dysarthric. Her upper limb examination revealed mild 
weakness of the right arm but no sensory change. She had a number of cerebellar function 
abnormalities including nystagmus, dysarthria, ataxia, past pointing and intention tremor of the 
left arm and her syndrome was described as a cerebellar CIS. 
Her MRI brain during this episode demonstrated that the previous lesions were much smaller in 
comparison to the previous scan (partial resolution) but that there were new lesions in the 
white matter of the cerebellum, corpus callosum, frontal, temporal, parietal and occipital lobes 
that were bilaterally distributed (Figure 4-9). 
Figure 4-9 MRI brain performed 2 months after initial presentation during 2nd clinical relapse. Left: Coronal 
FLAIR sequence and Right: Axial FLAIR.  The previously seen hyperintense lesions predominantly in the 
centrum semi ovale bilaterally are now much smaller in size and intensity consistent with residual areas of 
gliosis. The lesions in the left cerebellum, corpus callosum, frontal, temporal, parietal and occipital lobes 
bilaterally are were not seen on the previous MRI. 
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Figure 4-10 Below left: T2 Sagittal of the spine done 2 months after initial episode during second episode. This 
MRI shows hyperintense lesions in the cervical and thoracic cord (arrowed bracket). There was subtle 
enhancement of these lesions post-gadolinium (not shown).  
 Her MRI spine showed (Figure 4-10) an ill-defined T2 hyper-intensity in 
the peripheral aspect of the cervical cord on the right side at C4 as well as 
patchy lesions in the thoracic cord from T4-T10. These lesions were mildly 
enhancing with gadolinium.  
 Her ESR was again raised at 96 mm/hr. indicating that there was definitely 
an inflammatory and autoimmune component to AS’s disease.  
AS was again treated with high dose IVMP and IVIG followed by oral 
prednisone tapered over 6 weeks. On day 9 post admission, she had only 
mild residual signs consisting of ataxia and abnormal tracking on left lateral 
gaze. Her fine motor control with her right hand was still mildly affected. 
She was also mildly dysarthric.  
Although AS clearly met the criteria for MS with a clinical relapse but also with new lesions 
demonstrable on MRI, some of the features were reminiscent of NMO. Serum was sent for NMO 
IgG testing and again returned a negative result. CSF testing for oligoclonal bands was also 
negative on two occasions.  
In view of her persistently high ESR in combination with other biochemical indicators of there 
being a strong autoimmune and inflammatory component to her disease, AS was discharged 
with a view to have IVIG on a fortnightly basis in combination with the oral steroid taper.  
Third demyelinating episode 
A month after her 2nd episode, whilst still on tapering doses of prednisolone (Prednisolone 
orally 10mg, on alternate days), her vision deteriorated and she presented with a right sided 
optic neuritis. Her visual acuity on the right was found to be 6/60 but normal on the left. There 
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were no other abnormalities found apart from subtle lower limb findings that were residual 
deficits related to her previous demyelinating events.  
MRI brain showed partial resolution of the lesions previously seen (Figure 4-11). No new 
lesions were identified however there was abnormal signal found in the optic nerves bilaterally 
with associated gadolinium enhancement on the right side. Her ESR was once again raised at 
97mm/hr. She was again given high dose IVMP. In view of her clinical picture and clinical 
suspicion that this was a chronic autoimmune disorder, she was started on mycophenolate 
(Mofetil (cellcept)©).  
Figure 4-11 MRI brain performed during 3rd clinical relapse (6 months after initial episode). Left: T2 coronal 
FLAIR showing partial resolution of previously seen lesions. Right: Axial T2 sequence showing resolving 
subcortical white matter lesions (arrows).  
   
On follow-up of AS, 18 months after her third demyelinating episode and on mycophenolate, she 
had had no further clinical relapses and had made a complete clinical recovery. Her progress 
MRI scans to date have shown partial resolution of the previous lesions described and 
importantly, no new lesions have been detected (Figure 4-12). Her ESR has also normalised. 
After 2 years of mycophenolate, this was stopped and she has been clinically well for 18 months 
off mycophenolate and two progress MRI brain scans during this time have shown minimal 
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residual white matter hyper-intensity and no new lesions. Her ESR remains marginally elevated 
between 30-55 mm/hr. She is being treated with Vitamin D and having ongoing monitoring.  
Figure 4-12 Brain MRI 18 months after her initial demyelinating episode. Left: T1 Coronal FLAIR and Right: T2 
axial sequence show no change in the white matter lesions and no new lesions compared with AS’s previous 
MRI brain scans.  
          
Commentary 
Although this patient fulfilled criteria for MS based on her initial episode combined with her 
initial MRI brain, there were a number of features of her presentation and relapses that were 
distinctive and unusual.  
Firstly, even on her first admission there were a number of inflammatory markers that were 
raised including her ESR and ASOT titres. This is atypical of MS and would indicate a systemic 
inflammatory component to her disease.  
Although AS responded well to steroids and IVIG during her first clinical episode, within 2 
weeks of weaning steroids she presented with new symptoms and new lesions. Furthermore 
she developed a third clinical event whilst being weaned off steroids following her second 
clinical event.  Her inflammatory markers improved with treatment.  
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Her clinical syndrome was more reminiscent of NMO although her NMO IgG was negative. Her 
disease course is of a steroid responsive relapsing autoimmune demyelinating syndrome which 
is NMO-like. She is strongly positive on anti-MOG antibody testing on samples from her first and 
second clinical events.   
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 Case 2 – Anti-MOG Ab positive and relapsing disease 
First episode of demyelination 
DK was a previously well child that presented at 5 years of age with a 2 week history of 
headache following a 24 hour period of vomiting.  He initially improved but then became 
increasingly lethargic and saw his local doctor who thought he was listless and confused. A full 
blood count which showed a raised white cell count (WCC 19.9, neutrophils 15.57, lymphocytes 
1.72). He had also developed an urticarial like rash which was slowly resolving. He was referred 
to the local hospital and by this time he was not able to recognise his sibling, moaning to direct 
questioning and was confused.  
On arrival he was afebrile and his observations were stable. He was encephalopathic. On 
examination he had truncal ataxia, falling to the left whilst walking. He had no other cerebellar 
signs. He otherwise had normal tone, power and reflexes in his limbs and a normal cranial nerve 
examination.  
 An MRI brain was performed which showed evidence of demyelination (Figure 4-13). There 
was diffuse, bilateral T2 hyper-intensities involving the subcortical white matter, corpus 
callosum, basal ganglia and the grey matter to a lesser degree. There was no restriction 
diffusion. There was multi-focal gadolinium enhancement involving both basal ganglia and the 
right parietal region medially (Figure 4-14). His baseline MRI scan fulfilled McDonald 2010 MRI 
MS criteria (however he was under 10 years of age).  
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Figure 4-13 MRI brain of TH during first clinical event. Upper Left: Axial T2 MRI brain showing extensive 
involvement of the basal ganglia (worse on the right) as well as deep white matter, posterior limb of internal 
capsule and external capsule demyelination. Upper Right Axial T2 MRI brain showing diffuse poorly defined 
white matter changes which are asymmetrically and bilaterally distributed in the juxtacortical, deep white and 
periventricular white matter.  Below Left: T2 coronal sequence showed diffuse, bilateral white matter and 
thalamic inflammatory changes. There is also right sided juxtacortical, deep white matter as well as corpus 
callosal demyelination evident. Below Right: T2 coronal sequence showed inflammatory changes in the corpus 
callosum (especially on the right), juxtacortical and subcortical white matter. The lesions are bilateral, 
asymmetrical and poorly defined. 
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Figure 4-14 Post contrast MRI brain scans performed during first episode. Left: T1 coronal showing patchy 
uptake of contrast in the basal ganglia and parietal lobe on the right. Right: T1 coronal shows uptake in the 
deep white matter bilaterally although more pronounced on the right.  
                
 
A lumbar puncture revealed his CSF protein was 0.43 (0.15-0.42), glucose 6.4, lactate of 2.0, 
polymorph cells 0, mononuclear cells 24 and red blood cells of 5/mm3.  There was no growth on 
culture and Polymerase chain reaction (PCR) for enterovirus was negative. His CSF pterins were 
raised with a neopterin-N of 40.3 (6.0-30.0). He had no oligoclonal bands (OCB) in his CSF.  
His ESR was 36 (0-20.0). He was found to have a raised Anti-Streptolysin titre of 1070 (0-200), 
and a raised Mycoplasma IgM. However Epstein Barr Virus, Enteroviral, Herpes serology were 
all negative. His ANA and anti-double stranded DNA antibody were normal as were his 
immunoglobulin levels. His active vitamin D was low at 38 (51-250). He had an EEG performed 
which was within normal limits.  
He was treated with high dose IV methylprednisolone for 3 days followed by oral prednisone 
that was tapered over 5 weeks. He made a full recovery physically however he had difficulties 
with concentration and learning on returning to school.  
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Second episode of demyelination 
Three months after completing his steroid treatment and four months after his first clinical 
event, DK presented with his second demyelinating episode.  
Five days prior to presentation DK had lethargy and then became irritable. His irritability 
improved with sleep however two days later he developed ataxia and became poorly co-
ordinated (difficulty doing buttons whilst dressing). He was confused at times (e.g. urinated on 
floor instead of toilet). His affect was also altered and he was giggling inappropriately.  
On examination he was alert and orientated, with normal speech. He was afebrile and his vitals 
were normal. He did not appear encephalopathic on examination. He had an ataxic gait and was 
falling to the right when walking. His head was also tilted to the right. He could not perform 
complex gait manoeuvres because of ataxia. On coordination testing he had poor Knee-heel-shin 
and foot tap with the left lower limb. He also had poor finger-nose-finger testing and had 
dysdiadochokinesia of the left upper limb. His cranial nerve examination was normal apart from 
fine nystagmus on bilateral gaze. His lower limb tone was normal however power was reduced 
on the left (4/5). His upper limb examination was normal for power and tone. His reflexes were 
normal 2+ bilaterally. There was no clonus and his toes plantar responses were down going. His 
findings were consistent with a left sided hemi-cerebellar syndrome.  
A lumbar puncture was performed and it showed glucose of 5.4, protein 0.3, lactate 2.1. There 
was 1 polynuclear cell, 2 mononuclear cells and 1 red blood cell/mm3 in his CSF. There was no 
growth on culture and PCR for enterovirus was negative.  
An MRI brain was performed (Figure 4-15) which showed a new hyperintense T2 signal lesion 
affecting the left cerebellar hemisphere, vermis, superior and middle cerebellar peduncle and 
dentate nucleus. This lesion exerted mild mass effect onto the fourth ventricle however was not 
obstructing it. There was also two new hyperintense T2 foci are noted within the right occipital 
lobe (which shows enhancement in the post contrast images).   
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 233 of 279 
Figure 4-15 MRI brain during second clinical relapse. Left: T2Coronal FLAIR showed left cerebellar 
inflammatory changes. New areas of hyper-intensities were seen in the right occipital lobe. Right: Coronal T2 
Flair shows juxtacortical inflammatory changes in the right posterior hemisphere.  
      
 
The cerebellar lesion showed heterogeneous enhancement post contrast, but did not 
demonstrate restricted diffusion on the ADC maps (Figure 4-16). 
Figure 4-16 Pre and post contrast scans during 2nd clinical relapse. Left Sagittal T1 FLAIR pre-gadolinium. The 
hypo-dense cerebellar lesion is seen.  Right: T1 Sagittal FLAIR post gadolinium shows heterogeneous 
enhancement of the vermis, superior and middle lobes of the cerebellum.  
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He was treated with high dose IV methylprednisolone for 3 days. He was then given oral 
prednisone which was weaned over 3-4 months. 
As this patient had mildly elevated inflammatory markers on his first presentation (ESR, 
neurotransmitters) and had atypical findings, anti-MOG antibodies were tested on the patients’ 
serum and were found to be positive. In addition, the second scan had shown clear evidence of 
atrophy and gliosis indicating a damaging process.  Given his clinical and imaging findings, in an 
attempt to prevent further relapses, he was started on Mycophenolate (Mofetil).  
This patient would fulfil criteria for MS based on the new consensus criteria (2013) but would 
otherwise be a patient who would be uncategorised with the 2007 consensus criteria as he had 
had one episode of ADEM followed by a CIS episode.  
Commentary: 
This patient’s fulfilled criteria for paediatric onset MS according to the 2012 Criteria 
(unclassified according to the 2007 consensus) however there were a number of features of his 
presentation that were atypical for MS. 
Firstly his initial episode was ADEM which has a lower risk of MS. His clinical presentation and 
MRI findings are consistent with ADEM even though his imaging does fulfil McDonald 2010 MRI 
MS criteria. He was however under 10 years of age during this episode.  
His inflammatory markers (ESR and neurotransmitters) were elevated during his presentation 
which is known to be atypical for MS and suggest a more global inflammatory process.  
Thirdly his 2nd episode MRI showed evidence of gliosis and atrophy from his first episode 
indicating that a damaging process was occurring and suggests the need for disease modifying 
therapy.  
Whilst DK had a second event with an MRI that would be supportive of an MS diagnosis, we feel 
his clinical picture, antibody findings and imaging are not typical MS. This case exemplifies the 
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need to better delineate further subtypes of chronic inflammatory demyelination which would 
currently be all grouped under the diagnosis of MS according to the 2012 consensus definitions.  
His primary physician (RCD) nominated to treat him as having an autoimmune inflammatory 
demyelinating disorder like NMO, rather than MS. He is tolerating the mycophenolate well (for 8 
months) and is currently well and due further progress scans.  
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4.9 Results of gene study 
HLA-DRB1*1501 typing was performed on 40/73 patients in the MOG cohort (18/31 anti-MOG 
antibody positive and 22/42 anti-MOG antibody negative).   
A negative correlation was found between anti-MOG antibody status and HLA typing; 3/18 
(17%) of the anti-MOG antibody positive patients were HLA positive compared with 7/22 
(32%) anti-MOG antibody negative patients, although this was not significant (p=0.27). 
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4.10 Discussion of clinical, laboratory and genetic findings in MOG cohort 
Children with a relapsing inflammatory CNS demyelinating disorder are currently classified as 
having MS, NMO and less often CRION. However the discovery of pathogenic antibodies (such as 
anti-NMO IgG) in children and adults with CNS demyelination has begun the search for further 
inflammatory demyelinating disorder phenotypes or subgroups.  Not all patients diagnosed 
with MS respond to the same therapies and in particular children have a higher relapse rate 
compared to their adult counterparts. It is possible that MS has a number of immunologic 
and/or clinical subtypes.  
Anti-MOG antibodies have been shown to cause severe demyelination in animals with 
experimental autoimmune encephalitis (EAE) that have a disrupted blood brain barrier (157, 
159).  
In vivo studies have also shown that anti-MOG antibodies cause natural killer cell-mediated 
cytotoxicity which may be pathologically important in explaining the process by which these 
antibodies cause demyelination in humans (164).  
The association of an auto-antibody with specific subtypes of CNS inflammatory demyelination 
is not a new theme as shown previously with the APQ4 auto-antibody and its association with 
NMO (81, 96).  
Studies performed in both adults and children have begun to demonstrate an association 
between anti-MOG antibodies and a distinct clinical phenotype of inflammatory demyelination 
that may be distinct from MS.  
Previous studies have shown that anti-MOG antibodies are more commonly found in children as 
opposed to adults (166) and in younger compared to older children (167, 170). In fact the 
relationship between age and anti-MOG antibody positivity is inversely proportional to the 
onset of MS which classically presents in adults between 20-40 years of age.  
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Previous studies have shown anti-MOG Ab to be more commonly found in patients with 
relapsing ON in the context of normal baseline and progress MRI scans which would be atypical 
of MS and more comparable with CRION (172, 174).  Similarly anti-MOG antibody has been 
found in patients classified within the spectrum of NMO (NMOSD) who were sero-negative for 
the NMO IgG antibody (176). The NMO-like clinical phenotype of patients who are positive for 
the anti-MOG Ab is an emerging theme. 
In general, we found 31/73 (42%) patients positive for anti-MOG antibodies whereas all 
patients tested for AQP4 Antibody were negative. In our study patients who were anti-MOG 
antibody positive were younger than those who were anti-MOG Ab negative (mean 7.5 years vs 
9.5 years, p=0.05) and this is consistent with previous studies (167, 170). This association was 
found even when we divided patients according to their initial clinical phenotype (TM, ON, CIS 
other, ADEM) with the exception of patients presenting with TM.  
Previous studies have shown that the anti-MOG antibodies were found in 20-50% of children 
with ADEM (168, 173, 189). We too confirmed that 50% of children with ADEM in our cohort 
were anti-MOG antibody positive.  
Anti-MOG antibody status was phenotypically differentiating in our study. We found that anti- 
antibodies were more commonly found in children presenting with optic neuritis compared to 
all other CNS demyelinating clinical phenotypes (10/15 vs 21/58, p=0.03).  
We also found that children with bilateral optic neuritis (BLON) were more likely to be anti-
MOG positive compared to those with unilateral disease (ULON) with p=0.01.  
Previous studies have not differentiated BLON from ULON with regards to anti-MOG antibody 
status although this may be because the number of patients with bilateral disease in the 
previous studies was small compared with the patients presenting with unilateral disease. For 
example in the study by Rostasy et al (172) there were 37 patients with ON enrolled in the 
study, 34 of these patients presented with unilateral ON and only 3 with bilateral disease.   
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Rostasy et al (172) found relapsing ON patients had a higher rate of anti-MOG antibody 
positivity than the monophasic patients. We did not confirm this finding although our relapsing 
ON group was small (n=4).  
The ON patients with positive anti-MOG antibodies less commonly had MRI brain lesions than 
the anti-MOG negative patients (not significant). 
Combining these findings, an emerging NMO-like syndrome with anti-MOG Ab positivity is 
emerging as proposed by Rostasy et al in a study on children (173) and Kitely et al in a study on 
adults (176). 
In our cohort patients who were anti-MOG Ab positive were less likely to have brainstem 
abnormalities (7% vs 38%, p<0.00) and bulbar dysfunction (0% vs 14%, p=0.03). 
Characteristically ‘brainstem’ clinical features are typical of CIS presentations in patients with 
MS and therefore support the theme that anti-MOG antibody may be a biomarker of a different 
disease that is distinct from ‘classic MS’.   
When we divided our MOG cohort according to the diagnosis at follow-up there were 19/73 
who had recurrent episodes of CNS demyelination whilst 54 remained monophasic.  
Of the 19 patients with recurrent episodes of demyelination, 15 had a follow-up diagnosis of MS 
and four had chronic relapsing inflammatory optic neuropathy (CRION). Whilst the group with 
the highest percentage of anti-MOG positive patients were in the monophasic ON group (86%), 
the recurrent ON (CRION) group also had a high percentage of anti-MOG antibody positive 
patients (75%). Rostasy et al has previously shown that anti-MOG antibodies are found in 80% 
of patients with recurrent ON with a normal MRI (172).  
Anti-MOG Ab positive patients more commonly had a raised erythrocyte sedimentation rate 
(ESR) compared with those who were anti-MOG Ab negative (90% vs 17%, p=0.02). Although 
we know that a raised ESR is non-specific, it is atypical for MS and is often one of the clues that 
the diagnosis is not MS. A raised ESR may be found in vasculitides and other systemic 
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autoimmune disorders. In the context of our cohort we hypothesise that the raised ESR 
supports the hypothesis that the presence of anti-MOG antibody defines an immunologically 
distinct syndrome. We found that having a raised ESR was not age related. 
Cerebrospinal fluid polymorph (neutrophil) cell count was another significant differentiating 
finding in our cohort. Patients who were anti-MOG antibody positive had a higher mean 
polymorph cell count compared with those who were anti-MOG Ab negative (mean count of 11 
vs 3, p<0.00). A raised polymorph count is also atypical of MS.  A previous study compared the 
CSF findings of patients with NMO IgG sero-positive NMO/NMOSD to those with MS and found 
that the NMOSD patients had significantly higher CSF white cell counts compared to those with 
MS (190). The CSF white cell types that predominated in the NMO IgG seropositive 
NMO/NMOSD patients was lymphocytes and monocytes followed by neutrophils (190). 
Therefore the presence of CSF polymorphs (neutrophils) further supports the hypothesis that 
the presence of anti-MOG antibody defines an ‘NMO-like’ syndrome that is different to MS.   
As anti-MOG positive patients had both a raised ESR as well as a raised CSF polymorph cell 
count, there is evidence of a systemic immune response, and activation of the innate immune 
system. This may help with targeted therapy in the future with the use of, for example, 
neutrophil elastase inhibitors as used in other systemic inflammatory disorders (191). 
None of the patients who were anti-MOG antibody positive had intrathecal OCB (0/16) 
compared to 19% (5/27) of those who were anti-MOG antibody negative. This finding furthers 
the hypothesis that anti-MOG antibody may define a different syndrome to ‘classic MS’ although 
it is possible some of these findings are confounded by age and timing of CSF sampling.  
A similar trend was found in an adult based study that compared the CSF of patients with NMO 
IgG seropositive NMO/NMOSD with MS patients (190). In this study only 16% of patients with 
NMO IgG seropositive NMO/NMOSD had intrathecal OCB in their CSF compared with over 90% 
of patients with MS (190).  
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We compared the radiological features of patients who were anti-MOG Ab positive and negative 
and there were no significant differences. There was a general trend for patients who were anti-
MOG positive to less frequently fulfil McDonald 2010 criteria compared to those who were anti-
MOG negative (37% vs 63%, p=0.63) however this was not statically significant.  
The two case examples that we presented demonstrate the fact that relapsing demyelinating 
disease in children is heterogeneous and these children were atypical of ‘classic MS’. Both 
children in our examples had raised ESR’s in conjunction with very steroid dependent relapses. 
Treatment with mycophenolate in both cases has prevented further relapses so far (short term 
follow-up). Both these patients were anti-MOG antibody positive and responded to immune 
suppression similar to patients with NMO in contrast to MS. There are currently no clear 
therapeutic recommendations for patients with CNS inflammatory demyelination who have 
raised inflammatory markers and who are anti-MOG antibody positive.  
We used our two case examples to develop the hypothesis that relapsing demyelination with 
positive anti-MOG antibody appear different to ‘classic MS’ and may benefit from an ‘NMO-like’ 
therapy approach with immune suppression.  
HLA DRB1501 typing was performed on a proportion of our MOG cohort and there was a 
negative correlation between anti-MOG Ab status and HLA genotyping however this was not 
significant. This would further fit with our hypothesis that anti-MOG antibodies are not strongly 
associated with ‘classic MS’. The cohort size in this part of the study was small (n=40) and 
therefore further larger studies are needed to confirm this finding.   
In summary, a subtype of monophasic and recurrent demyelination has been emerging in 
paediatric demyelination associated with the presence of anti-MOG antibody. Previous studies 
have shown anti-MOG antibodies are more common in children presenting with and in 
recurrent optic neuritis compared with other clinical demyelinating phenotypes. In our study 
we confirmed these findings but also found an association of the anti-MOG Ab with the 
presentation of bilateral versus unilateral ON and less commonly in children presenting with 
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brainstem dysfunction. We also found that patients with the anti-MOG antibody more 
commonly had a raised ESR, increased CSF polymorph count and they did not have OCB on CSF 
analysis.  
Although anti-MOG antibodies have been found to cause natural killer cell-mediated cytotoxicity 
the pathogenicity of the antibody in causing central nervous system demyelination is yet to be 
proven outright. It could be argued that the anti-MOG antibody is an epiphenomenon hence and 
further in vitro and animal studies are needed.   
Further longitudinal, preferable international studies are needed to further delineate this 
clinical phenotype. Furthermore treatment ‘best practise’ of this disorder is as yet to be 
determined.  
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5. CONCLUSION OF STUDY 
The potential to diagnose MS or other forms of chronic recurrent demyelinating disorders at 
disease onset has implications for disease surveillance (MRI scans) as well as individualised 
treatment. The lesion load and tissue damage in MS and NMO accumulates with time therefore 
early, directed monitoring and treatment is warranted. 
Prior to the 2007 consensus criteria there were inconsistent definitions used for MS and related 
disorders. The introduction of the 2007 consensus criteria has led to a more consistent 
approach to the categorization and clinical/radiological comparison of children experiencing an 
episode of CNS demyelination between nations.  
This is the first retrospective study with follow-up in a paediatric cohort from Australia 
comparing the clinical, immunological and radiological characteristics of patients during their 
first demyelinating episode and after follow-up.  
We compared the clinical and radiological characteristics of patients presenting with acute 
disseminated encephalomyelitis (ADEM) with those presenting with clinically isolated 
syndrome (CIS) during their first demyelinating episode. We found a number of clinical 
characteristics that were more frequent in ADEM versus CIS patients in our cohort, including a 
younger mean age of onset, association with fever and an inter-current infection, as well as 
pyramidal tract dysfunction and these findings are compatible with previous studies. We were 
able to confirm the usefulness of the consensus definitions comparing international studies. 
Patients who presented with ADEM had a lower risk of MS compared with those who presented 
with CIS, and this also supports previous study findings and confirms the efficacy of the 2007 
diagnostic criteria.  
On neuroimaging we were able to confirm that patients presenting with ADEM have a 
characteristic MRI compared to those with CIS. ADEM patients more commonly have bilaterally 
distributed, poorly defined lesions found in the deep white matter, juxtacortical, internal 
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capsule, basal ganglia, thalamus, brainstem and cerebellum, whereas CIS patients more 
commonly had smaller lesions and a combination of both well and poorly defined lesions. The 
combination of these clinical and radiological findings helps to differentiate between ADEM and 
CIS and also the likelihood of relapse. This study confirms previous study findings from 
international cohorts thereby showing that children in NSW, Australia experience similar 
demyelinating syndromes to those described previously.  
Disease morbidity is not well studied in children following acute demyelination and we have 
shown that there are a significant number of parents and/or patients that report incomplete 
recovery following an acute demyelinating event. This is clearly an area that needs further 
formalised study to elicit which disorders or types of demyelination are likely to cause ongoing 
cognitive or physical dysfunction and how can we improve the outcomes. Further questions 
arise in this domain including; what are the effects of treatment on cognitive outcome? Do 
disease modifying therapies affect the maturation of the developing brain? What roles do 
vitamins and in particular Vitamin D have in preventing further events in children? Are there 
other environmental influences that need to be considered such as age of exposure to certain 
viruses?  
We have shown that as in adult MS studies, geographical latitude appears to influence the risk of 
MS, with disease rates rising with increasing distance from the equator in both the northern and 
southern hemispheres. We are able to report that despite the long follow-up, the rate of MS was 
15% in our cohort which is the lowest reported rate in international paediatric demyelination 
cohorts. Although the reason for this geographical latitude influence is as yet unexplained, 
further exploration into the vitamin D hypothesis and other local viral influences need further 
investigation. It would be useful to perform a similar study in multiple Australian centres to 
examine the ‘latitude hypothesis’ across the country, as has been done in adults. 
Furthermore, we confirmed using multivariate analysis that radiological features are more 
predictive of MS than clinical features. Our data supports the use of McDonald 2010 radiological 
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criteria, particularly when applied to children with CIS as has been recently recommended in 
the revised consensus criteria of 2012.  
We have shown that anti-MOG antibodies are commonly found in children with ON, ADEM and 
MS. Patients with recurrent ON (CRION) are significantly more likely to be anti-MOG antibody 
positive, although our numbers with CRION were small. An NMO-like subtype has been 
previously proposed and our study confirms this emerging clinical subtype, particularly in 
bilateral optic neuritis..  
We found raised inflammatory markers to be significantly more common in patients with anti-
MOG antibodies, a finding that is atypical of ‘classic MS’. This was highlighted in our case study 
examples where patients with relapsing CNS demyelination and positive anti-MOG antibodies 
had evidence of a systemic inflammatory response and steroid dependent relapses. These 
patients have been treated with immune-suppressive therapy, which is more commonly used in 
NMO patients. It seems likely that there may be more than one clinical manifestation of patients 
who are anti-MOG antibody positive and that these patients may differ from ‘classical MS’. 
Further multicentre international studies are needed to explore the association between anti-
MOG antibodies, systemic inflammation and CNS demyelination. Furthermore studies are also 
needed to demonstrate the pathogenicity of the anti-MOG antibody in causing central nervous 
system demyelination. 
Our study is not without limitations. As the study is retrospective, some key data were 
incompletely collected or sampled, and this is exemplified in our CSF analyses for OCB which 
were incompletely performed in our cohort. Furthermore not all patients in our cohort had 
serial progress MRI scans and therefore this comparison was also incomplete. The selection of 
patients in our study is highly dependent on coded diagnoses, which may miss a number of 
patients with demyelination, as they may not have been appropriately classified at the time of 
their admission/discharge.  The cohort was selected from patients presenting to a tertiary 
institute and whilst most episodes of demyelination require tertiary referral, some milder forms 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 246 of 279 
may have been treated at peripheral hospitals and therefore our cohort may not be a true 
reflection the entire paediatric demyelinating population for our area.  
The main lessons from my thesis are the importance of international consensus criteria, the 
need for prospective national and international collaboration and an open minded scientific 
discussion.  
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6. APPENDICES  
6.1 Appendix A: Clinical and biochemical profile for first episode of CNS demyelination 
used in retrospective review.  
Clinical findings Options 
Name Name 
DOB Date 
Medical record number (MRN) Number 
Home Address Telephone number 
Telephone number Number 
Consultant involved Name 
GP involved Name & address 
Date of admission Date 
Age at onset  Age in months 
Sex Male/Female 
Duration of hospital stay Days 
Preceding infection Yes/No 
Type of infection Description 
Latency to ADEM if applicable Days 
Significant past medical History As described 
Fever at time of presentation Yes/No 
Meningism present Yes/No 
Encephalopathy Present /Absent 
Details of encephalopathy Description of mood, behaviour, GCS 
Cognitive changes Description 
Pyramidal Signs Yes/No 
Hemiplegia or Quadriplegia None, Paraplegia, hemiplegia (left or right), 
Quadriplegia 
Cerebellar Signs Yes/No 
Trunk or Peripheral Cerebellar Signs None, Gait/trunk signs vs Upper limb or lower 
limb signs 
Brainstem involvement  Yes/No 
Details of brainstem involvement Which cranial nerve, clinical signs 
Bulbar involvement Yes/No 
Clinical Optic Neuritis present Yes/No 
If Optic Neuritis present – unilateral or bilateral N/A, Unilateral, Bilateral 
Transverse myelitis present Yes/No 
Bowel and/or bladder disturbance Yes/No 
Seizures present Yes/No 
Extrapyramidal signs Yes/No 
Peripheral neuropathy present Present/Absent 
Classification ADEM, TM, Hemispheric CIS, Optic Neuritis, 
Brainstem CIS 
International Classification (new consensus 
criteria) 
ADEM, CIS 
Treatment options 
Intravenous Methylprednisone used Yes/No 
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Duration of Methylpredinsone use Time in days 
Oral prednisone used Yes/No 
Duration prednisone prescribed Time in weeks 
Intravenous Immunoglobulins used Yes/No 
Other immunotherapy prescribed No or description if Yes 
Other treatment prescribed Listing of drug, surgery, procedure 
Biochemical and serological tests 
Laboratory evidence of infection None identified, Virus found and by which 
serological test (e.g. PCR etc.) 
Strength of evidence Non-applicable, Titre trend 
Lumbar puncture performed for Cerebrospinal 
fluid (CSF) 
Done/Not done 
CSF polymorph cells Number 
CSF mononuclear cells Number 
CSF red blood cells Number 
CSF Protein Number 
CSF corrected protein (adjusted for RBC count) Number 
CSF Glucose Number 
Oligoclonal band (OCB) detection Done/Not done 
Intrathecal OCB found Yes/No 
OCB mirrored in serum and CSF Yes/No 
OCB Negative Yes/No 
Other CSF findings Neurotransmitter changes (e.g. raised pterins), 
amino acid changes 
Neuroimaging compatible with diagnosis Yes/No 
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6.2 Appendix B: Information Letter for Follow-Up Study 
 
 
 
 
 
 
Investigators: 
Assoc Prof Russell Dale, Academic Child Health, Tel: 02 
98453404 
Dr Esther Tantsis, Advanced Trainee Registrar, Tel: 02 98453404 
 
We would like you to consider participating in a research study at The Children’s Hospital at 
Westmead. 
What is the study about? 
You/your child was admitted to The Children’s Hospital at Westmead with a brain illness 
resulting in ‘inflammation of the brain’. This study aims to find out how children have done since 
that time. 
What will the study involve? 
This study will involve one telephone call for a 3-5 minute telephone interview. We will ask you 
whether your child has any neurological, educational or other problems since the illness. We hope 
that by doing this study we will better understand this illness for children in the future. 
Are there any benefits for you participating in the study? 
There are no benefits to you or your family for participating in this study. If you have any 
questions, we will answer them during the telephone call. 
 
Other information 
The information derived from this study will be confidential. If you are happy to be telephoned, 
please sign the consent form including your telephone number (and best time to ring), and return 
the form in the stamp-addressed envelope.  
Participation in this project is voluntary and if you decide not to take part or decide to withdraw 
at any time this will not affect your child’s future care at The Children’s Hospital at Westmead. 
Corner Hawkesbury Road 
and Hainsworth Street 
 
 
Locked Bag 4001 
Westmead NSW 2145 
Sydney Australia  
 
DX 8213 Parramatta 
 
Tel +61 2 9845 0000 
Fax +61 2 9845 3489 
www.chw.edu.au 
ABN 53 188 579 090 
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If you have any concerns about the conduct of this study, please do not hesitate to discuss them 
with Dr Russell Dale (02 98453404) or with Carolyn Casey (9845 1316) Secretary of the Ethics 
Committee that has approved this project. This Information Sheet is for you to keep.  
 
_________________ 
Dr Esther Tantsis 
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6.3 Appendix C: Consent Form for Follow-Up Study 
 
 
CONSENT FORM (when patient still <18 years of age) 
 
FOLLOW-UP STUDY OF PATIENTS WITH 1ST EPISODE OF 
BRAIN AND SPINAL CORD INFLAMMATORY 
DEMYELINATION 
Investigators: 
Assoc Prof Russell Dale, Academic Child Health, Tel: 02 98453404 
Dr Esther Tantsis, Advanced Trainee Registrar, Tel: 02 98453404 
 
I have read and understood the information sheet, and give consent for my child 
____________________________(name) to participate in this research study. I understand that this 
research study involves a short telephone call and that during the telephone call we will be 
asked a few questions. I understand that the study is trying to determine if my child has any 
ongoing problems after the brain illness he/she suffered when he/she was treated at The 
Children’s Hospital at Westmead. I understand that my participation in this research study is 
not obligatory and that my decision will not otherwise affect my child’s current or future 
relationship with The Children’s Hospital at Westmead.  
 
NAME OF CHILD: ______________________________________________ (Please print) 
NAME OF PARENT OR GUARDIAN: ________________________________ (Please print) 
SIGNATURE OF PARENT OR GUARDIAN: _________________________ Date: _______ 
PREFERRED TELEPHONE NUMBER ________________________________ 
PREFERRED TIME OF DAY TO TELEPHONE __________________________ 
  
Corner Hawkesbury Road 
and Hainsworth Street 
 
Locked Bag 4001 
Westmead NSW 2145 
Sydney Australia  
 
DX 8213 Parramatta 
 
Tel +61 2 9845 0000 
Fax +61 2 9845 3489 
www.chw.edu.au 
ABN 53 188 579 090 
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6.4 Appendix D: Telephone questionnaire used for follow-up study 
Name:__________________________________________ 
DOB:____________________ MRN:__________________ 
Date of Telephone Call: ____________________________ 
Hello, my name is Esther Tantsis and I am a paediatric neurology registrar at the Children’s 
Hospital at Westmead. A few weeks ago you received an information pack outlining a study that 
I am doing into the neurological disease which you/your child suffered from. Thankyou for 
participating in the study and allowing me to call and speak to you today. The information we 
discuss is of course confidential. 
_____________(name) suffered from his/her/your inflammatory illness in ________(yrs.) 
Has your/your child’s illness left you/him/her with any problems? 
Y/N_____________________________________________________________________________ 
Has the illness left you/him/her with any movement or coordination problems? 
Y/N____________________________________________________________________________ 
Has the illness left you/him/her with any visual problems? 
Y/N____________________________________________________________________ 
Has the illness left you/him/her with any learning problems? 
Y/N_____________________________________________________________________________ 
Has there been any other health problems? Y/N [if yes get date and event] 
____________________________________________________________________________ 
Have you/your child had any further neurological illnesses since we last saw you/them in 
________? Y/N________________________________________________ 
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I have a question regarding blood specimens – during any patient’s hospitalization when blood 
is removed for testing, a small amount is often kept frozen in case further testing is required. 
Would you consent to my use of that left over blood (if available) in testing for a new marker of 
inflammation that is being tested? Y/N________________ 
If yes, can I send you out another consent form to return for this? 
Lastly, we think some people may be genetically more vulnerable to brain inflammation. This 
research may improve our understanding of why this happens. Would you be willing to provide 
a sample of saliva for us to test for those genes? It would involve us sending you a small tube for 
collection of a few mills of saliva. Y/N___________________________ 
Thank you very much for your valuable time that concludes all my questions. Do you have any 
questions for me? 
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6.5 Appendix E: Radiological data recorded for each patient on basis of initial MRI. 
Name     
DOB  MRN:   
Date of MRI     
 Reviewer 1 Reviewer 2 
Lesion Site     
Binary (present or absent):     
                     periventricular lesions     
                     deep white matter lesions     
                     Juxtacortical white matter lesions     
                     corpus callosum lesions     
                     Dawson’s fingers (ovoid lesions perpendicular 
to long axis of corpus)
    
                     internal capsule lesions     
                     cortical grey matter     
                     basal ganglia     
                     thalamus     
Any infratentorial lesions? If so number in     
                     brainstem     
                     cerebellar     
Are there bilateral lesions (y/n)     
Total number of T2: 1 =<5, 2 =>5, 3 =>9     
Number of periventricular lesions 1=>2, 2 =>3     
Radiologically ON? (y/n)     
Lesion characteristics     
Symmetrical or asymmetrical white matter lesions     
Symmetrical or asymmetrical deep grey matter lesions     
Well defined or poorly (diffuse) defined lesions      
Sole presence of well-defined lesions     
Sole presence of poorly defined     
Presence of T1 black holes?     
Contrast enhancing lesions? If yes how many? 
- Is there asymp enhancing & non-enhancing lesions  
    
    
Presence of large lesions (>2 gyri)?   
     
Spinal cord imaging     
Are there any lesions?      
Location of lesions (tick of present):     
    Cervical     
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    Thoracic     
    Lumbar     
Length of cord lesions 1 = <3 vert lengths, 2 = >3 vert 
lengths, 3 = whole cord 
    
Are lesions diffuse or discrete?      
   
FU scans (is there one?)     
date of repeat scan     
time from 1st scan     
lesions: 1= complete resolution, 2= partial, 3=new lesions     
Conclusion from scan ?MS or not     
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6.6 Appendix F: Published paper 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 257 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 258 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 259 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 260 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 261 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 262 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 263 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 264 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 265 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 266 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 267 of 279 
 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 268 of 279 
7. REFERENCES 
1. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. 
Nature reviews Neuroscience. 2008;9(11):839-55. Epub 2008/10/22. 
2. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability 
and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. 
Brain. 2008;131(Pt 3):808-17. Epub 2008/02/01. 
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N 
Engl J Med. 2000;343(13):938-52. Epub 2000/09/28. 
4. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. 
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in 
multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898-904. 
5. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early 
interferon treatment on conversion to definite multiple sclerosis: a randomised study. 
Lancet. 2001;357(9268):1576-82. 
6. Brass SD, Caramanos Z, Santos C, Dilenge ME, Lapierre Y, Rosenblatt B. Multiple 
sclerosis vs acute disseminated encephalomyelitis in childhood. Pediatr Neurol. 
2003;29(3):227-31. 
7. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric 
multiple sclerosis and related disorders. Neurology. 2007;68(16 Suppl 2):S7-12. Epub 
2007/04/18. 
8. Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated 
encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in 
children. Brain. 2000;123 Pt 12:2407-22. Epub 2000/12/02. 
9. Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and 
neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 
2001;56(10):1308-12. 
10. Murthy JM. Acute disseminated encephalomyelitis. Neurol India. 2002;50(3):238-43. 
11. Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a 
long-term follow-up study of 84 pediatric patients. Neurology. 2002;59(8):1224-31. 
12. Anlar B, Basaran C, Kose G, Guven A, Haspolat S, Yakut A, et al. Acute disseminated 
encephalomyelitis in children: outcome and prognosis. Neuropediatrics. 2003;34(4):194-9. 
13. Singhi PD, Ray M, Singhi S, Kumar Khandelwal N. Acute disseminated 
encephalomyelitis in North Indian children: clinical profile and follow-up. J Child Neurol. 
2006;21(10):851-7. 
14. Tenembaum S, Chitnis T, Ness J, Hahn JS. Acute disseminated encephalomyelitis. 
Neurology. 2007;68(16 Suppl 2):S23-36. 
15. Venkateswaran S, Banwell B. Pediatric multiple sclerosis. Neurologist. 2010;16(2):92-
105. Epub 2010/03/12. 
16. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple 
sclerosis in an MS center population from the Northeastern United States. Mult Scler. 
2009;15(5):627-31. Epub 2009/03/21. 
17. Ghezzi A, Deplano V, Faroni J, Grasso MG, Liguori M, Marrosu G, et al. Multiple 
sclerosis in childhood: clinical features of 149 cases. Mult Scler. 1997;3(1):43-6. Epub 
1997/02/01. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 269 of 279 
18. Mikaeloff Y, Suissa S, Vallee L, Lubetzki C, Ponsot G, Confavreux C, et al. First episode 
of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple 
sclerosis and disability. J Pediatr. 2004;144(2):246-52. 
19. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early onset multiple 
sclerosis: a longitudinal study. Neurology. 2002;59(7):1006-10. Epub 2002/10/09. 
20. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of 
multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603-13. Epub 
2007/06/22. 
21. Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-
onset multiple sclerosis. Neurology. 2006;67(3):511-3. 
22. Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, et al. Safety and 
tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472-
6. Epub 2006/03/01. 
23. Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Meysamie A. Treatment of early 
onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics. 
2006;37(4):257-60. Epub 2006/12/21. 
24. Belman AL, Chitnis T, Renoux C, Waubant E. Challenges in the classification of 
pediatric multiple sclerosis and future directions. Neurology. 2007;68(16 Suppl 2):S70-4. 
Epub 2007/04/18. 
25. Kurtzke JF. Multiple sclerosis in time and space--geographic clues to cause. J 
Neurovirol. 2000;6 Suppl 2:S134-40. Epub 2000/06/29. 
26. Islam T, Gauderman WJ, Cozen W, Mack TM. Childhood sun exposure influences risk 
of multiple sclerosis in monozygotic twins. Neurology. 2007;69(4):381-8. 
27. Scheibel AB. Reticular Formation and the Brain Stem. In: Larry RS, editor. 
Encyclopedia of Neuroscience. Oxford: Academic Press; 2009. p. 145-9. 
28. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS 
guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 
2010;17(8):1019-32. Epub 2010/06/10. 
29. Fung EL, Tsung LL, Dale RC. Aquaporin-4 autoantibody: a neurogenic cause of 
anorexia and weight loss. Dev Med Child Neurol. 2012;54(1):45-7. Epub 2011/12/17. 
30. Ogasawara M, Shikishima K, Sakai T, Takagi M, Tanaka K. A case of neuromyelitis 
optica developing into myelitis 25 years after optic neuritis. Jpn J Ophthalmol. 
2010;54(4):372-3. Epub 2010/08/12. 
31. Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, et al. 
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. 
Neurology. 2008;70(5):344-52. 
32. Dale RC, Tantsis E, Merheb V, Brilot F. Cerebrospinal fluid B-cell expansion in 
longitudinally extensive transverse myelitis associated with neuromyelitis optica 
immunoglobulin G. Developmental medicine and child neurology. 2011;53(9):856-60. Epub 
2011/06/18. 
33. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a 
clinicopathological study of 8 patients. Ann Neurol. 1993;34(2):162-8. Epub 1993/08/01. 
34. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A 
role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 
2002;125(Pt 7):1450-61. Epub 2002/06/22. 
35. Bencherif MZ, Karib H, Tachfouti S, Guedira K, Mohcine Z. [Devic's neuromyelitis 
optica. A childhood case and review of the literature]. J Fr Ophtalmol. 2000;23(5):488-90. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 270 of 279 
Epub 2000/06/09. Neuromyelite optique de Devic chez l'enfant. Un nouveau cas rapporte et 
revue de la litterature. 
36. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis 
optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012;18(1):5-10. Epub 
2011/12/08. 
37. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New 
diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 
1983;13(3):227-31. 
38. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic 
criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 
2011;69(2):292-302. Epub 2011/03/10. 
39. Love S. Demyelinating diseases. J Clin Pathol. 2006;59(11):1151-9. 
40. Young NP, Weinshenker BG, Parisi JE, Scheithauer B, Giannini C, Roemer SF, et al. 
Perivenous demyelination: association with clinically defined acute disseminated 
encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain. 
2010;133(Pt 2):333-48. Epub 2010/02/05. 
41. Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of acute 
disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin 
Neurol. 2007;20(3):343-50. 
42. Breij EC, Brink BP, Veerhuis R, van den Berg C, Vloet R, Yan R, et al. Homogeneity of 
active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008;63(1):16-25. 
43. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the 
newly forming lesion. Ann Neurol. 2004;55(4):458-68. 
44. Leake JA, Albani S, Kao AS, Senac MO, Billman GF, Nespeca MP, et al. Acute 
disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory 
features. Pediatr Infect Dis J. 2004;23(8):756-64. 
45. Mikaeloff Y, Caridade G, Husson B, Suissa S, Tardieu M. Acute disseminated 
encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol. 
2007;11(2):90-5. 
46. Pohl D, Hennemuth I, von Kries R, Hanefeld F. Paediatric multiple sclerosis and acute 
disseminated encephalomyelitis in Germany: results of a nationwide survey. Eur J Pediatr. 
2007;166(5):405-12. 
47. Pohl D. Diagnosing paediatric multiple sclerosis versus acute disseminated 
encephalomyelitis. Dev Med Child Neurol. 2007;49(12):884. 
48. Atzori M, Battistella P, Perini P, Calabrese M, Fontanin M, Laverda A, et al. Clinical 
and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in 
pediatric patients: a single centre prospective study. Mult Scler. 2008. 
49. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. 
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International 
Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-7. 
50. Dale RC, Pillai SC. Early relapse risk after a first CNS inflammatory demyelination 
episode: examining international consensus definitions. Dev Med Child Neurol. 
2007;49(12):887-93. Epub 2007/11/28. 
51. Alper G, Heyman R, Wang L. Multiple sclerosis and acute disseminated 
encephalomyelitis diagnosed in children after long-term follow-up: comparison of 
presenting features. Dev Med Child Neurol. 2008. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 271 of 279 
52. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, et al. Clinical features 
and viral serologies in children with multiple sclerosis: a multinational observational study. 
Lancet neurology. 2007;6(9):773-81. Epub 2007/08/11. 
53. Neuteboom RF, Boon M, Catsman Berrevoets CE, Vles JS, Gooskens RH, Stroink H, et 
al. Prognostic factors after a first attack of inflammatory CNS demyelination in children. 
Neurology. 2008;71(13):967-73. 
54. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic 
criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 
2005;58(6):840-6. 
55. Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, et al. 
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute 
demyelination: a prospective national cohort study. Lancet Neurol. 2011;10(5):436-45. Epub 
2011/04/05. 
56. Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, et al. 
Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 
2009;72(3):232-9. Epub 2009/01/21. 
57. Absoud M, Lim MJ, Chong WK, De Goede CG, Foster K, Gunny R, et al. Paediatric 
acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging 
features. Mult Scler. 2012. Epub 2012/04/21. 
58. Riikonen R, Donner M, Erkkila H. Optic neuritis in children and its relationship to 
multiple sclerosis: a clinical study of 21 children. Dev Med Child Neurol. 1988;30(3):349-59. 
59. Lucchinetti CF, Kiers L, O'Duffy A, Gomez MR, Cross S, Leavitt JA, et al. Risk factors for 
developing multiple sclerosis after childhood optic neuritis. Neurology. 1997;49(5):1413-8. 
Epub 1997/12/31. 
60. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, 
MRI findings, and outcome of optic neuritis in children. Neurology. 2006;67(2):258-62. 
61. Alper G, Wang L. Demyelinating optic neuritis in children. J Child Neurol. 
2009;24(1):45-8. Epub 2008/10/22. 
62. Waldman AT, Stull LB, Galetta SL, Balcer LJ, Liu GT. Pediatric optic neuritis and risk of 
multiple sclerosis: meta-analysis of observational studies. J AAPOS. 2011;15(5):441-6. Epub 
2011/11/24. 
63. Kerr DA, Ayetey H. Immunopathogenesis of acute transverse myelitis. Current 
opinion in neurology. 2002;15(3):339-47. Epub 2002/06/05. 
64. Kaplin AI, Krishnan C, Deshpande DM, Pardo CA, Kerr DA. Diagnosis and 
management of acute myelopathies. Neurologist. 2005;11(1):2-18. Epub 2005/01/06. 
65. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 
2002;59(4):499-505. Epub 2002/09/19. 
66. Scott TF, Kassab SL, Singh S. Acute partial transverse myelitis with normal cerebral 
magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. Mult 
Scler. 2005;11(4):373-7. Epub 2005/07/27. 
67. De Goede CG, Holmes EM, Pike MG. Acquired transverse myelopathy in children in 
the United Kingdom--a 2 year prospective study. Eur J Paediatr Neurol. 2010;14(6):479-87. 
Epub 2010/01/22. 
68. Pidcock FS, Krishnan C, Crawford TO, Salorio CF, Trovato M, Kerr DA. Acute 
transverse myelitis in childhood: center-based analysis of 47 cases. Neurology. 
2007;68(18):1474-80. Epub 2007/05/02. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 272 of 279 
69. Torisu H, Kira R, Ishizaki Y, Sanefuji M, Yamaguchi Y, Yasumoto S, et al. Clinical study 
of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse 
myelitis in Fukuoka Prefecture, Japan. Brain Dev. 2010;32(6):454-62. Epub 2009/11/28. 
70. Thomas T, Branson HM, Verhey LH, Shroff M, Stephens D, Magalhaes S, et al. The 
Demographic, Clinical, and Magnetic Resonance Imaging (MRI) Features of Transverse 
Myelitis in Children. J Child Neurol. 2012;27(1):11-21. 
71. Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, Boon M, van Dijk KG, 
Eikelenboom MJ, et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch 
children: a nationwide study. J Neurol. 2012. Epub 2012/02/22. 
72. Adams C, Armstrong D. Acute transverse myelopathy in children. Can J Neurol Sci. 
1990;17(1):40-5. Epub 1990/02/01. 
73. Defresne P, Hollenberg H, Husson B, Tabarki B, Landrieu P, Huault G, et al. Acute 
transverse myelitis in children: clinical course and prognostic factors. J Child Neurol. 
2003;18(6):401-6. Epub 2003/07/31. 
74. Ketelslegers I, Visser I, Neuteboom R, Boon M, Catsman-Berrevoets C, Hintzen R. 
Disease course and outcome of acute disseminated encephalomyelitis is more severe in 
adults than in children. Mult Scler. 2010. Epub 2010/12/15. 
75. Suppiej A, Vittorini R, Fontanin M, De Grandis D, Manara R, Atzori M, et al. Acute 
disseminated encephalomyelitis in children: focus on relapsing patients. Pediatr Neurol. 
2008;39(1):12-7. Epub 2008/06/17. 
76. Deery B, Anderson V, Jacobs R, Neale J, Kornberg A. Childhood MS and ADEM: 
investigation and comparison of neurocognitive features in children. Dev Neuropsychol. 
2010;35(5):506-21. Epub 2010/08/20. 
77. Hahn CD, Miles BS, MacGregor DL, Blaser SI, Banwell BL, Hetherington CR. 
Neurocognitive outcome after acute disseminated encephalomyelitis. Pediatr Neurol. 
2003;29(2):117-23. 
78. Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in 
children. Pediatrics. 2002;110(2 Pt 1):e21. 
79. Bonhomme GR, Waldman AT, Balcer LJ, Daniels AB, Tennekoon GI, Forman S, et al. 
Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis. Neurology. 
2009;72(10):881-5. Epub 2009/03/11. 
80. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The 
spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-15. Epub 2007/08/21. 
81. Wingerchuk DM. Neuromyelitis optica. Int MS J. 2006;13(2):42-50. Epub 2006/04/26. 
82. Huppke P, Bluthner M, Bauer O, Stark W, Reinhardt K, Huppke B, et al. Neuromyelitis 
optica and NMO-IgG in European pediatric patients. Neurology. 2010;75(19):1740-4. Epub 
2010/11/10. 
83. Collongues N, Marignier R, Zephir H, Papeix C, Fontaine B, Blanc F, et al. Long-term 
follow-up of neuromyelitis optica with a pediatric onset. Neurology. 2010;75(12):1084-8. 
Epub 2010/09/22. 
84. Gebhardt A, Buehler R, Wiest R, Tewald F, Sellner J, Humpert S, et al. Mycoplasma 
pneumonia as a cause of neuromyelitis optica? J Neurol. 2008;255(8):1268-9. Epub 
2008/06/20. 
85. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of 
neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-14. Epub 1999/09/25. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 273 of 279 
86. Sellner J, Luthi N, Buhler R, Gebhardt A, Findling O, Greeve I, et al. Acute partial 
transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol. 
2008;15(4):398-405. Epub 2008/03/04. 
87. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea 
with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65(9):1479-82. Epub 
2005/11/09. 
88. de Seze J, Stojkovic T, Ferriby D, Gauvrit JY, Montagne C, Mounier-Vehier F, et al. 
Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci. 
2002;197(1-2):57-61. Epub 2002/05/09. 
89. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A 
serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. 
Lancet. 2004;364(9451):2106-12. Epub 2004/12/14. 
90. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal 
multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-7. 
Epub 2005/08/10. 
91. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and 
aquaporin 4. J Neuroinflammation. 2008;5:22. Epub 2008/05/31. 
92. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. 
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch 
Neurol. 2006;63(7):964-8. Epub 2006/07/13. 
93. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. 
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. 
Ann Neurol. 2006;59(3):566-9. Epub 2006/02/03. 
94. Wingerchuk DM, Weinshenker BG. Neuromyelitis Optica. Curr Treat Options Neurol. 
2005;7(3):173-82. Epub 2005/04/09. 
95. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of 
neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 
2008;65(11):1443-8. Epub 2008/09/10. 
96. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised 
diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-9. Epub 
2006/05/24. 
97. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability 
status scale (EDSS). Neurology. 1983;33(11):1444-52. Epub 1983/11/01. 
98. Collongues N, Marignier R, Zephir H, Papeix C, Blanc F, Ritleng C, et al. Neuromyelitis 
optica in France: a multicenter study of 125 patients. Neurology. 2010;74(9):736-42. 
99. Delves PJM, Seamus J. Burton, Dennis R. Essentials : Roitt's Essential Immunolog. 
Hoboken, NJ, USA: Wiley-Blackwell 11/2011. 
100. Dale RC, Brilot F, Banwell B. Pediatric central nervous system inflammatory 
demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, 
neuromyelitis optica, and multiple sclerosis. Current opinion in neurology. 2009;22(3):233-
40. Epub 2009/05/13. 
101. Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006;354(12):1273-80. Epub 
2006/03/24. 
102. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International 
Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-
mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. 
Mult Scler. 2013. Epub 2013/04/11. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 274 of 279 
103. Verhey LH, Branson HM, Shroff MM, Callen DJ, Sled JG, Narayanan S, et al. MRI 
parameters for prediction of multiple sclerosis diagnosis in children with acute CNS 
demyelination: a prospective national cohort study. Lancet Neurol. 2011;10(12):1065-73. 
Epub 2011/11/10. 
104. Mikaeloff Y, Adamsbaum C, Husson B, Vallee L, Ponsot G, Confavreux C, et al. MRI 
prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. 
Brain. 2004;127(Pt 9):1942-7. 
105. Callen DJ, Shroff MM, Branson HM, Li DK, Lotze T, Stephens D, et al. Role of MRI in 
the differentiation of ADEM from MS in children. Neurology. 2009;72(11):968-73. Epub 
2008/11/29. 
106. Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, et al. Aquaporin-4 antibodies 
in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 
2008;65(7):913-9. Epub 2008/07/16. 
107. Atzori M, Battistella PA, Perini P, Calabrese M, Fontanin M, Laverda AM, et al. Clinical 
and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in 
pediatric patients: a single centre prospective study. Mult Scler. 2009;15(3):363-70. Epub 
2008/11/07. 
108. Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired 
CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 
2011;77(12):1143-8. Epub 2011/08/26. 
109. de Seze J, Blanc F, Kremer S, Collongues N, Fleury M, Marcel C, et al. Magnetic 
resonance spectroscopy evaluation in patients with neuromyelitis optica. J Neurol 
Neurosurg Psychiatry. 2010;81(4):409-11. Epub 2010/04/03. 
110. Duran ND, Dale R, McNamara DS. The action dynamics of overcoming the truth. 
Psychon Bull Rev. 2010;17(4):486-91. Epub 2010/08/13. 
111. Banwell B, Bar-Or A, Giovannoni G, Dale RC, Tardieu M. Therapies for multiple 
sclerosis: considerations in the pediatric patient. Nat Rev Neurol. 2011;7(2):109-22. Epub 
2011/01/13. 
112. Nakamura M, Nakazawa T, Doi H, Hariya T, Omodaka K, Misu T, et al. Early high-dose 
intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness 
in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol. 
2010;248(12):1777-85. Epub 2010/03/20. 
113. Hammond SR, de Wytt C, Maxwell IC, Landy PJ, English D, McLeod JG, et al. The 
epidemiology of multiple sclerosis in Queensland, Australia. J Neurol Sci. 1987;80(2-3):185-
204. Epub 1987/09/01. 
114. Chabas D, Ness J, Belman A, Yeh EA, Kuntz N, Gorman MP, et al. Younger children 
with MS have a distinct CSF inflammatory profile at disease onset. Neurology. 
2010;74(5):399-405. Epub 2010/02/04. 
115. Leon DA, Pablo-Casas J, Dale C, Polikina O, Tomkins S, McKee M. Re: "Alcohol 
consumption in young adults and incident hypertension: 20-year follow-up from the 
Coronary Artery Risk Development in Young Adults Study". Am J Epidemiol. 
2010;172(6):743-4; authors reply 4-5, 6. Epub 2010/08/07. 
116. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et 
al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple 
sclerosis: a consensus statement. Arch Neurol. 2005;62(6):865-70. Epub 2005/06/16. 
117. Ghezzi A, Pozzilli C, Liguori M, Marrosu MG, Milani N, Milanese C, et al. Prospective 
study of multiple sclerosis with early onset. Mult Scler. 2002;8(2):115-8. Epub 2002/05/07. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 275 of 279 
118. Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple 
sclerosis. Neurology. 2004;63(10):1966-7. 
119. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin 
antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating 
event. N Engl J Med. 2003;349(2):139-45. Epub 2003/07/11. 
120. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in 
pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1):54-9. 
Epub 2009/01/14. 
121. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive 
dysfunction in multiple sclerosis. II. Impact on employment and social functioning. 
Neurology. 1991;41(5):692-6. Epub 1991/05/01. 
122. Amato MP, Zipoli V, Portaccio E. Cognitive changes in multiple sclerosis. Expert Rev 
Neurother. 2008;8(10):1585-96. Epub 2008/10/22. 
123. MacAllister WS, Belman AL, Milazzo M, Weisbrot DM, Christodoulou C, Scherl WF, et 
al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology. 
2005;64(8):1422-5. Epub 2005/04/27. 
124. Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Moiola L, et al. Cognitive and 
psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 
2010;75(13):1134-40. Epub 2010/09/30. 
125. Portaccio E, Goretti B, Lori S, Zipoli V, Centorrino S, Ghezzi A, et al. The brief 
neuropsychological battery for children: a screening tool for cognitive impairment in 
childhood and juvenile multiple sclerosis. Mult Scler. 2009;15(5):620-6. Epub 2009/03/26. 
126. Banwell BL. The long (-itudinally extensive) and the short of it: transverse myelitis in 
children. Neurology. 2007;68(18):1447-9. Epub 2007/05/02. 
127. Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic 
neuropathy (CRION). Brain. 2003;126(Pt 2):276-84. Epub 2003/01/23. 
128. Sellner J, Luthi N, Schupbach WM, Gebhardt A, Findling O, Schroth G, et al. 
Diagnostic workup of patients with acute transverse myelitis: spectrum of clinical 
presentation, neuroimaging and laboratory findings. Spinal Cord. 2009;47(4):312-7. Epub 
2008/11/19. 
129. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et 
al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 
24 patients. Arch Neurol. 2009;66(9):1128-33. Epub 2009/09/16. 
130. Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Isabel Leite M, Levy M, et al. 
Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and 
Related Disorders. 2012;1(4):180-7. 
131. de Seze J. [Multiple sclerosis: clinical aspects, acute disseminated encephalomyelitis, 
neuromyelitis optica and other inflammatory variants]. Rev Neurol (Paris). 2007;163(6-
7):647-50. Sclerose en plaques: aspects cliniques, encephalomyelites aigues disseminees, 
neuromyelites optiques et variantes inflammatoires. 
132. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison 
of MRI criteria at first presentation to predict conversion to clinically definite multiple 
sclerosis. Brain. 1997;120 ( Pt 11):2059-69. 
133. Hahn CD, Shroff MM, Blaser SI, Banwell BL. MRI criteria for multiple sclerosis: 
Evaluation in a pediatric cohort. Neurology. 2004;62(5):806-8. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 276 of 279 
134. Sedani S, Lim MJ, Hemingway C, Wassmer E, Absoud M. Paediatric multiple sclerosis: 
examining utility of the McDonald 2010 criteria. Mult Scler. 2012;18(5):679-82. Epub 
2011/10/21. 
135. Sadaka Y, Verhey LH, Shroff MM, Branson HM, Arnold DL, Narayanan S, et al. 2010 
McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol. 2012;72(2):211-
23. Epub 2012/08/29. 
136. Tintore M, Rovira A, Rio J, Nos C, Grive E, Sastre-Garriga J, et al. New diagnostic 
criteria for multiple sclerosis: application in first demyelinating episode. Neurology. 
2003;60(1):27-30. 
137. Banwell B, Shroff M, Ness JM, Jeffery D, Schwid S, Weinstock-Guttman B. MRI 
features of pediatric multiple sclerosis. Neurology. 2007;68(16 Suppl 2):S46-53. 
138. Callen DJ, Shroff MM, Branson HM, Lotze T, Li DK, Stephens D, et al. MRI in the 
diagnosis of pediatric multiple sclerosis. Neurology. 2009;72(11):961-7. Epub 2008/11/29. 
139. Ketelslegers IA, Neuteboom RF, Boon M, Catsman-Berrevoets CE, Hintzen RQ. A 
comparison of MRI criteria for diagnosing pediatric ADEM and MS. Neurology. 
2010;74(18):1412-5. Epub 2010/03/26. 
140. Singh S, Prabhakar S, Korah IP, Warade SS, Alexander M. Acute disseminated 
encephalomyelitis and multiple sclerosis: magnetic resonance imaging differentiation. 
Australas Radiol. 2000;44(4):404-11. 
141. Chitnis T, Pirko I. Sensitivity vs specificity: progress and pitfalls in defining MRI 
criteria for pediatric MS. Neurology. 2009;72(11):952-3. Epub 2009/03/18. 
142. Verhey LH, Branson HM, Makhija M, Shroff M, Banwell B. Magnetic resonance 
imaging features of the spinal cord in pediatric multiple sclerosis: a preliminary study. 
Neuroradiology. 2010;52(12):1153-62. Epub 2010/08/20. 
143. Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E. Vanishing 
MS T2-bright lesions before puberty: a distinct MRI phenotype? Neurology. 
2008;71(14):1090-3. Epub 2008/10/01. 
144. Alper G, Heyman R, Wang L. Multiple sclerosis and acute disseminated 
encephalomyelitis diagnosed in children after long-term follow-up: comparison of 
presenting features. Developmental Medicine & Child Neurology. 2009;51(6):480-6. 
145. Kitley JL, Leite MI, George JS, Palace JA. The differential diagnosis of longitudinally 
extensive transverse myelitis. Mult Scler. 2012;18(3):271-85. Epub 2011/06/15. 
146. Kalra V, Sharma S, Sahu J, Sankhyan N, Chaudhry R, Dhawan B, et al. Childhood acute 
transverse myelitis: clinical profile, outcome, and association with antiganglioside 
antibodies. Journal of child neurology. 2009;24(4):466-71. Epub 2009/02/07. 
147. Alper G, Petropoulou KA, Fitz CR, Kim Y. Idiopathic acute transverse myelitis in 
children: an analysis and discussion of MRI findings. Mult Scler. 2011;17(1):74-80. Epub 
2010/09/23. 
148. Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, et al. Multiple Sclerosis 
Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Arch Neurol. 2010. Epub 
2010/12/15. 
149. Wingerchuk D, Liu Q, Sobell J, Sommer S, Weinshenker BG. A population-based case-
control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. 
Neurology. 1997;49(2):626-8. Epub 1997/08/01. 
150. McLaughlin KA, Wucherpfennig KW. B cells and autoantibodies in the pathogenesis 
of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol. 
2008;98:121-49. Epub 2008/09/06. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 277 of 279 
151. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an 
overview. Brain Pathol. 2007;17(2):210-8. Epub 2007/03/29. 
152. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion 
with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-88. 
Epub 2008/02/15. 
153. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, et al. Antibodies 
against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple 
sclerosis and other neurological diseases: a comparative study. Brain. 1999;122 ( Pt 
11):2047-56. Epub 1999/11/05. 
154. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte 
glycoprotein. J Neurochem. 1999;72(1):1-9. Epub 1999/01/14. 
155. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential 
ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, 
and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. J Neurochem. 
1989;52(1):296-304. Epub 1989/01/01. 
156. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of 
multiple sclerosis. Nature reviews Neuroscience. 2002;3(4):291-301. Epub 2002/04/23. 
157. Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a 
myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous 
system autoimmune disease. J Immunol. 1987;139(12):4016-21. Epub 1987/12/15. 
158. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of 
demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal 
antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol. 
1988;130(3):443-54. Epub 1988/03/01. 
159. Linington C, Lassmann H. Antibody responses in chronic relapsing experimental 
allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to 
the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol. 1987;17(1):61-9. Epub 
1987/12/01. 
160. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies 
associated with myelin damage in multiple sclerosis. Nat Med. 1999;5(2):170-5. Epub 
1999/02/04. 
161. Kennel De March A, De Bouwerie M, Kolopp-Sarda MN, Faure GC, Bene MC, Bernard 
CC. Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis. J 
Neuroimmunol. 2003;135(1-2):117-25. Epub 2003/02/11. 
162. Markovic M, Trajkovic V, Drulovic J, Mesaros S, Stojsavljevic N, Dujmovic I, et al. 
Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of 
multiple sclerosis patients. J Neurol Sci. 2003;211(1-2):67-73. Epub 2003/05/28. 
163. Mantegazza R, Cristaldini P, Bernasconi P, Baggi F, Pedotti R, Piccini I, et al. Anti-MOG 
autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical 
association. Int Immunol. 2004;16(4):559-65. Epub 2004/03/25. 
164. Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, et al. Antibodies to 
native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating 
central nervous system disease. Ann Neurol. 2009;66(6):833-42. Epub 2009/12/25. 
165. Berger T, Reindl M. Immunopathogenic and clinical relevance of antibodies against 
myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis. J Neural Transm Suppl. 
2000(60):351-60. Epub 2001/02/24. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 278 of 279 
166. O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-
antigen tetramers discriminate between myelin autoantibodies to native or denatured 
protein. Nat Med. 2007;13(2):211-7. Epub 2007/01/24. 
167. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, et al. Age-
dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J 
Immunol. 2009;183(6):4067-76. Epub 2009/08/19. 
168. Di Pauli F, Mader S, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, et al. Temporal 
dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol. 
2011;138(3):247-54. Epub 2010/12/21. 
169. A.K. Probstel KD, PhD, R. Bittner, P. Sperl, D. Jenne, MD, S. Magalhaes, MSc, C. 
Breithaupt, PhD, R. Weissert, MD, U. Jacob, PhD, M. Krumbholz, MD, A. Blaschek, MD, W. 
Stark, MD, J. Gartner, MD, D. Pohl, MD, K. Rostasy, MD, F. Weber, MD, I Forne, PhD, M. 
Khademi, MD, T. Olsson, MD, F. Brilot, PhD, E. Tantsis, MD, R.C.Dale, MD, PhD, H. Wekerle, 
MD, R. Hohlfeld, MD, B. Banwell, MD, A. Bar-Or, MD, E. Meinl, MD. Antibodies to MOG are 
transient in childhood acute disseminated encephalomyelitis. Neurology. 2011;77(1-1):tba. 
170. Probstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to 
MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 
2011;77(6):580-8. Epub 2011/07/29. 
171. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, et al. Lack of 
association between antimyelin antibodies and progression to multiple sclerosis. N Engl J 
Med. 2007;356(4):371-8. Epub 2007/01/26. 
172. Rostasy K, Mader S, Schanda K, Huppke P, Gartner J, Kraus V, et al. Anti-Myelin 
Oligodendrocyte Glycoprotein Antibodies in Pediatric Patients With Optic Neuritis. Arch 
Neurol. 2012. Epub 2012/03/01. 
173. Rostasy K, Mader S, Hennes E, Schanda K, Gredler V, Guenther A, et al. Persisting 
myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric 
neuromyelitis optica. Mult Scler. 2013;19(8):1052-9. Epub 2012/12/22. 
174. Huppke P, Rostasy K, Karenfort M, Huppke B, Seidl R, Leiz S, et al. Acute 
disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in 
pediatric patients. Mult Scler. 2013;19(7):941-6. Epub 2012/11/07. 
175. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement 
activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and 
related disorders. J Neuroinflammation. 2011;8:184. Epub 2011/12/30. 
176. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-
oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. 
Neurology. 2012;79(12):1273-7. Epub 2012/08/24. 
177. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol. 
2004;3(2):104-10. Epub 2004/01/30. 
178. Ramagopalan SV, Byrnes JK, Orton SM, Dyment DA, Guimond C, Yee IM, et al. Sex 
ratio of multiple sclerosis and clinical phenotype. Eur J Neurol. 2010;17(4):634-7. Epub 
2009/12/09. 
179. Disanto G, Magalhaes S, Handel AE, Morrison KM, Sadovnick AD, Ebers GC, et al. 
HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired 
demyelination. Neurology. 2011;76(9):781-6. Epub 2011/02/04. 
180. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: 
a critical evaluation. Tissue Antigens. 1991;38(1):1-15. Epub 1991/07/01. 
Esther Margaret Tantsis  SID: 199630181 
 
 
 
 
Page 279 of 279 
181. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, et al. Genome-
wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum 
Mol Genet. 2009;18(4):767-78. Epub 2008/11/18. 
182. Ramagopalan SV, Dyment DA, Giovannoni G, Sadovnick AD, Ebers GC. HLA-DRB1*15, 
low infant sibling exposure, and multiple sclerosis gene-environment interaction. Ann 
Neurol. 2010;67(5):694-5. Epub 2010/05/04. 
183. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, et al. 
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. 
Nature. 2011;476(7359):214-9. Epub 2011/08/13. 
184. Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M, et al. A 
predominant role for the HLA class II region in the association of the MHC region with 
multiple sclerosis. Nat Genet. 2005;37(10):1108-12. Epub 2005/09/28. 
185. Boiko AN, Gusev EI, Sudomoina MA, Alekseenkov AD, Kulakova OG, Bikova OV, et al. 
Association and linkage of juvenile MS with HLA-DR2(15) in Russians. Neurology. 
2002;58(4):658-60. Epub 2002/02/28. 
186. Brilot F, Merheb V, Ding A, Murphy T, Dale RC. Antibody binding to neuronal surface 
in Sydenham chorea, but not in PANDAS or Tourette syndrome. Neurology. 
2011;76(17):1508-13. Epub 2011/03/18. 
187. Dale RC, Lang B, Brilot F, Polfrit Y, Smith GH, Wong M. Treatment-responsive 
pandysautonomia in an adolescent with ganglionic alpha3-AChR antibodies. Eur J Paediatr 
Neurol. 2012;16(4):396-8. Epub 2011/12/02. 
188. Amatoury M MV, Langer J, Wang XM, Dale RC, and Brilot F. . High-throughput flow 
cytometry cell-based assay to detect antibodies to N-Methyl D-Aspartate receptor or 
Dopamine-2 receptor in human serum. Journal of Visualized Experiments. 2013;Accepted 
for publication on March 27th 2013. In press. 
189. O'Connor KC, Appel H, Bregoli L, Call ME, Catz I, Chan JA, et al. Antibodies from 
inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J 
Immunol. 2005;175(3):1974-82. Epub 2005/07/22. 
190. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. 
Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results 
from 211 lumbar punctures. J Neurol Sci. 2011;306(1-2):82-90. Epub 2011/05/10. 
191. Togo S, Matsuo K, Ishibe A, Nagano Y, Takahashi M, Mochizuki H, et al. Usefulness of 
a selective neutrophil elastase inhibitor (sivelestat) in septic ARDS patients after 
gastrointestinal surgery. Hepato-gastroenterology. 2008;55(84):967-73. Epub 2008/08/19. 
 
 
 
 
 
 
 
